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Introduction Despite recognition that hallmark features of psoriatic arthritis (PsA) are 
predominant and persistent in the foot and ankle, limited foot-specific research exists 
and there are no validated outcome measures to comprehensively assess the impact of 
foot involvement from the perspective of people living with PsA. Previous research 
has shown merit in linking to the International Classification of Functioning, Disability 
and Health (ICF) in order to better define and understand the impact of global disease 
associated with PsA, but little is known about the impact of localised disease in the 
foot. Current understanding of foot involvement in PsA is based on a limited number 
of studies with relatively small sample sizes of predominantly discrete sub-populations 
of PsA, which fail to adequately incorporate the perspective of those living with PsA. 
Therefore, foot involvement in PsA remains under-researched and poorly understood 
with a lack of large-scale data to provide the basis for targeted disease-specific 
assessments and interventions. This thesis aimed to investigate foot involvement in 
PsA from the patient perspective, and to develop a national Australasian-based survey 
in order to comprehensively describe the nature, extent and location of foot problems 
and their impact on the daily life of people with PsA.  
 
Methods A qualitative study explored the perspectives of those with PsA and health 
professionals on the impact of PsA-related foot problems on daily life in order to gain 
insight into the patient experience. Concepts important and relevant to the patient 
experience of foot involvement in PsA, derived from the qualitative study, were used 
to systematically link the effect of foot problems in PsA to the ICF. The qualitative 
research findings and ICF linking exercise were used to generate the conceptual 
framework for the survey and subsequent item generation. A multi-stage survey 
development process followed, using best practice methods in survey design and 
conduct, which included; cognitive debriefing, cultural sensitivity review, survey 
design expert validation, subject expert validation and pilot testing. Targeted postal 
and online survey dissemination strategies were developed in order to optimise 
implementation of the national survey, which collected data for a total of 6 months.  
 
Results Key themes on PsA-related foot involvement and its impact on daily life were 
revealed from the qualitative study, which comprised 1) disease manifestations in the 
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feet and ankles, 2) foot functional impairments and visual differences that impacted on 
daily activities, work, social and family life, and 3) mediating factors (such as coping 
strategies, self-care ability, footwear, social support, access to healthcare and climate) 
that influenced the severity of impact from foot involvement on daily life. An 
important concept from people with PsA was the psychological impact of foot 
problems on daily life, which was poorly recognised by the health professionals. 
Health professionals perceived limited expertise in detecting and managing foot 
involvement in PsA and a lack of specialist foot health service provision in Australia 
and New Zealand. Concepts, obtained from the qualitative study, were subsequently 
linked to the ICF model and a list of over 100 distinct ICF categories were identified, 
which confirmed the profound impact of PsA-related foot involvement on daily 
functioning and comprehensively defined what should be included in the evaluation of 
PsA-specific foot disease burden. A novel, robust survey was developed and 
successful survey outcomes confirmed that extensive survey pre-testing and rigorous 
mechanisms for survey distribution were worthwhile. Successful survey outcomes 
included; a high survey response (n=649), high completion rates (83% reached the end 
of the survey), inconsequential item non-response (5% missing data), and achieving a 
broadly representative PsA-specific population-based sample. Survey results 
demonstrated that foot problem in PsA were common, heterogeneous in nature and 
caused substantial burden. Important impact domains identified were 1) site-specific 
impact of hallmark disease features in the foot (such as rearfoot enthesitis, dactylitis, 
skin and toenail psoriasis) on daily routine, social participation, footwear choice and 
emotional well-being, 2) reduced physical activity and exercise due to foot problems 
with potential impact related to obesity and falls in PsA, and 3) the importance of 
support and understanding about the disease from health professionals and its impact 
on the perceived ability to cope with foot problems among people with PsA. 
 
Conclusion Findings highlight the importance of involving those with PsA to generate 
survey items, which resulted in relevant concepts being included in the survey that 
were not considered to be important by health professionals. This programme of work 
provides a comprehensive view of the wide-reaching impact of PsA foot-specific 
involvement from the patient perspective, which will inform the future research 
priorities on targeted strategies towards improving foot health and the patient 
experience in PsA.  
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WA   Western Australia 










This chapter provides a brief introduction and justification of the rationale, aims and 
objectives of the programme of work presented in this thesis. An outline of the overall 
thesis structure and content are also provided. 
1.1 Research Justification and Rationale 
It is now well recognised that psoriatic arthritis (PsA) can lead to marked 
musculoskeletal damage with consequent functional impairment and reduced quality 
of life (Gladman, et al., 1998; Gladman, 2005). Two principal themes are established 
throughout the literature that describe inflammatory involvement in PsA: 1) an 
established higher involvement of the lower limbs compared with the upper limbs, and 
2) the persistence of localised disease activity in the foot independent of global disease.  
Localised pain and disease features in the foot have been identified in those with 
clinically important levels of foot-related impairment and disability in PsA (Hyslop, 
et al., 2010a). Despite recognition that characteristic features of PsA, such as 
enthesitis, dactylitis and peripheral arthritis are predominant in the foot and ankle, 
limited foot-specific research exists. Few previous studies that comprise small sample 
sizes (range n=9 to 101) have focused on distinct anatomical sites of the foot affected 
by PsA (such as the MTPJs, Achilles tendon, toe dactylitis) (Hyslop, et al., 2010a; 
Hyslop, et al., 2010b; Woodburn, et al., 2013; Turner, et al., 2014; Wilkins, et al., 
2016). Involvement of other sites in the foot is less well understood and it is not known 
how individual features may affect other disease manifestations, with few studies 
providing a comprehensive description of the foot in PsA.  
 
Whilst previous studies have contributed useful initial insights into PsA-related foot 
involvement, how foot problems impact on the lives of people with PsA have not been 
explored in detail. Incorporation of the patient perspective in the development of 
disease domains and outcome measures has been strongly advocated by the Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome 
Measures in Rheumatology for use in Clinical Trials (OMERACT) groups in PsA 
(Kirwan, et al., 2011a; Kirwan, et al., 2011b; de Wit, et al., 2013; Tillett, et al., 2014; 
2 
 
Tillett, et al., 2015a). Patient participation in qualitative studies and use of international 
health frameworks have improved understanding of global PsA disease impact and 
domain measurement (Stamm, et al., 2007b; Taylor, et al., 2010; Gudu, et al., 2017). 
In contrast, little is known about the patient experience of foot involvement and how 
this may link to recognised frameworks to capture and describe localised disease 
impact in PsA.  
 
Early identification of PsA leads to better functional outcomes, mitigating disease 
progression and destructive joint changes. To better target and treat inflammation, 
validated disease-specific outcome measures to assess PsA impact domains are 
required. Currently, no validated foot-specific measures in PsA exist. However, prior 
to the future development of self-report instruments, a better understanding of the 
localised disease impact at a patient-level is needed in order to ensure that concepts 
important and relevant to people with PsA-related foot involvement are adequately 
covered. In addition, it is important to explore foot problems among people with PsA 
living in the local context of the current study, Australia and New Zealand. Foot-
related functional impairments in other rheumatic conditions have been shown to be 
influenced by healthcare access and footwear choice associated with climate and 
sociocultural factors. These influencing factors are likely to be important to the 
experience of PsA-related foot problems and are likely to be different in different 
countries.  
 
Foot involvement in PsA remains under-researched and poorly understood with a lack 
of large-scale data needed to provide the basis for targeted disease-specific 
assessments and interventions. Despite the presence of some previous studies 
examining the foot, a full and comprehensive description of the foot is warranted in 
order to understand the impact of foot involvement from the perspective of people with 
PsA living in Australia. Development of a national survey would provide the ideal 
opportunity to sample a large population over a wide geographical area across 
Australia and New Zealand, including different regions (rural and urban) and climate 
zones (temperature and humidity). The objective of this programme of work was to 
develop a national survey based on the views of people with PsA and health 




1.2 Aims and Objectives  
The primary aim of this programme of work was to establish the nature, extent and 
location of foot problems and their impact on the daily lives of people with PsA living 
in Australia and New Zealand. The secondary aim was to determine the footwear and 
foot care needs of this patient group. The research focus of this programme of work 
was to provide a comprehensive description of the foot affected by PsA, which 
includes the impact of PsA on foot-specific structure and function, activity and 
participation, and environmental factors such as footwear and foot healthcare.  
 
The specific objectives for this programme of work were 1) to determine the nature, 
severity and frequency of foot involvement in PsA, 2) to evaluate site-specific 
involvement in the foot, 3) to explore the impact of foot problems on functioning from 
the patient perspective in PsA, 4) to investigate the footwear preferences of an 
Antipodean and PsA-specific population, and 5) to determine the foot care needs 
among people with PsA in the context of foot healthcare provision in Australia and 
New Zealand. 
1.3 Thesis Structure 
This thesis investigates the foot problems in people with PsA. The thesis is structured 
as follows: 
 
Chapter 2. provides a detailed review of the literature relevant to the key concepts of 
this work with a focus on study justification.  
 
Chapter 3. presents a theoretical framework that summarises the existing knowledge, 
gaps in the literature and the resultant research focus.  
 
Chapter 4. describes the qualitative investigation into the patient experience of foot 
involvement related to PsA, including the background, method, results and discussion. 
 
Chapter 5. describes the linking of qualitative concepts to the International 
Classification of Functioning, Disability and Health, including the background, 




Chapter 6. presents a robust survey development protocol for a national survey on 
PsA-related foot involvement, with a focus on best practice methods in survey design, 
pre-testing and implementation.  
 
Chapter 7. provides a preface to the results that explains the rationale for undertaking 
a focused analysis of the survey data with a statement of intent  
 
Chapter 8. presents a focused, mainly descriptive analysis of the survey results mapped 
to key domains of impact informed by the qualitative research findings and ICF linking 
exercise 
 
Chapter 9. provides a focused discussion of key survey findings in the context of the 
literature, study limitations, contribution of knowledge, clinical implications and with 























2 Literature Review 
This chapter will review and critically appraise the literature relating to psoriatic 
arthritis (PsA) with emphasis on foot involvement and its impact on foot-related 
functional impairment and disability. Important themes in the literature include the 
early identification of active disease in the foot, the lack of validated disease-specific 
outcome measures to assess the foot, the impact of this omission on persistent foot 
disease among patients in clinical remission, use of ultrasound imaging and gait 
analysis techniques to explore the impact of localised disease, and the clinical 
implications of treatment alongside the treat-to-target approach. This chapter reviews 
the literature relevant to this field during the PhD timeframe from March 2018 to 
March 2020 in order to present the most contemporary information prior to thesis 
submission. 
 
2.1 Statement of Intent 
The literature will be interrogated for studies with PsA-specific cohorts. In the absence 
of such literature, the search will be extended to spondyloarthritis and rheumatoid 
arthritis (RA). The rationale being that historically RA disease metrics have been 
applied to PsA based on the assumption of shared pathogenic and clinical features, 
thus some transferability exists in relation to disease evaluation. Data from published 
research in Australasian populations will be sought and, when not available, study data 
from Europe and North America will be presented. Local data is preferable because 
potential differences in climate-related footwear may influence foot functional 
impairments and future podiatry treatment decisions, but most published studies in 
PsA have been conducted in European countries. Previous studies on foot function and 
gait characteristics in PsA will be reviewed and, in the absence of PsA data, knowledge 
will be drawn from published studies in RA. The rationale for this approach is based 
on RA having been the focus of many gait analysis studies compared to other 
inflammatory arthropathies, and thus aspects of conceptual methods may be 




Effective disease management requires the standardized assessment of disease activity 
and its impact. However, in PsA there are challenges related to disease assessment on 
a global and foot region-specific level. In order to gain appreciation of key issues 
relating to the lack of validated disease measures and the consequent gaps in 
knowledge and understanding, the principles of management and assessment of global 
and local disease in PsA will be presented in the early stages of this review.  
 
In this thesis clinical joint damage will be defined as the presence of a limited 
movement that is more than 20% of range, and is not related to the presence of joint 
effusion, deformities or ankyloses (Gladman, et al., 1990a; Bond, et al., 2007; 
Cresswell, et al., 2011; Gladman, et al., 2011). A clinically active joint will be defined 
as either tender (presence of stress pain and/or joint line tenderness) or swollen (joint 
swelling with or without tenderness) (Cresswell, et al., 2011). 
 
A narrative literature review was undertaken instead of a systematic review in light of 
the limited research available on foot-specific assessment and management in PsA. 
Historically PsA has been under-researched and to date there has been a lack of 
research focused on localised disease in the foot. A recently published narrative review 
with expert commentary on foot involvement in PsA supports the necessity for a non-
systematic approach taken by podiatry-led PsA research teams (Patience, et al., 2018). 
Whilst the scope of the literature review may be limited by few, small-scale 
investigations, it highlights that the foot and ankle remains a neglected area in PsA and 
provides strong justification for the research planned in this thesis. The aim of the 
narrative literature review was to provide detailed insight into the most relevant and 
important aspects of PsA-specific foot involvement using the limited research 
available, whilst accounting for the biases associated with small-scale studies.   
 
2.2 Background to Psoriatic Arthritis  
PsA is a chronic inflammatory musculoskeletal disease associated with psoriasis 
(Taylor, et al., 2006) and is characterized by a wide clinical spectrum and a variable 
disease course (Gladman, et al., 2005). The heterogeneous clinical manifestations 
include axial and peripheral arthritis, enthesitis, tendinopathy, dactylitis, and psoriatic 
skin and nail disease. In addition, PsA is associated with a higher prevalence of 
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cardiovascular disease (Han, et al., 2006; Tam, et al., 2008; Gladman, et al., 2009; 
Jamnitski, et al., 2013), obesity and type 2 diabetes than the general population 
(Horreau, et al., 2013; Russolillo, et al., 2013; Husni, 2015), attributed to accelerated 
atherosclerosis from chronic systemic inflammation (Eder, et al., 2013). Typically 
affecting young adults of working age between 30 to 50 (Gladman and Chandran, 
2011), PsA incurs a significant socioeconomic burden with high levels of 
unemployment (25-50%) and work disability (16-39%)  (Tillett, et al., 2012; Tillett, et 
al., 2015b). PsA can have a broad and profound impact on quality of life (Husted, et 
al., 2001; Strand, et al., 2012), comparable to that experienced in other inflammatory 
conditions (Husted, et al., 2001; Mease, 2009). Although the direct and indirect costs 
of PsA are considered to be substantial (Ackermann and Kavanaugh, 2008; Lee, et al., 
2010; Cortesi, et al., 2012), no Australian or New Zealand data exist characterising the 
healthcare costs for PsA and limited studies from other countries have unknown 
applicability to the local health system context. 
 
PsA is now recognised as a unique disease entity that is different from other forms of 
chronic inflammatory arthritis, in relation to clinical manifestations, pathogenesis, 
response to treatment and prognosis (O'Neill and Silman, 1994; Helliwell and Taylor, 
2005; Olivieri, et al., 2015). There have been variable estimates of prevalence of PsA 
owing to historical differences in classification criteria applied (McHugh, 2015). In 
2006, classification criteria for PsA (CASPAR) was developed and is now the most 
widely used criteria in randomised controlled trials and longitudinal observational 
studies (Ogdie and Weiss, 2015). Current prevalence estimates of PsA range from 
0.16% to 0.35% in the general population (Gelfand, et al., 2005; Gladman, et al., 2005; 
Haroon, et al., 2013a; Löfvendahl, et al., 2014) and between 20% to 30% among 
people with psoriasis (Prey, et al., 2010), with the incidence of PsA being equal in men 
and women. An accurate indication of the incidence and prevalence of PsA in Australia 
and New Zealand from pooled data is not available (Alinaghi, et al., 2019), with one 
observational study from Australia reporting an 8.7% estimated prevalence of PsA 
among 453 people with psoriasis (Spelman, et al., 2015). Skin involvement precedes 
the development of arthritis in 60-80% of cases (Tillett, et al., 2017a) and around 30% 
of people with psoriasis will develop PsA (Mease, et al., 2013; Henes, et al., 2014). 
Although psoriasis affects quality of life, the presence of articular involvement 
produces an additional impact in PsA. People with PsA have reduced functional 
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capacity and health-related quality of life compared to people with psoriasis alone and 
healthy controls (Husted, et al., 1997; Husted, et al., 2001).  
 
The heterogeneity of clinical features and variability of the disease makes the diagnosis 
and management of PsA difficult (D’Angelo, et al., 2016; Coates and Helliwell, 2017; 
Raychaudhuri, et al., 2017). Unlike conditions such as RA, there are no diagnostic 
criteria or diagnostic markers for PsA. Major challenges recognised in previous studies 
on the management of PsA include under-diagnosis, diagnostic delays and under-
treatment (Armstrong, et al., 2013; Coates, et al., 2016a; Lebwohl, et al., 2016; 
Garrido-Cumbrera, et al., 2017). Several studies have shown that PsA is under-
diagnosed among people with psoriasis, which may be due to under-recognition of 
musculoskeletal symptoms and lack of effective screening tools (Ibrahim, et al., 2009; 
Reich, et al., 2009; Haroon, et al., 2013b; Villani, et al., 2015). An additional 
diagnostic challenge includes the 10-15% of people that develop arthritis prior to 
psoriasis, as skin involvement can help differentiate PsA from other rheumatic 
conditions (Coates and Helliwell, 2017).  
 
Historically, PsA was considered a mild and rare disease (Wright, 1956), characterized 
by fewer long-term sequelae and unlikely to progress to permanent joint damage 
(Scarpa, et al., 2008). However, in the last 20 years research has shown that PsA is 
deforming and destructive in 40% to 60% of cases with consequent functional 
impairment, decreased quality of life, psychosocial disability and increased risk of 
death compared with the general population (Gladman, 2005; Gladman, et al., 1990; 
McHugh, et al., 2003; Torre Alonso, et al., 1991). Several prospective and longitudinal 
studies have demonstrated that joint damage appears in the first years of disease onset 
(Gladman, et al., 1990b; Torre Alonso, et al., 1991; Wong, et al., 1997; Kane, et al., 
2003b; McHugh, et al., 2003; Lindqvist, et al., 2008; Geijer, et al., 2015), and that a 6 
month diagnostic delay contributes to a poorer long-term radiographic and functional 
outcome (Haroon, et al., 2015). Therefore, early diagnosis and treatment are essential, 
with the aim of preventing irreversible joint damage (D’Angelo, et al., 2016; 
Raychaudhuri, et al., 2017). Treatment of PsA has vastly improved with the 
introduction biological therapies in the last decade (D'Angelo, et al., 2012; Perrotta, et 
al., 2015; Gossec, et al., 2016), which have demonstrated a reduction in disease activity 
and radiographic progression of joint damage (Mease, et al., 2004; Mease, et al., 2005; 
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Kavanaugh, et al., 2006; Gladman, et al., 2007a; van der Heijde, et al., 2007; 
Kavanaugh, et al., 2009; Ash, et al., 2012a; Ramiro, et al., 2016).  
 
In summary, the relative paucity of scientific research in PsA contrasts with that of 
other inflammatory arthropathies due to the prior lack of 1) a validated case definition, 
2) universally accepted classification criteria, 3) recognition that it is not a benign 
condition, and 4) available drugs to alter the disease course (Helliwell and Taylor, 
2005; El Miedany, et al., 2015; Gossec, et al., 2016).  
2.3 Management of Psoriatic Arthritis 
The concept of treat-to-target is well established in RA (Grigor, et al., 2004; 
Verstappen, et al., 2007; NICE, 2009). In PsA, research evidence strongly suggests a 
link between inflammation and joint damage (both clinical and radiographical) 
(Gladman and Farewell, 1999; Bond, et al., 2007). Therefore, a target for therapy has 
been extended to the management of PsA, with the goal of achieving minimal disease 
activity or remission in order to maximise clinical improvement and minimise long 
term damage (Coates, et al., 2010; Schoels, et al., 2010; Smolen, et al., 2014; Coates, 
et al., 2015). The heterogeneity of disease manifestations and lack of validated 
outcome measures makes defining targets particularly challenging in PsA (Coates, et 
al., 2010; Coates, 2015b). Consensus exists that central to the approach of tight control 
for PsA should be the patient preference for their own target and the means to achieve 
it (Coates, et al., 2015; Mease and Coates, 2018; Van den Bosch and Coates, 2018). 
Widespread patient dissatisfaction in the management of PsA has been reported and 
associated with lack of patient and health professional disease awareness, and disparity 
between patient and health professional priorities for treatment goals (Armstrong, et 
al., 2013; Lebwohl, et al., 2016; Garrido-Cumbrera, et al., 2017). Therefore, obtaining 
the patient’s perspective and the clinician’s view has been recognised as critically 
important in the assessment and management of PsA (Betteridge, et al., 2016; 
Lebwohl, et al., 2016; Garrido-Cumbrera, et al., 2017; Orbai, et al., 2017a). 
 
In summary, active disease detected early can be treated more aggressively and 
monitored regularly, potentially leading to better patient outcomes. Patient 
involvement has been strongly advocated in the management of PsA in order to 
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identify and prioritise disease features by taking into consideration what is important 
and relevant to them. 
2.4 Psoriatic Arthritis Core Domain Set  
Treating inflammation as early as possible to minimise structural joint damage and 
functional disability has been shown to be effective in PsA (Chandran, et al., 2008; 
Coates, et al., 2015; Haroon, et al., 2015). This approach requires precise evaluation 
of disease activity, functioning and response to therapy through validated outcome 
measures (Mease, 2011). Historically, instruments developed to assess RA have been 
used in PsA with the knowledge of limitations which include disparities in 
pathophysiology, patterns of joint involvement, cutaneous manifestations, range of 
musculoskeletal features (Gladman, et al., 2005; Veale and Fearon, 2015; Coates, et 
al., 2016b), as well as differences in the impact of the diseases on health-related quality 
of life (Husted, et al., 2001; Strand, et al., 2012). The lack of validated clinical 
outcomes measures led to the development of a PsA core domain set with the purpose 
to standardise the assessment and reporting of outcomes in PsA (Orbai, et al., 2017b).  
 
In 2016, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 
(GRAPPA) and the Outcome Measures in Rheumatology (OMERACT) proposed the 
core set of 6 domains in order to identify accurate, reliable and feasible disease activity 
measures for clinical trials and daily practice (Gladman, et al., 2007b; Coates, et al., 
2014; Orbai, et al., 2017b) (Figure 2.1). It was updated from the initial 2006 PsA core 
set in order to incorporate patient involvement and advances in the field in core set 
development. Domains refer to what should be measured and instruments specify how 





Figure 2.1. Updated 2016 PsA core domain set (Orbai, et al., 2017b).  
Musculoskeletal (MSK) disease activity includes peripheral joints, enthesitis, 
dactylitis and spine symptoms; skin activity includes skin and nails; patient global is 
defined as patient-reported disease-related health status. The inner circle (core) 
includes domains that should be measured in PsA randomised controlled trials and 
longitudinal observational studies. The middle circle includes domains that are 
important but may not be feasible to assess in all randomised controlled trials and 
longitudinal observational studies. The outer circle or research agenda includes 
domains that may be important but need further study. 
 
The heterogeneity of clinical features makes measuring disease activity and disease 
impact difficult in PsA (Mease and Armstrong, 2014). Although disease-specific 
instruments for PsA have been developed and validated during the last decade 
(McKenna, et al., 2004; Mease, 2011; Gossec, et al., 2014), there is currently no 
consensus on a standardised outcome measurement set for PsA (Coates, et al., 2018). 
Indeed, great heterogeneity of outcome measures per domain exists (Palominos, et al., 
2012; Kalyoncu, et al., 2016). Whilst outcome measures commonly evaluate 
individual features or domains, it is recognised that the impact of the disease depends 
on the interaction of multiple domains (Her and Kavanaugh, 2014; Coates, 2015a). 
Lack of a PsA core outcome measurement set limits the optimal evaluation of domains 
in the core outcome set for PsA, comparability across study results and enhancement 




Patient-reported outcomes have been increasingly recognised as critical to identifying 
the full burden of disease on health and daily functioning in people with PsA 
(McKenna, et al., 2004; Gossec, et al., 2014; Tillett, et al., 2014; Tillett, et al., 2015a). 
However, there has been limited incorporation of the patient perspective in the 
development of outcome measures and disease domains in PsA (Palominos, et al., 
2012; Tillett, et al., 2014), which is essential given that discrepancies have been 
reported between the views of patients and health professionals (Dandorfer, et al., 
2012). Consequently, few patient-reported outcome measures for PsA have evidence 
of quality criteria (Højgaard, et al., 2018), described by the Consensus-based Standards 
for the Selection of Health Status Measurement Instruments (COSMIN) as validity, 
reliability and responsiveness and by the OMERACT filter as truth, discrimination and 
feasibility (Boers, et al., 1998; Mokkink, et al., 2010b). Obtaining the patient’s 
perspective on how they feel and function with respect to their disease provides a basis 
for defining what should be measured to represent comprehensively the experience of 
people with PsA and important domains of impact. Therefore, involvement of people 
with PsA in the development of outcome measures and disease domains in order to 
ensure patients concerns are appropriately assessed has been the focus of research led 
by the GRAPPA and OMERACT groups (Kirwan, et al., 2011a; Kirwan, et al., 2011b; 
de Wit, et al., 2013; Tillett, et al., 2014; Tillett, et al., 2015a).  
 
In summary, key limitations to improving the understanding of PsA and effective 
management have been due to 1) the use of generic and RA-specific outcome measures 
in PsA, 2) few validated instruments developed specifically for PsA, 3) the lack of 
standardisation of domains and instruments used, and 4) little incorporation of the 




2.5 ICF Model in Psoriatic Arthritis 
To assess the impact of disease on daily functioning, the World Health Organisation 
(WHO) International Classification of Functioning, Disability and Health (ICF) 
provides a unified language and common framework that has been widely used in 
rheumatic conditions (Stamm, et al., 2005; Stamm and Machold, 2007; Stamm, et al., 
2007a; Boonen, et al., 2010). Previous research has shown merit in linking domains of 
impact in PsA to the ICF to categorise the effect of global disease (Taylor, et al., 2010; 
Gudu, et al., 2017). The components that are addressed in the ICF framework include 
1) body functions and structures, 2) activity and participation, 3) environmental factors 
and 4) personal factors (Figure 2.2).  
 
Figure 2.2. The International Classification of Functioning, Disability and Health 
(ICF) framework by the World Health Organisation (WHO, 2001). 
 
As an internationally accepted conceptual model, the ICF has become the reference 
model for the conceptualisation of OMERACT domains addressing aspects of 
functioning and disability (Stucki, et al., 2007). OMERACT groups involved in the 
development of OMERACT Core Sets have used ICF Core Sets as a basis to specify 
disease domains and to appraise instruments that measure the OMERACT domains 
(Stucki, et al., 2007). ICF Core Sets are selections of ICF categories necessary to 
describe the influence of the disease on functioning and provide an overview of the 
effect of the disease (Boonen, et al., 2009a). An ICF Core Set integrates the 
perspectives of patients, clinicians and researchers as well as expert knowledge and 
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evidence (Stucki, et al., 2007; Boonen, et al., 2009a). Qualitative methods have been 
used to explore the patient and clinician perspective in order to identify relevant 
concepts, which can be mapped to the ICF classification for integration of these 
perspectives in the assessment of the disease.  
 
Whilst ICF Core Sets have been developed for other rheumatic diseases (Stucki, et al., 
2004; Boonen, et al., 2010), the PsA ICF Core Set remains in an advanced stage of 
development (Stucki, et al., 2007; Boonen, et al., 2009a). This represents a gap in the 
literature concerning all relevant aspects of functioning and impact of PsA (Taylor, 
2012). Furthermore, the ICF has been used in previous research to determine that 
concepts derived from patients in qualitative studies are not adequately covered by 
patient-reported outcome measures used in PsA (Stamm, et al., 2007b). Therefore, 
standard instruments that assess impact on functioning in PsA encompass a limited 
part of the full spectrum of consequences of PsA on global functioning and do not 
satisfy the truth component of the OMERACT filter that comprises content, face and 
construct validity. 
 
In summary, the ICF has facilitated the OMERACT process of defining what to 
measure and how to measure, and has provided a way to study the truth component of 
the OMERACT filter. This work has reinforced the importance of patient and clinician 
involvement as a central component of research design in PsA. However, there are 
gaps in current knowledge on the typical impact of PsA with no established ICF Core 
Set.  
2.6 Psoriatic Arthritis Foot-Specific Outcome Measures  
The GRAPPA-OMERACT PsA core domain set has influenced recommendations for 
management and the use of validated disease-specific outcome measures (Figure 2.3). 
Whilst there are useful overarching principles for the management of PsA and broad 
recommendations for how to measure global disease activity and its impact, 
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Figure 2.3. PsA core domain set aligned with the recommended outcome measures and management guidelines for global disease and localised 
foot disease. 
Adapted from Gossec, et al., 2016 and Leung, et al., 2018. DIPJs Distal interphalangeal joints, DMARDs Disease-modifying anti-rheumatic drugs, 
IA Intra-articular injection, NRS Numerical rating scale, NSAIDS Non-steroidal anti-inflammatories, physio Physiotherapy, PROMs Patient-
reported outcome measures, PsA Psoriatic arthritis, PUVA Psoralens ultraviolet A therapy, UVB Ultraviolet B therapy, VAS Visual analogue scale.
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In the absence of a validated disease- and foot region-specific outcome measure to 
assess the impact of localised disease in the foot in PsA, the Leeds Foot Impact Scale 
in Rheumatoid arthritis (LFIS-RA) (Helliwell, et al., 2005a) has been used in previous 
foot-specific studies (Hyslop, et al., 2010a; Hyslop, et al., 2010b; Woodburn, et al., 
2013; Wilkins, et al., 2016). However, the LFIS is an RA disease-specific outcome 
measure unlikely to capture both the musculoskeletal and dermatological impact in 
PsA and with limited incorporation of the patient perspective. It has been suggested 
that researchers and clinicians looking for instruments should first identify an outcome 
according to the concepts relevant to people with PsA and then select an instrument 
that covers the identified outcome (Stamm, et al., 2007b). However, concepts 
important and relevant to people with PsA-related foot involvement have not been 
explored in order to inform on localised disease impact and the measurement of 
relevant outcomes. Previous studies have assessed the perspectives of patients 
regarding the whole effect of PsA (Taylor, et al., 2010; Gossec, et al., 2014; Orbai, et 
al., 2017a), but the region-specific impact of foot involvement in PsA is still largely 
unknown. 
 
The ‘window of opportunity’ paradigm in podiatry advocates the use of the LFIS-RA 
for localised disease monitoring with the aim of preventing irreversible joint damage 
in the foot affected by RA (Helliwell, et al., 2005a; Woodburn, et al., 2010). Definitive 
strategies to attain suppression of localised inflammation in the foot and maintain 
optimal functionality are limited with no validated foot-specific outcome measures to 
define ‘tight control’ or to determine the typical impacts of local disease on daily 
functioning. Currently there is limited evidence to support the management of PsA-
specific foot problems (Patience, et al., 2018). Expert-led recommendations for PsA 
advocate the integration of podiatry within rheumatology multidisciplinary teams for 
rapid access to specialist foot care (Coates and Helliwell, 2017; Patience, et al., 2018). 
To better target and treat inflammation present in the foot it is important that the impact 
of local disease activity is better understood. 
 
In summary, our understanding of the localised foot disease impact in PsA is limited 
because the concepts important and relevant to people with PsA-related foot 
involvement have not been explored. Consequently, there is no validated foot-specific 
outcome measure to assess the impact of foot problems in PsA on functioning and 
17 
 
health. Further research to determine a patient-centred perspective on the burden of 
local foot disease and its impact on daily life in PsA is required. 
2.7 Disease Pathogenesis  
The pathogenesis of PsA is largely unknown (Sakkas, et al., 2013), but enthesitis 
(inflammation at tendon, ligament, joint capsule or fascia insertion sites to bone) is 
regarded as pathognomonic and a hallmark feature of PsA (Moll and Wright, 1973; 
Benjamin and McGonagle, 2001; Ritchlin, 2005; Aydin, et al., 2013). Not all entheses 
are targeted equally in PsA with the entheses typically involved being those subject to 
mechanical trauma (Benjamin and McGonagle, 2001). Emerging evidence from 
imaging, histological and genetic studies suggests that micro-damage triggered by high 
mechanical stress at entheses is central to the new anatomical model of disease 
pathogenesis in PsA (Benjamin and McGonagle, 2001; McGonagle, et al., 2001). This 
model supports the observation that PsA may be associated with a preceding joint 
injury (Scarpa, et al., 1992; Punzi, et al., 1997; Pattison, et al., 2008) and that micro-
damage or trauma to the skin is known to be a factor in expression of psoriasis, an 
example of Koebner response phenomenon (McGonagle, et al., 2008a). Koebner 
responses may also contribute to nail involvement in PsA (McGonagle, et al., 2009).  
 
Enthesitis has been proposed as the primary lesion in PsA that triggers secondary 
synovitis of the various structures (joint, tendon and bursa) through the release of pro-
inflammatory mediators from the inflamed entheses (McGonagle, et al., 1998; 
McGonagle, et al., 1999a). Enthesitis has been suggested as the anatomical basis for 
psoriatic nail disease and dactylitis (McGonagle, et al., 1999a; Aydin, et al., 2012). 
The association between dactylitis and distal interphalangeal joint arthritis, as well as 
the direct link between the nail unit and the distal interphalangeal joint via the 
entheseal unit of the distal interphalangeal extensor tendon, support the link between 
enthesitis, dactylitis, and psoriatic nail disease (Jones, et al., 1994; Williamson, et al., 
2004; Tan, et al., 2007; McGonagle, et al., 2009; Ash, et al., 2012b; Raposo and Torres, 
2015; Lai, et al., 2016). Consequently, people with psoriatic nail disease should be 






2.7.1 Enthesitis  
The reported prevalence of enthesitis is between 25% to 78% of cases (Frediani, et al., 
2002; Kane, et al., 2003a; Kane, et al., 2003b; Michet, et al., 2005; Helliwell, et al., 
2007; Kavanaugh, et al., 2009; Gladman and Chandran, 2011; Queiro, et al., 2011; 
Bandinelli, et al., 2013a), with the wide variation in part explained by the use of varied 
definitions, different methods of clinical, radiographic and ultrasound examination, 
and the different populations studied (Ogdie and Weiss, 2015). Enthesitis may be 
painful and disabling (D'Agostino and Olivieri, 2006) or asymptomatic and only 
revealed by imaging techniques (Lehtinen, et al., 1994; Balint, et al., 2002). Therefore, 
the clinical assessment of enthesitis is challenging because these structures are not 
often visibly inflamed and they can be located deep within surrounding tissue making 
it difficult to be precise (Ritchlin, 2006). Enthesitis consists of focal destructive, 
microscopic inflammatory lesions that progress to fibrous scarring and new bone 
formation (Benjamin and McGonagle, 2007). The presence of enthesitis is an adverse 
prognostic factor and is associated with elevated disease activity, self-reported pain, 
poorer functional status and greater overall disease burden compared to those without 
enthesitis (Mease, et al., 2017). 
 
Inflammation may occur at any entheses, but those of the lower extremities are 
involved more frequently than those of the upper limbs (D'Agostino, et al., 2003). 
Research evidence suggests that there are localised features associated with the classic, 
functional and digital entheses that may explain the predominance of inflammation in 
the foot in PsA (Benjamin, et al., 1995; Benjamin and Ralphs, 1997; Benjamin and 
McGonagle, 2001; McGonagle, 2009). The Achilles tendon insertion has been 
identified in the literature as the best example of a classic enthesis (Benjamin, et al., 
2006). Digital entheses include those where tendons or ligaments replace a joint 
capsule around a synovial joint (Benjamin and McGonagle, 2001), and functional 
entheses occur at sites where tendons wrap closely around bony pulleys (tibialis 
posterior and peroneal tendons)  (Benjamin and McGonagle, 2001).  
 
The main research focus on entheseal involvement of the lower limbs has been at the 
Achilles tendon and plantar fascia insertion (Balint, et al., 2002; D'Agostino, et al., 
2003; Mease, 2011). These entheses have been favoured not only due to the frequency 
of clinical involvement of PsA (D'Agostino, et al., 2003), but also because the Achilles 
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tendon is considered the archetypical enthesis (Benjamin, et al., 2006). The relatively 
large size and superficial location beneath the skin of the Achilles tendon makes it 
most suitable for study (Balint and Sturrock, 2000; McGonagle, et al., 2008b). 
However, previous studies in PsA have demonstrated tenosynovitis of the tibialis 
posterior tendon (Galluzzo, et al., 2000; Hyslop, et al., 2010a) and peroneal tendons 
(Harman and Tekeoğlu, 2017) in one third of participants. Based on the fundamental 
principles from the work of McGonagle, Benjamin and colleagues that link localised 
anatomical features to disease pathogenesis, many of the entheses sites in the foot 
should be prime sites for disease localisation in PsA (Benjamin, et al., 1995; Benjamin 
and Ralphs, 1997; Benjamin and McGonagle, 2001). However, in the PsA literature 
the functional and digital entheses in the foot are under-reported. In addition, the 
omission of many anatomical sites in the foot and ankle from standard clinical 
enthesitis indices (Mander, et al., 1987; Heuft-Dorenbosch, et al., 2003; Healy and 
Helliwell, 2008; Maksymowych, et al., 2009), may lead to active disease in the foot 
being missed along with the opportunity to prevent progression of PsA. 
 
In summary, whilst there is a wealth of literature on inflammatory features at the 
Achilles tendon and plantar fascia insertion in people with PsA, involvement of other 
sites in the foot are under-reported and less well understood. Few studies have 
examined a PsA-specific population and with limited focus on a comprehensive 
assessment of the foot in PsA. As a result, the prevalence and extent of enthesitis in 
the foot and ankle in PsA is largely unknown. 
2.7.2 Predominant and Persistent Inflammation in the Foot and Lower Limb 
The two main themes established throughout the literature that describe inflammatory 
involvement in PsA are 1) an established higher lower limb involvement, and 2) the 
persistence of localised disease activity that is largely independent of global disease. 
Inflammation of specific sites in the foot and lower limbs has been shown to be more 
common than in the upper limbs (Lehtinen, et al., 1994; Olivieri, et al., 1998; 
McGonagle, et al., 1999b; Balint, et al., 2002; D'Agostino, et al., 2003), with the 
Achilles tendon and plantar fascia insertion being the most frequently affected sites 
(Balint, et al., 2002; D'Agostino, et al., 2003). The high levels of micro-trauma at sites 
vulnerable to mechanical stress has been suggested to explain the greater involvement 




Despite intensive pharmacological management, imaging studies have shown that 
inflammation is detectable in the foot in a high proportion of people with PsA (n=26, 
83.9%, and n=77, 76.2% respectively) (Galluzzo, et al., 2000; Delle Sedie, et al., 
2011). This has been shown to poorly correlate with systemic parameters of disease 
activity and to be independent of disease duration (Hyslop, et al., 2010a). As disease 
activity in the foot has been linked to subsequent clinical joint damage (Cresswell, et 
al., 2011), early identification of foot involvement in PsA is of clinical importance. 
Clinical joint damage is a marker of severity and is associated with, and a predictor of, 
loss of function and mortality (Gladman, et al., 1998; Husted, et al., 2007; Leung, et 
al., 2008; Ravindran, et al., 2010). Therefore, limitations to our understanding of the 
localised disease impact in PsA has important prognostic implications for patient 
outcomes.  
 
In summary, the overarching concept from the literature to understand these findings 
is the indication that localised foot anatomy and biomechanics have an important role 
in disease pathogenesis in PsA. In order to better target and treat inflammation present 
in the foot, identification of the exact sites of inflammation in the foot is essential. 
2.7.3 Foot Function in Psoriatic Arthritis 
Few previous studies have investigated the biomechanics of the foot and ankle in PsA 
(Hyslop, et al., 2010b; Castro, 2013; Woodburn, et al., 2013; Turner, et al., 2014; 
Wilkins, et al., 2016). These studies had small sample sizes, were largely based on 
established disease, and focused on specific anatomical sites, including the Achilles 
tendon (Woodburn, et al., 2013), metatarsophalangeal joints (Turner, et al., 2014), and 
the toes (Wilkins, et al., 2016). Despite some existing information that demonstrates 
adapted gait patterns in PsA, a detailed description of the impact of foot-related 
functional impairment and disability is lacking.  
 
Conversely, the gait patterns and dynamic function of the foot and ankle among people 
with RA have been extensively measured (Baan, et al., 2012). In RA, these insights 
have led to paradigmatic changes in therapeutic approaches (Woodburn, et al., 2010). 
The non-pharmacological management of people with RA-related foot problems is 
effective at reducing foot pain and improving/maintaining foot function and mobility 
(Farrow, et al., 2005; Gossec, et al., 2006; Woodburn, et al., 2010; Hennessy, et al., 
2012). There are no guidelines or recommendations currently available on therapeutic 
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targets or effective interventions for the foot in PsA, and with distinctly different 
clinical features and pathogenesis these treatment approaches are unlikely to be 
directly transferable. Inflammatory changes in the foot in RA have been shown to lead 
to altered joint mechanics and increased plantar pressure (Van Der Leeden, et al., 
2010). However, two studies of PsA have shown that plantar pressures do not correlate 
with joint damage and pain (Turner, et al., 2014; Wilkins, et al., 2016). This suggests 
that a different interaction between inflammatory and mechanical factors may exist in 
PsA, and indicates that models of joint pain may be disease- and site-specific (Turner, 
et al., 2014). These inferences should be interpreted with caution as they are based on 
small sample sizes that increase the risk of error from inadequate power (34 and 24 
participants with PsA respectively), and on cross-sectional data sets that cannot 
determine causal relationships (Turner, et al., 2014; Wilkins, et al., 2016). Therefore, 
these interpretations represent an explanatory model of peripheral joint pain in PsA, 
limited by the lack of research in this specific area. 
 
In summary, our understanding of foot function in PsA is largely limited due to the 
lack of a comprehensive description of the impact of localised disease in the foot on 
functioning in PsA. Due to this, foot specific treat-to-target strategies have not yet been 
determined in the foot in PsA. Prior to the evaluation of interventions, a better 
understanding of foot-related function impairment and disability is indicated. 
2.8 Foot Involvement  
Despite recognition that typical features of PsA such as peripheral arthritis, dactylitis, 
enthesitis, tendinopathy, and skin and nail psoriasis, are predominant and persistent in 
the foot and ankle (Galluzzo, et al., 2000; Healy, et al., 2008; Hyslop, et al., 2010a; 
Delle Sedie, et al., 2011), limited research has focused on the foot. Few previous 
studies with small sample sizes have described the structural and functional changes 
in the foot affected by PsA (Galluzzo, et al., 2000; Bezza, et al., 2004; Hyslop, et al., 
2010a; Hyslop, et al., 2010b; Delle Sedie, et al., 2011; Woodburn, et al., 2013; Turner, 
et al., 2014; Wilkins, et al., 2016; Patience, et al., 2018) (Table 2.1). Whilst these 
studies provide useful early insights into foot involvement in PsA, the details of how 
foot problems impact on the lives of people with PsA, their experiences with footwear 




A cross-sectional survey of subjective health complaints in people with PsA found that 
pain in the feet was the fourth most prevalent single complaint (71.7%, n=264.6), 
behind tiredness, arm pain and lower back pain (Nordbø, et al., 2017). This suggests 
that, for a large proportion of people with PsA, foot involvement may be the major 
characteristic feature of their disease. The first large study to report on the clinical 
manifestations of foot involvement in PsA was a single cross-sectional survey of 104 
patients conducted in the UK (Hyslop, et al., 2010a). Disabling foot pain was reported 
in approximately two-thirds of people with PsA (62%, n=64), which is similar to that 
reported in RA (Hyslop, et al., 2010a). The main clinical findings showed that forefoot 
deformity (95%) was more frequent than rearfoot deformity (65%). Dactylitis was 
found in nearly one quarter of cases (24%), and skin psoriasis and nail involvement 
was found in 8% and 13% of cases, respectively (Hyslop, et al., 2010a). Hyslop et al 
(2010a) recorded a high frequency of enthesitis, most commonly found at the insertion 
of tibialis posterior tendon (34%), followed by the plantar fascia (26%), and the 
Achilles tendon (18%). Clinical examination of the peroneal, extensor and other flexor 
tendons were not reported in this study. Findings from this previous study may lack 
external validity as participants were recruited from one large teaching hospital 
regarded as a centre of excellence, and may not be a true representation of foot-related 
impairments experienced in different parts of the UK or in different countries.
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Table 2.1. A summary of current knowledge from studies focusing on foot involvement in a psoriatic arthritis-specific population. 








Foot Site Studied Method Significance 





26 Not stated - Foot, ankle Review of 
medical records 
between 1972 and 
1999 
Clinical and radiographic 
features of PsA-related foot 
involvement were common 
(most frequently in the rearfoot 
in 53% of cases) and occurred 
early in the course of disease 
Delle Sedie, et al., 
(2011) 
Italy  




- Joints: Talo-navicular, 
calcaneo-cuboid, 
navicular-cuneiform, 





halluces, extensor and 
flexor tendons, 
peroneus longus and 





US imaging (grey 
scale and power 
Doppler) 
Active foot disease (synovial 
hypertrophy, effusion) was 
identified with twice the 
frequency of clinical 
examination techniques (n=77, 
76.2%)  






















Joint: Ankle joint 
 
Soft tissues: Achilles 
tendon, retro-calcaneal 
bursa, calcaneal bursa, 
plantar fascia, tibialis 
posterior, flexor 
digitorum and peroneus 






US imaging (grey 
scale) 
Active foot disease persists in a 
large proportion of people with 
PsA (n=26, 83.9%). Clinical 
examination underestimates the 




Hyslop, et al., 
(2010a) 
UK 
Cross-sectional 104 10 (mean) LFIS-RA 
VAS 





Soft tissue: Achilles 
tendon, plantar fascia 




Clinically important levels of 
foot-related impairment and 
disability were identified in 
those with localised 
inflammatory features in the 
foot affected by PsA 










13 (mean) LFIS-RA 
VAS 
Foot joint count 
(0-14) 













Development of a multi-
segmented foot model to assess 
foot function in PsA. Excellent 
within-day reliability was 
found. Between-day reliability 
varied depending on the 
segments and kinematic 
variables studied, suggesting 
those variables should not be 
used in the analysis of foot 
function in PsA 





- - - - Literature review 
with expert 
commentary 
Highlights the manifestations 
of PsA in the foot and the need 
for foot-specific management 
strategies 












US imaging (grey 






MTPJ pain in PsA was 
independently predicted by 
high BMI, female gender, the 
presence of local inflammation 
(US-proven synovitis, erosion) 
and structural factors (joint 
subluxation). No significant 
evidence was found linking 
plantar pressure and MTPJ 
pain, which suggests models of 
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joint pain may be disease and 
joint specific 














(Most common (4th 
toe) and second most 
common (2nd toe) 













No significant evidence was 
found linking plantar forefoot 
pressures and the prevalence of 
toe dactylitis, suggesting that 
examining plantar pressure 
alone provides limited 
understanding of toe dactylitis 







10.6 (mean) ESR, CRP 
LFIS-RA 
VAS 
Joints: Ankle joint, 














US imaging (grey 
scale and power 
Doppler) 
Adapted gait patterns (reduced 
walking speed, lower Achilles 
tendon force) were identified 
among those with PsA and 
Achilles enthesitis, which were 
distinguishable from the 
healthy control and PsA 
participants without Achilles 
enthesitis This suggests a link 
between local inflammatory 
features in the foot and global 
functional adaptations 
CRP C-reactive protein, ESR Erythrocyte sedimentation rate, EQ-5D EuroQol five-dimensions, HAQ Health Assessment Questionnaire, LFIS-RA 
Leeds Foot Impact Scale in Rheumatoid Arthritis, MTPJs Metatarsophalangeal joints, PIPJs Proximal interphalangeal joints, PsA Psoriatic arthritis, 




The prevalence of enthesitis in the foot varies notably across studies (Figure 2.4). 
Contributory factors may be the wide variability observed among studies in the 
definition of enthesitis, lack of standardisation of the number and location of entheses 
examined, and the absence of a consensus on technical parameters and methods of 
examination including ultrasound and clinical assessment (Gandjbakhch, et al., 2011). 
Some authors might designate as “inflammatory enthesitis” conditions designated 
“tendonitis” by others (Gandjbakhch, et al., 2011). This highlights the possible 
misreporting of digital and functional enthesitis as tendon rather than entheseal 
abnormalities. Although the concept of digital and functional entheses are well 
recognised in the anatomy literature, it does not seem to have transferred to 
















Figure 2.4. Diagram to show the prevalence of foot entheses.  
1Galluzzo, et al. 2000; 2Falsetti, et al. 2003; 3D’Agostino, et al. 2003; 4Hyslop, et al. 
2010; 5Delle Sedie, et al. 2011; 6Harman, et al. 2017. 
 
Figure 2.4. shows the prevalence at each site taken from published data on the specific 
assessment of the foot in PsA. The majority of prevalence estimates of enthesitis in the 
foot were derived from ultrasound imaging studies, as clinical examination has been 
= Functional enthesis 
= Classic enthesis 
= Digital enthesis  
Plantar fascia  
enthesitis 
Flexor tendon enthesitis 





















No specific data 
available 
No specific data 
available 
No specific data available 
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shown to lack the sensitivity and specificity of ultrasound to detect active disease in 
PsA. Lack of reliability in clinical foot examination further limits our understanding 
of foot involvement in PsA, which is covered in more detail in section 2.9 and 2.10. 
 
Skin manifestations in the feet have been described in few expert review articles, with 
psoriatic plaques found often on the dorsum of the foot and palmoplantar psoriasis 
accounting for relatively few cases (3-4%) (Engin, et al., 2017; Patience, et al., 2018). 
Nail disease in PsA has a reported incidence of about 66% (Sandre and Rohekar, 
2014), most commonly onycholysis and nail pitting, which have been found to predict 
the development of PsA (Wilson, et al., 2009). Nail disease is associated with pain, 
function loss, disfigurement and psychological distress (de Jong, et al., 1996). Despite 
the recognized significance of nail disease, it is often overlooked and under-treated (de 
Jong, et al., 1996; Williamson, et al., 2004). This is particularly the case in the feet, 
with most studies of nail disease omitting toenails and focusing only on fingernails 
(Brazzelli, et al., 2012). On clinical assessment it is difficult to differentiate fungal 
infections that mimic the presentation of nail psoriasis (Essayed, et al., 2015; Patience, 
et al., 2018), and few scoring systems used to assess the extent of nail disease have 
been validated in PsA (Rich and Scher, 2003). Importantly, there is a dearth of research 
on the extent and impact of foot-specific dermatological manifestations from the 
patient perspective.  
 
Dactylitis (uniform swelling of an entire digit, also referred to as sausage digit) is a 
hallmark feature of PsA that can be tender or non-tender (Healy and Helliwell, 2006) 
and comprises tenosynovitis, synovitis and enthesitis (Bakewell, et al., 2013). 
Dactylitis occurs in 32-48% of people with PsA (Brockbank, et al., 2005; Gladman 
and Chandran, 2011; Kavanaugh and Mease, 2012; Gladman, et al., 2013), is 
associated with impaired function and is a marker of disease severity, with 
significantly greater joint damage occurring in dactylic than non-dactylic digits 
(Brockbank, et al., 2005; Geijer, et al., 2015). One cross-sectional study of 259 people 
with PsA in Canada found that toe dactylitis was more common compared with finger 
dactylitis (78% and 34% respectively) (Brockbank, et al., 2005), which may support 
the proposed mechanical pathogenesis given the load bearing function of the toes 
(Wilkins, et al., 2016). However, few studies have investigated the specific prevalence 
and impact of toe dactylitis in a PsA-specific population (Olivieri, et al., 1997; Kane, 
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et al., 1999; Brockbank, et al., 2005; Healy, et al., 2008; Payet, et al., 2012; Wilkins, 
et al., 2016). Dactylitis is often the inaugural feature of PsA and is considered one of 
the most discriminatory PsA manifestations (Gladman and Chandran, 2011; Caso, et 
al., 2014). However, clinical detection of dactylitis can be difficult and is often 
misdiagnosed in early or mild disease (Chandran and Maharaj, 2016). The small 
dimensions of the structures being evaluated, clinical and pathological heterogeneity, 
variation in imaging technology and methodology, prior lack of a standardized 
definition and diverse study design preclude understanding of the natural history of 
dactylitis in PsA (Healy and Helliwell, 2006; Kaeley, et al., 2018). 
 
Peripheral arthritis in PsA can be variable including oligoarticular and polyarticular 
disease that may be symmetric or asymmetric. Involvement of the distal and proximal 
interphalangeal joints in the foot is a common and distinguishing feature (Patience, et 
al., 2018), and synovitis of the metatarsophalangeal joints was found in 14% of people 
with PsA (Turner, et al., 2014). Forefoot structural damage and pain are common in 
people with PsA (Ghanem, et al., 2007; Delle Sedie, et al., 2011). In RA, higher levels 
of foot-related disability were found in people with rearfoot deformity than those with 
forefoot deformity, which may represent differences in the ability for functional 
adaptation for pain and structural impairments (Turner and Woodburn, 2008). This 
finding in RA should be interpreted with caution due to the study’s small sample size 
(28 participants with RA), lack of inferential statistical analysis and requirement for 
external validation of conclusions. The majority of studies reporting gait 
characteristics associated with inflammatory arthritis relate to RA, which will facilitate 
future pooling of results and meta-analyses (Carroll, et al., 2015). Conversely, the 
impact of region-specific foot involvement on people with PsA is not known with 
limited evidence of foot function relating to PsA. 
 
In summary, there is a lack of evidence defining the nature and extent of foot 
involvement in a PsA-specific population. Limitations to our understanding of foot 
involvement in PsA are due to few studies having focused on the clinical 
manifestations of PsA in the feet and insights into the full impact of foot disease have 
not been explored from the patient perspective.  
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2.9 Imaging of the Foot in Psoriatic Arthritis 
While plain radiographs can demonstrate established bony erosions and spurs in PsA, 
they provide minimal information regarding soft tissue structures, especially in the 
early stages of the disease (Wiell, et al., 2007). Developments in imaging techniques, 
such as magnetic resonance and ultrasonography have enabled detailed description of 
localised inflammatory features in PsA. Ultrasound is more sensitive and specific to 
the detection of active disease in PsA compared with clinical examination (Wiell, et 
al., 2007; Weiner, et al., 2008) and other imaging techniques such as radiography and 
magnetic resonance imaging (Kane, et al., 2003b; De Simone, et al., 2011; Coates, et 
al., 2012b; Bakewell, et al., 2013).  It also has proven value in establishing a diagnosis, 
evaluating disease activity, and has been widely applied to both clinical care and 
research of PsA (Delle Sedie and Riente, 2015). 
 
Despite advances in ultrasound, few studies have evaluated foot involvement in PsA 
using this imaging technique (Galluzzo, et al., 2000; Balint, et al., 2002; Falsetti, et al., 
2003; Wiell, et al., 2007; Weiner, et al., 2008; Delle Sedie, et al., 2011). The limitations 
of our understanding of ultrasound-detected inflammatory features in the foot in PsA 
can be attributed to studies 1) not using PsA-specific populations (Kaeley, 2011), 2) 
using different definitions of enthesitis and different sets of examined structures 
(Gandjbakhch, et al., 2011; Delle Sedie and Riente, 2015), 3) using ultrasound scoring 
systems that have not been validated for use in PsA (Her and Kavanaugh, 2014), and 
4) lacking standardisation of image acquisition and scoring (Coates, et al., 2012b).  
 
Previous ultrasound studies assessing the foot in PsA have focused on a limited 
number of structures commonly targeted by inflammation, as guided by the literature. 
The technical difficulty in accessing relatively small structures in the foot using 
ultrasound has been attributed to the low prevalence of tenosynovitis and enthesitis in 
one study (Delle Sedie, et al., 2011), and may explain why these structures are omitted 
from evaluation by most studies. There is no general agreement on which joints, 
tendons or entheses to include in the evaluation of PsA (Poggenborg, et al., 2011).  
 
In PsA, studies have combined the assessment of gait metrics with ultrasound imaging 
to detect local inflammatory disease in the foot (Hyslop, et al., 2010b; Woodburn, et 
al., 2013; Turner, et al., 2014). Although these previous studies are an important first 
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step in understanding some of the biomechanical and local inflammatory features 
associated with foot function impairment in PsA, further research is warranted to 
provide a more detailed investigation into these relationships.   
 
In summary, despite the presence of some published ultrasound studies examining the 
foot, there has been limited focus on a full and comprehensive ultrasound assessment 
of the peripheral joints, tendons and entheses in a PsA-specific population. The need 
exists to explore the specific distribution of foot involvement in people with PsA in 
order to determine site-specific involvement. 
2.10 Clinical Assessment of the Foot in Psoriatic Arthritis 
No guidelines exist for foot assessment in PsA. Most PsA disease activity measures 
are composite indices reliant upon clinical examination of inflammation in localised 
joints (Coates, 2015a). Previous use of the reduced 28-joint count in RA grossly 
underestimated the disease burden in PsA due to the omission of distal interphalangeal 
joint involvement shown to be characteristic of PsA (Gladman, 1998; Weishaupt, et 
al., 1999; Kane, et al., 2003a). Evidence-driven recommendations state that the full 
66–68 joint count be used routinely to assess people with PsA, as significant 
proportions of active disease can be missed in the feet and hands (Coates, et al., 2013). 
This may explain the persistence of active inflammation in the foot and ankle, which 
in turn would allow undetected and unsuppressed inflammation in the foot to progress 
in those classified in global remission or low disease activity, who are thus prescribed 
less intensive pharmacological treatments. 
 
In RA, high levels of agreement were detected between self-report and clinical 
examination for many foot problems, suggesting self-report can be utilised with a high 
degree of confidence (Wilson, et al., 2015). However, the heterogeneity of clinical 
symptoms in PsA is a major challenge in the assessment and evaluation of the disease 
(Gladman, et al., 2010), and as a result clinical examination has been shown to be 
unreliable (Balint, et al., 2002; D'Agostino, et al., 2003). In the foot specifically, this 
may be a consequence of 1) poor ability to detect different anatomical structures that 
are in close proximity, 2) patients reporting pain from other causes such as mechanical 
injury, 3) the presence of subclinical inflammation where there are no overt symptoms 
or signs, and 4) misinterpretation of swelling by the clinical assessor. Poor 
31 
 
concordance between tenderness at entheseal insertions and objective evidence using 
imaging has also been highlighted in the PsA literature (Freeston, et al., 2014; Perrotta, 
et al., 2016). Previous cross-sectional studies have found normal ultrasound images in 
symptomatic entheses with a dissociation between sensitivity to local pressure and 
ultrasound findings (Freeston, et al., 2014; Perrotta, et al., 2016). The reported 
discrepancy may be in part due to the fact that clinical examination and ultrasound 
measure different findings. Ultrasound cannot demonstrate osteitis that may cause 
tenderness at the enthesis, other factors such as an associated higher sensitivity to pain 
may also explain these findings (Perrotta, et al., 2016). The accurate assessment of 
disease activity in PsA is challenging but fundamental to effective treatment strategies 
such as early detection and treat-to-target. Therefore, it is important to determine 
whether the common methods used to establish foot involvement in PsA can provide 
accurate information. 
 
Research evidence in RA shows that feet are often neglected areas for assessment in 
clinical rheumatology practice (Williams and Graham, 2012). Contributory factors 
may include the perception that foot assessment is complicated and time-consuming 
(Galluzzo, et al., 2000; Cresswell, et al., 2011; Delle Sedie, et al., 2011), and the 
varying experience, training and confidence of rheumatologists and podiatrists in 
specialist foot assessments (Helliwell, 2003; Hitchen and Otter, 2010; Woodburn, et 
al., 2010; Hendry, et al., 2013a; Williams, et al., 2013). Although it is not known 
whether this is also the case in PsA, one UK-based study found that the majority of 
people with PsA reported foot pain but had not received professional foot care (Hyslop, 
et al., 2010a), which suggests that barriers to accessing care exist.  
 
In summary, the clinical assessment of localised disease activity has been shown to be 
unreliable in PsA and the foot is often omitted from standard clinical indices.  
2.11 Foot Involvement in Australia and New Zealand 
Previous studies have shown that foot kinematics have been influenced by footwear 
(Woodburn, et al., 2002; Zhang, et al., 2013). Whilst altered foot function related to 
different footwear features has not yet been established in PsA, footwear choice is 
influenced by local climate and sociocultural factors that are likely to be different in 




Current knowledge of the clinical manifestations in the feet is based on a few European 
studies that comprise small sample sizes. Research data from Europe is not likely to 
translate to the Australasian context due to; 1) differences in healthcare provision, with 
limited access to podiatry services in the public health system reported in Australia 
and New Zealand (Rome, et al., 2009; Hendry, et al., 2013b; Hendry, et al., 2013a), 
and 2) differences in climate and footwear choice that could affect the types of foot 
problems that occur.  
 
UK podiatry services are well embedded within rheumatology services in the public 
health system with specialised podiatry roles established (Woodburn, et al., 2010). 
There are centres of excellence in the UK and Europe with good access to specialist 
services led by rheumatologists with academic research interests in PsA. Therefore, 
the experience of foot problems and foot healthcare in patient cohorts from European 
studies may not be generalisable to Australia or New Zealand, where a distinct lack of 
podiatry services and expertise in managing rheumatic foot problems in the public 
health system have been previously described (Rome, et al., 2009; Hendry, et al., 
2013b; Hendry, et al., 2013a).  
 
With research data predominantly from European countries, the need to define the foot 
and footwear characteristics in local rheumatology populations has been recognised in 
previous studies (Silvester, et al., 2010; Rome, et al., 2011; Brenton-Rule, et al., 2014; 
Carter, et al., 2016). Footwear characteristics are important as various shoe features 
have been linked to the development of foot pain, deformity and functional impairment 
(Barton, et al., 2009; Doi, et al., 2010; Otter, et al., 2010; Riskowski, et al., 2011). 
Seasonal climate variation has been reported to influence footwear choice in people 
with rheumatic conditions (Naidoo, et al., 2011; Hendry, et al., 2013b; Brenton-Rule, 
et al., 2014; Carter, et al., 2016). Therefore, the clinical characteristics and severity of 
foot functional impairment reported in European countries may not be a true 
representation of those in other countries, due to the influence of climate-related 
footwear. It is important to note that open-type footwear such as flip-flops (known as 
thongs in Australia and jandals in New Zealand) commonly worn in Australia and New 
Zealand (Silvester, et al., 2010) are considered to lack support, cushioning and 
protection. Footwear intervention has the potential to alleviate pain, increase mobility 
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and independence  (Moncur and Ward, 1990; Fransen and Edmonds, 1997; Egan, et 
al., 2001; Farrow, et al., 2005; Williams, et al., 2007a; Cho, et al., 2009; Dahmen, et 
al., 2014), and awareness of footwear problems has the potential to improve patient 
outcomes. To date the choice of footwear, the key factors influencing footwear choice 
and the associated contribution of footwear to foot impairment (pain, deformity and 
disability), has not been reported in people with PsA. 
 
In summary, to the best of the authors’ knowledge no study has comprehensively 
investigated foot involvement related to PsA in Australia and New Zealand. There is 
a lack of locally representative data on PsA-related foot problems and there is no local 
data pertaining to footwear preferences and foot care needs of this patient group.  
 
2.12 Conclusion  
There is a known predilection for expression of persistent disease activity in the feet 
and lower limbs in those with PsA. Whilst it is generally recognised that foot 
involvement is common with PsA, there is a paucity of data to support this. Few 
European studies that comprise small sample sizes have focused on the clinical 
manifestations in the feet, but little is known about the impact of PsA on foot-specific 
structure and function, activity and participation, and environmental factors such as 
footwear and foot healthcare. To better target and treat inflammation present in the 
foot, a comprehensive understanding of the concepts important and relevant to people 
with PsA-related foot involvement is required. In line with the work undertaken by the 
GRAPPA and OMERACT, exploring the patient perspective should be central to the 
research approach, including use of the ICF classification to describe the typical 
impact of foot involvement in PsA and to help define what should be measured in the 
evaluation of foot disease burden.  
 
The premise of this research was to gain insight into, and a comprehensive 
understanding of, foot involvement and the associated impact on daily life from the 
perspective of people with PsA. Given that footwear can contribute to foot-related 
functional impairments and the lack of supportive footwear typically worn in Australia 
and New Zealand (flip-flops), it is important to explore foot problems in the local 
context in order to account for local differences in healthcare access, climate and 
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sociocultural factors that may influence footwear choice. Foot involvement in PsA 
remains under-researched and poorly understood with a lack of large-scale data needed 






























3 Theoretical framework and research focus 
The purpose of this chapter is to outline the theoretical framework for the proposed 
research, including the specific research questions and phases of the research The 
theoretical framework highlights the existing knowledge, gaps in the literature and the 





Key findings Gaps in the literature Emerging research focus
GAP: (1) limited research has 
focused on the foot in a PsA-
specific population, (2) previous 
studies have concentrated on 
specific anatomical sites of the 
foot with few providing a 
comprehensive description of foot 
and ankle characteristics in PsA, 
(3) the foot is often omitted from 
standard clinical indices used to 
measure disease activity, and (4) 
no guidelines currently exist for 















































Little is known about the 
nature, extent and location of 
foot involvement and its 
impact on people with PsA 
living in Australia and New 
Zealand. A better 
understanding of foot and 
ankle characteristics in PsA is 
required in order to provide 
insight into the full burden of 
localised disease in the foot 
from the patient perspective.
Current knowledge of 
foot involvement in 
PsA is based on 
research conducted in 
Europe
Exploring the patient 
experience of foot 
involvement in PsA 
is essential in order to 
define what to 
measure to represent 
relevant domains of 
impact and 
functioning
GAP: (1) data from few European 
studies that comprise small sample 
sizes is unlikely to translate to the 
local context, (2) lack of locally 
representative data on PsA-related 
foot problems, and (3) no data on 
local footwear preferences and 
foot care needs in PsA.
PsA is poorly 
understood and 
under-researched
GAP: (1) no validated foot-
specific outcome measures exist to 
assess the impact of foot 
functional impairments and 
disability in PsA, (2) RA-specific 
outcome measures used to assess 
the foot affected by PsA are 
unlikely to capture the full impact 
of PsA, (3) previous studies have 
focused on the clinical 
manifestations of the disease in the 
foot with little incorporation of the 
patient perspective, and (4) 
concepts important and relevant to 
people with PsA-related foot 
problems are largely unknown.
GAP: 1) few validated instruments 
developed specifically for PsA, 2) 
lack of standardisation of 
instruments used to assess disease 
domains, and 3) incorporation of 
the patient perspective in the 
development of outcome measures 
and disease domains in PsA is 
often lacking.
 
Figure 3.1. Theoretical framework and research focus.  
PsA Psoriatic arthritis, RA Rheumatoid arthritis. 
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The premise of this research was to provide a comprehensive description of foot 
involvement and its impact on daily life from the perspective of people with PsA 
through the development and implementation of a national survey. This provided the 
opportunity to sample a large population over a wide geographical area across 
Australia and New Zealand, including different regions (rural and urban) and climate 
zones (temperature and humidity). The programme of work was divided into a series 
of work packages that were undertaken in order to address the research questions 
(Table 3.1).   
 
Table 3.1. Research questions and related work packages. 
Question type 
Research question Research methods 
Quantitative Qualitative  
 X 
What are the 
perspectives of 
patients and health 
professionals on the 
experience of living 
with foot problems 
related to PsA? 
 
Qualitative investigation 
To answer this question, a qualitative 
study was undertaken. Semi-structured, 
one-to-one interviews of people with PsA 
about their foot problems and the impact 
they have on daily life were performed. 
Focus groups were undertaken with 
health professionals to explore their 
understanding of the patient experience 
of PsA-related foot problems. 
 X 
Linking to the ICF 
To answer this question, the ICF 
classification was used to categorise the 
impact of localised disease in the foot on 
daily life as obtained from the qualitative 
study. Linking to the ICF means to 
translate concepts into a common 
language in order to contextualise the 
impact of disease on daily functioning.  
 X 
What is the nature, 
extent and location 
of foot involvement 
and its impact on the 
daily life of people 
with PsA?  
 
Survey development protocol 
To answer this question, a novel high-
quality survey was developed and pre-
tested using robust, best practice methods 
in survey design and based on the views of 
patients and health professionals. 
X  
National survey  
To answer this question, a cross-sectional 
national survey about foot involvement 
among people with PsA was implemented 
in Australia and New Zealand. 





 perspectives of patients and health professionals on the experience of 












Linking to the International Classification of Functioning, 
Disability and Health (ICF):
to categorise the impact of foot involvement in psoriatic arthritis
Targeted survey dissemination strategy 
developed a priori for large-scale implementation of a 
national survey across Australia and New Zealand
A focused analysis of discrete themes from the survey 
aligned with key domains from the conceptual framework
Subject expert review
Cognitive de-briefing interviews of 
people with psoriatic arthritis
Multidisciplinary rheumatology focus 
group with health professionals
Cognitive de-briefing 
interviews of people 
with psoriatic arthritis
Usability testing of web-
based survey by people 
with psoriatic arthritis
New Zealand cultural 
sensitivity review
Subject expert validation 
(members from Australia, New Zealand and the UK) 
Survey Item Development
based on the findings of the qualitative work and linking to the ICF 










Multidisciplinary rheumatology focus 
group with health professionals
Survey design expert validation 







Survey Draft 6 
Item revision
 
Figure 3.2. Order of proposed studies. 
ICF International Classification of Functioning, Disability and Health. 
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The overall objective of this programme of work was to develop a national survey 
based on the views of people with PsA and health professionals on foot problems, their 
impact on daily life, footwear choice and foot care needs. The lack of standardised 
foot-specific clinical or image-based assessments and poor reliability of clinical 
examination in PsA, limited the potential value of conducting clinical-based studies. 
Data obtained through clinical encounters usually represent a small part of the patient 
experience and given the lack of specialist-led rheumatology services to target for 
recruitment in Australia and New Zealand, survey research was considered appropriate 
in order to sample a large population over a wide geographical spread of states.  
 
Each chapter will describe the study context, aims, methods, results, discussion and 
conclusion for the individual work packages. A brief description of the phases of 
research used to achieve the objective is provided below (Figure 3.2): 
3.1 Phase 1 Conceptual framework and survey content generation 
A Qualitative Investigation - To explore, in-depth the perspectives of people with PsA 
and health professionals on their understanding of the patient experience of PsA-
related foot problems a qualitative investigation was undertaken. Qualitative methods 
were used to obtain the level of rich and meaningful data required to gain a 
comprehensive understanding of the concepts important and relevant to the patient 
experience of foot involvement in PsA. Key themes developed from the qualitative 
investigation were used to inform the conceptual framework for the survey and to 
generate survey items. 
 
Linking to the International Classification of Functioning, Disability and Health (ICF) 
- To gain a better understanding of the extent and coverage of themes identified by the 
qualitative work, concepts derived from the interviews were linked to the ICF in order 
to use common terminology to describe the impact of localised disease in the foot. 
Widely used by the OMERACT groups, the WHO’s ICF was chosen as an 
internationally accepted theoretical model to comprehensively define the impact of 
localised disease on daily functioning and to determine what to include in the 
assessment of key impact domains. The list of ICF categories generated was used to 
inform the conceptual framework for the survey and to generate survey content. 
39 
 
3.2 Phase 2 Survey development and pre-testing  
To achieve a comprehensive evaluation of foot involvement in PsA and its impact at 
the patient-level across Australia and New Zealand, a national survey was developed 
using robust patient-centred methods in survey design. The survey development 
protocol comprised 3 stages 1) generation of the conceptual framework and survey 
content, 2) development of the survey and pre-testing, and 3) development of the 
survey dissemination strategy. Quality criteria for survey design and conduct have 
been developed but adoption is low with evidence that survey studies are poorly 
reported, which limits the validity and generalisability of survey findings. Following 
a rigorous, best practice approach has shown merit in the development of a survey 
protocol that presents a high-quality worked example of survey design and conduct.  
3.3 Phase 3 Survey dissemination strategy 
To optimise response rates and yield successful survey outcomes, a targeted postal and 
online survey dissemination strategies were developed a priori. With the prevalence 
of PsA unknown in Australasia and a lack of large databases of PsA populations to 
target for recruitment, the sampling strategy was to identify the major sites for 
dissemination and determine the response rate relative to the populations that were 
targeted. Robust strategies for sampling, survey dissemination and community 
engagement made a powerful contribution to response rates and the scale of 
information collected. Methods included mixed modes of survey administration, 
reminders sent to recruitment sites, a study website, Facebook page with weekly posts, 
video and animation for survey promotion.  
3.4 Phase 4 Survey results and discussion 
To comprehensively capture foot-specific domains of impact important and relevant 
to people with PsA, a national survey was implemented in Australia and New Zealand 
over a 6-month period. Survey research provided the opportunity to generate large-
scale data from a wide range and number of participants, and to measure a broad range 
of constructs with sufficient granularity. To provide valuable insights into the large 
amount data collected, a focused analysis of discrete themes was undertaken.  
3.5 Future implications  
The theoretical implications of this research are a detailed understanding of the 
relationship between local disease, key areas of life impact and dominant concerns of 
people with PsA-related foot involvement. This research aims to improve current 
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knowledge of foot involvement in PsA and provide new insights into the impact of 
localised disease in PsA. This may direct future work on the development of an 
instrument to measure the impact of foot involvement in PsA. 
 
The clinical and practical implications of this research will be to inform future 
randomised controlled studies on novel assessment techniques and targeted 
pharmacological and non-pharmacological management of foot disease in PsA. A 
better knowledge of foot involvement in PsA will facilitate early detection, effective 





























4 Qualitative study  
This chapter describes two separate qualitative studies. A qualitative research 
approach was chosen in order to identify concepts important and relevant to people 
with PsA and health professionals, and to be able to explore and gain an in-depth 
understanding of their views. Qualitative methods are used increasingly to contribute 
new knowledge and to provide new perspectives in healthcare (Tong, et al., 2007). 
Qualitative studies have found that patients may prioritise different outcomes to health 
professionals and may also identify additional important outcomes. Therefore, 
exploring the perspectives of both patients and health professionals provided the 
opportunity to determine any concordance or discordance between views. 
 
The philosophical underpinning of the qualitative research was based on the principles 
of naturalistic inquiry, which aims to study something (the lived experience with foot 
problems) in its natural state (Guba and Lincoln, 1982). This approach requires the 
researcher to remain close to the data and provide a comprehensive descriptive 
summary of the experience. The naturalistic approach is further supported by the use 
of constant comparative thematic analysis, which focuses on an explicit account of the 
data to develop themes, rather than through interpretation of the data. Whilst 
qualitative description may not be as interpretive as other qualitative methods, there is 
a level of interpretation placed on the description of the data (Sandelowski, 2000; 
Sandelowski, 2010). 
 
With a lack of previous research exploring the personal impact of PsA-specific foot 
involvement on daily life, the use of qualitative research methods was central to 
gaining a full understanding of the lived experience of people with PsA-related foot 
problems. In addition, the need to explore the participant’s experiences aligned with 
the holistic approach of the researcher in respect of their clinical practice having 
worked with people with complex, chronic diseases and with the wider 
multidisciplinary team, with the focus being on the person in the context of their 
problem rather than the problem alone. These influences led to an interpretivist 
approach to the process of qualitative inquiry (Koch, 1995; Dowling, 2004). 
Maintaining an extensive audit trail throughout the qualitative research process 
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facilitated continuous reflection on the approach taken to data collection and 
interpretation, and helped to ensure the authenticity and trustworthiness of the data. In 
qualitative research, it is acknowledged that the researcher becomes an integral part of 
the process and outcome. Reflecting on the experience of conducting qualitative 
research, the researcher recognised the personal responsibility connected with 
collating participants’ thoughts and feelings, the significant value of the information 
gathered, and the importance of involving participants in the research process. This 
reflection clarified the researcher’s worldview of qualitative research, a naturalistic 
worldview was driven by limited prior knowledge or preconceived assumptions of the 
impact of PsA-related foot problems and the desire to represent the participant’s views 
as authentically as possible through induction. 
 
The first study was the original research intention, which was to explore the lived 
experience of foot involvement in PsA. The second study focused on a distinct 
qualitative theme generated from data collected as part of the first study. In the first 
study, focus groups with health professionals explored their understanding of the 
patient experience of PsA-related foot problems, which contributed qualitative data for 
the generation of themes in the first study. During the focus group interviews, health 
professionals described the challenges relating to the management of foot problems in 
PsA from diagnosis, to assessment and treatment. These perspectives generated the 
distinct overarching theme of suboptimal foot disease management that required 
separate presentation and dedicated description. 
 
Study 1) Perspectives of patients and health professionals on the experience of living 
with psoriatic arthritis-related foot problems: A qualitative investigation. 
The objective of the first study was to explore how foot problems impact on the lives 
of people with PsA by interviewing patients and health professionals.  
Publication: Clinical Rheumatology. 2019;38(6):1605-1613. 
 
Study 2) Health professional views on the assessment and management of foot 
problems in people with psoriatic arthritis in Australia and New Zealand: a qualitative 
investigation.  
The objective of the second study was to explore the views of health professionals on 
the assessment and management of people with PsA-related foot involvement. 
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Publication: BMC Musculoskeletal Disorders. 2019;20(1):191. 
 
This research was presented at the Patient Experience Symposium, Sydney, Australia 
in April 2019 (Conference abstract in Appendix 4: The nature, burden and 
management of psoriatic-related foot problems from the perspective of patients and 
health professionals).  
 
The studies in chapter 4 are presented in the form of stand-alone published papers. In 
the context of the thesis they represent the exploratory phase of a programme of work 
towards developing a national survey to find out about how foot problems impact on 
the lives of people with PsA. Insights gained from this qualitative investigation will be 
used in sequential phases to inform the content and design of a large national survey. 
In the results section 4.1.3.1, exemplars, selected from the supplementary materials of 
the publication (Appendix 3), have been included in the chapter in order to better 


















Perspectives of patients and health professionals on the 
experience of living with psoriatic arthritis-related foot 
problems: A qualitative investigation 
 
Carter K, Walmsley S, Chessman D, Rome K, Turner DE. Perspectives of patients and 
health professionals on the experience of living with psoriatic arthritis-related foot 
problems: a qualitative investigation. Clinical Rheumatology. 2019;38(6):1605-13. 
4.1 Abstract 
Objective: The aim of the study was to explore how foot problems impact on the lives 
of people with psoriatic arthritis by interviewing patients and health professionals.  
 
Method: Participants were recruited from outpatient rheumatology clinics in Sydney, 
Australia and in Auckland, New Zealand, using a convenience sampling strategy. 
People with psoriatic arthritis were asked questions in semi-structured interviews 
about their foot problems and the impact they have on daily living until qualitative 
data saturation. Focus groups were undertaken with health professionals to explore 
their understanding of the patient experience of psoriatic arthritis-related foot 
problems. All interviews were audio-recorded and transcribed verbatim. Constant 
comparative analysis was used to identify emerging themes from the data.  
 
Results: Twenty-one people with psoriatic arthritis-related foot problems and 17 
health professionals participated. Three overarching key themes were derived from 
patients and health professionals: 1) structural and functional foot manifestations, 2) 
impact on daily life leading to social withdrawal and reduced work productivity and 
3) mediating factors influencing the severity of impact from foot problems on their 
lives such as social support, self-management strategies and experiences of healthcare.  
 
Conclusion: Foot problems caused functional disability and altered self-concept, 
which lead to a cascade of social, economic and psychological consequences. People 
with foot problems contend with profound disruption to their functioning and life roles. 
Whilst health professionals recognised the functional and visual impact that foot 
problems have on daily life, the emotional burden may be under-appreciated. Future 
work to determine the scale and types of foot problems in psoriatic arthritis is required.  
Key words: Psoriatic arthritis, foot, podiatry, qualitative, interviews. 
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4.1.1 Introduction  
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated 
with psoriasis (Taylor, et al., 2006) and is characterized by a wide clinical spectrum 
and a variable course (Gladman, et al., 2005). Clinical features of PsA, such as 
peripheral arthritis, enthesitis, dactylitis and tendinopathy, as well as skin and nail 
psoriasis, can affect the feet (Bezza, et al., 2004; Hyslop, et al., 2010a; Delle Sedie, et 
al., 2011; Patience, et al., 2018). Previous studies have described the structural and 
functional changes in the foot affected by PsA (Bezza, et al., 2004; Hyslop, et al., 
2010a; Hyslop, et al., 2010b; Delle Sedie, et al., 2011; Woodburn, et al., 2013; Turner, 
et al., 2014; Wilkins, et al., 2016). However, the details of how foot problems impact 
on the lives of people with PsA, their experiences with footwear and their foot care 
needs are limited.  
 
Previous studies have assessed the perspectives of patients and clinicians regarding the 
whole effect of PsA, confirming that it has a demonstrated detrimental effect on health-
related quality life (Taylor, et al., 2010; Gossec, et al., 2014; Orbai, et al., 2017a). One 
study found that pain in the feet was the fourth most prevalent single complaint, behind 
tiredness, arm pain and lower back pain (Nordbø, et al., 2017). This suggests that, for 
a large proportion of people with PsA, foot involvement may be the major 
characteristic feature of their disease. However, the specific consequences of PsA on 
foot functional impairment and disability has not been explored in detail. Obtaining 
the patient’s perspective on how they feel and function with respect to their disease 
and the clinician’s view has been recognised as critically important in the assessment 
and management of PsA (Betteridge, et al., 2016; Lebwohl, et al., 2016; Garrido-
Cumbrera, et al., 2017; Orbai, et al., 2017a). The aim of this study was to explore how 





Participants with PsA were recruited from rheumatology outpatient clinics in Sydney, 
Australia and Auckland, New Zealand. Health professionals with clinical experience 
of managing people with PsA, including podiatrists, physiotherapists and 
rheumatologists, were recruited to take part in focus groups. Participating sites were 
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selected to provide a representative sample from public and private sector, from lower 
and higher socioeconomic geographical areas and to provide local data from Australia 
and New Zealand. Ethical approval was granted by the South Western Sydney Local 
Health District (HREC/171/LPOOL/353), the Auckland University of Technology 
Ethics Committee (AUTEC 17/320) and the Waitemata District Health Board of 
Auckland New Zealand (RM/3907) (Appendix 1). Both participants and health 
professionals read the participation information sheet and provided written informed 
consent prior to data collection (Appendix 2).  
 
Participants with rheumatologist-diagnosed PsA, aged over 18 years old and who had 
current or previous experience of foot problems were recruited by their rheumatologist 
in Australia and New Zealand. Those who could not read or speak English or those 
with cognitive impairment precluding ability to answer health-related questions 
accurately were excluded. Convenience sampling was used to recruit people with PsA 
for semi-structured interviews. Semi-structured, one-to-one interviews were used to 
gain a rich description of their individual experiences of foot problems and their 
impact. This technique was selected as participants tend to be more inclined to disclose 
personal information in face-to-face interviews and with the researcher being able to 
respond accordingly (Legard, et al., 2003).  
 
Focus groups were selected as the method of data collection to explore the views of 
health professionals. Group dynamics and interactions are distinct features of this 
method, used to generate rich data (Thomas, et al., 1995). It was anticipated that health 
professionals who work together would be able to contribute freely to a group 
discussion. Exploring the patient experience from the perspective of health 
professionals facilitated further insight into the impact of foot problems reported by 
people with PsA. Sample size for each focus group was based on recommendations 
suggesting that 4-12 people will generate sufficient data (Liamputtong and Ezzy, 
2005). Potential participants were recruited by response to an invitation email 
containing an outline of the study, screening form and contact details of the primary 
researcher (KC).  
 
The interview guides (Table 4.1 and 4.2) were developed based on a review of the 
literature, which related to 1) PsA-specific foot involvement (Hyslop, et al., 2010a; 
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Hyslop, et al., 2010b; Woodburn, et al., 2013; Turner, et al., 2014; Wilkins, et al., 
2016; Patience, et al., 2018), 2) foot problems in other rheumatic diseases to identify 
relevant foot-specific concepts (Helliwell, et al., 2005a; Otter, et al., 2010; Hendry, et 
al., 2013a; Brenton-Rule, et al., 2014; de Souza, et al., 2016; Otter, et al., 2016; 
Williams, et al., 2017; Wilson, et al., 2017b; McCulloch, et al., 2018), and 3) the PsA 
Core Set and outcome measures to identify key domains of impact for inclusion 
(Mease, 2011; Her and Kavanaugh, 2014; Orbai, et al., 2017b). The purpose of this 
literature appraisal was not to provide a systematic review, but to select priority areas 
that could be explored to gain a better understanding of foot involvement specific to 
PsA. The interview guides were developed by the researcher based on the review of 
the literature. Finally, the interview guides were scrutinised by the research team, 
which comprised a consultant rheumatologist, specialist podiatrists and academic 
researchers. The interview guides were designed to cover priority areas of interest, 
which included (1) foot involvement in PsA, (2) its impact on daily life, (3) 
experiences with footwear and (4) foot care needs. The interview guides used open-
ended questions to encourage detailed descriptions. Additional probes were used to 
facilitate discussion and to maintain the focus on foot problems. All interviews and 
focus groups were conducted by the same researcher (KC), a podiatrist with 15 years 
of clinical experience. 
 
Table 4.1.  Semi-structured interview guide for people with psoriatic arthritis-related 
foot problems. 
Questions 
1 Tell me about any problems you experience with your feet because of your 
psoriatic arthritis? 
2 Can you point to the specific parts of your foot where you experience problems 
because of your psoriatic arthritis? 
3 How do your foot problems due to psoriatic arthritis affect your daily life? 
4 Do the problems you experience with your feet have any impact on your 
ability to work?   
5 How do you manage your foot problems? 
6 How do the problems in your feet due to psoriatic arthritis make you feel? 
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7 How important do you feel your foot problems are compared with other issues 
you may have related to your psoriatic arthritis? 
8 Can you tell me about your experiences with footwear in light of your psoriatic 
arthritis? 
9 Does your rheumatologist or doctor ask about your feet during consultations? 
10 Have you ever seen a podiatrist about the problems in your feet? 
11 Can you tell me about any problems or difficulties you experience with your 
nails because of your psoriatic arthritis? 
12 Is there anything else that we have not already talked about that you would 
like to add concerning the experiences you have or have had with your feet 
related to your psoriatic arthritis? 
 
 
Table 4.2. Focus group interview guide for health professionals with experience of 
managing people with psoriatic arthritis-related foot problems. 
Questions  
1 What do patients with psoriatic arthritis tell you about when they report 
problems with their feet? 
2 In your experience, have you found any differences between the reporting 
of foot problems and the demographic characteristics of your patients? 
3 In what ways do you find that foot problems arising from psoriatic arthritis 
impact on your patients’ day-to-day lives? 
4 In what ways, if any, do you find foot problems arising from psoriatic 
arthritis impact on the psychological/emotional health of your patients? 
5 In your experience, what footwear difficulties (if any) do your patients 
report as a result of psoriatic arthritis? 
6 How often do you examine the feet of patients with psoriatic arthritis? 
7 Have you encountered any barriers in relation to your patients receiving 
appropriate foot care services? 
8 Is there anything else that we have not already talked about that you would 
like to add concerning the experiences of your patients in relation to their 





Prior to interview, participant demographic information was collected including age, 
gender, ethnicity and occupation. Clinical characteristics were recorded including 
body mass index, disease duration, comorbidities, current medications, erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). Activity limitation was 
measured using the Health Assessment Questionnaire (HAQ) (Fries, et al., 1980) that 
includes 20 tasks for which participants are asked to rate their ability to perform them 
over the last week (without difficulty = 0, some difficulty = 1, much difficulty = 2 or 
unable to do = 3). Global disease activity over the last week was measured using a 
100mm Visual Analogue Scale (VAS) with the assessment of both joint and skin 
components, joint alone and skin alone. Global pain was also measured using a 100mm 
VAS.  
 
Foot functional impairment and disability was assessed using the LFIS-RA (Helliwell, 
et al., 2005a). The LFIS-RA is a self-completed questionnaire comprising 51 items in 
total (LFISTOTAL), divided into two subscales: impairments/shoes (LFISIF) and 
activities/participation (LFISAP). LFISIF scores ≤ 6 represent mild, 7–13 moderate and 
≥ 14 severe levels of foot related impairment. LFISAP scores ≤ 9 represent mild, 10–
19 moderate and ≥ 20 severe levels of activity limitation (Hooper, et al., 2012). 
Severity of foot pain on the day and over the last week were measured using a 100mm 
VAS.  Previous and current foot or lower leg ulceration, previous foot surgery and 
having previously seen a podiatrist were recorded.  
 
Data recorded from the health professionals prior to the focus groups included 
demographic information, professional qualifications and number of years of clinical 
experience. All interviews and focus groups were audio-recorded and transcribed 
verbatim immediately after each session. Recruitment to the study continued until 
qualitative data saturation of emerging concepts was achieved (Francis, et al., 2010). 
Data was collected between October 2017 and March 2018. 
 
 Data analysis  
All demographic and clinical data were described as mean (SD) for continuous data 
and n (%) for categorical data. Qualitative data were analysed using a constant 
comparative method (Morehouse and Maykut, 1994) and a thematic framework 
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approach to facilitate conceptual mapping (Attride-Stirling, 2001). ATLAS-ti version 
7.5.7 software (Scientific Software Development GmbH, Berlin, Germany) was used 
to analyse the data (www.atlas-ti.com). The researcher (KC) read each transcript 
several times and meaningful units within the data such as words, phrases and concepts 
were assigned codes, framed by the researcher’s focus of inquiry. This method 
combines inductive category coding with a simultaneous comparison of all units of 
meaning obtained. The codes were continuously refined, compared and subsequently 
grouped with similar units of meaning and then organised into themes (Morehouse and 
Maykut, 1994). The emergent themes were scrutinised and agreed by the research team 
to increase analytical rigor. The conceptual framework of themes was verified by both 
participants and health professionals. This methods approach required the researcher 
to remain close to the data in qualitative description (Sandelowski, 2000) and 
naturalistic inquiry (Guba and Lincoln, 1982). 
 
4.1.3 Results   
Participant demographic and clinical data are summarised in Table 4.3. Twenty-one 
people with PsA and self-reported foot involvement were recruited, the majority of 
which were women (62%, n=13). The mean (SD) age was 53 (13) years and the mean 
(SD) disease duration was 11 (9) years. The HAQ found mild overall activity limitation 
with a mean (SD) of 1.0 (0.5). Moderate levels of global disease activity were reported 
for joints and skin, joints alone and skin alone. Seven participants with elevated CRP 
levels had global assessment scores greater than 70mm. 
 
All participants had experienced previous foot pain (n=21, 100%) and over 80% 
(n=17) of participants had current foot pain (Table 4.4).  The mean (SD) of the LFISIF 
was 12 (4) and the LFISAP was 18 (7) indicating moderate levels of foot impairment 








Table 4.3. Demographic and clinical characteristics of participants with psoriatic 
arthritis, (n=21). 
Variables   Value 
Ages, years  53 (13) 
Women, n (%)  13 (62%) 
Ethnicity, n (%)  
     Caucasian 18 (86%) 
     Fiji-Indian 2 (10%) 
     Indian 1 (5%) 
Body Mass Index, Kg/m2   32.1 (7.4) 
Geographic location, n (%)  
     Sydney, Australia 18 (86%) 
     Auckland, New Zealand 3 (14%) 
Employment status, n (%)  
     Employed 6 (29%) 
     Unemployed (health reason) 8 (38%) 
     Unemployed (other reason: student, home-maker) 2 (10%) 
     Retired 5 (24%) 
Disease type, n (%)  
     Psoriatic arthritis with skin psoriasis 19 (90%) 
     Psoriatic arthritis without skin psoriasis 2 (10%) 
Disease duration, years  11.2 (9.1) 
Medications, n (%)  
     Methotrexate 11 (52%) 
     Other DMARD (leflunomide, salazopyrin, hydroxychloroquine) 12 (57%) 
     Biologics 7 (33%) 
     Prednisone 1 (5%) 
Other medications, n (%)  
     NSAID 15 (71%) 
     Opioid 3 (14%) 
     Other pharmacological treatment 16 (76%) 
Comorbidities, n (%)  
     Cardiovascular conditions 14 (67%) 
     Musculoskeletal conditions 12 (57%) 
     Depression 3 (14%) 
     Diabetes Mellitus 9 (43%) 
     Cancer 4 (19%) 
HAQ score 1.0 (0.5) 
CRP, mg/L *1 7.0 (7.1) 
ESR, mm/h *2 20.5 (15.6) 
Patient global disease activity (joint and skin) VAS (VAS 0-100), 
mm 
52 (24) 
Patient global skin disease activity VAS (VAS 0-100), mm  43 (31) 
Patient global joint disease activity VAS (VAS 0-100), mm 56 (28) 
Patient global pain VAS (VAS 0-100), mm 49 (28) 
Data presented as mean (SD) unless specified. 
DMARD Disease modifying anti-rheumatic drug, NSAID Non-steroidal anti-
inflammatory drug, VAS Visual analogue scale, ESR Erythrocyte sedimentation 





Table 4.4. Foot and ankle characteristics and footwear type of participants with 
psoriatic arthritis (n=21). 
Variables   Value 
Previous foot pain, n (%) 21 (100%) 
Presence of current foot pain, n (%) 17 (81%) 
Current foot pain VAS (VAS 0-100), mm* 43 (29) 
Foot pain over the last week VAS (VAS 0-100), mm* 49 (24) 
Previous foot or lower leg ulceration, n (%) 3 (14%) 
Current foot or lower leg ulceration, n (%) 0 (0) 
Previous foot surgery, n (%) 3 (14%) 
Has seen a podiatrist before, n (%) 11 (52%) 
Leeds Foot Impact Scale  
     LFISTOTAL score 30 (10) 
     LFISIF subscale score 12 (4) 
     LFISAP subscale score 18 (7) 
Type of footwear worn on the day of the interview, n (%)   
     Walking shoe (lace-up shoe, sports shoe) 8 (38%) 
     Sandal (contoured) 3 (14%) 
     Sandal  2 (10%) 
     Sketchers (slip-on shoe) 2 (10%) 
     Thong 2 (10%) 
     Thong (contoured) 1 (5%) 
     Backless slipper 1 (5%) 
     Therapeutic sandal 1 (5%) 
     Other  1 (5%) 
Data presented as mean (SD) unless specified. 
VAS Visual analogue scale, LFIS TOTAL Leeds Foot Impact Score total, LFIS IF Leeds 
Foot Impact Score foot impairment/footwear restriction, LFIS AP Leeds Foot Impact 
Score activity limitation/participation restriction. 
*n=20 (two participants did not fully complete the questionnaire in different sections). 
 
 
The demographic characteristics of the health professionals are shown in Table 4.5. 
Three focus groups were undertaken and a total of 17 health professionals participated, 
12 from Australia and 5 from New Zealand. The majority of focus group participants 
were rheumatologists (n=10, 59%), working in the public sector (n=7, 70%), with over 
15 years of clinical experience managing this patient group (n=6, 35%). The other 
focus group members were rheumatology registrars (n=2, 12%) and allied health 
professionals (n=5, 29%). The mean (SD) number of years of clinical experience 
amongst the allied health professions was 13 (6) years. The interviews and focus 





Table 4.5. Demographic characteristics of the health professionals with experience of 
managing people with psoriatic arthritis (n=17). 
Variables   Value 
Age, years 44 (8) 
Women, n (%)  9 (53%) 
Ethnicity, n (%)  
     Caucasian 12 (71%) 
     Chinese 4 (24%) 
     Indian 1 (6%) 
Occupation, n (%)  
     Rheumatologist 10 (59%) 
     Rheumatologist registrar 2 (12%) 
     Podiatrist 3 (18%) 
     Physiotherapist 1 (6%) 
     Rheumatology care coordinator 1 (6%) 
Clinical experience, years 12 (8) 
Qualifications, n (%)  
     Bachelor of Medicine (MBBS) 11 (65%) 
     Fellow of the Royal Australasian College of Physicians 
(FRACP) 
9 (53%) 
     Bachelor of Science (BSc) 10 (59%) 
     Master of Science (MSc) 2 (12%) 
     Doctor of Philosophy (PhD) 6 (35%) 
Geographical location, n (%)  
     Sydney, Australia  12 (71%) 
     Auckland, New Zealand 5 (29%) 
Health sector, n (%)  
     Public sector 13 (77%) 
     Private sector 4 (24%) 
Data presented as mean (SD) unless specified. 
 
 Qualitative results 
Three overarching themes emerged from the analysis of interviews of people with PsA 
and focus groups with health professionals (Table 4.6). The conceptual framework of 
themes was verified by both participants and health professionals (Figure 4.1). 
Exemplars from the transcripts were identified to support each of the themes 
(Appendix 3). People with PsA will be referred to as participants and health 




Figure 4.1. The conceptual framework of themes.  
The manifestations of psoriatic arthritis in the feet and ankles (Theme 1) caused foot functional impairments and visual differences that impacted 
on daily activities, social participation, work productivity and family life (Theme 2). Mediating factors (Theme 3) influenced the severity of impact 
from foot involvement on the lives of people with psoriatic arthritis. 
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Table 4.6. Key themes emergent from the interviews of people with psoriatic arthritis 
and focus groups with health professionals. 
No. Overarching themes Sub-themes  
1. Foot and ankle structural and 
functional manifestations of PsA 
Foot pain, swelling, stiffness, foot 
cramp, numbness, hot and cold 
sensations, joint deformity and skin 
and toenail changes 
2. The impact of foot problems on the 
lives of people with PsA 
Body image, physical function, daily 
activity, social, family and work life 
3. Mediating factors that influenced 
the severity of impact of PsA 
related-foot problems 
Demographic and disease 
characteristics, importance and 
severity of foot problems, self-
management strategies, footwear, 




Overarching Theme 1 – Foot and ankle structural and functional manifestations of 
PsA. 
Pain was the most commonly reported symptom and the main descriptors for the nature 
of foot pain were ‘persistent’ and ‘unpredictable’. The duration of current foot pain 
ranged from 3 months to 5 years. Foot pain severity varied according to the time of 
day and the level of priority given to the feet within the context of their whole 
experience of living with PsA. Pain was exacerbated mostly by walking and pressure 
from footwear, but also by changes in the weather and increased global disease activity 
and body weight. All participants experienced some foot pain during or following 
walking activity.   
 
“…having a long day if I am on my feet for a long time is just you know a world 
of pain by the end of the day” (participant 2) 
 
“…as soon as I start walking I’m aware of it, it’s not terribly painful but I’m 
aware it’s there. So it never actually goes away, it’s always there and you feel 





Musculoskeletal involvement in the feet was reported by all participants and health 
professionals, which included arthritis, enthesitis (Achilles enthesitis and plantar 
fasciitis), tendinopathy (tibialis posterior and peroneal tendons), bursitits (retro-
calcaneal and intermetatarsal) and dactylitis. Variable clinical presentations of foot 
pain were described by the health professionals, but the most common were deemed 
to be related to localised inflammation, mechanical dysfunction or a ‘mixed’ type 
presentation and were described within the context of disease duration. Toenail 
psoriasis was commonly reported and over a quarter of participants reported having 
skin psoriasis that affected their lower legs, soles of the feet, tips of the toes or in 
between the toes. For 2 participants plantar skin psoriasis was their most troublesome 
foot problem. 
 
“I can’t walk. It really stops me from functioning. Um to really do anything 
especially when the psoriasis is really really bad on my feet it, just the skin 
builds up so quickly, it it actually just splits and I mean real deep deep cuts 
into the foot. And it’s like needles when you walk so it's very uncomfortable 
like I’ve been at times I’ve been crawling on the ground to get from A to B until 
I went to the hospital. Because it’s really yeah, I can’t explain it it’s just like 
stepping on glass” (participant 14)   
 
“…that’s about the worst for me… The only thing that does stop me is breaks 
in the feet…yes it does stop you doing a lot of things. But that’s just the nature 
of it when it flares up it really is bad… you can’t walk anywhere if you haven’t 
got your feet” (participant 3) 
 
One third of participants reported that their feet were the first site affected by PsA and 
9 participants described that their feet were the most severely affected site compared 
with symptoms elsewhere in the body. Self-reported foot manifestations at disease 
onset were dactylitis, plantar skin psoriasis, metatarsophalangeal joint synovitis, ankle 
joint synovitis, tibialis posterior tendinopathy, plantar fasciitis and Achilles enthesitis. 
 
Overarching Theme 2 – The impact of foot problems on the lives of people with PsA. 
Six impact areas were identified as sub-themes including altered body image, 
functional limitations, daily activity limitations, social participation restrictions, 
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family and work life restrictions. Health professionals described the impact of foot 
problems on the lives of people with PsA as ‘incapacitating’, ‘disturbing’, 
‘debilitating’, ‘really impossible’, ‘disaster’, ‘psychologically distressing’ and ‘a 
nightmare’. 
 
Altered body image - Change to the physical appearance of the feet and footwear 
restrictions, regardless of the social context, had a negative impact on body image. 
Participants felt demoralised and stigmatised by the appearance of their feet relating 
to skin and toenail changes, swelling, deformity and the visible changes to their gait. 
Strategies to hide the appearance of foot problems included the non-disclosure of their 
disease to others, closed-in footwear, clothes to cover, disuse of walking aids and 
limiting social participation. Increased body weight attributed to foot pain that 
impeded exercise revealed the far-reaching effects of PsA-related foot involvement.  
 
“I mean they look hideous and I hate the way they look… I think they’re 
revolting. Because they’re so wide now as well… They look like little claws to 
me” (participant 11 - female)  
 
“…it does bother me. Yeah. Every time I don’t wear socks you know, I just 
wear thongs or something then everybody’s eyes goes there - you feel very bad 
for yourself you know” (participant 1 – male) 
 
“…I don’t like to go out because I hate wearing, I can’t wear some sort of 
shoes [laugh]. And so I don’t really want to go out.... It’s like affected a little 
bit of my life but like I just have to try and just move on you know” (participant 
9) 
 
“…you can’t really dress to look good… you kind of miss that because you see 
all these people all dressed up nice and they’ve always got lovely shoes on you 
know. I try and dress nice but I have to wear these shoes you know [laugh]. I 
have to wear the shoes for my, that are best for my feet. Um so it gets me down 




“…patients talk a lot about the vicious cycle. Between I have this terrible foot 
pain, and I know some of its because I’m overweight, but I can’t exercise 
because of my foot pain so I can’t lose the weight” (rheumatologist 6) 
 
Functional limitations – Foot problems had an impact on the ability to sit, stand, walk 
and function normally for all participants. Foot pain and stiffness was described by all 
participants in relation to the time of day, their activity level and with either 
maintaining or changing body positions. Walking disability was attributed to a variety 
of foot problems including pain, stiffness, swelling, plantar skin psoriasis, corns and 
calluses, toe deformity, ankle surgery and uncomfortable footwear. Functional 
limitations included being unable to walk barefoot, short or long distances and being 
unable to run, as well as difficulty walking on uneven ground, up-hill or down-hill and 
up or down stairs. Changes to the spatiotemporal parameters of gait were described as 
walking slower, limping, shuffling, hobbling and feeling unstable on their feet. Pain 
avoidance behaviour was associated with all functional limitations and dictated life 
choices.  
 
“Well when its bad you just can’t walk… I’ve only had one fall and that was 
because I was not aware that I didn’t have the balance in my foot” (participant 
3)  
 
“The most troublesome thing at the moment is just not being able to walk at a 
normal speed [exhale]… or run if I need to um yeah… and um having to 
[exhale] plan things out a lot more um because I can’t necessarily rely on 
running to catch a bus or um running to the train [exhale] um so yeah having 
to be more conscious about that” (participant 12)  
 
“The feet is the main thing to move me here and there you know. So when the 
pain is there I am just locked. The other things ok so I don't move my hands or 
move my arms, my fingers I can do, but if I can’t drive, can’t walk, that's the 
worst thing” (participant 1)  
 
Daily activity limitations - Most participants were limited in their ability to undertake 
their daily routine because of the structural and functional manifestations of PsA in the 
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feet and ankles. Participants described how they had stopped, modified or reduced the 
frequency of household tasks such as shopping, cleaning, cooking, gardening and 
home maintenance. Sleep and driving were also reported to be affected, as maintaining 
or changing position increased the severity of foot symptoms. Not having the physical 
capacity to undertake basic foot care activities was a concern for some participants and 
was reported by the health professionals, which included maintaining foot hygiene, 
nail cutting, skin care and taking shoes/socks on and off. Comorbid diseases such as 
obesity, PsA related-axial involvement and of the shoulder, hips and hands also 
interfered with the ability to self-care.  
 
“…things like mowing the lawn you don't tend to do that as much now… things 
like walking the dog you just don't do that… it’s a big problem just walking 
from one end of the shopping centre to the other” (participant 16) 
 
Some participants explained how they felt ‘stuck at home’ (confined and isolated), 
which was associated with pain avoidance behaviour but also with stress, frustration, 
decreased motivation and a sense of ‘losing control’. Many statements about daily 
activity limitations revealed negative emotions such as anxiety, bad temper, 
depression, embarrassment, helplessness and low self-worth. These feelings were 
reinforced by the perception that others do not understand and might be forming 
judgements about them. Existing coping strategies included accepting limitations, 
stoicism, pacing and planning. Most pushed themselves to undertake daily activities 
despite the foot pain either because of necessity or to maintain a sense of control. A 
limited range of coping strategies (accepting limitations and stoicism) and emotional 
states (frustration and fear for the future) were reported by the health professionals 
suggesting a potential under-appreciation of the psychological impact of foot 
involvement on the daily lives of people with PsA. 
 
“I have to change my life around… I can’t do a quarter of the stuff I used to 
do” (participant 4)  
 




“I don't do much for the simple fact I get embarrassed if I’ve got to, in front of 
people because your feet are just look horrible” (participant 14)  
 
Social participation restrictions - The majority of participants reported difficulty 
socialising, maintaining friendships and taking part in leisure activities due to foot 
problems. Functional limitations and negative body image had a profound impact on 
social participation. The exacerbation of foot symptoms during and after the social 
activity reduced their enjoyment and motivation, which consequently led to social 
withdrawal. Fear of foot injury also led to a disruption of social activities involving 
the use of public transport, going to concerts, dancing and walking through crowds.  
 
“Well as I mentioned yeah you know my social life was ruined” (participant 
10) 
 
“Oh very painful yep. And I can’t really go out with friends much. I really just 
stay at home” (participant 7) 
  
“I’ve constantly got a fear of somebody um stepping on my feet…it impacts 
where I go out, so if I go out with friends and they’re going for long walks, I 
don’t go. But if we are going out to dinner or something like that where I’m 
sitting down, that’s where I’ll tend to go. So it impacts me socially” 
(participant 5)    
 
“So that does impact your social activities because you don't want to go out 
there and feel like you’re burdening people” (participant 16) 
 
Family life impact - Spending time with family was disrupted due to foot symptoms 
and functional limitations. Participants described how being pre-occupied with pain 
altered their mood, which led to a loss of enjoyment and negative interactions. An 
increased reliance on family members for physical and emotional support was 
identified and parents specifically talked about fearing a deterioration in their 
functioning and becoming a burden. Those participants who had a family member with 
psoriasis, PsA or other inflammatory arthropathies described a greater level of 
understanding about the disease by family members and felt generally better informed 
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about their own disease. Conversely 4 participants who reported that they were the 
only family member with PsA associated it with a sense of isolation and fear for the 
future. Enduring foot pain in favour of social and family participation and hiding pain 
from others was frequently reported by participants, but these strategies were not 
recognised by the health professionals. 
 
“I think because I’ve got kids it’s not really the worry for myself. I don’t want 
to miss out on stuff for them. Like I don’t want to be you know the mum that 
can’t go in the three legged race at school because you know she’s got 
arthritis” (participant 13)  
 
“But I like to hide my pain. I do not like to show my pain to others. I take my 
pain myself… I do not like to disturb my wife. I have a pain here. I have a pain 
here” (participant 1) 
 
“if I go to a social function I feel a bit embarrassed to walk alongside with my 
family members because I mean, I used to be limping” (participant 10) 
 
Work life impact - Severe foot related-disability directly contributed to the loss of paid 
work in 4 participants. Whilst the health professionals did not identify the full impact 
of the disease on family and social life, they described the devastating impact of long-
term work disability with most citing the provision of documentation to employers. Of 
the 6 participants who were in employment, all experienced some difficulty 
performing their job roles because of foot pain and stiffness, which related to taking 
longer to get to work, managing to travel to and from work sites, prolonged sitting at 
a desk and being slower at completing work tasks. Footwear restrictions negatively 
impacted on job roles (i.e. with the inability to wear smart business shoes or safety 
boots), walking activities and social participation including special occasions such as 
weddings. Difficulties with footwear were related to skin and toenail psoriasis, 
swelling, deformity and a wider/bigger foot shape, which triggered foot pain, 
discomfort and rubbing in shoes. Difficulty finding shoes that were comfortable, well 
fitting, supportive and nice looking were frequent experiences, which provoked 




“I know one patient needed to wear steel toe-capped boots, I think it was in a 
factory or something, and that was a real problem for him because he was 
going to lose his job if he couldn’t wear the steel capped boots” 
(rheumatologist 5)  
 
“I can’t really work at the moment so I quit my job...because it’s mostly you 
have to stand, serve the customer, get on the ladder… physically get down on 
the floor… It’s very physical. I liked the job and everything but I can’t do 
that…” (participant 7) 
 
“So standing up for long periods of time is difficult, which makes it difficult 
when I’m training a group of people. So I have to go between sitting and 
standing and it just yeah. So it impacts the way I facilitate” (participant 5) 
 
Overarching Theme 3 – Mediating factors that influenced the severity of impact from 
foot problems on the lives of people with PsA. 
 
There was evidence of a unique combination of situations and experiences for each 
participant that facilitated or impeded their ability to influence the severity of impact 
from PsA-related foot involvement on their daily life. These mediating factors were 
considered to be intrinsic or extrinsic to the individual. Characteristics such as 
demographic (age, gender, ethnicity and socioeconomic status), disease (disease onset, 
duration, course and activity and morbidity), foot and ankle (perceived importance and 
severity of foot problems) and psychological (coping strategies and emotional well-
being) were considered as intrinsic factors. Social support (availability of help from 
family, friends and employers), self-care strategies (effectiveness of non-
pharmacological interventions including footwear), climate (influencing foot 
symptoms and footwear choice) and healthcare support (access to healthcare and 
effectiveness of medical management) were considered as extrinsic factors. The 
interface between these mediating factors was considered to determine the ability of 




“…females in general are quite attached to their sort of um the persona they 
want to project in terms of dress and clothing… I think that’s probably more 
acute for woman” (rheumatologist 5) 
 
“…younger patients say if you’ve got crooked toes or funny looking toes it can 
be quite disfiguring…” (rheumatologist 9) 
 
Health professionals associated younger age, female gender, lower socioeconomic 
status, later disease diagnosis, longer disease duration and high disease course 
variability with a greater severity of foot disease impact. The severity of foot problems 
and the level of importance attributed to them were considered to influence the 
participant’s emotional well-being (sadness and frustration) and their ability to cope 
(accepting and adapting), which consequently affected the severity of impact on daily 
life. Effective self-management strategies included positive coping skills, the ability 
to self-care, readily available social support, finding suitable footwear and accessing 
healthcare. Stoicism was the most commonly identified coping mechanism used by 
participants when describing their foot disease burden. Five participants reported that 
they found it easier to confide in people with PsA due to a mutual understanding of 
the experience and one participant found it beneficial to attend a local arthritis support 
group. With six participants receiving regular podiatry treatment, the majority engaged 
in self-care activities with variable levels of effectiveness and expenditure. The ability 
to self-manage foot problems and reduce foot symptoms to a certain extent was 
associated with a sense of relief and control.  
 
“…if I was in pain I would still force myself to participate” (participant 1) 
 
“I’m at the point now where I wouldn’t mind. In the past I wouldn’t have done 
it” [wearing open-toed shoes] (participant 2) 
 
“… I still have to do what I have to do. I just try and do less of it. Like I try and 
rest in between… but some days I can’t keep pushing myself to go and do it. So 




A mix of good and bad experiences were reported by participants and health 
professionals in relation to footwear. A few participants described that their footwear 
choice had improved their mobility and reduced foot pain. Closed-in shoes helped to 
hide foot problems, protected feet from injury and kept feet warm, whilst open shoes 
helped improve skin psoriasis, were easier to get on and off and kept feet cool. 
Footwear restrictions along with the resultant loss of clothes choice due to foot 
problems had a greater severity of impact on women, who harboured feelings of shame 
and judgement. Climate-related footwear difficulties increased the severity of impact 
of foot problems on body image, functioning and participation. 
 
“… it feels so good to be able to walk around and not be in pain you know what 
I mean. Like um or not have to shuffle around or err know confidently that you 
can, you know, you can go for a walk at lunch time and you’re not going to, 
you know, be in pain by the time you get back” (participant 2) 
 
“I’ve got them shoes for wearing around at day time – they are the best thing 
that happened to me. They’re great” (participant 4) 
 
“I guess shoes are the biggest problem for me…. I need to wear closed-in shoes 
for work... the relief I have when I take them off is unbelievable… I struggle to 
get my shoes on in summer” (participant 11)  
 
Previous healthcare experiences and the level of satisfaction with and effectiveness of 
foot disease management appeared to influence all aspects of a participant’s lived 
experience. Accessing healthcare led to empowering relationships with health 
professionals and improvements to foot symptoms and functioning for some 
participants. Improved understanding of foot manifestations and knowledge of non-
pharmacological foot care interventions appeared to have a positive influence on 
reducing the impact of foot problems. Participants who reported disappointing 
experiences with healthcare services described diagnostic delay in those presenting at 
onset with foot problems; a lack of understanding about foot involvement by health 
professionals and by themselves; unmet expectations of treatment benefit; and 
dissatisfaction with the limited scope of podiatry care received. These concepts were 
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consistent with comments made by the health professionals who discussed in detail 
their patients’ experiences of suboptimal foot disease management. 
 
“Other people… they don't understand how it does affect your life with getting 
up, walking, just simple things” (participant 14) 
 
“…thankfully my wife and my son they’re quite understanding. They 
understood the problem and they helped me a lot” (participant 10)    
 
“I’ve got family members with it so I mean - that’s just us [laugh] …it’s what 
we’ve inherited… just got to get on with it and they’ve all got that same 
attitude” (participant 20) 
 
“…it’s just hard to talk to anyone about it, like I said I must say um if they’ve 
got it themselves they understand…” (participant 14) 
 
4.1.4 Discussion  
This is the first study to explore the impact of foot and ankle problems on people with 
PsA from Australia and New Zealand by interviewing patients and health 
professionals. PsA is associated with musculoskeletal disability (McHugh, et al., 
2003), reduced health-related quality of life (Husted, et al., 2001) and incurs a high 
socioeconomic burden (Tillett, et al., 2015b). This study highlights the specific 
contribution of foot involvement to the disease burden in PsA, which can be spread 
across core disease domains (Orbai, et al., 2017a) such as pain, physical function, 
economic cost, emotional well-being and participation. The complex nature of the 
manifestations of PsA in the foot and ankle were subsequently mirrored in the 
multifaceted functional impairments and activity limitations experienced by 
participants. This qualitative study revealed that people with PsA experienced 
difficulties with foot problems from symptom onset, through to diagnosis and 
management. Our findings show how suffering with debilitating and uncontrollable 
foot symptoms can impact on the lived experience of an individual, and how important 
it can be to gain back control by adopting positive self-management strategies and 
making empowered decisions. In routine healthcare consultations people with PsA 
66 
 
may not have the opportunity to describe in-depth the impact of foot problems on their 
lives.  As a result, the burden may not be properly appreciated by health professionals.  
 
This study provides preliminary insight and understanding of the impact of PsA-
specific foot involvement from the perspective of people with PsA and health 
professionals. Previous studies have linked domains of impact in PsA from qualitative 
studies to the International Classification of Functioning (ICF) framework to allow the 
effect of PsA to be structured and categorised (Taylor, et al., 2010; Gudu, et al., 2017). 
Concepts relevant and important to people with PsA-related foot problems have been 
identified and linking them to the ICF would help to define what should be measured 
in the evaluation of foot disease burden. Establishing a core set of foot-specific 
measures would inform a standardised assessment of the foot in PsA, representing the 
work supported by the GRAPPA (Group for Research and Assessment of Psoriasis 
and Psoriatic Arthritis) (Taylor, et al., 2010). Further research will be to use the ICF 
classification to describe the impact of foot involvement in PsA based on the current 
study findings.  
 
The impact of foot problems in PsA described in this study appear to be similar to 
those reported in other foot-related rheumatic conditions such as altered body image 
(Firth, et al., 2011; Naidoo, et al., 2011), reduced functional capacity and participation 
(Hendry, et al., 2013b; Williams, et al., 2017; Wilson, et al., 2017b), footwear 
restrictions (Naidoo, et al., 2011; Martini, et al., 2012; Hendry, et al., 2013b) and 
suboptimal standards of foot care (Williams and Graham, 2012; Hendry, et al., 2013b; 
de Souza, et al., 2016; Wilson, et al., 2017b). However, in contrast to other rheumatic 
conditions, foot involvement in PsA remains under-researched and poorly understood 
with a lack of large-scale data needed to develop targeted disease-specific 
interventions. Future work will be to develop a survey in order to obtain information 
about foot involvement from a wider range and number of people with PsA across 
Australia and New Zealand, which includes different regions (rural and urban) and 
climate zones (temperature and humidity). Improving our understanding of foot 
involvement in PsA and its impact will also help to inform the development of a PsA-




Limitations of this study included a convenience sampling strategy, as participants 
who volunteered to take part in the study may not be representative of all people with 
foot involvement in PsA or the health professionals who have insight into their 
experiences.  However, both people with PsA and health professionals were invited 
from different socioeconomic geographical locations and healthcare settings within 
the study regions to ensure that a wider range of opinions were collected. The study 
sample was considered to reflect the epidemiology of PsA and is comparable with 
other PsA studies (Gladman, et al., 1987; Torre Alonso, et al., 1991). Foot problems 
from comorbidities such as diabetes and obesity remains a factor in determining their 
relative contribution to symptoms and functioning.  Therefore, findings from this study 
may be subject to bias as confounding variables were not adjusted for. However, 
eliminating the impact of co-morbidities comes at the expense of external validity and 
loss of generalisability in a real-world context. 
 
4.1.5 Conclusion   
In conclusion, people with PsA contend with profound disruptions to their functioning 
and self-image due to foot problems, the effects of which are wide-reaching and spread 
across all aspects of life. Health professionals may underappreciate the psychological 
impact of living with foot problems related to PsA.  
 
4.1.6 Significance and Innovations 
 A diverse expression of PsA disease in the foot caused functional disability and 
altered body-image, which impacted on work, social and family life and had 
psychological consequences. 
 
 Despite the region-specific focus of the current study, the impact of localised 
disease in the foot was profound and widespread across all aspects of life.   
 
 Coping strategies, self-care ability, the availability of social support, finding 
suitable footwear and accessing healthcare were key factors that facilitated or 
impeded the ability of people with PsA to influence the severity of impact from 




 Discordance between the views of people with PsA and health professionals 
were identified. Whilst health professionals recognised the functional and 
visual impact that PsA-related foot problems have on daily life, the emotional 




























Health professional views on the assessment and 
management of foot problems in people with psoriatic 
arthritis in Australia and New Zealand: a qualitative 
investigation 
 
Carter K, Walmsley S, Rome K, Turner DE. Health professional views on the 
assessment and management of foot problems in people with psoriatic arthritis in 
Australia and New Zealand: a qualitative investigation. BMC Musculoskeletal 
Disorders. 2019;20(1):191. 
4.2 Abstract 
Objective: Active foot disease persists in a high proportion of people with psoriatic 
arthritis despite the availability of pharmacological and non-pharmacological 
interventions to modify the course of the disease. Limited information exists on the 
provision of healthcare for foot disease in psoriatic arthritis. The objective of this study 
was to explore the views of health professionals on the assessment and management 
of people with psoriatic arthritis-related foot involvement. 
 
Methods: Convenience sampling was used to recruit health professionals working in 
rheumatology outpatient clinics in Sydney, Australia and Auckland, New Zealand.  
Three focus groups were undertaken to explore the views and experiences of health 
professionals on the assessment and management of foot problems in people with 
psoriatic arthritis. All interviews were audio-recorded and transcribed verbatim. 
Qualitative data was analysed using a constant comparative analytic approach to 
identify themes. 
 
Results: A total of seventeen health professionals participated including 
rheumatologists, podiatrists and a physiotherapist. Key themes derived from the focus 
groups suggest that health professionals perceived that people with psoriatic arthritis-
related foot problems experience suboptimal management from symptom onset, to 
diagnosis and treatment. Frustration was expressed throughout discussions relating to 
lack of appropriate training and expertise required for the specialised management of 
foot problems typically encountered with psoriatic arthritis and poor access for patients 




Conclusions: This study provides new insight into the perspectives of health 
professionals on the management of foot problems related to psoriatic arthritis. 
Deficiencies in the diagnosis, assessment and treatment of foot problems were 
revealed. To meet the foot health needs of people with psoriatic arthritis, reducing 
diagnostic delay, improving knowledge and awareness about the disease among people 
with psoriatic arthritis and health professionals, and increasing specialist podiatry 
service provision may be required. 
 
Key words: Psoriatic arthritis, foot problems, health professionals, qualitative. 
 
 
4.2.1 Introduction  
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterised by a variety 
of musculoskeletal and dermatological manifestations (Coates and Helliwell, 2017). 
The heterogeneity of clinical features makes the diagnosis and management of PsA 
difficult (D’Angelo, et al., 2016; Coates and Helliwell, 2017; Raychaudhuri, et al., 
2017). Major challenges recognised in previous studies on the management of PsA, 
which include under-diagnosis, diagnostic delays and under-treatment (Armstrong, et 
al., 2013; Coates, et al., 2016a; Lebwohl, et al., 2016; Garrido-Cumbrera, et al., 2017), 
are reflected in reports of high foot disease burden associated with PsA (Hyslop, et al., 
2010a). Despite intensive pharmacological management, imaging studies have shown 
that inflammation in the foot is detectable in a high proportion of people with PsA 
(Galluzzo, et al., 2000; Healy, et al., 2008; Delle Sedie, et al., 2011). Clinically 
important levels of foot-related impairment and disability have been identified in those 
with localised inflammatory features in the foot affected by PsA (Hyslop, et al., 
2010a).  
 
Despite UK podiatry services being well established in the public health system, one 
UK-based study found that the majority of people with PsA reported foot pain and had 
not received professional foot care (Hyslop, et al., 2010a). UK podiatrists have 
developed extended scope practices in rheumatology that include specialist training in 
corticosteroid injection therapy, musculoskeletal diagnostic ultrasound, gait analysis 
and rehabilitation (Woodburn, et al., 2010). However, it is generally perceived that 
Australia and New Zealand podiatrists have limited role extension and limited service 
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provision in the public health system and therefore the severity of PsA-related foot 
disease reported in the UK may not represent those in other countries. 
 
Previous studies conducted in Australia (Hendry, et al., 2013b; Hendry, et al., 2013a) 
and New Zealand (Rome, et al., 2009) suggest there is inadequate provision of podiatry 
services and significant unmet demand for foot care amongst people with rheumatoid 
arthritis (RA). It is possible that barriers to foot care exist for people with PsA, but the 
challenges specific to this patient group have not been investigated. Currently there is 
limited evidence to support the management of PsA specific foot problems (Patience, 
et al., 2018). Expert-led recommendations for PsA advocate the integration of podiatry 
within rheumatology multidisciplinary teams for rapid access to specialist foot care 
(Coates and Helliwell, 2017; Patience, et al., 2018). However, little is known about the 
assessment and treatment of foot problems in PsA in Australia and New Zealand. The 
objective of this study was to explore the views of health professionals on the 
assessment and management of people with PsA-related foot involvement. 
 
4.2.2 Methods 
 Study design 
A qualitative research approach was chosen to identify concepts important to health 
professionals and to be able to explore and understand their views. Focus groups were 
used to provide a rich and deep examination of the experiences of health professionals 
through semi-structured, facilitated discussion. Sample size for each focus group was 
based on recommendations suggesting that 4–12 people will generate sufficient data 
(Liamputtong and Ezzy, 2005). Questions relating to the assessment and management 
of foot problems specific to PsA formed the interview guide (Table 4.7). These 
questions were developed based on a review of relevant literature (Hendry, et al., 
2013a; de Souza, et al., 2016; McCulloch, et al., 2018) and were identified as being 
important by the research group, which comprised clinicians and academics.  
 Participants 
A convenience sampling strategy was used to recruit health professionals from 
rheumatology outpatient clinics in Sydney, Australia and Auckland, New Zealand. 
Participating sites were selected to include health professionals from public and private 
sectors in hospital and community-based services, from lower and higher 
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socioeconomic geographical areas and to provide local data from Australia and New 
Zealand. Health professionals with clinical experience of managing people with PsA, 
working in Australia or New Zealand were eligible for inclusion (Carter, et al., 2019a). 
Potential participants were recruited by response to an invitation email containing an 
outline of the study, screening form and contact details of the primary researcher (KC). 
Ethical approval was granted by the South Western Sydney Local Health District 
(HREC/171/LPOOL/353), the Auckland University of Technology Ethics Committee 
(AUTEC 17/320) and the Waitemata District Health Board of Auckland New Zealand 
(RM/3907) (Appendix 1). Written informed consent was provided by all participants 
prior to data collection (Appendix 2). 
 Procedure 
Prior to the focus groups, demographic data was recorded including gender, ethnicity, 
occupation and the number of years of clinical experience. The focus groups were 
conducted by the same researcher (KC) and supported by a second investigator (SW). 
All focus groups were audio-recorded and transcribed verbatim immediately after each 
session. Data was collected between October 2017 and March 2018. 
 Data analysis 
Demographic data was summarised using descriptive statistics. Focus group 
transcripts were anonymised and imported into a data analysis software package 
(ATLAS-ti version 7.5.7 Scientific Software Development GmbH, Berlin, Germany, 
https://atlasti.com). Constant comparative analysis was used to identify themes from 
the data by inductive category coding and simultaneous comparison of all meaningful 
units (Morehouse and Maykut, 1994). Codes were generated by the first author (KC) 
and validated by the second author (SW). Themes and sub-themes were developed and 
refined by discussion between KC and SW. The full research team reviewed and 
agreed the final themes, which were subsequently validated by two randomly selected 








Table 4.7. Focus group interview guide for health professionals with experience of 




1 How often do you examine the 
feet of patients with psoriatic 
arthritis? 
Why do you think that is? 
 
2 Have you encountered any 
barriers in relation to your 
patients receiving appropriate 
foot care? 
Do patients seek help with foot 
problems? From whom? 
Have your patients reported any 
barriers to accessing appropriate foot 
care services to you? 
What factors do you think make it 
difficult for patients to access 
appropriate foot care? 
3 Is there anything else you would 
like to add concerning the 
experiences of your patients in 





Three broad themes underpinning suboptimal foot disease management were derived 
from the data (Table 4.8). Exemplars were identified from the transcripts to support 
each theme. Suboptimal foot disease management was the overarching description of 
the sub-themes and represents the unmet need in the screening, assessment, diagnosis 
and treatment of people with PsA-related foot problems. Suboptimal foot healthcare 
describes clinical practice that falls below recognised standards of care that promote 
early detection and tight control of disease in PsA. 
 
Table 4.8. Emergent themes from the focus groups with health professionals.  
Emergent themes Sub-themes 
1. Missed opportunities and 
diagnostic delay 
Lack of recognition of foot problems by health 
professionals  
Lack of patient knowledge relating to foot problems 
Socioeconomic disparities in care 
2. Challenges related to the 
management of foot problems 
in PsA 
Varied and fluctuating clinical presentations of PsA 
Complexity of foot examination 
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Lack of appropriate training and knowledge across 
professions for the management of foot health 
problems associated with rheumatic disease  
3. Lack of specialist podiatry 
service provision 
Lack of specialised podiatrists working within 
multidisciplinary rheumatology teams  
Lack of allied health professionals with a specialist 
interest and expertise in inflammatory arthritis  
Perceived patient dissatisfaction with limited scope 
of podiatry practice and high cost of ineffective 
treatments such as foot orthoses 
 
 
Theme 1: Missed opportunities and diagnostic delay. Diagnostic delays in those 
presenting at disease onset with foot problems were reportedly due to patients either 
not seeking early medical attention or that foot problems were initially mistaken by 
health professionals as non-inflammatory musculoskeletal conditions. The health 
professionals recognised that a PsA diagnosis depends, in part, on whether a GP, allied 
health professional or dermatologist has the specific knowledge and skill to recognize 
the symptoms and promptly refer the patient to a rheumatologist. There was a general 
consensus amongst the rheumatologists that more information about PsA should be 
provided to people with psoriasis attending dermatology clinics.  
 
“…they’ll be sent through by musculoskeletal physicians who have been 
treating for tendonitis thinking that’s due to injury” (rheumatologist 9)  
 
An earlier diagnosis was described in relation to achieving better disease outcomes 
and was associated with patients attending private rheumatology practice, having a 
higher socioeconomic status and presenting with acute inflammatory foot 
involvement. 
“…the patients I see in (private practice) would be presenting much earlier 
because they’re more likely to go and speak with their GP sooner about 
problems and they have the resources to get into see a specialist quickly. So 
they come when they’re in their early inflammatory phase” (rheumatologist 
6) 
The rheumatologists identified the focus of consultations to be on the medical 
management of PsA. Although it was recognised that some patients may not mention 
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foot problems during rheumatology consultations, nearly all the rheumatologists 
agreed that they would not routinely ask about or assess the feet unless the patient 
reported having foot and ankle symptoms. This combined with the perceived view that 
many patients fail to disclose foot problems to the rheumatologists suggests that the 
opportunities for diagnosis of foot involvement and referral to podiatry services are 
being missed.  
 
“…it’s what’s most important because they might feel like they’ve got 5 
minutes to tell you. So they’ll come in with a list of things they want to tell 
you…So it depends…if everything else is going really well but this is the 
biggest thing at the moment they might mention it” (rheumatologist 5) 
 
Theme 2: Challenges related to the management of foot problems in PsA. Foot 
pain in PsA was described in relation to global disease activity, local disease activity 
and/or mechanical pathology, and given this potential for diverse clinical presentations 
it was acknowledged to be challenging to assess and manage.  Frequent reference was 
made to active foot disease persisting in many patients, despite achieving tight control 
of their disease with pharmacological treatment.  
 
“The big difference with psoriatic arthritis is its periodicity and 
unpredictability so that people at times can do things and at other times it’s 
really difficult” (rheumatologist 13)  
 
“But once it’s established [foot involvement] it’s just hard…It’s probably one 
of the hardest things to treat” (physiotherapist 3) 
 
“…it’s such a heterogeneous disease…it’s a strange beast this disease” 
(rheumatologist 14) 
 
The most commonly highlighted barriers to the assessment of the foot in PsA by 
rheumatologists during consultations included high disease burden leading to time 
constraints; low priority of foot disease attributed by the patient; the complexity of 
foot assessments compounded by lack of training; and a lack of opportunity for onward 
referral. Difficulty with clinical examination of feet and ankles amongst the 
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rheumatologists was attributed to the complex nature of the structure and function of 
foot anatomy and the interpretation of swelling in the presence of gravitational oedema 
and obesity. Further training on clinical and image-based foot examinations was 
deemed important in order to improve identification of pathologies that would benefit 
from appropriate referral and intervention.  
 
“The feet I think are architecturally a bit complex and not always as straight 
forward as hands” (rheumatology registrar 11) 
 
“You know us rheumatologists…we are not really trained at all in terms of the 
functional, like the ankle or the heel and various things… like how the foot 
should work or take off” (rheumatologist 5)  
 
Health professionals reported that patients had difficulty with describing and localising 
foot pain, which appeared to be related to the fluctuating nature of symptoms and being 
unable to distinguish between joints and skin related symptoms. This further 
contributed to the difficulty of identifying and assessing foot problems. 
 
 “If you ask them to point they use their whole hand and sort of go ‘Oh here’ 
over like 80% of the surface of the foot. Even that’s hard so you’ve often got to 
focally press and find where they wince or are tender and that can help narrow 
down” (rheumatologist 16) 
 
An additional barrier to the identification of local inflammatory features in the foot, 
reported by rheumatologists in New Zealand, was having limited access to imaging 
and to the expertise required to accurately interpret the findings.  
 
“Here most of us don’t use that… we don’t use it routinely [Musculoskeletal 
diagnostic ultrasound]. We had a machine but it’s been taken away” 
(rheumatologist 9 – New Zealand) 
 
“…quite often the report will come back on ultrasound inter-metatarsal 
bursitis, what does that mean? A bit of fluid here and there you know so it’s 




“We don’t actually really know what the normal range is that’s the problem” 
[Musculoskeletal diagnostic ultrasound] (rheumatologist 12 – New Zealand) 
 
“I just haven’t got my head around what the normal is for MRI is of the feet” 
(rheumatologist 13 – New Zealand) 
 
Theme 3. Lack of specialist podiatry service provision. One of the major barriers to 
rheumatologists performing foot examinations was the lack of access to specialised 
podiatry services in both public hospitals and private clinics.   
 
“I’ve heard before people will say ‘Why ask patients about their feet because 
I’ll uncover something that I actually can’t help with’. So why open Pandora’s 
box effectively” (podiatrist 7) 
 
 “…sometimes I wonder if we sort of give up a bit. In our hearts because yeah 
what’s the point of assessing when we can’t do anything about it…we’re not 
the experts on feet, we are you know we’re rheumatologists, but we don’t 
necessarily have access to the experts” (rheumatologist 6)  
 
It was identified by health professionals in Australia and New Zealand that whilst 
adequate podiatry service provision had been made in the public health system for 
people with diabetes who have foot problems, only a few high risk foot clinics would 
accept people with inflammatory arthritis-related foot problems. 
 
“I do find this quite bizarre that you’re really much better off to have diabetes 
if you’re going to have bad feet…I’ve had to watch people being shown the 
door with big ulcerations because they don’t have diabetes, which does seem 
a bit potty doesn’t it” (podiatrist 8)  
 
The lack of a multi-disciplinary team approach to preventative care, effective 
intervention and patient-centred management of PsA was a key topic of discussion 
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during the focus groups, which revealed feelings of frustration. Lack of podiatrists and 
physiotherapists (in both public and private sectors) with specialist interest, training 
and knowledge in inflammatory arthritis was a problem reported by the 
rheumatologists signposting to professional foot care.  
 
“I find it hard to find the right podiatrist… I don’t know that any of them really 
specialise in inflammatory foot conditions. But finding someone with an 
interest in inflammatory arthritis is very difficult” (rheumatologist 6) 
 
Other barriers preventing uptake of podiatry services by people with PsA perceived by 
the health professionals were financial constraints and dissatisfaction with podiatry 
care received based on ineffective treatment and/or unfulfilled expectations due to 
limited scope of practice. Whilst there was awareness amongst the podiatrists of 
limited extended-scope practice, ineffective foot care was also linked to the limited 
evidence to date for non-pharmacological interventions for foot disease in PsA. 
 
“Yes, a lot of podiatrists would just simply scrape some hard skin down and 
perhaps don’t have enough insight to be able to comprehensively assess 
patients as well” (podiatrist 7)  
4.2.4 Discussion 
This is the first study to explore the views of health professionals involved in the 
management of foot problems in people with PsA. The results indicate that foot health 
needs were not being fully met due to deficiencies in the diagnosis, assessment and 
treatment of foot problems related to PsA in Australia and New Zealand. A recent 
expert review stated that the identification and treatment of PsA were still not optimal 
(Coates and Helliwell, 2017), which suggests that unmet needs in the management of 
PsA is a much broader problem. The finding of suboptimal foot disease management 
in the current study may help to explain the reported persistence of active inflammation 
in the foot and ankle with a lack of specialist foot care for early detection and tight 
control of the disease. Suboptimal foot disease management was the overarching 
description of the sub-themes, with the term suboptimal encompassing limitations in 
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the diagnosis and assessment of localised foot disease and inadequacies in the 
provision of timely and effective foot healthcare, thus identifying the need for 
improvement in the current management of foot health among people with PsA. 
 
Focus group discussions identified that detecting early signs of PsA in the foot was 
challenging for health professionals due to a lack of awareness about the disease. This 
study finding supports previous reports of significant delays in PsA diagnosis (Coates, 
et al., 2016a; Garrido-Cumbrera, et al., 2017). Contributing factors to the under-
diagnosis of PsA reported in previous studies are the failure to connect skin and joint 
symptoms and the difficulty in differentiating between inflammatory arthritis and 
mechanical joint pain (Lebwohl, et al., 2016; Coates and Helliwell, 2017).  
 
Foot examination during routine rheumatology consultations was reported to be 
variable in this study, despite the recognition among health professionals of disease 
persistence in the feet. This finding is consistent with our knowledge of foot problems 
being overlooked in other rheumatic conditions (de Souza, et al., 2016; Williams, et 
al., 2017). Early identification of foot involvement in PsA is of clinical importance as 
this has been shown to be a predictor for joint damage (Cresswell, et al., 2011). 
Evidence-driven recommendations state that the full 66-68 joint count be used 
routinely to assess people with PsA, as significant proportions of active disease can be 
missed in the feet and hands (Coates, et al., 2013; Coates and Helliwell, 2017). No 
guidelines exist for foot assessment in PsA and the omission of many anatomical sites 
in the foot and ankle from standard clinical indices, may lead to active disease in the 
foot being missed along with the opportunity to prevent joint damage.  
 
The complexity of foot examination has been acknowledged within the PsA literature 
and is partly due to the heterogeneity of clinical symptoms (Galluzzo, et al., 2000; 
Cresswell, et al., 2011; Delle Sedie, et al., 2011). This study identified the need for 
specialist training of podiatrists and rheumatologists to develop advanced skills for 
managing foot health in rheumatic disease. Inadequate podiatry service provision in 
the public health system reported in this study may in part explain the lack of foot care 
specialists in the rheumatology field because health service demand typically drives 
training need. Postgraduate training courses have been implemented in the UK in 
response to such concerns within the wider rheumatology community (Woodburn, et 
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al., 2010). This model may need to be expanded in Australia and New Zealand to 
facilitate knowledge transfer between rheumatologists and allied health professionals 
in the absence of multidisciplinary rheumatology teams.  
 
Establishing locally representative data on the challenges of foot disease management 
in PsA is an important step towards improving management approaches in the future. 
Limited information from European studies on the provision of healthcare for foot 
disease in PsA (Hyslop, et al., 2010a) may not translate to other countries, due to 
differences in healthcare structure, organisation and provision. Although previous 
research has focused on local RA foot care provision (Rome, et al., 2009; Hendry, et 
al., 2013b), PsA is a distinct disease entity with different challenges associated with 
disease management, which is supported by the current study themes.   
 
Difficulty experienced by patients with describing and localising symptoms in the foot 
and ankle was recognised by the health professionals in this study. Although this issue 
has been previously highlighted in RA (Hitchen and Otter, 2010), it has heightened 
relevance in PsA with previous studies demonstrating that patients have difficulty 
distinguishing between the musculoskeletal and dermatological components of their 
disease (Cauli, et al., 2011). To facilitate foot pain self-report and localisation, foot 
manikins have been utilised in both clinical practice and population-based research 
(Garrow, et al., 2004; Roddy, et al., 2011; Otter, et al., 2016). However, it is not known 
how accurately pain locations are transferred on to foot manikins by people with PsA-
related foot pain. Routine use of musculoskeletal diagnostic ultrasound in clinical 
practice would further optimise the identification of localised disease activity in the 
foot in PsA, and the health professionals in this study highlighted the training and 
development of expertise required to accurately interpret image-based findings.  
 
Key concepts regarding foot disease management in PsA comprise reducing diagnostic 
delay, improving knowledge and awareness among patients and health professionals 
and increasing specialist podiatry service provision. A better understanding of disease 
persistence in the foot in PsA is required to inform the direction of future research in 
this area. Future work involves implementation of a survey to obtain information about 
foot involvement from people with PsA, generating population-based data for 
Australia and New Zealand. Early identification of foot and ankle problems using a 
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screening tool or outcome measure specific to PsA may help to prevent non-disclosure 
of foot problems by patients and promote more timely referral and intervention. 
Currently there are no validated outcome measures specific to foot involvement and 
its impact in PsA, which limits our understanding of foot disease in PsA and impedes 
definitive strategies for ‘tight control’ of disease activity in the foot. Further work to 
validate the use of foot manikins in PsA may help to improve foot pain reporting by 
patients.   
 
This study was preliminary and exploratory in nature, involving a small number of 
participants.  As such, the findings may not be representative of health professional in 
other regions of Australia and New Zealand.  However, the small sample size provided 
the opportunity for deeper exploration within a qualitative paradigm and recruitment 
continued until qualitative data saturation was reached. Rheumatology nurses and 
dermatologists were invited to take part in the study but were unable to attend, 
resulting in an under representation of these professional groups. The views of people 
with PsA-related foot problems were not sought in this current study as the focus was 
to explore experiences related to foot health assessment and management from the 
perspective of rheumatology health professionals working with this patient group. 
Future work on patient’s views is required. 
 
4.2.5 Conclusions  
This study has generated preliminary evidence that suggests the identification and 
management of PsA-related foot involvement may potentially be suboptimal in 
Australia and New Zealand. Further work is required to investigate the nature and 
extent of foot involvement and related impacts from the patient perspective, and to 
further examine current foot care deficiencies in PsA with a view to remediation.   
 
4.2.6 Significance and Innovations  
 Preliminary evidence suggests deficiencies in the diagnosis, assessment and 
treatment of foot problems related to PsA in Australia and New Zealand. 
 
 Frustration among health professions unable to meet the needs of their patients 
was attributed to a lack of appropriate training in managing foot health in 




 Key priorities regarding foot disease management in PsA comprise reducing 
diagnostic delay, improving knowledge and awareness among patients and 






























5 Linking to the International Classification of 
Functioning, Disability and Health (ICF) 
This chapter describes a study that linked concepts, obtained from the previous 
qualitative investigation on the patient experience of PsA-related foot involvement, to 
the International Classification of Functioning, Disability and Health (ICF). The ICF 
has been developed and endorsed by the World Health Organisation (WHO) as a 
universal framework and classification system to describe functional states associated 
with health conditions. To gain a better understanding of the extent and coverage of 
themes identified by the qualitative work in Chapter 4, concepts derived were linked 
to the ICF in order to 1) use common terminology to comprehensively describe the 
impact of localised disease in the foot on functioning and 2) to identify what should 
be included in the future development of foot-specific PsA assessment tools. Detailed 
descriptions of the preliminary work, prior to linking to the ICF, have been previously 
reported (Carter, et al., 2019a; Carter, et al., 2019b) (studies presented in Chapter 4). 
 
Study 1) Linking the patient experience of foot involvement related to psoriatic 
arthritis to the International Classification of Functioning, Disability and Health. 
The study objective was to categorise the patient experience of PsA-related foot 
involvement by linking it descriptive concepts from the qualitative study to the ICF. 
 
This manuscript has been accepted for publication in the journal Rheumatology 
Advances in Practice and the authors include Carter K, Tannous C, Walmsley S, Rome 
K and Turner DE.  
 
This research was presented at the European League Against Rheumatism (EULAR) 
conference, Madrid, Spain in June 2019 (Conference abstract and poster in Appendix 
4: Linking the patient experience of foot involvement related to psoriatic arthritis to 
the International Classification of Functioning, Disability and Health). 
 
The study in chapter 5 is presented in the form of a stand-alone published paper. In the 
context of the thesis it is directly linked to the initial qualitative study and therefore 
represents the next step in the survey development process. This subsequent study used 
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concepts derived from the initial qualitative study that were relevant to people with 
PsA-related foot problems and mapped them to a recognised health framework. This 
mapping exercise was integral to the development of a national survey on foot 
involvement in PsA, since the categorisation of concepts determined what should be 
measured by the survey. Therefore, this study informed both the conceptual framework 
of the survey and survey content generation. In the results section 5.5.3 pages 102-
104, additional commentary on the difficulties encountered when linking to the ICF 
was included in the chapter, taken from the supplementary material of the publication. 
In the discussion section 5.6 page 105, commentary on the current study in the context 




















Linking the patient experience of foot involvement 
related to psoriatic arthritis to the International 
Classification of Functioning, Disability and Health 
5.1 Abstract 
Objective. To categorise the patient experience of psoriatic arthritis (PsA)-related foot 
involvement by linking it to the International Classification of Functioning, Disability 
and Health (ICF) framework.  
 
Methods. Concepts, obtained from a previous qualitative investigation of people with 
PsA and health professionals into their perspective of PsA-related foot involvement, 
were linked to the full version of the ICF classification. Concepts were linked to the 
most appropriate ICF category using established linking rules, which enable a 
systematic and standardised linking process. All concepts were independently linked 
to the ICF by 2 investigators, followed by a third investigator for adjudication. 
Investigator professional backgrounds included occupational therapy and podiatry.       
 
Results. Over 100 distinct ICF categories were linked to the interview concepts. The 
most represented ICF category was body functions (35%), followed by environmental 
factors (31%), activities and participation (19%) and body structure (15%). Concepts 
that could not be linked to the ICF were related to coping, aspects of time and 
knowledge. Health professionals identified a greater proportion of body functions and 
fewer activity and participation categories compared with patients, indicating a 
possible mismatch of key concerns. Interdisciplinary group analysis demonstrated 
merit. 
 
Conclusion. A list of ICF categories was generated, defining aspects of functioning 
important and relevant to the impact of PsA-related foot involvement. Despite the 
localised anatomical focus of this study, the effect of foot problems in PsA was linked 
to all components of the ICF, confirming the profound impact on functioning and daily 
life. 
 
Key words: Psoriatic arthritis; Foot; International Classification of Functioning, 




5.2 Glossary of ICF-specific terms  
 
s  Body Structure  
b  Body Function 
d  Activities and Participation 
e  Environmental Factors 
pf   Personal Factors 
nc  not covered 
hc  health condition 
nd   not definable 
nd-gh  not definable general health 
nd-ph  not definable physical health 

























Previous research has shown merit in linking domains of impact in psoriatic arthritis 
(PsA) to the International Classification of Functioning, Disability and Health (ICF) 
to categorise the effect of global disease (Taylor, et al., 2010; Gudu, et al., 2017; 
Sunkureddi, et al., 2018). Identifying ICF categories relevant to PsA provides a 
conceptual basis to define what should be measured in the development of outcome 
measures and assessment tools (Boonen, et al., 2009a; Taylor, et al., 2010; Gudu, et 
al., 2017). As an internationally accepted framework, the ICF has been widely used 
and advocated by the OMERACT (Outcome Measures in Rheumatology Clinical 
Trials) as a reference model to better describe the OMERACT domains relating to 
functioning and to evaluate health outcome measurement (Stucki, et al., 2007; Boonen, 
et al., 2009a). Previous studies have used the ICF to show that concepts important to 
people with PsA are not adequately covered by the standard self-report instruments 
currently used to measure functioning in PsA (Stamm, et al., 2007b; Escorpizo, et al., 
2011). The main reasons for this are that existing instruments often contain items that 
cover different domains (for example, joints, skin, enthesitis, dactylitis, spine, pain, 
physical function, quality of life) due to the heterogeneity of clinical manifestations in 
PsA, and many of the instruments have been adapted from other rheumatic diseases 
with few disease-specific instruments for PsA currently available (Gladman, et al., 
2004; Mease, 2011). Furthermore, incorporation of the patient perspective in the 
development of outcome measures and domains in PsA is often lacking (Palominos, 
et al., 2012; Tillett, et al., 2014), which limits the potential value of the outcome as 
discrepancies have been reported between the views of patients and health 
professionals (Dandorfer, et al., 2012).  
 
Localised pain and disease persistence in the foot in PsA is well recognised (Galluzzo, 
et al., 2000; Healy, et al., 2008; Hyslop, et al., 2010a; Delle Sedie, et al., 2011; Turner, 
et al., 2014), but limited foot-specific research exists and there are no outcome 
measures to comprehensively assess foot involvement in PsA and its impact on a 
person’s function and participation. Previous studies have used the Leeds Foot Impact 
Scale (LFIS) (Helliwell, et al., 2005a) to assess foot-related disability in PsA (Hyslop, 
et al., 2010a; Hyslop, et al., 2010b; Woodburn, et al., 2013; Turner, et al., 2014; 
Wilkins, et al., 2016), which consists of sub-scales aligned to the ICF. Whilst this 
approach has merit in that the LFIS was robustly developed using patient perspectives 
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in rheumatoid arthritis, it is unlikely to adequately capture the combined 
musculoskeletal and dermatological impact in PsA. Indeed, few qualitative studies 
have identified that local foot disease in PsA can cause substantial functional 
impairments and visual differences, which can negatively impact on emotional well-
being and on all aspects of life (Carter, et al., 2019a; Carter, et al., 2019b). To date 
little is known about the patient experience of foot involvement and how this may link 
to the ICF to capture and describe disease impact. The objective of this study was to 
categorise the patient experience of PsA-related foot involvement by linking 
descriptive concepts to the ICF. 
 
5.4 Methods 
5.4.1 Concepts from previous qualitative study  
A qualitative study was previously performed based on semi-structured, one-to-one 
interviews of people with PsA (n=21) and three multidisciplinary focus groups among 
health professionals (Carter, et al., 2019a). A total of 17 health professionals with 
clinical experience of managing this patient group participated in 3 separate focus 
groups (comprising groups of n=8, n=5, n=4), including podiatrists, physiotherapists 
and rheumatologists. The interviews and focus groups covered specific areas of 
interest, which included (1) foot involvement in PsA, (2) its impact on daily life, (3) 
experiences with footwear and (4) foot care needs. Each interview and focus group 
was audio-recorded, transcribed verbatim and analysed using the constant comparative 
method for qualitative data (Morehouse and Maykut, 1994). Meaningful concepts 
within the text, such as words or sentences containing relevant contextual information, 






Qualitative investigation to explore the patient experience of the impact of 
foot involvement in psoriatic arthritis
Meaningful concepts were identified from the qualitative data 
using an inductive method of qualitative analysis
Concepts were independently  
linked to the ICF by 
investigator 1 (podiatrist)
Concepts were independently 
linked to the ICF by investigator 2
(occupational therapist)
Consensus-based process between investigators 1 and 2 with adjudication by 
investigator 3 for final agreement on linking of concepts to ICF categories
A list of ICF categories defining the typical spectrum of problems in functioning 
relevant to foot involvement in psoriatic arthritis  




Figure 5.1. The study design process. 
ICF International Classification of Functioning, Disability and Health. 
 
 
Qualitative research typically uses small sample sizes with a diverse range of 
participants in order to obtain rich data that allows in-depth exploration and 
understanding of the research question (Ritchie, et al., 2009). A representative sample 
was sought from the public and private sector, and from lower and higher 
socioeconomic geographical areas in Australia and New Zealand. Recruitment to the 
study continued until qualitative data saturation of emerging concepts was achieved 
(Francis, et al., 2010). Ethical approval was granted by; the South Western Sydney 
Local Health District (HREC/171/LPOOL/353), the Auckland University of 
Technology Ethics Committee (AUTEC 17/320) and the Waitemata District Health 
Board of Auckland New Zealand (RM/3907) (Appendix 1), and informed consent was 
obtained from all participants (Appendix 2). Detailed descriptions of the preliminary 
work have been previously reported (Carter, et al., 2019a; Carter, et al., 2019b) (studies 
presented in Chapter 4). 
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5.4.2 Linking to the International Classification of Functioning, Disability and 
Health  
The International Classification of Functioning, Disability and Health (ICF) has been 
developed and endorsed by the World Health Organisation (WHO) as a universal 
framework and classification system to describe functional states associated with 
health conditions (WHO, 2001). The ICF framework supports the biopsychosocial 
model of health by recognising the influence of contextual factors on functioning and 
disability. Based on this model, functioning is described as the complex interplay of 
the main health components; Body Structure, Body Functions, Activities and 
Participation, Environmental and Personal Factors (Figure 2.2, Chapter 2, section 2.5). 
By shifting the focus from health condition to functioning, the ICF places all health 
conditions on an equal footing, allowing them to be compared in terms of their related 
functioning via a common framework. The ICF provides a standard language and 
conceptual basis for the definition and measurement of disability (WHO, 2001). The 
ICF classification system comprises 1454 categories that are an exhaustive list of 
globally accepted descriptions of what can be relevant to people with a health 
condition experiencing decrements in functioning (WHO, 2001). 
 
The structure of the ICF has two parts, part 1 covers functioning and disability that 
includes the components Body Structure (categories with the letter s), Body Functions 
(categories with the letter b), and Activities and Participation (categories with the letter 
d). Part 2 covers contextual factors that includes the components Environmental 
Factors (categories with the letter e) and Personal Factors (whole component specified 
with the letters pf). Within each component (except Personal Factors), there are 
multiple categories that are hierarchically grouped within chapters and denoted by 
unique alphanumeric codes. Within each chapter there are 2nd level, 3rd level and 4th 
level categories, which are the units of the classification (WHO, 2001). Within each 
chapter, the categories are arranged in a stem, branch, leaf scheme. Consequently, a 
lower-level category shares the attributes of the higher-level category to which it 
belongs. Hierarchically grouped, the 2nd, 3rd and 4th level categories represent 
increasingly more detailed frames of reference. Higher-levels of linking indicate 
greater specification (Figure 5.2). For example, b2 Sensory functions and pain (1st 
level/chapter), b280 Sensation of pain (2nd level), b2801 Pain in body part (3rd level) 





Figure 5.2. Structure of the ICF (WHO, 2001). 
ICF International Classification of Functioning, Disability and Health. 
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Personal factors are defined in the ICF as the particular background of an individual’s 
life and living, and comprise features of the individual that are not part of health 
condition. These factors include gender, race, age, other health conditions, fitness, 
lifestyle, habits, upbringing, coping styles, social background, education, profession, 
past and current experience, overall behaviour pattern and character style, individual 
psychological assets and other characteristics (WHO, 2001).  
 
Linking refers to the procedure in which the concepts within the items of the 
instrument or interviews are translated into ICF language, meaning the concepts are 
fitted to the most related ICF category (Boonen, et al., 2009a). The number of 
categories should be as low as possible but as high as needed to accurately reflect 
functioning for the particular health condition. Linking rules have been developed to 
standardise the process of connecting outcome measures and qualitative data to the 
ICF classification (Cieza, et al., 2002; Cieza, et al., 2005; Cieza, et al., 2019).  
 
Each concept, obtained from the previous qualitative interviews and focus groups, was 
linked to the most appropriate ICF category according to established linking rules 
(Cieza, et al., 2002) and their updates (Cieza, et al., 2005; Cieza, et al., 2019).  The 
linking rules inform a systematic linking process and facilitate the standardised 
identification of the linkage between qualitative concepts and ICF categories (Cieza, 
et al., 2002; Cieza, et al., 2005; Cieza, et al., 2019). Using the online ICF classification 
tool in its full version, each concept was linked to the most precise ICF category. If a 
concept contained sub-concepts it was linked to more than one ICF category. For 
example, a statement from the qualitative data is “Due to the pain in my feet I didn’t 
want to meet up with my friends”, in which the concepts would be ‘foot pain’ and 
‘impact - meeting up with friends’ and the ICF categories linked to them would be 
‘b28015 pain in the lower limb’ and ‘d9205 socialising’ (more examples are provided 
in Appendix 5 in Supplementary Table 1). 
 
Concepts that could not be linked to the ICF were assigned ‘not covered’ (nc), such as 
the concept “disease progression” in the current study. Concepts related to personal 
factors were linked to the ICF whole component ‘personal factors’ (pf) because this 
ICF component does not include separate categories. Concepts relating to health 
conditions other than PsA were assigned as ‘health condition’ (hc). If there was 
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insufficient information to make a decision about which ICF category should be 
linked, it was assigned as not definable (nd), including concepts referring to general 
health (nd-gh), physical health (nd-ph) and quality of life in general (nd-qol). The 
‘other specified’ and ‘unspecified’ categories at the end of each chapter were used if a 
concept was not explicitly specified. 
  
 Accuracy of analysis 
All concepts were independently linked to the ICF by 2 investigators (KC, CT). After 
the independent linking process was complete, the investigators discussed differences 
in their linking in order to obtain consensus regarding a final set of categories. The 
third investigator (DET) assessed all categories, adjudicated cases of disagreement and 
determined the final category. If required, interview transcripts were reviewed to 
ensure that the concept had been interpreted accurately. Investigator professional 
backgrounds included occupational therapy and podiatry, and all three investigators 
undertook self-directed training in linking concepts to the ICF using the eLearning 
resources developed by the WHO (WHO, 2015). Full understanding of the concepts 
and structure of the ICF was required by the investigators prior to commencing the 
linking process (Cieza, et al., 2019). In addition, the three investigators had experience 
of qualitative research methods and 15 years of clinical practice experience.   
 
The degree of agreement between the 2 investigators in linking concepts to the ICF 
was calculated using total percentage agreement and the unweighted kappa statistic 
(Cohen, 1960). Data were recorded for each of the 4 main components of the ICF for 
linking of the patient and health professional concepts individually and combined. 
Kappa values can range from 0 to 1, where 1 indicates perfect agreement and 0 
indicates no additional agreement beyond what is expected by chance alone. When 
interpreting kappa statistics, published definitions were used to determine the degree 
of agreement (Landis and Koch, 1977). The analysis was performed using SPSS 
version 25 software (SPSS, Inc., Chicago, IL). Descriptive statistics were used to 





A total of 1363 relevant concepts were identified from the interviews of people with 
PsA and the focus groups with health professionals. The frequency with which each 
of these concepts were reported among all participants was 4774, of which 924 were 
from health professionals and 3850 were from people with PsA.  
5.5.1 Frequency of ICF categories  
One hundred and forty-eight distinct ICF categories were linked to the interview and 
focus group concepts, which related to Body Structures (n=17, 12%), Body Functions 
(n=48, 32%), Activities and Participation (n=55, 37%), and Environmental Factors 
(n=28, 19%).  
 
The most represented ICF component was Body Functions (35%), followed by 
Environmental Factors (31%), Activities and Participation (19%) and Body Structure 
(15%) (Tables 5.1, 5.2, 5.3 and 5.4). The most frequent 3rd level categories were body 
image (b1801), maintaining one’s health (d5702) and footwear that was linked to 
general products and technology for personal use in daily living (e1150). The most 
frequent 2nd level categories were emotional functions (b152), walking (d450), 
carrying out daily routine (d230) and health services, systems and policies (e580). Also 
cited frequently was the major life area of remunerative employment (d850), followed 
by the impact on family (d760) and social life (d920).  
 
The majority of concepts reported by people with PsA were linked to 3rd level (more 
precise) ICF categories across all 4 components. Environmental Factors most relevant 
to people with PsA were footwear and assistive devices such as insoles, access to 
healthcare, support from family and health professionals, drugs and climate. High 
levels of self-care activity were reported among people with PsA, which covered 
maintaining and looking after one’s health, and caring for skin and toenails, and these 
concepts were linked to healthcare access, financial assets and assistive devices. 
Toenail changes, relating to structure and function, were also frequently cited by 
people with PsA and linked to domains of body image and social relationships. Lack 
of understanding about the disease was a strong theme from the patient experience and 
was linked to the attitudes of friends, family, colleagues, strangers and health 
professionals, but it was difficult to link aspects of knowledge and education that did 




Body Structures that were not foot-specific were related to spine and hand 
involvement. Proximal issues at spine level impacted on mobility and stability at foot 
level, and problems with hands and fingernails were reported by way of comparison 
with foot and toenail problems.   
 
Table 5.1. The frequency of ICF categories for the component Body Structure that 
were linked from concepts obtained from people with psoriatic arthritis and health 
professionals.  
ICF categories 








arthritis, n (%) 
s75021 Ankle joint and joints foot and toes 73 (33%) 305 (34%) 
s8104 Skin of lower extremity  14 (6%) 194 (21%) 
s8301 Toenails 31 (14%) 143 (16%) 
s7502 Structure of ankle and foot 62 (28%) 142 (15%) 
s75022 Muscles of ankle and foot 19 (9%) 53 (6%) 
s75012 Muscles of lower leg 0 23 (3%) 
s7302 Structure of hand 4 (2%) 13 (1.5%) 
s750 Structure of lower extremity 0 8 (0.9%) 
s75023 Ligaments and fasciae of ankle and foot  13 (6%) 7 (0.7%) 
S7703 Extra-articular ligaments, fasciae, 
extramuscular aponeuroses, retinacula, septa, 
bursae, unspecified 
3 (1.5%) 5 (0.5%) 
s7501 Structure of lower leg 0 4 (0.4%) 
s75011 Knee joint 0 3 (0.3%) 
s8300 Fingernails 1 (0.5%) 2 (0.2%) 
s7600 Structure of vertebral column 0 2 (0.2%) 
s75020 Bones of ankle and foot 0 1 (0.1%) 
s73021 Joints of hands and fingers 0 1 (0.1%) 
s7401 Joints of pelvic region 0 1 (0.1%) 
Total 220 907 




Table 5.2. The frequency of ICF categories for the component Body Function that were 
linked from concepts obtained from people with psoriatic arthritis and health 
professionals.   
ICF categories 








arthritis, n (%) 
b28015 Pain in lower limb 166 (39.1%) 657 (29.5%) 
b152 Emotional functions 48 (11.3%) 245 (11%) 
b1801 Body image 44  (10.3%) 149 (6.7%) 
b860 Functions of nails 20 (5%) 122 (5.5%) 
b8 Functions of skin  13 (3.1%) 119 (5.4%) 
b126 Temperament and personality functions 9 (2%) 114 (5.1%) 
b770 Gait pattern functions 8 (1.8%) 88 (4%) 
b810 Protective functions of the skin 4 (1%) 68 (3%) 
b7800 Sensation of muscle stiffness 12 (2.8%) 64 (2.9%) 
b2700 Sensitivity to temperature 1 (0.2%) 56 (2.5%) 
b2702 Sensitivity to pressure 0 55 (2.4%) 
b735 Muscle tone functions 0 45 (2%) 
b710 Mobility of joint functions 15 (3.5%) 43 (1.9%) 
b760 Control of voluntary movement 
functions 
0 38 (1.7%) 
b28016 Pain in joints 0 37 (1.6%) 
b435 Functions of the immune system 37 (9%) 34  (1.5%) 
b7801 Sensation of muscle spasm  0 30 (1.4%) 
b134 Sleep functions 1 (0.2%) 29 (1.3%) 
b455 Exercise tolerance functions 8 (1.8%) 26 (1.2%) 
b265 Touch functions 0 26 (1.2%) 
b280 Sensation of pain  0 24 (1.1%) 
b530 Weight maintenance functions 19 (4.5%) 23 (1%) 
b820 Repair functions of the skin 0 20 (0.9%) 
b4152 Function of veins 1 (0.2%) 16 (0.8%) 
b1644 Insight 1 (0.2%) 15 (0.7%) 
b1645 Judgement 0 14 (0.6%) 
b715 Stability of joint functions 0 9 (0.4%) 
97 
 
b415 Blood vessel functions 0 9 (0.4%) 
b5501 Maintenance of body temperature 0 9 (0.4%) 
b755 Involuntary movement reaction 
functions 
0 6 (0.3%) 
b4552 Fatigability 2 (0.5%) 5 (0.2%) 
b7303 Power of muscles in lower half of the 
body 
0 5 (0.2%) 
b6601 Functions related to pregnancy 0 5 (0.2%) 
b1301 Motivation 2 (0.5%) 4 (0.2%) 
b1642 Time management  0 4 (0.1%) 
b840 Sensation related to skin  0 4 (0.1%) 
b270 Sensory function related to temperature 
and other stimuli (e.g. burning sensation, 
vibration) 
1 (0.2%) 2 (0.08%) 
b1142 Orientation to person 0 2 (0.08%) 
b830 Other functions of the skin (e.g. 
sweating) 
0 2 (0.08%) 
b7808 Sensations related to muscles and 
movement functions, other specified (e.g. 
strain sensation) 
0 2 (0.08%) 
b730 Muscle power functions 0 2 (0.08%) 
b7353 Tone of muscles of lower half of body 0 2 (0.08%) 
b28013 Pain in back 1 (0.2%) 1 (0.04%) 
b1265 Optimism  1 (0.2%) 1 (0.04%) 
b1300 Energy level 1 (0.2%) 1 (0.04%) 
b2800 Generalised pain  5 (1.2%)  0 
b650 Menstruation functions (e.g. 
menopause) 
2 (0.5%) 0  
b114 Orientation functions 2 (0.5%) 0 
Total 424 2232 




Table 5.3. The frequency of ICF categories for the component Activities and 
Participation that were linked from concepts obtained from people with psoriatic 
arthritis and health professionals.  
ICF categories 








arthritis, n (%) 
d450 Walking 22 (10%) 156 (13%) 
d5702 Maintaining one’s health  21 (9%) 146 (12%) 
d850 Remunerative employment 76 (34%) 132 (11%) 
d5200 Caring for skin  0 57 (5%) 
d230 Carrying out daily routine 2 (0.9%) 57 (5%) 
d570 Looking after one’s health  4 (1.8%) 51 (4.3%) 
d5204 Caring for toenails 8 (3.6%) 46 (3.9%) 
d760 Family relationships 8 (3.6%) 45 (3.8%) 
d9205 Socialising 8 (3.6%)  41 (3.4%) 
d5700 Ensuring one’s physical comfort 5 (2.2%) 41 (3.4%) 
d920 Recreation and leisure 12 (5.4%) 31 (2.6%) 
d4154 Maintaining a standing position  8 (3.6%) 30 (2.5%) 
d4551 Climbing (e.g. stairs) 2 (0.9%) 27 (2.3%) 
d4153 Maintaining a sitting position  3 (1.3%) 25 (2%) 
d240 Handling stress and other psychological 
demands 
0 22 (1.8%) 
d4104 Standing 2 (0.9%) 21 (1.8%) 
d9201 Sports 9 (4%) 19 (1.7%) 
d7101 Appreciation in relationships 1 (0.4%) 17 (1.4%) 
d4501 Walking long distances 3 (1.3%) 16 (1.3%) 
d179 Applying knowledge, other specified 
and unspecified 
2 (0.9%) 15 (1.3%) 
d4502 Walking on different surfaces 0 14 (1.2%) 
d640 Doing housework 0 13 (1.1%) 
d210 Undertaking a single task 0 13 (1.1%) 
d6505 Gardening 0 12 (1%) 
d4602 Moving around outside the home and 
other buildings 
0 12 (1%) 
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d750 Informal social relationships 7 (3%) 11 (0.9%) 
d4552 Running  5 (2.2%) 11 (0.9%) 
d650 Caring for household objects 0 10 (0.8%) 
d4500 Walking short distances 0 10 (0.8%) 
d5701 Managing diet and fitness 0 10 (0.8%) 
d220 Undertaking multiple tasks 0 10 (0.8%) 
d475 Driving 1 (0.4%) 9 (0.7%) 
d6200 Shopping 0 9  (0.7%) 
d410 Changing basic body position 4 (1.8%) 8 (0.7%) 
d7600 Parent-child relationships 5 (2.2%) 5 (0.4%) 
d4452 Reaching 3 (1.3%) 5 (0.4%) 
d4103 Sitting 2 (0.9%) 5 (0.4%) 
d5 Self-care 0 5 (0.4%) 
d4600 Moving around within the home  0 4 (0.3%) 
d455 Moving around  0 3 (0.25%) 
d4702 Using public motorised transportation 0 3 (0.25%) 
d4106 Shifting the body’s centre of gravity 1 (0.4%) 2 (0.2%) 
d9204 Hobbies 0 2 (0.2%) 
d5402 Putting on footwear 0 2 (0.2%) 
d5100 Washing body parts 0 2 (0.2%) 
d740 Formal relationships 1 (0.4%) 1 (0.08%) 
d9100 Informal associations 0 1 (0.08%) 
d4102 Kneeling  0 1 (0.08%) 
d5203 Caring for fingernails 0 1 (0.08%) 
d5403 Taking off footwear 0 1 (0.08%) 
d4750 Driving human-powered transportation 0 1 (0.08%) 
d177 Making decisions 0 1 (0.08%) 
d7201 Terminating relationships 0 1 (0.08%) 
d4105 Bending  0 1 (0.08%) 
d4300 Lifting 0 1 (0.08%) 
Total 225 1195 




Table 5.4. The frequency of ICF categories for the component Environmental Factors 
that were linked from concepts obtained from people with psoriatic arthritis and health 
professionals. 
 ICF categories 








arthritis, n (%) 
e1150 General products and technology for 
personal use in daily living 
150 (29%) 712 (40%) 
e580 Health services, systems and policies 78 (15%) 261 (14%) 
e5800 Health services 44 (8.3%) 105 (6%) 
e1151 Assistive products and technology for 
personal use in daily living  
22 (4%) 101 (5.5%) 
e355 Health professionals 44 (8.3%) 89 (5%) 
e225 Climate 10 (2%) 81 (4.5%) 
e1101 Drugs 32 (6%) 80 (4.4%) 
e445 Attitudes of strangers 5 (1%) 64 (3.5%) 
e310 Immediate family  1 (0.2%) 57 (3.2%) 
e425 Attitudes of colleagues 9 (1.7%) 44 (2.4%) 
e1650 Financial assets 42 (8%) 32 (1.7%) 
e410 Attitudes of immediate family  0 32 (1.7%) 
e415 Attitudes of extended family  0 32 (1.7%) 
e2450 Day/night cycles 10 (2%) 27 (1.5%) 
e450 Attitudes of health professionals  15 (3%) 22 (1.2%) 
e420 Attitudes of friends  0 18 (1%) 
e590 Labour and employment services, 
system and policies 
1 (0.2%) 10 (0.6%) 
e1201 Assistive products and technology for 
personal indoor and outdoor mobility and 
transportation 
2 (0.4%) 9 (0.5%) 
e340 Personal care providers and personal 
assistants 
0 9 (0.5%) 
e245 Time-related changes 2 (0.4%) 5 (0.3%) 
e510 Services, systems and policies for the 
production of consumer goods 
1 (0.2%) 4 (0.2%) 
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e2250 Temperature 0 4 (0.2%) 
e115 Products and technology for personal use 
in daily living 
0 4 (0.2%) 
e515 Architecture and construction services, 
systems and policies 
2 (0.4%) 1 (0.03%) 
e1651 Tangible assets 0 1 (0.02%) 
e1351 Assistive products and technology for 
employment 
2 (0.4%) 1 (0.02%) 
e5850 Education and training services 44 (8.3%) 0 
e215 Population  6 (1.2%) 0 
Total 522 1805 
ICF International Classification of Functioning, Disability and Health. 
 
About half the number of Body Function (n=26, 57%) and Activities and Participation 
categories (n=27, 49%) were identified by health professionals compared with 
participants with PsA (n=45, 94% and n=55, 100% respectively), indicating a possible 
mismatch of key concerns. The majority of concepts reported by health professionals 
were linked to 2nd level (less precise) ICF categories from the components Body 
Functions and Activities and Participation. Over one-third of the ICF categories 
identified from the health professional focus group concepts related to Environmental 
Factors (n=522, 38%), with the majority being 3rd level ICF categories. This reflected 
key concerns about the limited access to, and provision of, specialist foot care services, 
which was the most frequent Environmental Factor reported by health professionals 
followed by concerns relating to footwear restrictions among patients and the lack of 
training across professionals on the management of rheumatic foot disease.   
  
5.5.2 Levels of linking  
Over half of the ICF categories identified were 3rd level categories (n=76, 51%), 
followed by 2nd level categories (n=60, 40%). The ICF component that had the most 
specific categories (higher-level) was Body Structures, with 44% of concepts being 
linked to seven 4th level categories (relating to the bones, joints, muscles, ligaments 
and fascia in the foot and ankle). This was followed by Body Functions with 76% of 
concepts being linked to three 4th level categories, which mainly related to ‘pain in the 
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lower limb’. The two 1st level categories were self-care (d5) and more frequently 
functions of skin (b8). Psoriatic skin changes were mainly reported in relation to the 
physical and psychological consequences, which was reflected in the interview 
concept focusing on the impact of skin change and not specifically on the skin quality 
(b810) or sensation (b840).  
 
5.5.3 Difficulty with linking to the ICF 
Fifty-seven interview codes containing 5 concepts could not be linked to the ICF 
categories including the disease course (n=27, 47%) (which comprised disease 
variability, duration, progression, chronicity and established foot disease), 
comorbidity (n=24, 42%), illness knowledge (n=4, 7%), quality of life in general (such 
as “life is ruined”, “life is impossible”, “nightmare”) (n=1, 2%), and general physical 
health (such as “debilitating”, “incapacitating”) (n=1, 2%). Fifty-nine interview codes 
containing 7 concepts were assigned to the ICF component Personal Factors, which 
included coping styles (n=23, 39%), age (n=10, 17%), gender (n=10, 17%), ethnicity 
(n=5, 8%), family history of inflammatory arthritis (n=9, 15%), lifestyle (n=1, 2%), 
and concerns and priorities (n=1, 2%) (Table 5.5 and 5.6).  
 
Table 5.5. Concepts that were linked to the ICF component personal factors.  







Coping styles 13 201 
Family history of inflammatory arthritis 1 19 
Age 10 2 
Personal concerns and priorities 6 3 
Gender-specific 20 0 
Ethnicity-specific 9 0 
Lifestyle 3 0 
Total 62 225 





Table 5.6. Concepts that were not covered or were not definable by the ICF 
classification.  







nc – Illness knowledge 1 41 
nc - Health condition (e.g. comorbidities) 21 40 
nc - Disease course 63 19 
nd-qol (e.g. life ruined) 1 7 
nd-ph (e.g. debilitating) 4 5 
Total 90 112 
ICF International Classification of Functioning, Disability and Health, nc not covered, 
nd-qol not definable quality of life, nd-ph not definable physical health. 
 
Concepts that could not be precisely linked to the ICF were related to coping strategies, 
aspects of time, knowledge of global and local disease, discomfort, rest, swelling, 
muscle cramp, tendon and enthesis, falls and instability, fatigue and treatment side-
effects. Difficulties in linking highly specific information to categories such as 
sensations of pain, sensations of skin and emotional functions revealed a limitation in 
the ICFs ability to discriminate between various effects of the disease. 
 
Swelling was assigned to the ICF category b435: immunological system functions to 
capture inflammation related to the immune response, which covered concepts such as 
joint and soft-tissue swelling. Swelling of body parts has previously been linked to 
b454: water, mineral and electrolyte balance functions (Stamm, et al., 2007a). 
However, the majority of concepts related to generalised, non-specific swelling in the 
foot, ankle and lower leg that were associated with a variety of factors, which included 
climate, time of day, activity levels, body position and overall change of foot shape. 
The swelling was unrelated to inflammation or venous insufficiency and was difficult 
to code in that respect.  
 
Rest was initially assigned to the ICF category b735: muscle tone functions that refers 
to the tension present in resting muscles, which was later rejected in a consensus-based 
discussion among the investigators. Rest is seen as a body function with an activity 
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component and has been linked to b1349: sleep function unspecified and d9209: 
recreation and leisure unspecified in previous studies (Stamm, et al., 2006). Other 
categories considered were b4552: fatigability, b455: exercises tolerance functions, 
b130: energy and drive functions, and pf-coping strategy. However, these categories 
stem from mental and cardiovascular functions that did not reflect the meaning of rest 
from the qualitative codes.  
 
Enthesis and tendon disorders were linked to s75022: muscles of ankle and foot as the 
best-matched ICF category and in order to avoid the non-specific ‘other specified’ 
category. This hallmark feature of PsA is not fully represented by the structure 
categories available of the ankle and foot. 
  
5.5.4 Accuracy of analysis 
The overall total percentage agreement in the linking of patient and health professional 
concepts combined ranged from a maximum of 86.3% for Body Functions to a 
minimum of 72.0% for Activities and Participation. Moderate to very good levels of 
interrater agreement were identified across the ICF components in relation to the 
linking of patient and health professional concepts combined, ranging from moderate 
interrater reliability for Activities and Participation at 0.59 (CI 0.53, 0.64) to very good 
for Body Functions at 0.81 (CI 0.78, 0.85) (data on the total percentage agreement and 
Cohen’s kappa for interrater agreement is provided in Appendix 5 in Supplementary 
Tables 2 and 3). 
 
The key difference between the raters was the perception of activity functions (d) and 
mental and attitudinal functions (b). For example, some aspects of coping were 
assigned to the ICF category handling stress and other psychological demands (d240) 
by the 1st rater, but were assigned to temperament and personality functions (b126) by 
the 2nd rater. Whilst coping style is defined as a Personal Factor present as a pre-morbid 
state in the linking rules, it could be attributed to a consequent impairment of the 
disease. This overlap in meaning of coping resulted in b126 being the 6th most 
frequently cited Body Function category and being the most frequent concept assigned 




5.6 Discussion  
To the best of our knowledge this study is the first to identify ICF categories of 
importance to people with PsA-related foot involvement and relevant to the health 
professionals involved in their care. Emergent concepts from the foot-specific 
qualitative-based work were linked to all components of the ICF, confirming that local 
disease in the foot in PsA has a broad impact on daily life with physical, psychological 
and societal consequences. The OMERACT and the GRAPPA (Group for Research 
and Assessment of Psoriasis and Psoriatic Arthritis) have endorsed work using the ICF 
to identify global aspects of functioning in PsA (Taylor, et al., 2010; Gudu, et al., 
2017). However, with recognition that hallmark features of PsA are predominant and 
persistent in the foot and ankle (Galluzzo, et al., 2000; Healy, et al., 2008; Hyslop, et 
al., 2010a; Delle Sedie, et al., 2011; Turner, et al., 2014), this study describes the extent 
to which functioning is influenced by body region-specific involvement. Despite the 
region-specific focus of the current study, the impact of localised disease in the foot 
was widespread and consistent with previous studies that assessed global PsA disease 
(Stamm, et al., 2007b; Taylor, et al., 2010; Gudu, et al., 2017).  
 
Similar results were reported with 136 ICF categories identified in a previous 
systematic review article (Gudu, et al., 2017), which used the ICF to categorise the 
global effect of PsA as obtained from other qualitative studies. Gudu et al (2017) found 
the most represented ICF component to be Activities and Participation, followed by 
Body Functions. However, the same study reported that the purely qualitative studies 
had a higher proportional representation of Body Structures and Environmental 
Factors than in the studies with both qualitative and quantitative phases of the 
methodology (Gudu, et al., 2017). This is similar to the current study findings with a 
higher number of ICF categories classified as Environmental Factors and supports the 
suggestion by Gudu et al (2017) that detailed results from qualitative studies may 
better assess the disease effect and patients’ perspectives. Whilst previous qualitative 
studies have used the ICF to categorise the patient perspective of regional disease in 
the knee in osteoarthritis (Xie, et al., 2006a; Xie, et al., 2006b), to our knowledge there 
is no similar study linking qualitative work assessing the effect of localised disease in 
PsA to the ICF. The authors concluded that the ICF serves as a comprehensive and 
independent framework to identify and compare the typical patient experience, which 




Using the ICF, the full spectrum of foot-specific problems in PsA and the dynamic 
interaction between domains of impact can be better understood. The physical domain 
of body structure and function was well represented, reflecting the high foot disease 
burden and unmet need for specialist foot care reported in other studies in PsA 
(Hyslop, et al., 2010a; Carter, et al., 2019b). Important concepts in the component 
body function were body image and emotional well-being. Dermatological problems 
were frequently linked to both these concepts, indicating that assessing the 
consequences of psoriatic skin and toenail involvement could be helpful for effective 
patient-centred care. Although the impact on daily activity was most pertinent to 
people with PsA-related foot involvement, environmental and personal factors covered 
an array of positive and negative aspects that may play an important role in assessing 
functioning. Despite the diverse expression of PsA in the foot, limited research has 
focused on understanding the impact of local foot disease and from the patient 
perspective (Carter, et al., 2019a). This study has identified the most typical and 
relevant aspects of functioning from the patient experience of PsA-related foot 
involvement using the ICF classification as a universal model and language of 
functioning. The translation of aspects of functioning into ICF terms enables the 
meaning of the patient experience to be condensed, defined and compared (Stamm and 
Machold, 2007; Boonen, et al., 2009a). 
 
Whilst the benefits of early detection and tight control of active foot disease in PsA 
have been acknowledged (Cresswell, et al., 2011; Patience, et al., 2018), recent 
qualitative research revealed deficiencies in the assessment and management of foot 
problems related to PsA reported by patients and health professionals in Australia and 
New Zealand (Carter, et al., 2019a; Carter, et al., 2019b). The need for personalised, 
targeted assessment and management strategies focused on the manifestations and 
impact of foot disease in PsA has been identified in previous studies (Healy, et al., 
2008; Patience, et al., 2018; Carter, et al., 2019b). Establishing what are the key 
concerns from the patient perspective is an important step towards identifying ‘what 
to measure’ in the assessment and management of PsA (Boonen, et al., 2009a; Taylor, 
et al., 2010). Findings from this study confirm that the views and personal importance 
attributed to different aspects of functioning vary between and among patients and 
health professionals, which supports similar published work (Hewlett, et al., 2001; 
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Carr, et al., 2003; Hewlett, 2003; Coenen, et al., 2005; Tillett, et al., 2014). Linking 
was to lower-level categories (equating to lower specificity) for concepts obtained 
from the health professionals, which supports the patient perception of poor 
understanding of the impact of the disease by health professionals. Experienced health 
professionals did not appear to appreciate the broader aspects of functional and 
emotional impact that foot problems have on daily life. Failure to recognise concepts 
important to people with PsA could negatively influence patient compliance with, and 
efficacy of, treatment strategies, which suggests a need for more education in this area. 
Categorising the effect of PsA-specific foot disease using the ICF framework 
highlights the value of this approach in identifying concepts important to both patients 
and health professionals.  
 
Concepts that could not be precisely linked using the online ICF classification and the 
shortfalls of the ICF noted in this study were consistent with those reported in previous 
work in PsA (Taylor, et al., 2010; Gudu, et al., 2017), and in other rheumatic conditions 
(Stamm, et al., 2005; Stamm, et al., 2007a; Boonen, et al., 2009b; Campbell, et al., 
2014). Given that enthesitis is a hallmark feature of PsA, the inadequate representation 
of the enthesis and tendon by the body structure ICF categories for the foot and ankle 
significantly reduces specificity in describing localised involvement. Difficulties with 
linking psychological concepts reflect deficiencies in the ICF and is a major limitation 
in defining foot disease burden. Gaps and limitations in the linking process should be 
taken into account in order to accurately reflect functioning with full conceptual 
coverage.  
 
Interdisciplinary group analysis demonstrated merit as differences between the 
predominantly biomedical approach by podiatry and biopsychosocial approach by 
occupational therapy in clinical practice led to additional ICF categories being 
identified between the health professionals, which mostly related to cognitive 
functions. The ICF framework adheres to the biopsychosocial model of disease and 
recognises that function and health result from a complex interplay of the health 
components (Boonen, et al., 2009b). Occupational therapists have been identified to 
provide additional valuable perspectives that enhance the application of the ICF as a 
common framework, which is due to the strong conceptual connections between the 




Despite the lack of evidence on the efficacy of multidisciplinary involvement in the 
management of people with PsA, this approach has been advocated in published expert 
reviews (Taylor, 2012; Coates and Helliwell, 2017; Patience, et al., 2018). Whilst it 
may be considered that occupational therapists do not have a strong traditional role in 
managing the foot in PsA, findings of this study highlight that perspectives from 
different health professions provides a necessary holistic view on foot functional 
impairment and its impact that may optimise patient outcomes.  
 
Limitations of this study include lack of generalisability with a sample comprising 
participants from Australia and New Zealand. Participants in other settings and 
countries may experience problems with a different frequency or focus. Cross-cultural 
differences relating to environmental and personal factors may be revealed in other 
countries. Robust methods to ensure the quality of the linking process were employed 
in this study including the use of reliability checks, an iterative consensus-based 
process and multiple raters from different professional backgrounds. However, it 
remains unclear whether other health professionals would have applied the linking 
rules differently and decided on different categories, as previously identified (Coenen, 
et al., 2006). Lastly, this study did not report systematically problems of comorbidity 
and it is difficult to determine their relative contribution to problems in function. 
Therefore, findings from this study may be subject to bias as confounding variables 
were not adjusted for. However, comorbidities in PsA are common and eliminating the 
impact of co-morbidities comes at the expense of external validity and loss of 
generalisability in a real-world context. 
 
Future work will be to use the results of this study and the ICF as a common framework 
to assess the extent to which existing instruments adequately cover foot-specific 
concepts in PsA. This definitive list of ICF categories may also be used as a starting 
point for new instrument development to assess foot-specific functioning for research 
and in clinical practice, and it provides the opportunity to compare foot-related 
functioning across other rheumatic diseases (Stamm, et al., 2007b; Boonen, et al., 
2009a). A comprehensive understanding of foot functional impairments, limitations in 
activities and restriction in societal participation may provide the foundation for the 
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development of targeted assessment and intervention strategies that are mapped to key 
ICF domains.  
 
5.7 Conclusion 
Despite the localised anatomical focus of this study, the effect of foot problems in PsA 
was linked to all components of the ICF, confirming the profound impact on 
functioning and daily life. These findings offer new knowledge using the perspectives 
of patients and health professionals that could inform the development of an instrument 
to measure the impact of foot involvement in PsA. 
 
 
5.8 Significance and Innovations 
 This study comprehensively describes the functioning of people with PsA-
related foot involvement and explicitly identifies activities and participation 
impacted by the condition. 
 
 The list of ICF categories generated in this study will provide a useful reference 
to identify what should be included when future foot-specific PsA outcome 
tools are developed. 
 
 In clinical practice, the management of foot problems related to PsA should 
take into account the patient perspective on the impact of local disease in the 
foot on daily life. 
 
 The inclusion of different health disciplines improved the categorisation 
process of the patient experience, highlighting the importance of a 











6 Survey Development and Pre-Testing 
This chapter describes the methods and study design for the survey development and 
implementation process. A multi-stage survey development protocol is presented 
including extensive survey pre-testing, a targeted survey dissemination strategy and a 
summary of the methods for survey data analysis. Study methods are described 
systematically in phases in order to show how each stage was deliberately designed to 
inform the next stage.  
 
With limited large-scale data to date that comprehensively defines the nature, extent 
and impact of foot involvement in a PsA-specific population, the scale of the problem 
remains unclear. Survey research provided the ideal opportunity to sample a large 
population over a wide geographical area in Australia and New Zealand. In the absence 
of established empirical evidence on survey design and conduct, best practice methods 
in survey research were used in the current study.  
 
Study 1) Development of a national survey on foot involvement among people with 
psoriatic arthritis in Australia and New Zealand using a best practice approach: A 
survey development protocol. 
The study objective was to develop a national survey about foot involvement in people 
with PsA based on the views of patients and health professionals and in accordance 
with best practice standards for survey design, conduct and reporting. 
 
This manuscript has been submitted for publication in the Journal of Foot and Ankle 
Research and the authors include Carter K, Walmsley S, Rome K and Turner DE. 
 
This research was presented at the European League Against Rheumatism (EULAR) 
conference, Madrid, Spain, in June 2019 (Conference abstract and poster in Appendix 
4: Patient and clinician perspectives used for survey development to investigate the 






Development of a national survey on foot involvement 
among people with psoriatic arthritis in Australia and 
New Zealand using a best practice approach: A survey 
development protocol 
 
6.1 Abstract  
Background Limited research to date has defined the nature and extent of foot 
involvement in a psoriatic arthritis-specific population in Australia and New Zealand 
and the scale of the problem remains unclear. Survey research provides the ideal 
opportunity to sample a large population over a wide geographical area. Although 
quality criteria for survey research have been developed, research shows that 
adherence is low and that survey studies are poorly reported in peer-reviewed survey 
articles, which limits the ability to inform future survey design. The objective of this 
study was to develop a national survey about foot involvement in people with psoriatic 
arthritis using a best practice approach and based on the views of patients and health 
professionals. 
 
Methods A systematic, multi-stage process of survey development was undertaken, 
which comprised 3 phases: 1) the generation of the conceptual framework and survey 
content; 2) the development of the survey and pre-testing and 3) development of the 
survey dissemination strategy. A survey best practice approach was adopted using 
iterative pre-testing techniques, which included; cognitive debriefing, cultural 
sensitivity review, survey design expert validation, subject expert validation and pilot 
testing. Targeted postal and online survey dissemination strategies were developed a 
priori to optimise the response rates anticipated. In the absence of known prevalence 
estimates of PsA in Australia and New Zealand, the target population was 6000 people 
with PsA based on estimates provided from the major sites for survey dissemination. 
 
Results A 59-item survey with 8 sections was developed. Findings demonstrated a 
high survey response (n=649), high data completeness (83% of respondents reached 
the end of the survey) and low rates of missing data (below 5% for 95% of 
respondents). Extensive survey pre-testing among the target population, health 
professionals and experts improved the overall quality, content validity, functioning 
and representativeness of the survey instrument, which optimised potential response 
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rates. Clear audit trails that mapped the analytical process at each stage substantiated 
the rigour of the survey development methods. Robust strategies for sampling, survey 
dissemination and community engagement were deemed to have made a powerful 
contribution to response rates and the scale of information collected. 
 
Conclusions Robust patient-centred methods in survey design were used to create a 
novel, high-quality survey to comprehensively evaluate psoriatic arthritis-related foot 
involvement. Transparent and precise description of the survey design and 
dissemination methods provides useful information to other researchers embarking on 
survey design in healthcare. 
 

























6.2 Introduction  
Psoriatic arthritis (PsA) is well recognised as a distinct clinical entity with a high 
disease burden (Husted, et al., 2001; Helliwell and Taylor, 2005; Strand, et al., 2012; 
Kavanaugh, et al., 2016). Typically affecting people between 30 and 50 years old 
(Duarte, et al., 2012), PsA is associated with high economic and societal costs with 
over 25% of those at working age unemployed (Tillett, et al., 2012; Tillett, et al., 
2015b). For a large proportion of people with PsA, localised disease in the foot is their 
single most prevalent health complaint (Nordbø, et al., 2017), which can have a 
profound impact on functioning and daily life (Carter, et al., 2019a). Current 
knowledge of foot involvement in PsA is based on a few European studies, with 
limited incorporation of the patient perspective (Hyslop, et al., 2010a; Woodburn, et 
al., 2013; Turner, et al., 2014; Wilkins, et al., 2016). Despite recognition that hallmark 
disease features are predominant in the foot and ankle (Galluzzo, et al., 2000; Healy, 
et al., 2008; Hyslop, et al., 2010a; Delle Sedie, et al., 2011), foot involvement in PsA 
remains under-researched and poorly understood with a lack of large-scale data to 
provide the basis for targeted disease-specific assessments and interventions.  
 
Survey research provides the opportunity to sample a large population over a wide 
geographical area and to measure a broad range of constructs with sufficient 
granularity (Aday and Cornelius, 2006; Johnson, 2015). However, patient surveys 
have often been criticised for the lack of conceptual and methodological rigor 
(Bennett, et al., 2011). Poorly designed surveys and inadequate reporting can lead to 
inappropriate application of research findings in decision-making, healthcare, health 
policy and future research (Tong, et al., 2007; Bennett, et al., 2011; Turk, et al., 2018). 
To overcome this, quality checklists and reporting guidelines have been developed in 
order to promote complete and transparent reporting among researchers and to 
indirectly improve the comprehensiveness and credibility of survey studies (Kelley, et 
al., 2003; Eysenbach, 2004; Burns, et al., 2008; Draugalis, et al., 2008; Grimshaw, 
2014). The checklists include the SUrvey Reporting GuidelinE (SURGE) for paper-
based surveys (Grimshaw, 2014) and the CHEcklist for Reporting Results of Internet 
E-Surveys (CHERRIES) for web-based surveys (Eysenbach, 2004). Despite the 
development of guidance for reporting of surveys nearly a decade ago, previous 
reviews of published survey research have found that key quality criteria relating to 
design, conduct and results were under-reported in the majority of studies (Bennett, et 
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al., 2011; Turk, et al., 2018). Omitting important information, such as the development 
of the survey, participant recruitment, survey administration, data management and 
ethical considerations, can compromise the transparency and reproducibility of survey 
research (Turk, et al., 2018). Although best practice guidelines for paper-based 
(Kelley, et al., 2003; Burns, et al., 2008; Draugalis, et al., 2008; Grimshaw, 2014) and 
web-based survey research exist (Eysenbach, 2004), there is limited empirical 
evidence for optimal survey design (Reynolds, et al., 1993; Edwards, 2010). 
Furthermore, there is no global consensus on the optimal conduct and reporting of 
surveys, and few medical journals provide guidance to authors regarding the reporting 
of survey-based studies (Bennett, et al., 2011). It is well established that the methods 
used in conducting health surveys can significantly affect the reliability, validity and 
generalisability of study findings (McColl, et al., 2001; Edwards, 2010) and that 
concordance with guidelines improves the quality of reporting research (Plint, et al., 
2006; Smidt, et al., 2006; Nicholls, et al., 2016). However, with major discrepancies 
in survey reporting identified (Turk, et al., 2018), there are few high-quality worked 
examples of survey design and conduct to help researchers implement robust reporting 
practices. Therefore, the objective of this study was to develop a national survey about 
foot involvement in people with PsA living in Australia and New Zealand, using a best 
practice approach and based on the views of patients and health professionals. In the 
absence of established empirical evidence on survey design, the current study methods 
were developed in accordance with best practice standards for the development of self-
administered surveys (Gehlbach, et al., 2010; Artino Jr, et al., 2014) and the 
subsequent description of survey conduct adhered to good reporting practices 
(Eysenbach, 2004; Grimshaw, 2014; Turk, et al., 2018).  
 
6.3 Methods 
A cross-sectional observational study design was used to develop a self-administered 
paper-based and web-based survey. Prevalence of PsA in Australia and New Zealand 
have not yet been established by epidemiological studies. Using worldwide prevalence 
estimates of PsA (Gelfand, et al., 2005; Gladman, et al., 2005; Prey, et al., 2010; 
Haroon, et al., 2013a; Löfvendahl, et al., 2014), it can be extrapolated that in Australia 
there could be approximately 40,000 to 80,000 people with PsA in the general 
population and in New Zealand about 7600 and 16,700 people with PsA (target 
population calculations are provided in Appendix 5). High variability in worldwide 
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estimates of PsA prevalence have been due to historical differences in classification 
criteria applied (McHugh, 2015; Ogdie and Weiss, 2015). Therefore, with PsA 
prevalence in Australia and New Zealand unknown a priori and in the absence of 
national databases to determine the potential target population and estimate response 
rates, the study approach was to identify target estimates from the major sites for 
dissemination in order to establish the potential reach of survey to people with PsA.  
 
A systematic, multi-stage process of survey development was undertaken (Figure 6.1), 
which comprised 3 phases: 1) the generation of the conceptual framework and survey 
content; 2) the development of the survey and pre-testing and 3) development of the 
survey dissemination strategy. Phase 1 provided the theoretical underpinning of the 
survey items by clearly defining and conceptualising the important and relevant 
constructs to be assessed. Phase 2 used recognised qualitative survey development 
methods for pre-testing and piloting the draft survey, which resulted in 7 iterative 
revisions that corrected for key features including; wording clarity, instruction 
comprehension, item interpretation, navigation, timescales (recall), repetition, 
redundancy, response options, emotiveness, overall design and responder burden 
(number of items, time to complete). Phase 3 encompassed the sampling strategy to 
identify the major sites for dissemination in order to determine the response rate 
relative to the populations that were targeted. The order and timing of the pre-test and 
pilot studies were intentionally organised to allow for analysis and revision of survey 
items between stages and prior to full-scale survey dissemination. The survey was 
developed over 18 months (phases 1 and 2 between October 2017 and April 2019) and 





 perspectives of patients and health professionals on the experience of 









Linking to the International Classification of Functioning, 
Disability and Health (ICF):
to categorise the impact of foot involvement in psoriatic arthritis
Targeted survey dissemination strategy 
developed a priori for large-scale implementation of a 
national survey across Australia and New Zealand
Subject expert review (n=2)
Cognitive debriefing interviews of 
people with psoriatic arthritis (n=6)
Multidisciplinary rheumatology focus 
group with health professionals (n=9)
Cognitive debriefing 
interviews of people with 
psoriatic arthritis (n=6)
Usability testing of web-based 
survey by people with psoriatic 
arthritis (n=6)
New Zealand cultural 
sensitivity review (n=4)
Subject expert validation 
(members from Australia, New Zealand and the UK) (n=8)
Survey Item Development
based on the findings of the qualitative work and linking to the ICF 
Survey Draft 2 
Item revision: simplified instructions, added content
Survey Draft 3
Item revision: simplified wording, improved response options
Survey Draft 4
Item revision: changed formatting
Survey Draft 5 
Item revision: simplified instructions, changed formatting, reduced length
Survey Draft 7
Item revision: reduced length
Multidisciplinary rheumatology focus 
group with health professionals (n=17)
Survey design expert validation 
(n=2) 
Pilot testing among people with psoriatic arthritis: 







Review of the literature
Expert opinion and clinical experience of 
research advisory group
Survey Draft 6
Item revision: improved navigation
 
Figure 6.1. Survey development process.  
ICF International Classification of Functioning, Disability and Health. 
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People with PsA and rheumatology health professionals involved in phases 1 and 2 
were recruited using a convenient sampling technique with attention to ensuring 
diversity across health sectors and regions. A total of six sites across Australia and 
New Zealand were included, comprising three rheumatology public hospital outpatient 
departments, two university-based podiatry departments and a multidisciplinary 
rheumatology private practice with ethical approval granted for each participating site 
(Appendix 1 and 2). Written informed consent was provided by all participants prior 
to data collection.  
 
Demographic and clinical information were collected from people with PsA for the 
purpose of describing the sample and have been previously reported for Phase 1 
(presented in Chapter 4) and are represented in Table 6.1 for Phase 2. Key 
demographic and practice details were collected for the health professionals (Table 
6.2). All qualitative data collection in phase 1 and 2, including the focus groups, 
interviews and reviews, were conducted by the principal investigator (KC) and 
supported by a second investigator (SW). Both investigators had experience of 
qualitative research methods and 15 years of clinical podiatry experience. Results were 
refined by discussion between the investigators (KC, SW and DET).  
 
Table 6.1. Demographic and clinical characteristics of participants with psoriatic 
arthritis. 
 Round 1 Round 2 Round 3 




















Ages, years  45 (15) 48 (12) 56 (14) 48 (9) 58 (12) 
Women, n (%)  5 (83%) 2  (33%) 2 (33%) 2 (67%) 2 (67%) 
Ethnicity, n (%)      
     Australian European 6 (100%) 5 (83%) 3 (50%) 1 (34%) 1 (34%) 
     New Zealand European   1 (17%)   
     Indian  1 (17%) 1 (17%)   
     South American   1 (16%) 1 (33%)  
     British     1 (33%) 1 (33%) 
     Bosnian     1 (33%) 
Body Mass Index, Kg/m2   34 (12) 29 (6) 30 (8) 35 (11) 26 (2) 
Marital status, n (%)      
     Single 1 (17%) 2 (33%)  1 (33%)  
     Married  4 (66%) 4 (67%) 6 (100%) 2 (67%) 3 (100%) 
     Widower 1 (17%)     
Employment status, n (%)      
     Employed full-time 3 (50%) 3 (50%) 3 (50%) 1 (34%) 1 (34%) 
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     Employed part-time 1 (17%)    1 (33%) 
     Self-employed 1 (17%)  1 (17%)   
     Unemployed (health  
     reason) 
 1 (17%) 1 (17%) 1 (33%)  
     Unemployed (other:  
     student, home-maker) 
 1 (17%)    
     Retired 1 (16%) 1 (16%) 1 (16%) 1 (33%) 1 (33%) 
Education level, n (%)      
     No school certificate 1 (17%) 1 (17%)  1 (34%) 1 (33%) 
     School certificate 1 (17%)   1 (33%)  
     Higher school certificate  2 (33%) 1 (17%)   
     Trade/apprenticeship  1 (17%) 3 (50%)   
     Diploma 2 (33%)     
     University degree or  
     higher 
2 (33%) 2 (33%) 2 (33%) 1 (33%) 2 (67%)  
Disease type, n (%)      
     Psoriatic arthritis with  
     skin psoriasis 
4 (67%) 6 (100%) 6 (100%) 2 (67%) 3 (100%) 
     Psoriatic arthritis without  
     skin psoriasis 
2 (33%)   1 (33%)  
Disease duration, years  15 (12) 15 (9) 5 (4) 14 (10) 3 (2) 
Comorbidities, n (%)      
     Cardiovascular conditions 3 (50%)     
     Musculoskeletal  
     conditions 
 1 (17%) 2 (33%)  2 (67%) 
     Depression 1 (17%)   1 (33%)  
     Diabetes Mellitus  1 (17%) 2 (33%) 2 (67%)  
     Cancer 1 (17%) 1 (17%)    
     Inflammatory conditions  
     (Crohn’s, fibromyalgia) 
2 (33%) 1 (17%) 1 (17%)   
Patient global assessment 
joint and skin (VAS 0-100), 
mm 
74 (15) 37 (37) 40 (24) 40 (38) 50 (26) 
Patient global assessment 
skin (VAS 0-100), mm  
36 (37) 28 (29) 25 (19) 7 (6) 37 (40) 
Patient global assessment 
joint (VAS 0-100), mm 
66 (25) 37 (35) 47 (16) 40 (36) 50 (26) 
Global pain (VAS 0-100), 
mm 
69 (21) 37 (36) 53 (21) 40 (26) 47 (38) 
Foot pain (VAS 0-100), mm 
 
73 (22) 37 (37) 38 (43) 33 (6) 60 (26) 
Hospital Anxiety and 
Depression Scale 
  *2 *2 *2 
     Normal (0-7) 1 (17%) 2 (34%)    
     Borderline abnormal (8- 
     10) 
2 (33%) 2 (33%)    
     Abnormal (11-21) 3 (50%) 2 (33%)    
Length of interview, minutes 63 (21) 60 (23) 6 (3) *3 *3 
Time to complete survey  *1 *1 29 (6) 26 (6) 22 (4) 
Data presented as mean (SD) unless specified. VAS Visual analogue scale. 
*1 Participants were interviewed about the survey to obtain their views but did not complete it.  
*2 Not recorded for miscellaneous reasons; for example, to reduce participant burden. 
*3 Following survey completion, participants were asked if they had experienced any 
difficulties. There was no audio-recorded interview.  
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Table 6.2. Demographic characteristics of the health professionals with experience of managing people with psoriatic arthritis and subject experts. 





expert review  
(=2) 
Health professional 
focus group review 
(n=9) 
Cultural  
sensitivity review  
(n=4) 
Survey 
expert review  
(n=2) 
Subject 
expert review  
(n=8) 
Women, n (%)  11 (65%) 2 (100%) 4 (44%) 3 (75%) 1 (50%) 3 (38%) 
Geographic location, n (%)       
     New South Wales, Australia 10 (59%) 2 (100%) 9 (100%)  1 (50% 3 (38%) 
     Queensland, Australia 3 (18%)      
     South Australia, Australia 3 (18%)      
     Northern Territory, Australia 1 (5%)      
     Auckland, New Zealand    4 (100%)  1 (12%) 
     United Kingdom     1 (50%) 4 (50%) 
Occupation, n (%)       
     Rheumatologist 4 (24%) 1 (50%) 1 (11%)   3 (38%) 
     Podiatrist  1 (50%) 8 (89%) 3 (75%)  5 (62%) 
     Physiotherapist 4 (24%)      
     Exercise physiologist 1 (6%)      
     Nurse 6 (35%)      
     Clinical researcher 1 (6%)      
     Pharmacist 1 (5%)      
     Maori research advisor    1 (25%)   
     Survey & outcome measure specialty     2 (100%)  
Clinical experience, years 13 (13) 13.5 (9)     12 (10) 11 (10) 8 (1) *2 15 (13) 
Estimated experience in managing PsA, 
years 
      
     0-5 9 (53%)  4 (44%) 1 (25%)  3 (38%) 
     6-10 6 (35%) 1 (50%) 1 (11%) 1 (25%) 2 (100%)*2 1 (12%) 
     11-15 1 (6%) 1 (50%) 1 (11%) 1 (25%)   
     16-20   1 (11%)   2 (25%) 
     >20  1 (6%)  2 (12%) 1 (25%)  2 (25%) 
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Qualifications, n (%)       
     Bachelor of Medicine and Surgery 
(MBBS) 
4 (24%) 1 (50%) 1 (11%)   3 (38%) 
     Fellow of the Royal Australasian 
College of Physicians (FRACP) or 
Fellow of the Royal College of 
Physicians (FRCP) 
4 (24%) 1 (50%) 1 (11%)   3 (38%) 
     Bachelor of Science (BSc) 10 (59%) 1 (50%) 8 (89%) 4 (100%) 2 (100%) 6 (75%) 
     Master of Science (MSc) 1 (6%)  4 (44%) 1 (25%) 1 (50%) 4 50%) 
     Doctor of Philosophy (PhD)  2 (100%) 1 (11%) 2 (50%) 1 (50%) 7 (88%) 
Health sector, n (%)    *1 *3  
     Public sector 9 (53%)  5 (56%)   6 (75%) 
     Private sector 5 (29%)      
     Mixed 3 (18%) 2 (100%) 4 (44%)   2 (25%) 
Length of interview, minutes  53 45 57 66 *4 97 
Data presented as mean (SD) unless specified. PsA Psoriatic arthritis. 
*1 Health professionals of the cultural sensitivity review were academic staff at Auckland University of Technology and not currently practicing 
in the health sector. 
*2 Not relating to clinical experience but to experience of survey development, evaluation and implementation. 
*3 The survey experts were not practicing in the health sector. 









6.3.1 PHASE 1: Generation of the Conceptual Framework and Survey Content 
Conceptual frameworks are developed to provide the theoretical underpinning for 
identifying what should be included when measurement tools are developed (Alam, et 
al., 2020). Qualitative methods provide the opportunity to explore the patient and 
health professional perspective in order to identify relevant and important concepts. In 
the current study, these perspectives informed the conceptual framework for defining 
‘what should be measured’ to represent comprehensively the experience of people with 
PsA-related foot problems and important domains of impact. Qualitative research 
typically uses small sample sizes with a diverse range of participants in order to obtain 
the required level of rich and meaningful data (Ritchie, et al., 2009), whilst following 
strategies of saturation during data analysis (Francis, et al., 2010). 
 
 (1) Qualitative investigation of the patient experience of PsA-related 
foot involvement  
A review of the literature was undertaken to develop the interview guides for the 
qualitative study, which related to 1) PsA-specific foot involvement (Hyslop, et al., 
2010a; Woodburn, et al., 2013; Turner, et al., 2014; Wilkins, et al., 2016; Patience, et 
al., 2018), 2) foot problems in other rheumatic diseases to identify relevant foot-
specific concepts (Helliwell, et al., 2005a; Otter, et al., 2010; Brenton-Rule, et al., 
2014; Otter, et al., 2016; Williams, et al., 2017; Wilson, et al., 2017b), and 3) the PsA 
core set and outcome measures to identify key domains of impact for inclusion (Mease, 
2011; Her and Kavanaugh, 2014; Orbai, et al., 2017b). The Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in 
Rheumatology (OMERACT) groups used qualitative research methods and an 
international theoretical framework to develop the core domains and outcome sets in 
order to integrate all perspectives into the effective and comprehensive assessment of 
PsA (Stucki, et al., 2007; Keeley, et al., 2016). Establishing foot-specific impact 
domains by similar methods to inform the development of a survey to assess the impact 
of localised disease, represents the work supported by the GRAPPA-OMERACT. The 
interview guides were reviewed for relevance and coverage by the research team and 
designed to cover priority areas of interest, which included (1) foot involvement in 




In the current study people with PsA-related foot problems (n=21) were asked 
questions in semi-structured, one-to-one interviews about their foot problems and the 
impact they have on daily life. A representative sample was sought from public and 
private sector, and from lower and higher socioeconomic geographical areas in 
Sydney, Australia (n=18) and Auckland, New Zealand (n=3). Three multidisciplinary 
focus groups were undertaken with health professionals on their understanding of the 
patient experience (n=17); two in Sydney, Australia (n=12) and one in Auckland, New 
Zealand (n=5). Health professionals working in rheumatology teams with different 
professional backgrounds were invited.  
 
A diverse range of participants were sought by recruiting from participating sites in 
different health sectors and regions, and a convenience sampling strategy was used to 
recruit people with PsA and health professionals from the different rheumatology 
outpatient clinics. Recruitment to the study continued until no new relevant knowledge 
was being generated and qualitative data saturation of emerging concepts was achieved 
(Popay, et al., 1998; Francis, et al., 2010). All focus groups and interviews were audio-
recorded and transcribed verbatim. Qualitative data analysis utilised the constant 
comparative method (Morehouse and Maykut, 1994). Themes and sub-themes were 
developed by discussion between KC and SW. The research team reviewed and agreed 
the final themes. Standards for reporting qualitative research were adhered to 
(O’Brien, et al., 2014), ensuring complete and transparent description of the study 
findings in subsequent publications (Carter, et al., 2019a; Carter, et al., 2019b). 
 
 (2) Linking the patient experience of PsA-related foot involvement to 
the International Classification for Functioning, Disability and Health 
In order to gain a better understanding of the extent and coverage of themes identified 
by the qualitative work, concepts derived were linked to the World Health 
Organisation’s International Classification for Functioning, Disability and Health 
(ICF) in order to use common terminology to describe the impact of localised disease 
in the foot on functioning (WHO, 2001). A detailed description of the qualitative 
investigation and linking to the ICF in phase 1 can be found in previous studies (Carter, 
et al., 2019a; Carter, et al., 2019b; Carter, et al., 2020) (presented in Chapter 4 and 5). 
The ICF can be used as a conceptual platform to specify aspects of functioning, 
limitations in activities and restrictions to societal participation, whilst recognising the 
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influence of contextual environmental factors that may act as barriers or facilitators to 
health and disability (WHO, 2001). A comprehensive conceptual framework was 
developed based on the findings from the qualitative work mapped to the ICF (Figure 
6.2), which clearly defined the domains of impact to be considered in the measurement 
of the patient experience of localised disease impact in PsA. The qualitative 
exploration was a required step to better understand the patient experience. Indeed, 
important discrepancies between the health professionals and patient views were 
identified (Carter, et al., 2019a), which supports the need to define the construct from 
multiple perspectives. The conceptual framework provided support of content validity 
and served as the foundation for the subsequent stages of survey development (Figure 
6.3).   
 
Content validity is the degree to which the content of the instrument is an adequate 
reflection of the construct to be measured and face validity is the degree to which it 
looks as though it does (Mokkink, et al., 2010a). The content validity of an instrument 
has been asserted by an international working group in outcome measurement 
instruments as the most important of all the required measurement properties 
(Mokkink, et al., 2016). Importantly, validity and reliability are not properties of the 
survey instrument per se, but of the survey’s development (AERA, et al., 1999). The 
process of validation involves the accumulation of evidence during the survey 
development process to build a scientifically sound and relevant measurement tool 
(Artino Jr, et al., 2014). Therefore, it is extremely important to include the patient 
perspective in survey development as personal views on outcomes vary between and 
among patients and health professionals. Qualitative research in the exploration and 
development phase of survey development allows these perspectives to be identified, 















Figure 6.2. Development of a conceptual framework for psoriatic arthritis-related foot involvement.  
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Figure 6.3. The conceptual framework of psoriatic arthritis-related foot involvement using qualitative themes and the International Classification 
of Functioning, Disability and Health framework.  
The structure of the International Classification of Functioning, Disability and Health is divided into four main components; Body Structures, 
Body Functions, Activities and Participation, and Environmental Factors, which divide into chapters and then categories. The three overarching 
themes that emerged from the qualitative investigation are indicated in italics; 1) the disease manifestations in the feet and ankles (disease-related 
constructs), 2) foot functional impairments and visual differences that impacted on daily activities, work productivity, social and family life (impact 
on daily life), and 3) mediating factors (coping strategies, self-care ability, footwear, social support, access to healthcare, climate) that influenced 
the severity of impact from foot involvement on daily life (mediating factors).
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 (3) Survey item development  
Use or adaptation of existing tools is often supported with the benefit that results may 
be comparable, whilst conserving limited healthcare resources required to develop a 
new tool (Boynton and Greenhalgh, 2004; Edwards, 2010; Artino Jr, et al., 2014).  
However, no previously validated outcome measures or surveys to assess PsA-specific 
foot involvement existed, which established the need to develop a new tool based on 
a PsA- and foot- specific conceptual framework.  
 
Key themes from the qualitative investigation, relevant impact domains from the ICF 
mapping, previous PsA- and foot- specific research, and clinical experience were used 
to inform the conceptual coverage of the survey and to generate survey items. A review 
of existing outcome measures and surveys was undertaken and, where possible, a 
number of survey items were derived from established tools and adapted to meet the 
needs of the current study (including Australian-based health surveys (Up Study 
Collaborators, 2007), generic and disease-specific foot health questionnaires 
(Budiman-Mak, et al., 1991; Bennett, et al., 1998; Garrow, et al., 2000; Robinson, et 
al., 2001; Helliwell, et al., 2005b; Barton, et al., 2009; Otter, et al., 2010; Roddy, et 
al., 2011; Walmsley, et al., 2013; Otter, et al., 2016), PsA-specific quality of life 
instruments (Finlay and Khan, 1994; McKenna, et al., 2004; Gossec, et al., 2014), 
survey (Lebwohl, et al., 2014) and patient global assessment (Mease, 2011)). For 
example, categories of local ethnic groups, employment status, education level and 
physical fitness were adapted from The 45 and Up Study Questionnaire, a Government 
endorsed survey known to perform well in an Australian population (Up Study 
Collaborators, 2007). The search was conducted using PubMed, EMBASE and 
CINAHL electronic databases and using search terms that combine the disease and 
construct of interest, with useful articles identified using a common sense approach. 
 
The qualitative study identified that whilst priorities for health professionals included 
the diverse expression of disease and determining the nature of foot symptoms as 
mechanical or inflammatory, a key theme from patients was the psychological impact 
of foot involvement on daily life coupled with self-management strategies (coping 
skills, self-care activities and social support), which was poorly recognised by the 
health professionals (Carter, et al., 2019a). Consequently, nearly a quarter of survey 




Survey items were generated by the research advisory group using a consensus based 
approach, and were organised into sections measuring defined constructs. The 
advisory group comprised the principal investigator (KC), two subject experts (DET, 
DC), an experienced qualitative researcher and measurement expert (SW), an 
experienced researcher in podiatry rheumatology (KR), and two consultant 
rheumatologists (GH, MO). The purpose of the research advisory group was to assist 
with study progress and support the review of the pre-testing results. Consolidation of 
data provided a comprehensive list of survey items, reflecting how foot problems were 
understood and described by people with PsA using their terminology. Current best 
practices in survey design provided guidance on writing items, response anchors, 
response options, survey scales and visual design (Fowler Jr FJ and C, 2009; Artino 
Jr, et al., 2011; Artino Jr and Gehlbach, 2012; McCoach, et al., 2013; Dillman, et al., 
2014; DeVellis, 2016). To completely and precisely assess the extent of foot 
involvement and its impact, survey scales were designed in order to capture frequency, 
severity, satisfaction, effort and level of importance. All draft survey items were 
included for subsequent pre-testing (n=60) to determine if items remained necessary 
for inclusion.  
 
6.3.2 PHASE 2: Survey Development and Pre-testing 
Pre-testing is the critical examination of the survey to determine if it will function 
properly as a valid and reliable research tool (Bolton, 1991; Reynolds, et al., 1993). 
Despite its recognised importance (Reynolds, et al., 1993), it is the stage of survey 
research most often restricted due to cost or time pressures (Hunt, et al., 1982). 
Commonly used pre-testing techniques include focus groups, cognitive debriefing, 
expert validation and pilot testing. Focus groups use professionals to ensure survey 
items capture key priorities related to the construct. In-depth cognitive debriefing 
interviews among the target population provide insights into how participants 
comprehend questions, process and recall information and decide what answers to give 
(Willis, 1999). Expert validation uses content experts to systematically review the 
survey in order to establish that each item is relevant to the construct being measured 
and that key items have not been omitted (Polit and Beck, 2004; Polit and Beck, 2006; 
Waltz, et al., 2010). Pilot testing is a ‘dry run’ of the entire survey administration; the 
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target population completes the survey in the planned delivery mode, final versions to 
the survey process are made and ready for full-scale administration (Ruel, et al., 2016). 
 
Pre-testing enables researchers to refine survey design, identify and correct errors, 
reduce respondent burden and determine if survey items are relevant, clearly 
articulated and interpreted correctly by respondents. It is an iterative process, with 
further pre-testing required to ensure that the changes made were desirable and that no 
new problems had been introduced. Sample sizes for pre-testing are typically small 
ranging from 5-10, but should try to cover the variety of respondents from the target 
population and relevant professionals (Reynolds, et al., 1993). Although there is 
limited empirical evidence to guide the number and type of pre-testing techniques 
required, there are recognised best practice methods based on expert opinion 
(Reynolds, et al., 1993). Researchers often use a combination of methods, as critical 
appraisal from multiple perspectives increases the likelihood of success for the final 
survey (Artino Jr, et al., 2014; Ruel, et al., 2016). Qualitative feedback from pre-testing 
sessions was used to make inclusion, exclusion and revision decisions for individual 
items, with data tabulated and examined for patterns in responses to each question 
(Grimm, 2010). Pre-testing is the process of collecting validity evidence to support the 
content validity of the final survey (Polit and Beck, 2006; Artino Jr, et al., 2014). The 
scope of pre-testing should include a wide range of survey features such as the 
appearance, layout, typeface, skip patterns and flow (Table 6.3). 
 
In the current study, involvement of patients, health professionals and experts 
throughout survey development was a central component of the protocol design, which 
comprised 6 pre-testing techniques;  
 
(1) focus groups with health professionals in rheumatology,  
(2) cognitive debriefing interviews of people with PsA,  
(3) cultural sensitivity review with New Zealand-based health professionals,  
(4) survey design expert validation,  
(5) content expert validation, and  




A clear audit trail of survey revisions and refinements were recorded in order to ensure 
the comprehensive integration of responses from pre-testing sources and document the 
refinement of the survey (Appendix 7). The extent of survey item revision reduces in 
number and complexity with each subsequent stage of pre-testing.  
 
Table 6.3. Definitions of the categories used to assign responses from the cognitive 
debriefing interviews, focus groups and expert reviews in order to organise decisions 
for survey item revision.  
Categories Description  Example(s) 
Poor wording  Word changed or 
spelling error 
Do you see any errors in wording? 
For example, ‘crocked’ changed to 
‘crooked’, ‘ethic group’ changed to 








its meaning and to 
follow the item 
instructions 
What does ‘anxiety’ and ‘depression’ 
mean to you?  
Can you tell me, in your own words, 
what the instructions are asking you to 
do? 
Can you repeat this question in your 
own words? 
Judgement Ability to make 
considered 
decisions  
How confident are you that you are 
able to mark accurately where you have 
or had experienced pain on the 
diagram?   
How confident are you that you can 
remember how many times you fell 
over the past 12 months?   
Navigation Navigate features of 
the survey and 
progression through 
the survey 
Is it easy or hard to scroll to see the 
questions? 
Would you like the option to go back 
and review or edit your responses? 




Is it easy or hard for you to remember 
when your symptoms first started? 
Do you feel that the timescale of this 
question is appropriate 
Redundancy and 
repetition 
Survey item is not 
required, no longer 
useful, or is too 
similar to another 
item 
Do you think that any of the questions 
are repetitious? 
Is this question relevant to you? 
130 
 
Response options Acceptable number 
and range of 
response options  
Do you think that the answers you can 
choose from allow you to answer the 
questions in the way that you want? 
Emotiveness Triggers an 
unwanted emotional 
response 
How does answering this question 




Number of survey 
items, time taken to 
complete the survey, 
survey length  
 
Do you think that the respondents will 
have the motivation, knowledge and 
ability to answer the questions? 
Do you think the length of the survey is 
burdensome? 
Unclear purpose Survey items 
collecting data that 
do not appear to 
alignment with the 
research purpose 
For example, collecting information 
about global disease is not related to the 
purpose of the survey about foot 





within the survey  
Suggestion to add a question: 
To find out if patients access services in 
the public or private settings 
To identify the impact of proximal 
issues on the foot and mobility 
Cultural 
sensitivity 
Cultural factors that 
affect the 
functioning of the 
survey in a different 
country 
Can you think of any problems or issues 
that patients in New Zealand might 
encounter? 
Do you feel that the survey has 
reasonable cultural sensitivity (taking 
into account the cultural and language 
differences between Australia and New 
Zealand) and can be adapted for people 
with psoriatic arthritis living in New 
Zealand? 
For example, the wording of different 
types of footwear will be different 
between countries 
Face and content 
validity 
Sufficient coverage 
of items, meaningful 
to patients   
Does the survey consist of a broad 
range of items that are all relevant, in 
their coverage, to the nature, extent, 
location and impact of psoriatic 
arthritis-related foot involvement on 
patients’ daily lives?           
Does the survey appear, on the face of 
it, to measure the problems you have 





 Conduct focus groups with health professionals (Pre-testing 1 of 6) 
Multidisciplinary rheumatology focus groups systematically evaluated the survey 
content in order to improve the overall quality and representativeness of the items. 
Health professionals, such as rheumatologists, podiatrists, physiotherapists and nurses, 
were recruited based on a priori selection criteria, which included current or previous 
experience of managing people with PsA and working in rheumatology teams. These 
criteria were also dependent on the willingness and availability of the individuals being 
asked to participate. A total of 2 focus groups were conducted at different stages in the 
survey development process and the number of health professionals in each review 
ranged from 9 to 17, as recommended to generate consensus on proposed scale items 
(Rubio, et al., 2003). Health professionals in the first focus group were recruited from 
a national Australian rheumatology conference in 2018 with diversity of participants 
from different states and territories, professions and health sectors. Health 
professionals in the second focus group were recruited from an outpatient 
rheumatology and podiatry hospital department in Sydney, Australia. Open debate was 
encouraged and an interview guide ensured discussion on priority areas including the 
acceptability of each item, anticipated responder burden, relevance of items, clarity of 
instructions and that key items had not been omitted. All focus groups were audio-
recorded, transcribed verbatim and analysed using qualitative data matrices to 
categorise responses (Miles and Huberman, 1994). Survey items were revised and 
reduced based on data from each focus group, which improved the overall functioning 
of the survey. 
 
 Conduct cognitive debriefing interviews (Pre-testing 2 of 6) 
Cognitive debriefing interviews of people with PsA were used to identify potential 
sources of error and problems with the interpretation of items and response anchors by 
respondents (Tourangeau, et al., 2000; Willis, 2005). An interview script was designed 
using a standardised protocol that involved the think-aloud technique with concurrent 
verbal probes. Specifically, respondents were asked to provide their interpretation of 
each survey item, followed by a series of probe questions to elicit specific information 
about any parts that were unclear (Willis and Artino Jr, 2013). All participants were 
encouraged to speak freely and not to worry about criticising the survey. All cognitive 
interviews were audio-recorded, transcribed verbatim and analysed using qualitative 




Three rounds of cognitive interviews of people with foot problems related to PsA were 
undertaken; 2 using the paper-based survey and 1 the web-based version. Each of the 
3 rounds of cognitive interviews comprised 6 participants, in total involving 18 people 
with PsA. Convenience sampling was used to recruit participants with PsA from 
rheumatology and podiatry outpatient clinics, in the public and private sector, based in 
different socioeconomic geographical areas in Sydney, Australia. Participants with 
rheumatologist-diagnosed PsA, aged over 18 years old and who had current or 
previous experience of foot problems were recruited by their rheumatologist or 
podiatrist.  
 
Paper and online formats of survey administration were developed to increase response 
rates and reduce selection bias. Survey content remained the same irrespective of the 
method of completion. Given the broad geographical spread of states and territories 
across Australia and New Zealand and increasing internet usage among adults in both 
countries (Stats Govt New Zealand, 2012; Australian Bureau of Statistics, 2016e), 
using a web-based survey administration was considered appropriate in order to obtain 
information from as wide a range and number of people as possible. The online version 
of the survey was developed using Qualtrics software [Qualtrics, Provo, UT, USA], a 
widely used platform for health-based and market survey research.  
 
An increasing portion of survey respondents are opting to complete surveys via mobile 
phones or tablets (Callegaro, 2010; Millar and Dillman, 2011). With mobile response 
rates up to 25% and expected to grow (Bosnjak, et al., 2013; Wells, et al., 2014; Stern, 
et al., 2016), it is important to pre-test and adapt survey designs on small screens. 
Usability pre-testing of the web-based survey involved participants completing the 
survey on their own mobile devices (smartphone or tablet) or other electronic devices 
(home computer or laptop). The evaluation of the web-based survey included all the 
elements of the paper version, but participants were additionally asked to comment on 
the online layout and design of the survey items and navigation features (skip patterns, 
ability to scroll, click and use of the next/back button). Users experienced challenges 
that led to errors and frustration. For example, recommendations were made by 
respondents to: correct content validation errors for entry fields to allow the 
appropriate number or text response, increase the space between response options to 
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avoid tapping incorrect answers, reduce the amount of text in the grid questions to 
improve the visual appearance on mobile screens, and clearly number questions to aid 
navigation. Web-based design modifications were introduced as a result in order to 
optimise the user experience and ensure response options would display on different 
types of electronic devices as intended (Geisen and Bergstrom, 2017; Olmsted-
Hawala, et al., 2017).  
 
The survey was modified and improved based on feedback from each round of 
cognitive debriefing, which related to wording, comprehension and interpretation, 
navigation, judgement, timescales (recall), content, repetition, redundancy, response 
options, number of items, overall survey design and responder burden. This resulted 
in the development of a set of items that respondents could interpret easily and respond 
to accurately, which was integral to the validity of the survey and reliability of 
resulting data. For example, instructions for completing visual analogue scales (VAS) 
were poorly understood by the majority of respondents on pre-testing of the paper-
based survey. Although the GRAPPA recommend using a VAS to record the Patient 
Global Assessment in PsA (Mease, 2011), all VAS in the survey were replaced by 
numerical rating scales (NRS) in order to optimise user satisfaction and enable 
accurate completion.  
 
In addition to the drawbacks associated with the utility of the paper-based VAS, the 
visual display of the web-based VAS slider bar was poorly optimised for use on 
smaller mobile screen sizes. Utilisation of the NRS avoided issues that had been 
identified in the web-based version. Previous studies comparing web-based sliding 
scales with numeric scales found no difference in the reliability or validity between 
the scales, but revealed that the sliders took significantly longer to complete than the 
radio button version of the scale (Cook, et al., 2001; Couper, et al., 2006). Therefore, 
both the research evidence of poor efficiency with slider completion and the current 
study findings of poor comprehension of VAS instructions, supported the use of the 
NRS in the paper- and web-based survey. 
 
Body and foot pain line diagrams were used in the survey to record the location and 
distribution of self-reported pain among respondents. Scoring of body (Lacey, et al., 
2005) and foot pain diagrams (Chatterton, et al., 2013) has been shown to be reliable 
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and repeatable for use in survey population-based research. The current study 
researchers sought to determine whether foot pain line diagrams or photograph images 
of the feet were preferred by participants with PsA. Briefly, it was established that line 
diagrams were preferred to photograph images, they were able to understand the 
instructions for diagram completion and the recall period of one month for presence of 
foot pain was acceptable. Previous research has found, when compared with clinical 
examination of the foot, self-completed foot pain diagrams by people with 
inflammatory arthritis have shown reasonable accuracy (Waller, et al., 2012). Foot 
pain scoring grids were adapted from previous studies (Garrow, et al., 2004; Otter, et 
al., 2010; Chatterton, et al., 2013), based on consensus of the research team on the 
addition of medial and lateral scoring areas of the foot. Additional scoring areas 
included the medial and lateral midfoot dorsal aspect, and the medial and lateral 
rearfoot anterior and posterior aspects. Additional medial and lateral views of the foot 
were used in order to capture pain in those regions and enable the interpretation of site-
specific pathology affecting different anatomical regions of the foot. Validation of the 
adapted scoring grids will be undertaken in future work. On the web-based survey, 
completion of the pain diagrams was possible using the heat map function of the 
Qualtrics software, which was optimised to improve comparability with the paper 
version. A limitation of the software restricts a maximum of 10 marks per diagram and 
does not permit shading. Although previous research has confirmed that pain location 
captured using paper and online pain diagrams are satisfactorily comparable (Jones, et 
al., 2013), differences in the methods of pain diagram completion between the two 
survey modes will be accounted for during data analysis (presented in section 8.1.4, 
Chapter 8). 
 
It was important to determine the reading level of the survey and a common approach 
is to use the Flesch reading ease score (Winzenberg, et al., 2003; Bennett, et al., 2007). 
Readability of the survey was 31.7 on the Flesch reading ease score (Flesch, 1948), 
indicating the survey would be difficult for use by most lay people. Scores of 60 or 
higher indicate that the text will be easy to read by most people with short sentences 
and no words of more than two syllables; the lower the score, the more difficult the 
text is to read (Flesch, 1948). Reading ease categories include 80-89 as easy to read, 
70-79 as fairly easy, 60-69 standard, 51-59 fairly difficult, 30-50 difficult and 0-29 
very difficult (Farr, et al., 1951). Whilst some items were simplified and written in 
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layman terms to account for varying levels of understanding, the majority of 
respondents were familiar with technical language such as plantar fasciitis, dactylitis 
and pitting toenails.  Although the readability score was relatively low, the cognitive 
debriefing interviews supported the respondents’ understanding of each item. 
Terminology complexity was a point of contrast between people with PsA and health 
professionals, with the majority of health professionals in the focus groups suggesting 
simpler alternatives to some medical terms considered to be poorly understood by 
potential respondents. Emphasis on patient-based testing and the discordance between 
their views and those of the health professionals was the reason for issues related to 
comprehension and interpretation continuing to be raised during survey items 
revisions (summaries of survey item revision included in Appendix 6). 
 
 Conduct cultural sensitivity review (Pre-testing 3 of 6) 
For both national and international multicentre studies, cultural sensitivity reviews are 
required to identify and correct for any cultural differences in the interpretation of 
survey items, particularly if translation of the survey into other languages is involved 
(Edwards, 2010). Although simple translation to and back from the second language 
might be sufficient, further cognitive debriefing and piloting is recommended in order 
to establish that it measures what is intended to be measured (Edwards, 2010). 
 
Variations in language and culture between Australia and New Zealand were 
considered during survey development. In Australia, pre-testing was conducted among 
respondents from different socioeconomic locations and healthcare settings to ensure 
that a wider range of opinions were collected. In New Zealand, in order to assess the 
usability and cultural sensitivity of the survey in the local context a focus group was 
conducted, which included 3 health professionals with expertise in podiatry-
rheumatology research and 1 Māori research advisor. Having a Māori voice on the 
review panel directly informed aspects of cultural sensitivity, which led to the addition 
of 1) open text options for the opportunity to capture more nuanced responses, 2) 
contact information for a Māori advisor, and 3) wording such as ‘Aotearoa’ (New 
Zealand) in the survey to achieve better recognition of a bicultural country. The order 
of ethnicity response options in the survey was also changed to better recognise those 
indigenous to both countries. There is very little evidence showing the prevalence of 
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PsA among indigenous groups in Australia and New Zealand, and what details do exist 
suggest a low prevalence. However, using cross-cultural survey development 
strategies may increase the likelihood of indigenous people participating in the survey 
and of survey findings contributing to strategies for indigenous health advancement. 
 
The majority of changes made to the survey related to language and footwear 
differences between Australia and New Zealand. For example, the term jandals, used 
predominantly in New Zealand and the South Pacific and known as thongs in 
Australia, was added; the term customised shoes was added to reflect local 
terminology, and the word sore was added in brackets as an alternative to wound for 
the same reason. A question about seasonal variation of footwear choice was removed 
based on comments relating to redundancy. Based on these changes, the survey was 
considered to have adequate cultural sensitivity in the Australian and New Zealand 
context.  
 
 Conduct survey design expert validation (Pre-testing 4 of 6) 
Experts (n=2) in the development and evaluation of healthcare surveys and patient-
centred outcome research reviewed the draft design of the paper- and web-based 
survey. Feedback was provided in the form of detailed free-text annotations on the 
survey and written comments to specific questions on how to optimise the look, flow 
and design of the survey. Consequently, survey items were re-grouped, streamlined 
and survey sections were numbered to improve consistency in navigation and layout 
between the paper and online versions of the survey. A list of the sections in the survey 
and their coverage was added to the survey introduction, in order to provide potential 
participants with a better appreciation of the study scope. Design features were added 
to the online survey such as forced responses. The layout of tabular matrices was 
changed in order to improve the on-screen view, and instructions were provided in 
order to optimise the user experience of functions such as save and continue later, the 
progress bar and back button. Valuable insights into the survey design were used to 




 Conduct subject expert validation for final item refinement (Pre-testing 
5 of 6) 
An eight-member specialist panel, including 4 international leading experts in PsA-
related foot involvement and 4 members of the research advisory group (DET, SW, 
KR, MO), reviewed the final survey items and response scales. The panel members 
were selected based on a priori criteria, which included having recent publications in 
PsA-specific foot involvement research, a track record of special interest in PsA and 
current specialised clinical practice in PsA. An innovative online collaborative 
platform (Google Forms included in Appendix 2) was used to design the data 
collection form that facilitated the instant recording of responses, while web-
conferencing allowed real-time audio/visual communication between panel members 
across 3 countries including the UK, Australia and New Zealand. Prior to the subject 
expert review, a PowerPoint presentation was delivered to the panel by the principal 
investigator (KC) describing the survey development process, the survey item content 
and rationale, research aims and objectives and the purpose of the review. In addition, 
panel members were provided with documents showing how survey items mapped to 
the ICF and to the PsA core domain set, and a data analysis plan that made explicit 
how each variable would be analysed and categorised in order to provide relevant 
context. Panel members independently rated the relevance and importance of each item 
to its assigned construct; demographics, pain and musculoskeletal disease, skin and 
toenail disease, function and participation, footwear, and treatment burden and 
emotional well-being. For each survey item the rating options were ‘Exclude’, ‘Needs 
improvement’ or ‘No action’. When ‘Exclude’ or ‘Needs improvement’ were selected, 
panel members were asked to provide written comments about the nature of the 
shortcoming and how it might be addressed. The review process was moderated (SW) 
in order to ensure that all panel members had rated and commented on each survey 
construct and progressed as a group. Following independent, real-time completion of 
the data form, results were presented to all members for open discussion in order to 
reach a consensus on the final survey items. Based on this feedback, 3 survey items 
were excluded due to redundancy and repetition, and 4 survey items were revised by 
adding qualifying statements in brackets in order to help emphasise and clarify the 
concept under investigation (Table 6.4). To ensure face validity, the revised items were 
then re-reviewed by the experts to confirm that they were acceptable for inclusion. No 
new issues were raised. The expert panel recognised the need for all items given the 
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heterogeneity of disease expression and potential impact. A specific line of questioning 
around item reduction was included, but recognition of the need to capture aspects that 
were deemed to be important prevented reduction of items for the specific purpose of 
reducing the survey length. 
 
Table 6.4. Survey item exclusions and revision suggested by the expert validation 
panel. 
Survey Item Exclusion Reason from Expert Panel 
Q21 When you get out of bed in the 
morning over the past week, do you 
feel stiff? If yes, how long does the 
stiffness generally last for? Less than 
30 minutes, 30 minutes to 1 hour, 1 to 2 
hours, 2 or more hours. 
Redundant as the duration of 
morning stiffness is not a good 
discriminator in terms of 
inflammatory disease 
Q39 Please indicate approximately how 
many toenails have been affected over 
the past month. 
Redundant as future work would 
be required to explore links 
between toenail involvement and 
dactylitis for this information to 
be useable 
Q53 Considering your foot problems 
overall, how much of a problem have 
your feet been over the past month? 
Numerical rating scale; 0 = no problem, 
10 = severe problem 
Duplication for participants with 
other NRS included in the survey 
relating to pain, trouble and 
coping with foot problems  
Survey Item Revision  Reason from Expert panel 
Q16 ‘Elbow’ changed to ‘Elbows’ Wording error 
Q42 Changed order of response option with 
‘vigorous activity’ to follow ‘moderate 
activity’ 
For logical, clear sequence 
Q46 'Work boot’ changed to ‘Work boot 
such as steel toe-capped' 
Required clarification  
Q51 ‘Considering all the people around you’ 
changed to ‘Considering all the people 
around you (family, partner, friends 
and others)’ 
Required clarification  
 
 Conduct pilot testing (Pre-testing 6 of 6) 
This work resulted in a 59-item survey with 8 sections. Whilst the number of survey 
items required to adequately assess the construct was considered as part of the survey 
design, the research priority was to assess the full complexity of the construct with a 
high level of granularity. Despite the substantial length of the survey, the majority of 
people with PsA interviewed during survey pre-testing suggested that it was 
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acceptable. Reasons for this included 1) having a desire to share their experience of 
foot problems that they felt had been neglected and/or poorly understood, and 2) 
resonance of patient-derived statements throughout the survey, which reportedly had 
a positive effect on encouraging survey completion. In contrast to this finding, the 
majority of health professionals in the focus groups reported that the length of the 
survey was likely to be prohibitive to potential participants. Therefore, it was important 
to conduct pilot testing in order to verify that respondents would be willing and 
motivated to answer the survey, without input from the principal investigator (KC). 
Research evidence supports the hypothesis that the response rate to a survey is 
inversely related to its length (Edwards, et al., 2004). In health research where the 
option to follow-up exists, it is recommended to use shorter surveys on each occasion 
(Edwards, et al., 2004). However, with only one opportunity to sample response and 
no provision for a follow-up survey, the current survey was designed to be as short as 
possible whilst compromising only minimally the data collection requirements of the 
study.  
 
Six prospective participants completed the survey in the planned delivery mode; 3 
paper-based surveys were self-administered in a clinical setting, and 3 web-based 
surveys were self-administered at home. Using a retrospective approach with verbal 
probe questions, no problems were reported about the time and number of sections 
required to complete the survey. Both versions of the survey took between 20 to 25 
minutes to complete. The pilot testing confirmed that respondents could complete the 
survey effectively, efficiently and found the survey length acceptable. Survey item 
reduction was not the central focus of the pre-testing methods, but it was important to 
consider the balance between comprehensive coverage of the construct and brevity in 
the final survey.  
 
The data obtained from the pilot test was reviewed to evaluate item responses and to 
identify any missing data. It was noted that question 52 was missed by 3 pilot test 
participants (1 in the paper survey, 2 in the online version), which stated ‘how effective 
do you feel you have been at managing your foot problems? Extremely effective, very 
effective, moderately effective, mildly effective, not at all effective. Non-response or 
missing data may be accidental, or due to the higher cognitive burden related to recall 
and judgement of self-care effectiveness, or due to respondents feeling uncomfortable 
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or frustrated when considering self-care effectiveness. Different wording or exclusion 
of the item was considered to avoid the potential for missing data. However, it was 
deemed necessary to retain it in its original form by the research team as it was 
anticipated that the impact would be minimal. Having established prior to the pilot test 
during the cognitive debriefing interviews that the question was clear and 
unambiguous among respondents, it was decided that altering the wording of the 
question could not make a meaningful difference to response levels.  
 
The pilot test also provided the opportunity to test data entry, data processing and 
coding procedures (Ruel, et al., 2016). A code book was created to convert survey 
responses into numerical data for efficient data input and management (the code book 
is provided in Appendix 7). For example, no = 0, yes = 1.  The pilot test confirmed the 
feasibility of data collection procedures and no changes to the survey administration 
processes were necessary. The data analysis plan was informed by the pilot test results 
by prompting decisions for defining and handling data and the following sub-headings 
describe the resultant analysis plan. 
 
 Data analysis plan 
Statistical data analysis - Data analyses were conducted using Statistical Package for 
Social Sciences (SPSS) 27.0 (Inc. Chicago. Illinois). Data from the online surveys was 
exported from Qualtrics into Excel and then, along with the data from the paper 
surveys, all data was manually entered into SPSS by one researcher (KC) with 
accuracy checking by a second researcher (SW) by double entry of all data. Data 
analysis was mainly descriptive statistics for summarising survey results and 
comparisons between characteristics. Continuous data were expressed as means and 
standard deviations (SD). For categorical data, proportions were calculated and 
expressed as percentages. Survey reporting recommendations of SURGE and 
CHERRIES were applied when presenting the findings (Eysenbach, 2004; Grimshaw, 
2014). Inferential statistical analyses were used to emphasise a few key relationships 
between the hallmark disease features in the foot, in the context of global disease and 
in relation to their impact on aspects of daily life. The Kruskal-Wallis test was used to 
determine significant relationships between variables followed by post hoc pairwise 
comparison of groups using Dunn’s procedure (Dunn, 1964), which incorporated a 
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Bonferroni correction. A Mann-Whitney U rank test was conducted to compare 
positions of median scores. The Chi-square test of independence and the 2-tailed 
Fishers exact test were used to determine any association between the frequencies of 
categorical variables, followed by appropriate post hoc testing.  
 
Missing data analysis - Valid and missing data for each survey item was evaluated:  
(i) Valid data refers to the number of responses from participants for each survey 
item.  
(ii) Missing data (or item non-response) refers to an unrecorded data value which, 
if recorded, would be meaningful for analysis and interpretation of a study (Li, 
et al., 2014), thus a survey item or response option that was missed by the 
respondent. Missing responses may be accidental due to poor survey 
navigation features or intentional due to high cognitive or responder burden. 
Missing data below 5% is considered inconsequential for non-biasing survey 
results and can be reported using descriptive analysis and not imputation 
techniques (Li, et al., 2014; Jakobsen, et al., 2017). 
(iii)Skipped data refers to an unrecorded data value due to the respondent 
accurately following a skip question (for example, ‘if no, skip to question 26).  
(iv) Non-completions (non-responses) were defined as participants who did not 
progress beyond the first information page to start the survey. 
(v) Partial completions were defined as participants who started the survey and the 
response included some missing data.  
(vi) Completions of 100% were defined as participants who completed 100% of the 
survey with no missing data (Eysenbach, 2004; Grimshaw, 2014).  
 
Socioeconomic data description – For planned socioeconomic evaluation the Index 
of Relative Socio-economic Advantage and Disadvantage (IRSAD) 2016 was selected 
as a measure of social deprivation to indicate health inequalities in the current study. 
The IRSAD 2016, produced by the Australian Bureau of Statistics (ABS), ranks areas 
in Australia according to relative socioeconomic advantage and disadvantage based on 
information from the 5-yearly census of population and housing (2016). The census 
collects information on individual level indicators of social deprivation (education 
level, income, occupation, household measures) and area level indicators (crime rates, 
unemployment rates, barriers to housing and services, living environment) (Grundy 
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and Holt, 2001; Pampalon, et al., 2009). The IRSAD 2016 is a weighted sum of these 
variables that indicates the collective socioeconomic characteristics of the people 
living in an area. IRSAD scores were obtained from postcodes provided in the survey, 
which were converted into postal area categories using geocoding tables. The IRSAD 
ordinal scale ranges from 1 to 10, where category 1 represents the areas with the least 
deprived scores (most affluent) and 10 the areas with the most deprived scores (least 
affluent). The categories were an index of comparative deprivation within the 
population sample (Australian Bureau of Statistics, 2016c).  
 
Numerical rating scales data analysis - The 0-10 numerical rating scales (NRS) used 
in the survey were for the patient global assessment (question 17, 18, 19), global pain 
severity (question 20), foot pain severity (question 23), how troublesome foot and 
ankle symptoms have been (question 27), and ability to cope with foot problems 
(question 47). The 0-10 NRS with a 1-week recall period are recommended in the PsA 
core outcome set to measure patient global assessment of disease activity and global 
pain intensity (Mease, 2011; Højgaard, et al., 2018). However, to the best of the 
authors knowledge, no studies have identified optimal cut-off points on a NRS or VAS 
in a PsA-specific population, with current guidance from GRAPPA-OMERACT 
stating that higher scores indicate worse pain or worse global health (Højgaard, et al., 
2018). Division of the NRS into the categories of 0-3 for mild, 4-6 moderate and 7-10 
severe for data analysis purposes and for clinical interpretation in the current study 
was selected based on cut-off points defined in the literature on pain-related 
interference with functioning (Palos, et al., 2006; Hirschfeld and Zernikow, 2013; 
Oldenmenger, et al., 2013; Boonstra, et al., 2014).  
 
Early and established disease duration in PsA data analysis - With no widely 
accepted definition of early PsA or late PsA (long-standing or established disease), 
cut-off points for the duration from symptom onset and disease diagnosis of: less than 
2 years (early PsA); 2 to 4 years (mid-late PsA); and more than or equal to 5 years (late 
PsA), were selected for data analysis purposes in the current study based on clinical 
studies and RCTs in PsA (Kane, et al., 2003b; Lindqvist, et al., 2008; Coates, et al., 




Body and foot pain diagram data analysis - For the paper surveys, pain diagrams 
were scored using a transparent overlay dividing the body and foot into mutually 
exclusive areas (Figure 6.4). The scoring was entered into Excel as ‘1’ if a template 
area was marked and ‘0’ if it was not marked. Scoring was undertaken by a single 
experienced rater (KC) who followed guidance previously described (Lacey, et al., 
2005; Chatterton, et al., 2013). For the online survey, the Qualtrics software 
automatically scored the pain diagrams by applying the same pre-defined scoring grids 
to the final data set as used for the paper surveys. The scores were downloaded into 







Figure 6.4. Body pain diagrams and scoring grid  and foot pain diagrams and scoring 
grid (Garrow, et al., 2004; Lacey, et al., 2005; Otter, et al., 2010; Chatterton, et al., 
2013).  
Body pain diagram 1: back view, body pain diagram 2: front view; Foot pain diagram 
1: left foot dorsal and plantar view, foot pain diagram 2: right foot dorsal and plantar 
view, foot pain diagram 3: left and right foot lateral view, foot pain diagram 4: left and 




Metric mapping of survey items - For a targeted approach to data analysis, survey 
items were mapped to key variables in order to determine associations and 
relationships that were formed a priori (Table 6.5). The data analysis strategy was 
informed by the conceptual framework developed in research phase 1, which was 
underpinned by the PsA core domain set and the ICF framework. The GRAPPA-
OMERACT PsA core domain set was used to inform interview guide development for 
the qualitative study in research phase 1 and survey item development in research 
phase 2, which enabled a pre-determined core set of foot-specific variables to be 
established (Figure 6.5). Furthermore, linking concepts derived from the qualitative 
study on the impact of foot involvement in PsA to the ICF model, highlighted 
important patient-focused areas such as coping, self-care, footwear, support and 
understanding, which ensured that information central to the patient experience 
relating to Environmental and Personal Factors was included in the survey metrics 
(Figure 6.6). Mapping survey items served to highlight the commonality across key 
domains for a focused presentation of key insights.  
 
Foot-specific impact domains framed by the ICF included:  
 
1) Body Structure; musculoskeletal and dermatology involvement of foot 
structures including location, extent and frequency  
 
2) Body Functions; Foot pain, nature of foot symptoms and their impact on body 
image, coping, physical function and gait changes  
 
3) Activity and Participation; impact of foot problems on walking, self-care 
activity and life areas such as daily routine, work, social and family life 
 










Figure 6.5. Survey items mapped to the psoriatic arthritis core domain set and establishing a core set of foot-specific impact domains.  




 Foot function: Q38, Q42
 Physical activity: Q40 
PERSONAL FACTORS
 Demographic information: Q1-10, Q14
 Disease duration: Q12, Q13
 Depression, anxiety: Q21
 Personal traits: coping style Q48
ENVIRONMENTAL FACTORS
 Footwear: Q34, Q37, Q44 - Q46
 Support from friends, family: Q48, Q49, Q50, Q51
 Support from health professionals: Q11, Q32, Q51, 
Q54, Q55, Q56, Q57, Q58
FOOT INVOLVEMENT IN 
PSORIATIC ARTHRITIS 
IMPAIRMENTS, LIMITATIONS AND RESTRICTIONS
PARTICIPATION
 Daily activity: Q34, Q37, Q41, Q42, Q46
 Work: Q8, Q9, Q41, Q46
 Social life: Q34, Q37, Q41, Q46
 Self-care activity: Q45, Q46, Q51, Q52, Q53
BODY STRUCTURE & FUNCTIONS
 Foot pain: Q22, Q23, Q24, Q25
 MSK involvement: Q24, Q25, Q26, Q28 
 Skin involvement: Q30, Q31, Q32, Q33, Q34
 Toenail involvement: Q35, Q36, Q37
 Cognitive functions: emotions/body image Q21, 
Q27, Q29, Q34, Q37, Q42, Q46, coping Q47, Q48 
CONTEXT
 




Table 6.5. Data analysis strategy for descriptive statistics of survey data. 
Data categories  Question 
number 
Data collected Type of 
data  
Data analysis strategy  




1 Where do you live  Nominal Description of sample, comparable sample, link 
between socioeconomic status, health literacy and 
health seeking behaviour, age-related differences, 
gender-related differences, ability to target specific 
ethnic groups  
2 Postcode – location Nominal 
3 Age Ratio 
4 Gender Nominal 
5 Height Ratio 
6 Weight Ratio 
7 Ethnicity Nominal 
8 Work status Nominal 
B) Global PsA 
presentation/description 
9 Work status change due to PsA Nominal Work participation, health economic impact 




10 Highest qualification Ordinal Health literacy, health seeking behaviour, ability to 
target specific groups 
C) Healthcare 
professional access, 
support and quality of 
care – general and foot 
specific 
11 Currently see a Rheumatologist 
for management of PsA 
Nominal  Description of sample, health seeking behaviour, 
disease management 
B) Global PsA 
presentation/description 
12 Onset of symptoms Ratio Description of sample, comparable sample, mean 




Global and local foot pain comparison, determine 
potential sample bias or study limitations related to 
13 Duration of diagnosis  Ratio 
14 Medication management for PsA Nominal 
15 Location of ache/pain due to PsA 
– past month 
Nominal 





Data categories  Question 
number 
Data collected Type of 
data  
Data analysis strategy  
Highlighted variables were independent in analyses 
17 Global rating of arthritis impact – 
past week 
Interval severity/importance attributed to foot problems and 
presence of comorbidities 
18 Global rating of psoriasis impact 
– past week 
Interval 
19 Global rating of psoriasis and 
arthritis impact – past week 
Interval 
20 Global rating of pain from PsA 
impact – past week 
Interval 
21 Comorbidity presence Nominal 
D) Foot symptomology 
potentially due to PsA 
involvement 
22 Pain presence in feet/ankles for 
one month or longer – past month 
Nominal Comprehensive description of foot and ankle 
characteristics in psoriatic arthritis; current foot pain 
prevalence, site-specific foot involvement, nature of 
foot pain, sub-group analysis of different patterns of 
foot involvement with associated impacts 
23 Severity of pain in feet/ankles – 
past month 
Interval 
24 Location of pain in feet/ankles – 
past month  
Nominal 
E) Foot involvement in 
PsA - impact 
25 Impact of symptoms in 
feet/ankles on a typical day 
Ordinal Nature of foot pain, foot-specific impact domains 
D) Foot symptomology 
potentially due to PsA 
involvement 
26 Frequency of other symptoms in 
feet/ankles 
Ordinal Nature of foot pain, foot-specific impact domains 
E) Foot involvement in 
PsA - impact 
27 Troublesome symptoms in 
feet/ankles 
Ordinal Description of the key foot-specific impact domains 
D) Foot symptomology 
potentially due to PsA 
involvement 
28 Current/past problems affecting 
feet 
Nominal Comprehensive description of foot and ankle 




Data categories  Question 
number 
Data collected Type of 
data  
Data analysis strategy  
Highlighted variables were independent in analyses 
E) Foot involvement in 
PsA - impact 
29 Embarrassment/self-conscious 
about foot problems 
Nominal Description of the key foot-specific impact domains 
F) Psoriasis – 
presentation/frequency 
30 Presence of psoriasis - foot Nominal Description of sample 





support and quality of 
care – general and foot 
specific 
32 Currently see a dermatologist for 
management of psoriasis  
Nominal Description of sample, health seeking behaviour, 




involvement - impact 
33 Problems with skin on feet/ankles 
– past month 
Nominal Comprehensive description of foot and ankle 
characteristics in psoriatic arthritis and key foot-
specific impact domains  34 Impact of skin problems on 
feet/ankles - past month 
Ordinal 
H) Toenail psoriasis – 
presentation/frequency 
35 Presence of toenail psoriasis  Nominal Description of sample 
 
Comprehensive description of foot and ankle 
characteristics in psoriatic arthritis and key foot-
specific impact domains 
36 Problems with toenail psoriasis – 
past month 
Nominal 
I) Toenail psoriasis 
involvement - impact 
37 Impact of toenail psoriasis – past 
month 
Ordinal 
J) Foot problems - 
impact 
38 Mobility difficulties due to foot 
problems 
Ordinal Description of the sample, identify potential barriers 
and facilitators related to physical activity, links with 
global and foot-specific impact domains 39 Mobility problems due to other 




Data categories  Question 
number 
Data collected Type of 
data  
Data analysis strategy  
Highlighted variables were independent in analyses 
40 Frequency of physical activities 
of varying degrees of intensity – 
past week 
Ordinal  
41 Impact of foot problems on 
various activities of daily living 
Ordinal 
42 Impact of mobility difficulties 
due to foot problems  
Ordinal 
43 Frequency of falls Ratio 
K) Footwear worn, 
selection factors and 
difficulties/impact 
44 Type of footwear worn most 
during a typical week 
Nominal Description of most commonly worn footwear, sub-
group analysis of site-specific foot involvement, key 
foot-specific impact domains associated with 
pathological features and self-management strategies 
45 Top 5 most important factors 
when choosing footwear 
Nominal 
46 Degree of difficulties experienced 
with footwear 
Ordinal 
L) Coping strategies 
with foot problems 
47 Ability to cope with foot 
problems - past month 
Interval Description of self-management strategies and key 
foot-specific impact domains, impact triad (severity, 
importance, coping) 48 Ways used to cope with foot 
problems 
Nominal 
M) Social support for 
foot problems 
49 Perceived lack of understanding 
and/or support from friends, 
family and others 
Nominal Description of self-management, health literacy, 




50 Belong to a patient support group Nominal 
N) Coping strategies 
with foot problems 
51 Assistance required to take care 
of feet properly 
Nominal Description of foot healthcare need, links with health 
seeking behaviour and health literacy, health 
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Data categories  Question 
number 
Data collected Type of 
data  
Data analysis strategy  
Highlighted variables were independent in analyses 
52 Effectiveness of self-management 




economic impact comparisons, cost/benefit 
evaluation 
53 Out-of-pocket expenditure on 




support and quality of 
care – general and foot 
specific 
54 Health professionals and non-
professionals seen about foot 
problems 
AND 
Effectiveness of help received by 
health professionals 
AND 
Confidence in health 







Description of foot healthcare need, health seeking 
behaviour, awareness of foot involvement in 
psoriatic arthritis, identify potential barriers and 




55 Rheumatologist asked about feet Nominal 
56 Rheumatologist examined feet Nominal 
57 Seen a podiatrist Nominal 
58 Received regular podiatry 
treatment  
Nominal 
59 Received foot/ankle surgery 
AND 




PsA Psoriatic arthritis.  
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6.3.3 PHASE 3: Survey Implementation 
Survey researchers typically seek a representative population-based sample. 
Throughout the process of recruiting research subjects and distributing surveys, bias 
can occur if a specific population is targeted without proper randomisation. Ambiguity 
relating to bias can be resolved by comprehensively reporting the recruitment process 
and the sample frame, characteristics, representativeness and sample size calculations 
(Turk, et al., 2018). The reporting of survey implementation and dissemination is 
crucial in order to determine the generalisability of study results. 
 
 Large-scale survey dissemination  
Sample size requirements for the study were difficult to estimate as the prevalence of 
PsA in Australia and New Zealand were unknown a priori. In the absence of large 
databases to target established PsA populations, the sampling strategy was to identify 
the major sites for dissemination and determine the response rate relative to the 
populations that were targeted.  
 
Targeted sites and organisations for dissemination of the survey were pre-identified 
including; patient community groups, patient support organisations (PsA, psoriasis, 
spondyloarthritis, arthritis, rheumatology, autoimmune, musculoskeletal), online 
patient support groups (Facebook, Reddit), professional associations (rheumatology, 
podiatry, dermatology, clinical immunology and allergy), specialist clinical services 
(PsA, rheumatology, podiatry), and research centres (clinical innovation, 
musculoskeletal) (Figure 6.7). Both the web-based and paper-based versions of the 
survey were run concurrently to optimise data collection. In the event that online 
survey completion was not possible, the paper survey would be provided with a 
stamped addressed envelope on request. Consent was implicit by the return/submission 
of the completed survey and participants were informed of this at the start of the paper 
and online survey.  
 
In total, 900 paper surveys were posted to the targeted patient community groups and 
specialist clinical services in Australia (n=650) and New Zealand (n=250), as well as 
2000 flyers and 300 posters. Paper survey packs sent to the targeted sites comprised 
an introductory letter, posters, flyers, copies of the survey with attached stamped 
153 
 
addressed envelope and participation information sheet (survey promotion materials 
are included in Appendix 8). Clinical services were asked to provide an estimate of the 
number of their patients with PsA, those with available figures indicated that the 
potential reach of the survey could be 2740 in Australia and no estimates were 
provided in New Zealand (Table 6.6). For dissemination of the online survey, all 13 
patient support organisations and 5 out of the 26 social media groups agreed to promote 
the survey to their membership via their monthly newsletters, website and/or Facebook 
page, with a potential reach of the survey to approximately 3260 people with PsA 
across Australia and New Zealand. This targeted approach to survey dissemination 
was followed by snowballing and crowdsourcing sampling techniques, where 
participants informed other potential participants of the research by liking posts and 
sharing links about the survey. Monthly email reminders were sent to all target sites 
and organisations to request for continued promotion of the survey during the study 
period (6-months).   
 
The estimated total target population identified from the major sites for dissemination 
was 6000 people with PsA in Australia and unknown in New Zealand. The total target 
population in Australia comprised PsA sample estimates from the online organisations 
(n=195), social media groups (n=3065) and specialist clinical services (n=2740) in 















Table 6.6. Summary of sites targeted for online and paper survey promotion. 




Online survey promotion   
Arthritis support organisations 
13 
Arthritis Australia  X 
Arthritis & Osteoporosis New South Wales X 
Arthritis Australian Capital Territory 122 
Arthritis South Australia X 
Australia & Osteoporosis Northern Territory X 
Australia Queensland X 
Australia & Osteoporosis Western Australia  X 
Australia & Osteoporosis Tasmania X 
Musculoskeletal Australia 73 
Arthritis New Zealand X 
Dragon Claw, Australia X 
Creakyjoints, Australia X 
Psoriasis Australia  X 
Social media groups  
5 
Young Women’s Arthritis Support Group, Australia  X 
Reddit Psoriatic Arthritis, worldwide X 
Spondyloarthropathy support group, Australia X 
Psoriasis and Psoriatic Arthritis in Australia, Australia  2272 
Psoriatic Arthritis Support Group, Australia 793 
7 
Professional organisations (n=6 Australia, n=1 New 
Zealand) *1 
NA 
2 Research centres (n=2 Australia) NA 
Paper survey promotional packs sent to individual sites 
6 




General rheumatology clinical services (public) (n=22 
Australia, n=22 New Zealand) 
X 
21 








University podiatry clinics (n=7 Australia, n=1 New 
Zealand) 
X 
 TOTAL  6000 
X = unknown number of members or patients with psoriatic arthritis. 
NA = not applicable as there is no patient membership, only health professionals. 
*1 Physiotherapy and Occupational Therapy professional associations required a charge to advertise to 























Psoriasis and psoriatic arthritis support group 
Creakyjoints, Dragonclaw Australia 
Spondyloarthritis support group
Reddit: psoriatic arthritis
Individuals with special 
interest in PsA or 
people with PsA
Australian Rheumatology Association
New Zealand Health Professionals in Rheumatology
New Zealand Rheumatology Association
Australasian College of Dermatologists
Australian Podiatry Council
Psoriatic arthritis support group
Rheumatologists and registras
People with PsA 
Specialist clinics in NSW Australia
Specialist clinics in VIC Australia
Public health services
Private health services
Western Sydney University, NSW Australia
Auckland University of Technology, New Zealand
La Trobe University, VIC Australia
Western Australia University, WA Australia
Queensland University of Technology, QLD Australia
University of South Australia, SA Australia
Central Queensland University, QLD Australia
Charles Sturt University, NSW Australia
Podiatry New Zealand
Australian Society of Clinical Immunology and Allergy
Young Women s Arthritis Support Group
 
 
Figure 6.7.  Targeted sites and individuals for survey dissemination in Australia and New Zealand.  
PsA Psoriatic arthritis, NSW New South Wales, QLD Queensland, SA South Australia, VIC Victoria, WA Western Australia. 
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A study website [www.psoriaticfootarthritis.com] and Facebook page 
[fb.me/footsurvey, psoriatic arthritis foot study] were created to generate research 
interest through online health social networks and communities (Figure 6.8 and 6.9). 
It also provided the opportunity to engage with interested respondents over an 
extended period by providing regular updates on the study progress and relevant 
information about the disease and its impact. Over the 6-month data collection period, 
the website had 109 views and the Facebook page had 83 followers, received 78 post 
likes and had a page research (an estimated metric for the number of people who saw 
a specific post or any content from the page) of 2678 people (Figure 6.10). There was 
a total of 41 enquiries via the website, 6 people were sent the paper survey as requested, 
28 people were sent the electronic survey link, 4 enquiries were from non-Australasian 
residents expressing interest in the study, and 3 were from people without a PsA 
diagnosis. Valuing the contribution of participants was key to developing a 
community-academic partnership, with the shared goal to move forward this area of 
research and to increase awareness about the disease and foot involvement. Robust 
strategies for sampling, survey dissemination and community engagement made a 
powerful contribution to response rates and the scale of information collected. 
 
During data collection, a poor response from male participants and people living in the 
Northern Territory (NT) state of Australia was noted. Potential male respondents were 
subsequently targeted in a Facebook page post and in the animation video in order to 
encourage participation. Despite having established online survey promotion with 
Arthritis and Osteoporosis NT, two additional organisations agreed to promote the 
survey online to their networks; Council of the Aging (COTA) NT and NT PHN health 
workforce agency. Such targeted dissemination was considered to increase the 











Figure 6.8. Facebook page and posts about the survey and issues relating to foot 
problems among people with psoriatic arthritis, including a video animation to further 
promote the survey. 
 
 
Figure 6.9. Website page to promote the survey.  
This included information about the survey, psoriatic arthritis, foot involvement, study 
outcomes to date, professional background of the principle investigator (KC), contact 
and enquiry details. A video of the principle investigator describing the purpose of the 
survey, background context, what participation involves and how to participant was 




Figure 6.10. Time line for online survey responses over the 6-month recruitment period showing incremental changes in responses related to study 
promotional activity. There was a total of 62 Facebook posts during the study period about the survey and relevant information about the disease 
and foot problems.  
PsA Psoriatic arthritis. 
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Evidence for methods to increase survey response rates (postal and electronic modes 
of administration) in a range of health and non-health settings have been presented in 
a Cochrane systemic review (Edwards, et al., 2009). Strategies adopted to increase 
response rates by the current study included; using a personalised approach in the 
survey introduction, assuring confidentiality, indicating that the survey originates from 
a University (rather than a government department or commercial organisation), using 
the non-monetary incentive of offering study results, providing stamped return 
envelopes for the paper survey (rather than pre-paid envelopes), offering the option of 
online response, putting easier questions first, and stating on the study Facebook page 
that others had responded, stressing the importance of responding and giving a 
deadline (Edwards, et al., 2009). In addition, reminders to respond were posted on 
Facebook and were sent to organisations who agreed to promote the survey (Nakash, 
et al., 2006). Strategies adopted to increase data completeness by the current study 
were to make the survey user friendly and to include interesting and salient questions 
(Edwards, et al., 2009). A strategy not adopted was to offer monetary incentives for 
survey completion, which can be unacceptable to some ethics committees when 
deemed likely to exert pressure on individuals to participate (McColl, 2007).  
 
Handling of missing data is a difficult and complex task (Jakobsen, et al., 2017), and 
is frequently underreported in survey research (Turk, et al., 2018). The impact of 
missing data on study results was reduced by using pairwise deletion to analyse all 
available data (Kenward and Carpenter, 2007). In addition, transparent reporting of 
missing data is the recommended standard of good practice when rates are considered 
negligible, such as in the current study at below 5% (Li, et al., 2014; Jakobsen, et al., 
2017). Therefore, both complete and partially completed surveys were analysed, with 
missing data provided. The survey development protocol was carefully designed and 
implemented in order to prospectively prevent and minimise missing data occurrence, 
which is supported as the best practice approach in the literature on handling missing 
data (Little, et al., 2012; O'Neill and Temple, 2012; Kang, 2013; Li, et al., 2014; 
Jakobsen, et al., 2017).  
 
Reporting guidelines for survey research were reviewed using the EQUATOR network 
(Enhancing the QUAlity and Transparency Of health Research) (Equator Network, 
2020). Best suited to the current study design was the SUrvey Reporting GuidelinE 
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(SURGE) for paper-based surveys (Grimshaw, 2014) and the CHEcklist for Reporting 
Results of Internet E-Surveys (CHERRIES) for web-based surveys (Eysenbach, 2004). 
Although the EQUATOR network recommends the STROBE (STrengthening the 
Reporting of Observational studies in Epidemiology) for observational studies, it does 
not include specific methodological characteristics that are unique to survey research 
(Bennett, et al., 2011; Turk, et al., 2018). Survey development, administration and data 
management were described using these reporting checklists. 
 
Whilst local lead investigators to support survey dissemination in New Zealand were 
established, it should be noted that there can be significant challenges to conducting 
research in different countries. These challenges include, but are not limited to, ethical 
requirements, logistical management and maintaining effective communication. In 
New Zealand, ethical approval processes did not fit within the time restrictions of the 
project and were postponed. Planned dissemination of the survey in New Zealand will 
constitute future post-doctoral work. Therefore, the results presented pertain to 
Australia survey dissemination and response only.  
 
6.4 Results 
The final 59-item self-administered survey was developed based on feedback from 
each of the stages involving people with PsA, health professionals and experts. Key 
survey domains included demographic (10%) and socioeconomic data (10%), global 
disease information (18%), foot and ankle characteristics (18%), and the impact of foot 
problems on daily life including daily routine, footwear choice, family life, work and 
accessing healthcare (44%). The percentage coverage of items directly reflects the 
dominant concerns of people with PsA-related foot problems and health professionals 
in rheumatology. The full survey instrument and advertising text are provided in the 
Appendix 8 and 9.  
 
Measures of outcome or success of survey research include those of quantity (survey 
and item response rates) and quality (non-response bias, validity, reliability and 
distribution of responses), as well as resource implications (McColl, et al., 2001). 
Quantity-related success outcomes in the current study included a total of 649 survey 
responses that comprised 602 (93%) unique online survey views and 47 (7%) 
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completed paper surveys (Figure 6.11). The majority of respondents progressed 
through 100% of the survey to reach the end (83%), with 7% of participants (n=43) 
not progressing beyond the first information page to enter the survey. In Australia, 
there was a 10% total survey response rate based on the estimated PsA sample of 6000 
identified from the major sites for dissemination. The paper survey had a response rate 
of 7% (n=47), with 650 paper surveys distributed in Australia. The online survey full 
completion rate was 84%, with 559 respondents starting the first page and 468 reaching 
the last page of the survey. Valid and missing data for each survey item was evaluated 
in order to determine data completeness. With the 43 participants who did not start the 
survey removed from analysis, the missing data for online and paper survey 
completions was below 5% for the majority of respondents (95%).  Time taken to 
complete the online survey was a mean (SD) 21 (8) minutes, with cut-off points of less 
than 10 minutes and more than 1 hour used to exclude survey entries with excessively 
short or long completion times, chosen for practical reasons to aid analysis 
(Eysenbach, 2004). The majority of survey respondents (82%) indicated that they 
would like to be contacted again about future studies related to this research, which 
























Australia n=650 New Zealand n=250
Reminders sent to online 
organisations n=65
Accepted invitation to 
promote survey n=19
Declined invitation to 
promote survey n=26 
Online survey responses 
n=602
Paper survey completions 
n=47
Number of Facebook posts 
to promote survey n=60
Postponed due to 
time restrictions
Reminders sent to targeted 
sites and individuals in 
rheumatology in New Zealand
n=32
Reminders sent to targeted 









Figure 6.11. Flow diagram of survey dissemination.
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Quality-related success outcomes in the current study included evidence from multiple 
iterations of pre-testing using different target samples, which confirmed that the 
instrument performed as intended in the target population. The comprehensive audit 
trail established that survey items were relevant to; foot involvement in the context of 
PsA, the target population in Australasia and the purpose of the survey, and that all 
items together comprehensively reflected the construct to be measured. Engaging 
people with PsA, health professionals and experts in the survey development methods 
ensured that content and face validity were achieved. Extensive pre-testing confirmed 
that the survey possessed sufficiently high cognitive and usability standards for 
potential respondents to effectively engage with and successfully complete the survey. 
In terms of sample representativeness, there were low reporting levels from male 
participants (11%), from those living in the Northern Territory state of Australia (0%) 
and nearly half the sample reported membership with a patient support group (41%). 
The results of the survey development, administration and data management were 
described using the SURGE and CHERRIES reporting checklists (Table 6.7 and 6.8).  
 
Table 6.7. Summary of paper-based survey design, conduct and results using the 
SURGE checklist. 
Checklist item Explanation 
Title and Abstract  
Design of study  A survey of foot problems among people with PsA 
 National survey conducted in Australia and New Zealand  
 Cross-sectional observational study design  
Introduction  
Background  Considerable improvement in the assessment and treatment 
of foot problems related to PsA is needed, but limited 
evidence exists in this area. With the right management, 
people with PsA might have the opportunity to minimise 
disabling foot pain and joint damage. Most of our 
knowledge comes from a few studies conducted in European 
countries. To better target and treat localised disease in the 
foot, a better understanding of the foot problems and the 
impact they have on daily life, footwear choice and the foot 
care needs of people with PsA is required. 
Purpose/aim of study The aim of the survey was to find out about the foot 
problems experienced by people with PsA and how they 
impact on daily life. 
Methods  
Research Tool   
Description of the survey 59-item self-administered survey  
 There were 8 sections to the survey: 
Section 1  About you  
Section 2  About your psoriatic arthritis  
Section 3  About your foot and ankle  
Section 4  About your psoriasis  
Section 5  About your toenails  
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Section 6  About your feet and your daily life  
Section 7  About your footwear  
Section 8  About how you manage your feet  
 
 Key survey domains included demographic (10%) and 
socioeconomic data (10%), global disease information 
(18%), foot and ankle characteristics (18%), and the impact 
of foot problems on daily life (44%) 
 Types of survey response options included: 
Text entry (n=7) 
Yes, or No (n=18) 
Two or three response options (n=3) 
Multiple choice (n=13)  
4-point Likert scales (n=3) 
5-point Likert scales (n=9) 
11-point numerical rating scales (n=7)  
Body pain diagram; back, front (n=1) 
Foot pain diagram; dorsal, plantar, medial, lateral, posterior 
(n=1) 
 Total number of potential skips, n=5 
 In total there were 27 pages of the paper-based survey  
Participation information sheet was attached separately (1 
page) 
 On the first page, participants were provided with the aim of 
the survey, inclusion criteria and an outline of the survey 
structure 
 On the final page, participants willing to be contacted in the 
future about studies related to this research had the option to 
provide their name and contact information  
 On the final page, participants wishing to find out the results 
from the survey were provided with the study website 
address and the contact information of the study 
investigators  
 The full survey instrument will be provided in 
supplementary materials of future publications 
Existing tool, psychometric 
properties 
There were no existing tools to assess PsA-specific foot 
involvement 
 Existing tool, references to original 
work 
New tool, procedures to develop 
and pre-test  
Survey items were generated by the research team based on 
previous work to develop a conceptual framework, a review 
of the related literature and clinical experience  
 Survey items were pre-tested using methods that comprised; 
1) cognitive debriefing of people with PsA, 2) focus groups 
with health professionals in rheumatology, 3) expert review 
panels of subject and survey design experts, 4) cultural 
sensitivity assessment and 5) pilot testing among people 
with PsA 
 Best practice methods in qualitative survey design were 
used that resulted in 7 iterations of the survey draft 
 Convenience sampling was used to recruit all participants 
involved in the development and pre-testing of the survey 
 Ethics approval was granted and written informed consent 
was provided by all participants prior to data collection of 
demographic information 
New tool, reliability and validity Pre-testing results suggested good face and content validity, 
and that cognitive and usability standards were achieved 
Scoring procedures Scoring procedures for survey responses and scales were 
provided as examples and in the full code book 
Sample selection   
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Survey population  Target population included those with PsA, aged 18 or over, 
with current or previous foot problems, living in Australia 
and New Zealand 
Sample frame Adults with current foot problems, with previous without 
foot problems, with no experience of foot problems, with 
self-reported PsA, without self-reported PsA including other 
inflammatory or non-inflammatory arthritis condition, living 
in Australia and New Zealand, not living in Australia and 
New Zealand. 
 
- Clinic based sample; rheumatology and podiatry outpatient 
clinics, specialist PsA clinics 
- Non-clinic based sample; arthritis community groups, 
online patient support groups and organisations, social 
media groups, self-selecting participant  
Sample representativeness Potential for bias and poor representativeness included: 
- Participants with foot problems were more likely to take 
part 
- Reliability of self-reported PsA  
- Members of patient support organisations or community 
groups 
- Those receiving podiatry or rheumatology healthcare  
- Reach to rural areas limited 
- English language survey requiring a certain level of 
English and literacy 
Sample size calculation, rationale or 
justification 
Sample size requirements for the study were difficult to 
estimate as the prevalence of PsA in Australia and New 
Zealand were unknown a priori. Estimates were provided 
based on 1) previous Australasian-based survey research in 
podiatry rheumatology, 2) calculations of global percentage 
estimates extrapolated to the local population, and 3) target 
sample estimates provided by the major sites for survey 
dissemination 
Survey administration  
Mode of administration Mixed simultaneous mode of administration included; 
 - Paper-based survey mailed to selected clinical services or 
to individuals requesting a paper copy 
 - Web-based survey advertised (see CHERRIES checklist)  
Type and number of contacts  1. Arthritis patient organisations, n=13 
2. Online patient support groups, n=26 
3. Specialist PsA clinic services, n=6 
4. General rheumatology clinic services (public), n=22 in 
Australia, n=22 in New Zealand 
5. Private rheumatology practice, n=68 in Australia, n=10 in 
New Zealand 
6. Rheumatologists with special interest in PsA, n=21 in 
Australia 
7. Health professional associations, n=7 
8. Research centres, n=2 
9. University podiatry clinic, n=8 
Financial incentives  No financial incentives were provided  
Description of who approach 
potential participants  
- Treating rheumatologist or podiatrist 
- Self-selecting participants (advertising posters and flyers 
sent to selected clinical services, online via study website 
and Facebook page) 
- Patient support organisations (advertising at community 
groups, on websites, on social media groups)  
Analysis   
Method of data analysis Descriptive statistical analysis 
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Method for analysis of non-
response error 
Characterisation of respondents in order to determine non-
response bias 
Method for calculating response 
rate 
With population prevalence unknown a priori and in the 
absence of national databases of PsA populations in order to 
estimate target population and response rates, the sampling 
strategy was to calculate the potential reach of the survey by 
samples of people with PsA identified by the major 
recruitment sites. 
Definition of complete completion Valid data was defined and reported 
n= 285 complete 100% for the online survey 
n= 5 complete 100% for the paper survey 
Definition of partial completion Both completed and partially completed surveys were 
analysed  
n= 274 partial completions for the online survey 
n= 42 partial completions for the paper survey 
Methods for handling item missing 
data 
Missing data was defined and reported. Pairwise deletion 
was used to analyse all available data  
Results   
Response rate reported 7% response rate for the paper survey  
10% response rate of the online and paper survey based on 
the 6000 people with PsA identified from the major sites 
targeted for survey dissemination 
All respondents accounted for n = 47 total number of paper survey respondents  
n = 559 total number of online survey respondents 
n= 43 total number of non-completions of the online survey 
(did not progression beyond the first information page) 
Information on how non-
respondents differ from respondents  
Sample representativeness was described; 
Low response from: males and people from the Northern 
Territory  
High response from: Australian European/British and people 
with foot pain, accessing healthcare 
Results clearly presented Yes 
Results address objective Yes 
Discussion  
Results summarised referencing 
study objectives 
Yes 
Strengths of the study Yes 
Limitations of the study Yes 
Generalisability of results  Information provided 
Ethical quality indicators  
Study funding  There was no funding source for the study 
Research Ethics Board review  Ethical approval was granted by South Western Sydney 
Local Health District (HREC/171/LPOOL/353) including 
site specific agreements for Liverpool Hospital 
(SSA/17/LPOOL/407), the BJC Health rheumatology clinic 
(SSA/17/LPOOL/407), Royal North Shore Hospital in North 
Sydney Local Health District (SSA/18/HAWKE/78, 
RESP/19/066); Western Sydney University Human 
Research Ethics Committee (H12973), Auckland University 
of Technology Ethics Committee (AUTEC 17/320), and 
Waitemata District Health Board of Auckland, New Zealand 
(RM/3907)  
Subject consent procedures  Survey development: Written informed consent was provided 
by all participants prior to data collection. 
Survey administration: Consent was implied, participation 
information sheet was provided. 




Table 6.8. Summary of web-based survey design, conduct and results using the 
CHERRIES checklist. 
Checklist item Explanation 
Design  
Survey design A survey of foot problems among people with PsA 
 National survey conducted in Australia and New Zealand  
 Cross-sectional observational study design  
Target population Adults with PsA, with past or present foot problems, living 
in Australia or New Zealand 
Sample frame - Clinic based sample; rheumatology and podiatry 
outpatient clinics, specialist PsA clinics 
- Non-clinic based sample; arthritis community groups, 
online patient support groups and organisations, social 
media groups, self-selecting participant 
Convenience sample type Yes 
Institutional Review Board 
approval and informed consent 
process  
 
Institutional Review Board approval  Yes 
 Western Sydney University Human Research Ethics 
Committee (H12973) 
Informed consent process Implied 
- how long the survey will take 20 to 30 minutes  
- data stored, where and how long Data electronically compiled from the paper- and web-
based survey was stored in a password-protected file, on a 
password-protected computer at Western Sydney 
University.  
Data will be kept for 5 years and then it will be destroyed 
- study investigators Miss Kate Carter, Dr Steven Walmsley, Professor Keith 
Rome, Professor Deborah Turner 
- purpose of the study The aim of the survey was to find out about the foot 
problems experienced by people with PsA and how they 
impact on daily life 
Data protection  
- personal information collected  Name and telephone number or email address (optional) 
- personal information stored  Participants had the option to take part in potential future 
studies by providing their contact details (name and 
telephone number or email address). For the web-based 
survey responses, the participant contact information was 
downloaded from Qualtrics and stored separately from the 
main survey data in a password protected file, on a 
password protected computer that could only be accessed 
by the research team. Each participant was allocated a 
unique identifying number under which all data was 
recorded 
- mechanism to protect unauthorised 
access to personal information 
Password protection  
Development and pre-testing   
Procedures to develop and pre-test The web-based survey was developed with testing the 
usability and technical functionality of the electronic survey 
by people with PsA and by a survey design expert 
Recruitment process and 
description of the sample with 
access to survey 
 
Type of survey Open type of survey to each visitor of the survey web-link, 
website and Facebook page  
Contact mode  Initial contact with potential participants was through: 
- internet (website, Facebook page) 
- e-mail (providing survey web-link on request) 
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- poster and flyer with survey web-link posted to 
sites/clinics 
Advertising of survey  Mixed advertising methods included: 
- online patient organisation website and Facebook page 
- health professional associations website and Facebook 
page 
- e-newsletters of patient organisations 
- social media (website, Facebook page, online support 
groups) 
- poster and flyer posted to sites/clinics with survey web-
link 
- study website and Facebook page   
Wording of the advertisement Provided in supplementary materials  
Survey administration  
Web or e-mail based survey  Web-based survey only, with link to web-based survey  
Data entry  Automatic web-based entry, no manual entry required  
Context 
- Describe the websites  
Visitors to websites, purpose of visit 
Websites on which the survey was posted: 
- Arthritis patient organisations, n=13 
Charitable, not-for-profit organisations, provides support 
and information to people with arthritis. Visitors may be 
seeking information or support, wanting to share 
information, donate or fundraise, or to take part in research 
 
- Online patient support groups, n=26  
Open or closed groups, promotes awareness of the 
challenges facing people with arthritis across the 
community, provides support and shares information. 
Visitors may be seeking information or support, wanting to 
share information, donate or fundraise, or to take part in 
research 
 
- Health professional associations, n=7 
Closed group of health professionals. Visitor may be 
seeking information on training, governance and job 
opportunities, to provide information, or to seek updates on 
current work practices and research projects  
 
- Study website and Facebook page, n=109 views, n=80 
followers 
People with PsA and/or people with foot problems. Visitors 
may be seeking to take part in the survey or wanting to find 
out more information about the study  
 There is a high degree to which the content of the websites 
could pre-select the sample or influence results. Selection 
bias cannot be ruled out 
Mandatory or voluntary  Voluntary  
Incentives  No incentives were provided  
Timeframe for data collection  July 2019 – December 2019, 6 months 
Randomisation of survey items  Not randomised or alternated 
Adaptive questioning  Adaptive questioning was used to reduce number and 
complexity of the questions. Certain questions and sections 
were displayed based on responses to other items.   
Adaptive view of survey (if no, automatic skip): 
- Information sheet (page 2) 
- Items 23-25 (page 14-16)  
- Items 31-34 (page 20) 
- Items 36-37 (page 22) 
Number of items per page Number of question items per page: 
Page Items per page 
Page 1  Introduction 
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Page 2  Information sheet 
Page 3  2 
Page 4  1 
Page 5  3 
Page 6  1 
Page 7  3 
Page 8  3 
Page 9 1 
Page 10 2 
Page 11 4 
Page 12 1 
Page 13 1 
Page 14 1 
Page 15 1 
Page 16 1 
Page 17 2 
Page 18 2 
Page 19 1 
Page 20 4 
Page 21 1 
Page 22 2 
Page 23 2 
Page 24 1 
Page 25 3 
Page 26 3 
Page 27 4 
Page 28 2 
Page 29 1 
Page 30 1 
Page 31 5 
Page 32 Willing to be contacted 
Page 33 Study investigator contact 
Page 34 Review responses  
Page 35 Thank you for taking part 
 
Number of screens/pages A total of 35 screens could be viewed and the minimum 
due to adaptive questioning is 29 screens. 
Completeness check  Completeness checks were done after the questionnaire was 
submitted. Forced response items related to inclusion 
criteria only including: 
- Item 1 Where do you live? 
- Item 3 How old are you?  
Mandatory selection of one response options was not 
enforced. 
A non-response option  A non-response option was provided on 4 occasions 
including ‘prefer not to state’, ‘not relevant’, ‘not sure’ and 
‘neither of these’ 
Review step  Respondents were able to review and change their answer 
through a back button and review step that displays a 
summary of the responses to check prior to submission 
Response rates   
Unique site visitor  The number of unique site visitors was 602 
View rate  The number of visitors to the first page of the online 
survey, n=602 
Participation/recruitment rate The number of people who filled in the first page of the 
online survey n=559, 93%  
Completion rate The number of people who submitted the last page of the 
online survey (n=468, 78%) divided by the number who 
agreed to participant (started the first page of the online 
survey) (n=559, 93%). Completion rate = 84% 
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Preventing multiple entry from 
the same individual  
 
Cookies used  Cookies were not used to prevent users from accessing the 
survey twice.  
IP check IP addresses were not used to prevent users from accessing 
the survey twice. IP address were used to identify 
duplicated entries from the same user. Duplicates were 
reviewed and eliminated before analysis. The first or last 
entry was selected based on completeness 
Log file analysis No other techniques were used to analyse the log file for 
identification of multiple entries 
Registration It was an open survey, IP addresses were used to identify 
duplications for later elimination before analysis 
Analysis   
Handling of incomplete surveys Both complete and partially completed surveys were 
analysed  
Survey submitted with an atypical 
timestamp 
Mean (SD) time taken to complete the survey was 21 (8) 
minutes 
Cut-off points were used to exclude survey entries with 
excessively short or long completion times, less than 10 
minutes (n=87, 14%) and more than 1 hour (n=29, 5%) 
Statistical correction  Methods to adjust for the non-representative sample were 
weighting of items/propensity scores  
PsA Psoriatic arthritis. 
 
6.5 Discussion 
To the best of our knowledge this is the first time a survey has been developed on foot 
involvement in PsA based on best practice methods in survey design. Extensive pre-
testing among key relevant stakeholder groups improved the overall quality, 
functioning and representativeness of the survey instrument. Although there is limited 
empirical evidence and few universal best practice recommendations for survey design 
and conduct (Reynolds, et al., 1993; McColl, et al., 2001; Edwards, 2010), 
comprehensive and transparent descriptions of survey design methods can allow 
clearer review of the usefulness and validity of the survey research (Turk, et al., 2018). 
This study presents a high-quality worked example of survey design and conduct, 
which can be used as a template by other research teams for broader application. The 
robust survey development protocol and pre-defined dissemination strategy positively 
influenced response rates and data completeness.  
 
Whilst the sampling strategy was to gain an appreciation of the potential survey reach 
and response relative to reach, the resultant 10% response rate does not meet the 
acceptable target response rates reported between 30% and 50% for survey research 
(Sue and Ritter, 2007; Nulty, 2008). Similar New Zealand-based podiatry surveys 
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reported sample sizes of 197 and 131 participants from a target sample of 400, with 
response rates of 49% and 32% respectively (Brenton-Rule, et al., 2014; Otter, et al., 
2016). Brenton-Rule, et al., (2014) surveyed across all groups of inflammatory arthritis 
using a web-survey promoted by Arthritis New Zealand. Based on these existing 
published sample sizes, the current study survey response of 606 PsA-specific 
participants was a very good response rate. The full survey completion rate from 
participants that attempted the survey was 91.95%, which is evidence of a successfully 
developed survey with few partial completions.  
 
Of the 43 participants who did not progress beyond the first information page to enter 
the survey, a proportion may have been other researchers, health professionals and 
administrators promoting the study that previewed the online survey and inadvertently 
contributed to the number of non-completions. A screening question to identify the 
difference between genuine non-responders with PsA and those interested in viewing 
the survey without PsA could have been included in order to better define non-
completion information. Nearly half of the respondents were members of a patient 
support group (41%), which could be a potential source of bias in the sample. 
However, with no national databases to target for recruitment there was no alternative 
approach other than to target the membership of patient support organisations and 
clinic-based samples. Despite attempts to target certain groups on social media, the 
underrepresentation from males and those in the Northern Territory reduced the 
representativeness of the sample, which should be considered in the interpretation of 
the results and requires further work to determine the foot health needs of non-
responders. In the pilot test prior to survey dissemination the poor completion of 
question 52 relating to self-care effectiveness was identified but not changed, which 
translated through to its poor completion in the final survey with 24% of missing data 
for that question. Exclusion or survey item revision to reduce difficulties related to 
recall, judgment and emotiveness may have prevented loss of data, which highlights 
the effectiveness of pilot testing in pre-identifying poor item performance issues.    
 
Patient self-report is increasingly used to assess the impact of PsA, to gain insight into 
the patient experience and to formulate new questions for investigation (Taylor, et al., 
2010; Tillett, et al., 2014; Orbai, et al., 2017a). The GRAPPA-OMERACT study 
groups have used qualitative self-reported information and the ICF model in the 
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preliminary stages of defining what to include in the measurement of disease impact 
domains and in the development of outcome measures (Stamm, et al., 2007b; Gudu, et 
al., 2017; Orbai, et al., 2017b). In accordance with the international working groups in 
PsA, this large national survey has incorporated the patient’s voice in the measurement 
of PsA by engaging patients in research activity throughout survey development 
protocol. Discordance between the views of people with PsA and health professionals 
were identified in phase 2 of survey development, which related to the use of technical 
language and the overall length of the survey with both issues being acceptable to 
patients but unacceptable to health professionals. These findings were consistent with 
similar research that found differences in the patient's and the health professional's 
perspective of disease in PsA (Dandorfer, et al., 2012), and emphasises the importance 
of embedding the patient perspective in the development of measures in PsA. 
 
A major strength of this study was the rigorous evidence-based approach used to 
develop the survey and the involvement of patients, health professionals and experts 
as a central component of survey research. The conceptual framework provided the 
basis for targeting the concerns and needs of patients in the measurement of PsA-
related foot involvement. The ICF provided a standardised approach to identify and 
describe relevant domains of impact on functioning that were used to inform the survey 
development, and enables the conceptual framework to be widely understood. 
Consequently, all components of the ICF framework were mapped to the survey, 
substantially improving the overall quality and relevance of the survey. By 
incorporating the views of those with the disease and of health professionals into the 
survey development process, good conceptual coverage of items important to both 
patients and health professionals was achieved and supports face and content validity. 
Their real-world experience provided insight into PsA symptoms and the associated 
impact that resonated with survey respondents and allowed them to describe their 
experience in a meaningful manner, which is likely to encourage higher response rates 
and fuller survey completions.   
 
The web-based survey was acceptable among respondents with PsA, was easy to 
complete and took no longer than the paper version, findings that are in concordance 
with previous studies in PsA (Chandran, et al., 2007; MacKenzie, et al., 2011; Magrey, 
et al., 2019). The current study employed an adaptive design to ensure the web-version 
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performed exactly as intended on different devices to collect equivalent data to the 
paper-version, and research evidence indicates that there is good comparability of data 
collected by paper and web-based surveys in PsA (MacKenzie, et al., 2011). Web-
based surveys are increasingly used to obtain patient data and this study highlights the 
significant value of usability pre-testing among patients and survey experts in the 
preliminary stages of survey design.   
 
Despite the widespread use of surveys in podiatry rheumatology research (Graham, et 
al., 2017; Brenton-Rule, et al., 2019; Stevens, et al., 2019), few studies have used 
rigorous methodologies or ‘best practices’ for high-quality survey design. 
Consequently, many surveys may lack the sound measurement properties required to 
collect reliable and valid data, which may be further demonstrated by limited research 
impact. Allied health research frameworks highlight the importance of research impact 
through engagement with patient communities and clinical networks, and through 
improvements that can be objectively measured and translate to clinical practice 
(NHMRC, 2020; NIHR, 2020; Victorian Allied Health Research Framework, 2020). 
Future work is planned to conduct a systematic review of existing surveys developed 
to research rheumatic foot conditions in order to 1) appraise explicit methodologies, 
2) determine survey content validity, and 3) establish the usefulness of this approach 
in yielding deliverable research impact.  It is acknowledged that the survey design 
methodology utilised in the current study does not represent the only way to develop 
a high-quality survey. However, it highlights important, evidence-based approaches to 
survey design that may be used in future podiatry survey-based research.  
 
Limitations of the survey development process (phase 1 and 2) include a potential 
sampling bias with all research participants chosen by convenience sampling. 
Therefore, participants who volunteered to take part in the survey development may 
not be representative of all people with foot involvement in PsA or the health 
professionals who manage this patient group. However, participants were recruited 
from multiple sites in order to achieve a diverse cross-section of the sample and 
recruitment continued until qualitative data saturation was reached. Although 
participants were recruited using convenience sampling based on our research 
collaboration network in Sydney, Australia and Auckland, New Zealand, it is possible 
for purposive sampling to recruit heterogeneous maximum variation samples (Patton, 
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2002). To ensure the survey captured differences related to socioeconomic and 
geographic contexts, the research advisory group pre-defined key variables relating to 
health economic data, which were included as part of the survey item development. A 
limitation to the study generalisability is that the multiple iterations of pre-testing and 
pilot testing required to develop a high-quality survey are resource and time intensive, 
which may be prohibitive for some research teams.  
 
6.6 Conclusion 
This study describes a robust survey development protocol using best practice methods 
in survey design and conduct, with the intent that this could be utilised as a framework 
for survey development in other areas of clinical practice. Involvement of people with 
PsA, health professionals and experts throughout the survey development process was 
a central component that ensured the survey functioned properly and yielded 
successful survey outcomes. Focus on high-standards of reporting survey research 
permits wider application of the protocol beyond the intended target population of the 
survey. Findings from the survey will provide useful data to inform clinical decision 
making and targeted research strategies. 
 
6.7 Significance and Innovation  
 This survey protocol presents a high-quality worked example of survey design 
and conduct, which can be used as a template by other healthcare researchers 
for broader application. 
 
 Involvement of patients throughout the survey development process was 
essential in order to ensure that survey items assessed constructs important and 
relevant to them, and that the survey functioned properly as a content-valid and 
usable research tool. 
 
 Systematic application of qualitative research methods used to design and 
develop a self-administered survey demonstrated merit in yielding successful 
survey outcomes determined by high response rates and data completeness, 
which were likely to have been driven by high levels of motivation among 
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respondents to complete the survey related to strong personal resonance with 
life impact areas.  
 
 This study highlights the use of best practice guidelines in order to achieve 
high-standards of reporting survey research, which was supported by a clear 






























7 Preface to Results  
The results and discussion section of this thesis present a focused, mainly descriptive 
analysis of outcomes related to the success of the survey and on the impact of foot 
involvement on daily life in people with PsA. Survey development activities formed a 
large component of the PhD structure and an a priori determination was made that a 
full in-depth discussion of the survey results would be beyond the scope of this PhD. 
Any inferential statistical analysis is restricted to the key pathological features of PsA 
in the foot, in the context of global disease and in relation to their impact on daily 
activities, ability to cope and foot care needs. The intention is that in-depth analysis 
will form the basis of a program of work at post-doc level and will include advanced 
statistical modelling to investigate complex relationships between domains of 
functioning and disease impact (see section 9.9.1 in Chapter 9). 
 
7.1 Context 
The intent of this PhD was to gain a better understanding of the nature, extent and 
location of foot involvement and its impact on the lives of people with PsA, which was 
driven by the sparsity of foot-specific research in PsA. Furthermore, to the best of the 
authors knowledge, no previous studies have explored the impact of PsA-related foot 
involvement from the patient perspective. From the initial phase of the qualitative 
study and International Classification of Functioning, Disability and Health (ICF) 
mapping, key concepts relevant and important to people with PsA-related foot 
problems were identified. A central component of this work was the development of a 
robust conceptual framework, which took into consideration the methodological 
recommendations of the GRAPPA-OMERACT to generate patient and clinician-
relevant domains using qualitative techniques and integration of the ICF (Boonen, et 
al., 2009a; Orbai, et al., 2017a). From a survey analysis perspective, the qualitative 
and ICF work provided valuable insight into important cognitive functions that 
mapped across different impact domains incorporated in the survey, which included 
coping strategies, emotional burden, and the perceived lack of understanding about the 
disease by people with PsA. The conceptual framework subsequently informed the 
content, design and implementation of a large-scale survey. Whilst the focus for the 
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PhD was to develop a comprehensive survey, the supervisory team recognised that 
implementation of a national survey (the first of its kind) presented a unique 
opportunity to collect important data beyond the initial scope of the PhD. This was an 
intentional approach to fully exploit the implementation of the first survey on foot 
involvement in PsA, with recognition that future surveys of this targeted group may 
not yield the same uptake. To avoid an extensive but superficial description of the 
substantial quantity of survey data collected, a focused data analysis plan with the a 
priori declaration was established. 
 
7.2 Statement of intent 
The main elements of the survey results will be summarised in order to determine the 
nature, extent and location of foot involvement in PsA, with a focus on key discrete 
areas of the survey relating to impact directed by the conceptual framework. Rationale 
for a focused approach to data analysis was 1) based on the recognised value of 
preceding methods in highlighting important concepts and 2) to gain a more in-depth 
description of the key impact areas with clinically relevant interpretations (for 
example, site-specific foot involvement and their impact on activities of daily living, 
emotional well-being related to embarrassment and frustration, ability to cope, 
footwear, perceived understanding and support related to foot care). Whilst it is 
acknowledged that these complex and multifaceted concepts require more advanced 
statistical analysis, a focused descriptive analysis with selected inferential analyses to 
facilitate clinical interpretation will provide useful preliminary insights into the 
determinants of impact from localised disease in the foot in PsA, and will direct the 
future research agenda beyond the study of disease features alone. Comprehensive 
exploration of the survey results will form significant post-doctoral investigation. 
 
Significant time and resources were invested in the robust survey development 
protocol and dissemination strategies in order to increase the likelihood of high survey 
response rates and the collection of valid and unbiased data from a representative 
sample. Evaluation of outcomes that indicate survey success were implemented in 
order to align with best practice and help validate the rigorous approach taken. The 
results chapter 8 will present the main survey findings in a similar manner to the 
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structure of the survey with emphasis on the impact of localised disease on daily life, 
footwear and foot care needs using the following sub-headings: 
 
(1) Sample response and data completeness  
(2) Survey results 
i) Demographic information and clinical characteristics 
ii) Foot and ankle characteristics 
iii) Activity and participation  
iv) Footwear  
v) Self-management  
























8.1 Sample response and data completeness  
8.1.1 Sample size and response rates 
Of the 649 survey responses, 602 (93%) were online and 47 (7%) were paper 
responses. A total of 650 paper surveys were sent to target sites and 47 were returned 
(7% response rate). Of the 602 unique online views of the survey, 43 participants did 
not start the survey or submit any data and so were removed from subsequent analysis. 
For the online survey 559 respondents started the first page of the survey and 468 
reached the last page (84% full data completion rate).  
 
8.1.2 Missing data  
The majority of respondents progressed through 100% of the survey to reach the end 
(83%). Missing data for online and paper survey completions was below 5% for the 
majority of respondents (95%). There were more partial completions of the paper 
survey compared with the online version, 89% and 46% respectively. There was 
gradual attrition of valid data through progression to the end of the paper and online 
survey. Time taken to complete the online survey was a mean (SD) 21 (8) minutes.  
 
Survey items with the highest amount of missing data (paper and online) was question 
53 (text entry of dollars for out-of-pocket expenditure on foot health self-care) (n=113, 
21%), question 52 (5-point Likert scale on the effectiveness of self-caring for foot 
problems) (n=103, 19%), and question 54 (5-point Likert scale on the level of 
confidence in the understanding of health professionals of PsA-related foot problems) 
(n=79, 13%).  
 
Pairwise deletion was used to handle the missing data and descriptive analysis was 
used for the transparent reporting of missing data for each survey item. Pairwise 
deletion is an approach to handling missing survey data that allows more of the data 
to be used in comparison with other methods for handling missing data such as listwise 
deletion. In order to preserve more information from the survey results this method 
was selected (Kang, 2013). A potential problem with the use of pairwise deletion is 
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that it can be unclear what sample size is used for tests of statistical significance, 
because the sample sizes for each survey item typically vary with different pairwise 
corrections. Therefore, explicit reporting of missing data is critical to allow 
interpretation of results with recognition of the implications of the procedures for 
handling missing data. In future post-doctoral work, advanced analysis of the missing 
data analysis will include analysis of patterns of missing data and multiple imputation, 
which replaces missing values with a set of predicted values based on the existing data 
from other variables and creates a full and statistically rigorous imputed data set.  
 
8.1.3 Comparison of paper survey response with the online response 
Differences between the paper survey sample and online sample were related to age, 
ethnic group, work status and education level. Those who completed the paper survey 
were older with a mean (SD) age of 56 (13) years compared with the online sample of 
51 (12) years. Whilst the largest ethnic groups were Australian European and British 
in both the paper and online samples, a greater proportion of other ethnicities 
completed the paper survey at 26% (n=12) compared with 15% (n=80) online. In 
addition, the majority of people who completed the paper survey were retired (n=18, 
38%), whereas most of the online sample were in full time or part time employment 
(30% and 21% respectively) with 12% who were retired (n=67). No differences were 
found between the paper and online samples related to social deprivation (postcode) 
or clinical characteristics (disease duration, symptom onset, current medications, 
presence of foot pain, severity of global pain and foot pain). 
 
The majority (n=40, 85%) of paper surveys were completed by participants from New 
South Wales (NSW). Of the 650 paper surveys that were distributed, 56% were sent 
to rheumatology clinical services in NSW (n=362). Therefore, the increased response 
was a result of the higher proportion of paper surveys distributed in NSW compared 
with other states, which was due to the local networks of the research team based in 
NSW and connections with specialist PsA services that are distinct in NSW.  
 
8.1.4 Body and foot pain diagram data analysis 
A limitation of the Qualtrics software was that it restricted each online survey 
participant to a maximum of 10 marks per pain diagram. The paper version allowed 
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unlimited marks. In addition, the online version of the survey did not permit shading 
in, whereas the paper version did. These differences between the paper and online 
survey versions were analysed (Table 8.1).    
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Data presented as mean (SD) unless specified. Body pain diagram 1: back view, body 
pain diagram 2: front view; Foot pain diagram 1: left foot dorsal and plantar view, foot 
pain diagram 2: right foot dorsal and plantar view, foot pain diagram 3: left and right 
foot lateral view, foot pain diagram 4: left and right foot posterior view, foot pain 
diagram 5: left and right foot medial view.    
 
Online survey results show that 100 people (17%) placed the maximum of 10 marks 
on body pain diagram 1 and 41 people (7%) on body pain diagram 2, indicating a 
potential underrepresentation of body pain in those individuals. For the online foot 
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pain diagrams 1 to 5; there were 35 (7%), 23 (4%), 4 (1%), 0 and 3 (1%) people who 
placed the maximum of 10 marks per diagram respectively, indicating that there were 
possibly more painful sites than could be recorded for up to 7% of the online sample. 
It is unknown from the online pain diagrams with 10 marks, whether a total of 10 were 
applied or if the participant intended to apply more than 10 marks.  
 
In the paper survey sample where there were no limits to the number of marks that 
could be recorded, a mean (SD) of 7 (6) marks were applied to each body diagram 
with a range of 0-24 for diagram 1 and 0-21 for diagram 2. A total of 12 participants 
placed more than 10 marks on body pain diagram 1 (25%) and 13 participants (28%) 
on body pain diagram 2. For foot pain diagrams 1 to 5 in the paper sample, the mean 
(SD) number of marks were 8 (8), 7 (8), 3 (4), 2 (3) and 3 (4) respectively, with 
between 5% and 34% (n=2 to 13) of the sample placing over 10 marks per foot pain 
diagram. 
 
Whilst the software limitation may have created a difference in data collection between 
the paper and online survey in the frequencies of pain location, it was reasonable to 
consider that the affect was minimal with the majority of paper survey respondent’s 
marking less than 10 painful sites on the body (72%) and foot (66%) pain diagrams, 
and a maximum of 17% and 7% of online survey respondents placing a total of 10 
marks on the body (n=100) and foot (n=35) pain diagrams respectively.  
 
8.2 Survey results 
8.2.1 Demographic information and clinical characteristics 
The demographic and clinical characteristics are summarised in Table 8.2. Survey 
respondents were predominately women of European descent, aged between 40 and 
60 years old, from the Eastern states of Australia (Figure 8.1). The majority of 
participants were in full time employment (30%), with a diploma or university degree 
education level (75%), living in relatively affluent socioeconomic areas (50%). Nearly 
half (n=266, 45%) reported that their work status had changed due to their PsA, with 




Participants reported having established disease (more than or equal to 5 years) with a 
mean (SD) disease duration of 8.5 (10) years. There was a mean (SD) diagnostic delay 
from symptom onset to diagnosis of 5.5 (2) years. A wide range of disease duration 
was reported from 1 month to 60 years. Nearly half (43%) of respondents were 
currently taking a biologic, 14% were taking methotrexate as a single line therapy, and 
36% were taking more than one category of disease modifying anti-rheumatic drug 
(DMARD). A total of 237 (41%) reported having depression, 39% had anxiety, 30% 
had osteoarthritis, 20% had fibromyalgia, with diabetes being the least reported 
comorbidity (10%). Over half (n=325, 56%) of respondents were obese (>30 kg/m2). 
Underrepresented groups in the study sample included low reporting levels from male 
participants (n=69, 11%), from those living in the Northern Territory of Australia 
(0%), and those with non-European ethnic backgrounds (7%). 
 
Figure 8.1. Distribution of survey responses across the states and territories in 
Australia, n (%).  
ACT Australian Capital Territory, NSW New South Wales, NT Northern Territory, 
QLD Queensland, SA South Australia, TAS Tasmania, VIC Victoria, WA Western 
Australia. (Valid data = 598. Missing data = 8).  
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Table 8.2. Demographic information and clinical characteristics of participant with 
psoriatic arthritis in Australia. 




Ages, years  51 (12) 604 2 
Women, n (%)  532 (89%) 601 5 
Body Mass Index, Kg/m2   31.3 (7) 589 17 
Ethnicity, n (%)  598 8 
     Australian European  459 (77%)   
     British 84 (14%)   
     European 15 (2%)   
     Aboriginal 6 (1%)   
     Other  34 (6%)   
Socioeconomic representation, n (%)  594 12 
     1 – 3 Most deprived  131 (23%)   
     4 – 6 165 (27%)   
     7 – 10 Least deprived  298 (50%)   
Work status, n (%)  588 18 
     Full time paid work  177 (30%)   
     Part time paid work  116 (20%)   
     Completely retired  85 (14.5%)   
     Looking after home/family  85 (14.5%)   
     Disabled or too sick to work 84 (14%)   
     Self-employed 46 (8%)   
     Casual or contracted paid work  41 (7%)   
     Studying 32 (5%)   
     Unpaid work  20 (3%)   
     Partially retired 16 (3%)   
     Unemployed 5 (0.8%)   
     Other (full time carer) 2 (0.2%)   
Education level, n (%)  595 11 
     University degree or higher  243 (41%)   
     Certificate/diploma 206 (35%)   
     School or intermediate certificate 45 (8%)   
     Higher school or leaving certificate 44 (7%)   
     Trade/apprenticeship 32 (5%)   
     No qualifications 25 (4%)   
Disease onset (from symptom onset), years 14 (12) 577 72 
     Less than 2 years (early disease) 42 (7%)   
     2 to 4 years 95 (17%)   
     5 years and more (established disease) 440 (76%)   
Disease duration (from diagnosis), years 8.5 (10) 581 68 
     Less than 2 years (early disease) 135 (23%)   
     2 to 4 years 140 (24%)   
     5 years and more (established disease) 360 (53%)   
Current medications, n (%)  580 26 
     Methotrexate 259 (45%)   
     Other DMARD (leflunomide,  
     salazopyrin, hydroxychloroquine,     
449 (77%)   
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     cyclosporine) 
     Biologics 249 (43%)   
     Prednisone 103 (18%)   
     NSAIDs 256 (44%)   
     Alternative or complementary  
     medicines 
79 (14%)   
     Other medications for PsA not listed 93 (16%)   
     No medications for PsA 43 (7%)   
Comorbidities, n (%)  573 33 
     Depression 237 (41%)   
     Anxiety 221 (39%)   
     Osteoarthritis 173 (30%)   
     Fibromyalgia 112 (20%)   
     Diabetes Mellitus 56 (10%)   
Data presented as mean (SD) unless specified. DMARDs Disease modifying anti-




In the context of PsA global disease characteristics, the mean (SD) patient global 
assessment scores rated on a numerical rating scale (NRS) for over the past week were; 
6 (2) for arthritis alone, 4 (3) for psoriasis alone, 6 (2) for arthritis and psoriasis 
together, and 6 (2) for global pain (Table 8.3). Despite current disease management, 
half the participants reported severe levels of global disease activity over the last week 
(n=287, 50%) and local foot and ankle pain over the past month (n=246, 47%). A 
significant relationship was identified between greater levels of foot and ankle pain 
severity over the past month and increased levels of global pain severity in PsA over 
the past week, as determined using the Kruskal-Wallis test (Figure 8.2). In relation to 
foot and ankle pain and global pain, the median foot and ankle pain scores were 
significantly different between groups, χ2(2)=180.887, p=<0.0001. The median foot 
and ankle pain score was significantly higher for severe global pain (7) compared with 
mild global pain (4) (p=<0.0001), significantly higher for moderate global pain (6) 
compared with mild global pain (p=<0.0001) and significantly higher for severe global 







Table 8.3. Patient global assessment scores and global pain rating by people with 
psoriatic arthritis. 
Patient global 
assessment over the 
past week, NRS (0-10) 
Arthritis*1 
n (%)   
Psoriasis*2 
n (%)   
Arthritis and 
psoriasis*3 




0 to 3, mild 92 (16%) 294 (52%) 89 (16%) 90 (16%) 
4 to 6, moderate 197 (34%) 148 (26%) 193 (34%) 235 (41%) 
7 to 10, severe 283 (50%) 122 (22%) 287 (50%) 248 (43%) 
Valid data = 572*1, 564*2, 569*3, 573*4. Missing data = 77*1, 85*2, 80*3,76*4 




Figure 8.2. Box plot and histogram to illustrate the distribution of foot and ankle pain 
scores over the past month in accordance with global PsA pain over the past week, 
which shows that there is a greater severity of foot and ankle pain with a greater 
severity of global pain in PsA. The histogram is counting the numbers from the box 
plot, where n indicates the number of respondents. The line across the box plot is the 
mean severity of foot and ankle pain across all groups.  
PsA Psoriatic arthritis. NRS Numerical rating scale, with 0 being no pain and 10 being 





The distribution of commonly symptomatic (ache/pain) areas affected by PsA were 
the feet/toes, hands/fingers and spine (Figure 8.3). Only one respondent reported that 
they had experienced no pain in any part of the body over the past month (Table 8.4). 
There were 30 (5%) respondents who indicated that were unable to determine the 
single most painful part of their body, which was due to being unsure or to attributing 
equal pain severity to more than one body part. 
 
Table 8.4. Global pain location of the most painful or sore part of the body over the 
past month reported by people with psoriatic arthritis. 




Most painful or sore part of the body over the 
past month, n (%) 
 577 29 
     Feet and toes 209 (36%)   
     Hands and fingers 67 (12%)   
     Back 66 (11%)   
     Hips 53 (9%)   
     Ankles 44 (8%)   
     Knees 39 (7%)   
     Shoulders 23 (4%)   
     Head and neck 22 (4%)   
     Wrists 12 (2%)   
     Elbows 11 (1.9%)   
     Not sure  11 (1.9%)   
     No pain 1 (0.2%)   






Figure 8.3. Location of global pain due psoriatic arthritis that lasted for one day or 
longer over the past month marked on a body pain diagram, n (%).  
(Valid data = 577diagram1, 576diagram2. Missing data = 29diagram1, 30diagram2).  
 
8.3 Foot and ankle characteristics  
8.3.1 Foot pain and other foot symptoms  
Ninety-two percent (n=519) of participants self-reported having experienced moderate 
to severe foot pain that lasted for one day or longer over the past month, with a mean 
(SD) numerical rating scale (NRS) score of 6 (2) (Table 8.5). Foot pain severity was 
relatively similar for those with early, mid and late PsA disease durations (Table 8.6). 
The location of foot pain experienced over the past month was most frequently 
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reported at the rearfoot (heel and ankle) (n=3797, 40%), followed by the forefoot 
(n=2358, 25%), toes (n=1750, 19%) and midfoot (n=1518, 16%), with similar levels 
of involvement between the medial and lateral aspects of the foot and ankle (Figure 
8.4). Of those with foot pain, 90% (n=473) had bilateral foot pain and 10% (n=51) had 
unilateral foot pain.  
 
Table 8.5. Presence and severity of foot pain reported by participants with psoriatic 
arthritis that lasted for one day or longer over the past month. 




Foot pain over the past month, n (%) 519 (92%) 562 44 
Foot pain severity, NRS (0-10)  519 44 
     0 to 3, mild 42 (8%)   
     4 to 6, moderate 231 (45%)   
     7 to 10, severe 246 (47%)   
NRS Numerical Rating Scale 
 
Table 8.6. Foot pain severity over the past month reported by participants with early, 
mid and late disease durations of psoriatic arthritis. 
Foot pain severity, 
NRS (0-10) 
Less than 2 years 
disease duration 
(early PsA) 
2 to 4 years disease 
duration (mid) 
5 years or more 
disease duration 
(late PsA) 
     0 to 3, mild 6 (5%) 12 (10%) 24 (9%) 
     4 to 6, moderate 60 (50%) 54 (46%) 116 (42%) 
     7 to 10, severe 55 (45%) 52 (44%) 134 (49%) 
NRS Numerical Rating Scale, PsA Psoriatic arthritis. 
 
During a typical day, most participants reported that their foot pain and discomfort was 
there all day (71%). For 68% of respondents (n=346) foot pain was worse at the end 
of the day, and 67% had foot pain that randomly changed from day to day. However, 
a lower proportion of the sample had symptoms that were better with activity (23%).  
 
Heterogeneity in foot and ankle symptoms were reported. Frequent symptoms 
included; tired feet and ankles (90%), stiffness (86%), swelling (68%), and numbness, 
burning and tingling sensations (63%). Nearly two thirds of participants found these 
symptoms extremely troublesome (64%). Whilst the qualitative concepts linked to the 
ICF model identified other foot and ankle symptoms such as hot feet, cold feet and 
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cramping sensations, these domains were reported less frequently by the survey sample 




Figure 8.4. Location of foot pain due to psoriatic arthritis that lasted for one day or 
longer over the past month marked on a foot pain diagram, n (%).  
(Valid data = 5241, 5242, 5253, 5244, 5235. Missing data = 391, 392, 383, 394, 405). 
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8.3.2 Musculoskeletal manifestations in the feet  
The full spectrum of disease features affecting the feet and ankles were reported, which 
included enthesitis (n=534, 95%), joint deformity (n=507, 91%), skin and toenail 
psoriasis (n=482, 86%), and dactylitis (n=223, 40%). The majority of responders 
(98%) reported the presence of one or more foot problems, and over half reported 4 or 
more foot problems (55%). The most common foot problem reported by almost two 
thirds of people with PsA was plantar fasciitis (57%), followed by dry cracked heels 
(49%) and toe deformities (45%) (Table 8.7). Although the type, frequency and 
severity of foot pain in men and women were relatively similar, more prevalent for 
women than men were bunions (30% and 16% respectively), the change in size of feet 
(40% and 25% respectively) and dry cracked heels (51% and 34% respectively). Over 
half of all respondents felt embarrassed or self-conscious about their foot problems 
(55%) and 80% felt frustrated by their foot problems. 
 
Table 8.7. Foot and ankle characteristics of participants with psoriatic arthritis. 




Previous or current foot problems, n (%)  560 46 
     Plantar fasciitis  321 (57%)   
     Dry cracked heels 275 (49%)   
     Toe deformity 254 (45%)   
     Dactylitis 223 (40%)   
     Size of feet (changes in length/width) 214 (38%)   
     Achilles enthesitis 213 (38%)   
     Hard skin or corns 209 (37%)   
     Bunions  160 (29%)   
     Flat feet 157 (28%)   
     Rearfoot deformity  49 (9%)   
     Ulceration 48 (9%)   
     Forefoot deformity (excluding toes) 46 (8%)   
Troublesome foot and ankle symptoms, NRS 
(0-10) 
 559 47 
     0 to 3, Not troublesome at all  54 (10%)   
     4 to 6 147 (26%)   
     7 to 10, Extremely troublesome 358 (64%)   
Embarrassed about foot problems, n (%) 309 (55%) 560 46 
Frustrated by foot problems, n (%) 440 (80%) 550 56 




 Enthesitis  
For the purposes of this study enthesitis was defined as self-reported problems with 
the ‘plantar fascia (under the heel or arch)’ and ‘Achilles tendon (back of the heel)’. 
High levels of rearfoot enthesitis (95%) were reported, which more frequently 
impacted on foot-related functional impairments and disability than forefoot 
pathologies. Achilles enthesitis were more disabling than plantar fasciitis, with more 
frequent impact on standing for 5 minutes (55% and 52% respectively), walking for 5 
minutes (49% and 44% respectively) and stair walking (66% and 62% respectively). 
In addition, 75% of people with Achilles tendon problems reported walking slower 
than others (n=156) compared with 71% of people plantar fasciitis (n=223). A total of 
238 (43%) participants felt embarrassed about the way that they walk and 46% of those 
had Achilles enthesitis (n=109) and changes to foot size (n=109). Nearly a third of 
participants reported staying indoors most of the day due to foot problems (n=158, 
29%) and one of the most frequent causes of staying indoors was a history of Achilles 
enthesitis (n=76, 48%).  A 2-tailed Fisher’s exact test was used to evaluate whether 
there was a gender difference in the presence of Achilles enthesitis or plantar fasciitis. 
Although there was no statistically significant association between gender and the 
presence of Achilles enthesitis (p=0.041), plantar fasciitis was found to be significantly 
more common in women (n=294, 92%) than men (n=27, 8%) (p=0.011) (Figure 8.5). 
Plantar fasciitis was found to be most frequently associated with foot symptoms that 
were worse with prolonged standing (n=208, 65%), worse in the morning (n=168, 
52%) and after rest (n=151, 47%), and with obesity (n=184, 57%). There was also a 
trend towards the presence of plantar fasciitis and reporting moderate (n=139, 43%) to 
severe global pain, and reporting moderate (n=116, 36%) to severe (n=171, 53%) 
global PsA disease activity (as determined by the patient global assessment scores).  
 
Rearfoot enthesitis (both Achilles enthesitis and plantar fasciitis) greatly impacted on 
daily life and most frequently interfered with sleep (n=411, 77%), followed by social 
activities (n=405, 76%), daily routine such as shopping and housework (n=397, 74%) 
and exercise participation (n=360, 67%). There was a trend between the presence of 
rearfoot enthesitis and greater levels of foot pain severity and a reduced ability to cope 
with foot problems, with severe foot pain reported in 47% of those with Achilles 
enthesitis and plantar fasciitis (n=101 and n=150 respectively) and with moderate to 
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coping very poorly with foot problems reported in 62% of those with Achilles 
enthesitis and plantar fasciitis (n=131 and n=200 respectively). 
 
 
Figure 8.5.  Mosaic plot representing the proportions of males and females with (yes) 
and without (no) plantar fasciitis, with the vertical axis indicating counts in relation to 
the proportions of the overall sample and the width of horizontal axis bars indicating 
the relative gender proportions. Plantar fasciitis was found to be significantly more 
common in women (n=294) than men (n=27). 
 
 Dactylitis 
A high proportion of those with dactylitis reported having difficulty with stairs (n=143, 
64%) and walking barefoot (n=129, 58%), and it interfered with driving (n=108, 48%). 
Dactylitis most frequently impacted on body image with nearly two thirds of 
participants feeling embarrassed or self-conscious about their feet (n=150, 67%).  
 
 Peripheral arthritis  
Whilst high levels of forefoot and rearfoot pain were reported, self-perceived levels of 
forefoot deformity (8%, excluding toes) and rearfoot deformity (9%) were relatively 
minimal. However, the impact from both types of deformity was high, with higher 
frequencies of foot functional impairment reported by those with rearfoot deformity 
than forefoot. Foot-related functional impairments relate to difficulties with standing, 
walking and climbing stairs due to foot pain and/or problems. Rearfoot deformity most 
frequently caused difficulties with stairs (n=36, 73%), standing for 5 minutes (n=32, 
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65%) and walking for 5 minutes (n=28, 57%), and forefoot deformity most frequently 
affected barefoot walking (n=29, 63%). Changes to global gait patterns were most 
frequently reported by people with rearfoot deformity (86%), changes to foot size 
(81%) and forefoot deformity (80%), which were also the most common foot problems 
in those with an established disease duration. Whilst embarrassment about gait changes 
was most frequently reported by people with forefoot deformity (n=27, 59%), 
frustration with gait changes was most frequently reported by those with rearfoot 
deformity (n=47, 96%).  
 
8.3.3 Dermatological manifestations in the feet 
Common features of skin psoriasis on the feet were scaling (76%) and itching (69%), 
and common toenail features were thickened (84%), discoloured nails (75%) with 
ridges (67%). Toenail psoriasis (n=320, 57%) was more prevalent than skin psoriasis 
affecting the feet and ankles (n=161, 29%). A significant association was identified 
between the co-occurrence of psoriatic nail and skin involvement on the foot at 
p=<0.0001, using a 2-tail Fisher’s exact test (Figure 8.6). Whilst dermatological 
symptoms (soreness, tenderness and pain) were commonly reported to be mild or not 
present and the interference from symptoms on daily activity minimal, the emotional 
burden and impact on footwear choice was high. Of those participants with skin and 
toenail psoriasis, the vast majority felt embarrassed by the dermatological features 
affecting their feet (74% and 80% respectively) and reported that they greatly 
influenced their footwear choice (85% and 84% respectively). Problems with footwear 
caused frustration among the majority of people with skin and toenails psoriasis (67% 
and 69%). The emotional impact from dermatological involvement of the feet was 
similar for both men and women, with relatively even proportions of those feeling 
embarrassed about their skin and toenail problems between genders (men: 73% and 
71%, women: 74% and 80% respectively). Emotional well-being/impact is reported in 
relation to feeling embarrassed or self-conscious and/or frustrated, which may be in 





Figure 8.6.  Mosaic plot representing the proportions of respondents with toenail 
psoriasis relative to those with (yes) and without (no) psoriasis on the foot, with the 
vertical axis indicating the proportion of respondents with and without toenail psoriasis 
and the width of the horizontal bars indicating the relative proportions of those with 
and without psoriasis on the foot. Toenail psoriasis was significantly more common in 
those with skin psoriasis affecting the feet than in those without skin psoriasis. 
 
8.4 Activity and participation  
The majority of respondents reported that they were not participating in the nationally 
recommended weekly amount of moderate (68%) and vigorous (93%) physical 
exercise. Over 80% of participants reported that foot problems had interfered with their 
ability to exercise over the past month, with the most frequently affected having flat 
feet (89%) and rearfoot enthesitis (88%). 
 
Going up and down stairs was moderately to very difficult due to foot problems for a 
greater proportion of respondents (58%), compared with walking barefoot (52%), 
standing for 5 minutes (45%) and walking for 5 minutes (39%). Nearly half of the 
respondents who had difficulty with stairs confirmed that problems in other parts of 
the body had contributed to limitations in such activities (n=264, 48%), which were 
predominantly in the back, hips and knees. Indeed, 74% of respondents had difficulties 
with standing and walking activities due to problems in other parts of the body 
(n=410). Rearfoot deformity (n=36, 73%) and forefoot deformity (n=32, 70%) were 
the most frequent foot pathologies in those having problems with stairs. Walking 
barefoot was difficult for participants with forefoot pathologies (toe deformity n=143, 
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56%; dactylitis n=85, 53%; bunions n=129, 58%) and rearfoot pathologies (Achilles 
enthesitis n=128, 60%; plantar fasciitis n=190, 59%; rearfoot deformity n=28, 57%), 
with similar reported frequencies.  
 
Daily life in general was adversely affected with two thirds of participants reporting 
that foot problems had interfered with their social and leisure activities (71%), and 
daily routine (66%) (Table 8.8). The extent to which foot problems affected family 
time, being a parent, driving and work life varied considerably between participants. 
High impact from foot involvement was reported by respondents where foot problems 
had prevented sleep (n=413, 75%) and had negatively affected their emotional well-
being (n=440, 80%). For nearly a third of participants the impact from foot problems 
had resulted in staying indoors for most of the day (social isolation) (n=158, 29%). 
Skin psoriasis on the feet and ankles more commonly interfered with daily routine and 
social activities (n=74, 46%) than toenail psoriasis (n=88, 28%). The most frequent 
musculoskeletal pathologies to impact on daily and social activities were rearfoot 
deformity (86%) and forefoot deformity (82%).  
 
Table 8.8. Extent to which foot problems had interfered with daily activities of 
participants with psoriatic arthritis over the past month. 
 Yes 
interfered 
a lot, n (%) 
Yes 
interfered 
a little,       
n (%) 
No not at 
all 
interfered,  




Going to the shops*1 134 (24%) 236 (42%) 171 (31%) 15 (3%) 
Looking after the home*2 147 (26.5%) 220 (40%) 174 (31%) 14 (2.5%) 
Leisure or social activities*3 154 (28%) 236 (43%) 144 (26%) 20 (3%) 
Being a parent or carer*4 61 (11%) 137 (25%) 171 (31%) 184 (33%) 
Spending time with family*5  62 (11%) 149 (27%) 279 (51%) 63 (11%) 
Exercise*6 244 (44%) 213 (39%) 66 (12%) 28 (5%) 
Sleep*7 154 (28%) 259 (47%) 132 (24%) 9 (1%) 
Driving*8  54 (10%) 160 (29%) 294 (53%) 46 (8%) 
Work*9 100 (18%) 153 (28%) 135 (25%) 160 (29%) 
Valid data = 556*1, 555*2, 554*3, 553*4, 553*5, 551*6, 554*7, 554*8, 548*9. 







Walking was adversely affected for over half of the respondents (66%). In total 238 
individuals with PsA felt embarrassed or self-conscious about the way that they walked 
(43%). Changes to global gait patterns were common with 70% walking slower and 
62% with a limp or unstable gait, and nearly half the survey sample had fallen in the 
past 12 months (49%) with a mean (SD) number of falls at 1 (1). A fall was defined in 
the current study as having ‘fallen to the floor or ground’ using a lay perspective as 
recommended in previous consensus guidelines for collecting falls data (Lamb, et al., 
2005). The total number of self-reported falls over the past 12 months was 560 and the 
total number of individual fallers was 268 (49%), with a mean (SD) age of 52 (12) 
years and mean (SD) disease duration of 8 (9) years. A significant relationship between 
the extent of foot and ankle trouble scores in relation to fall frequency was identified 
using the Kruskall-Wallis test (Figure 8.7). The foot and ankle trouble scores refer to 
respondents indicating on a NRS to what extent the symptoms in their feet and ankles 
have been troublesome (cause trouble, annoyance or difficulty), with 0 being not 
troublesome at all and 10 being extremely troublesome. Distributions of the foot and 
ankle trouble scores and the number of falls were assessed using box plots, including 
0 falls (n=277), 1 fall (n=99), 2 falls (n=87), 3 falls (n=41) and 4 or more falls (n=41). 
The mean rank of foot and ankle trouble scores was significantly different between the 
groups, χ2(4)=25.031, p=< 0.0001. Post hoc pairwise comparison of all groups 
identified that the foot and ankle trouble scores were significantly higher for 2 falls 







Figure 8.7.  Box plot and histogram to illustrate the distribution of the foot and ankle 
trouble scores in accordance with the number of falls reported by respondents over the 
past 12 months, which shows that the number of falls increases with the extent to which 
foot problems are troublesome. The histogram is counting the numbers from the box 
plot, where n indicates the number of respondents. 





Walking shoes (lace-up and slip-on) (67%) and sports shoes (24%) were the most 
frequently worn footwear type, followed closely by being barefoot or in socks/slippers 
(36%) most often. The most commonly worn footwear types were similar between 
men and women. However, a greater proportion of women than men wore supportive 
style sandals and prescribed footwear, and a greater proportion of men than women 
wore thongs (flip-flops) and work boots. Although widely regarded to be popular in 
Australian culture, thongs (flip-flops) accounted for 17% (n=92) of the footwear worn 
by the study sample. Of the total number of respondents that wore prescribed shoes 
(n=76, 14%), the majority had forefoot deformity (n=13, 28%), rearfoot deformity 
(n=12, 24%) and foot ulceration (n=10, 21%). In total, 173 people felt embarrassed 




Table 8.9. Extent of agreement with the following statements about difficulties with 








It is hard to find 
footwear that do 
not hurt my feet *1 
185 (33%) 205 (37%) 93 (17%) 54 (10%) 15 (3%) 
I have difficulty in 
finding footwear 
that fits my feet *2 
128 (23%) 167 (31%) 134 (25%) 100 (18%) 19 (3%) 
I am limited in the 
number of shoes I 
can wear *3 
214 (39%) 219 (40%) 54 (10%) 51 (9%) 11 (2%) 
I have difficulty 
with daily activities 
due to discomfort 
from my footwear 
*4 
69 (13%) 153 (28%) 160 (29%) 138 (25%) 26 (5%) 
I am limited in the 
kind of work I can 
do due to 
difficulties with my 
footwear *5 
55 (10%) 76 (14%) 179 (33%) 173 (31%) 65 (12%) 
I have difficulty 
finding footwear 
appropriate for a 
special occasion *6 
234 (43%) 183 (33%) 64 (12%) 56 (10%) 13 (2%) 
I feel frustrated 
about the problems 
I have with 
footwear *7 
179 (33%) 167 (30%) 107 (20%) 71 (13%) 22 (4%) 
I feel embarrassed 
about the footwear 
I wear *8 
79 (14%) 94 (17%) 156 (29%) 175 (32%) 43 (8%) 
I find that I am 
restricted to the 
same type of 
footwear all year 
round *9 
149 (27%) 184 (33%) 91 (17%) 101 (18%) 26 (5%) 
Valid data = 552*1, 548*2, 549*3, 546*4, 548*5, 550*6, 546*7, 547*8, 551*9.  
Missing data = 97*1, 101*2, 100*3, 103*4, 101*5, 99*6, 103*7, 102*8, 98*9. 
 
Cushioning sole (61%), support (55%), wider fit (51%), toe-box fit (44%) and ease of 
getting shoes on/off (42%) were the top 5 most frequently reported important footwear 
features. These top footwear features were important for all participants regardless of 
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the type or location of the foot problem. The need to accommodate a supportive insole 
was a key consideration in footwear choice for 41% of participants. Whilst closed-in 
(13%) and open-toed (5%) footwear features were key concerns identified by people 
with PsA as part of Environmental Factors in the ICF model, they were not rated highly 
as an important factor when choosing shoes by the survey sample. However, closed-
in style shoes were more frequently rated as important compared with open-toed shoes 
by participants with both dermatological and musculoskeletal foot pathologies, and 
with either forefoot, midfoot or rearfoot involvement.  
 
Difficulties with footwear were experienced by the majority of respondents, which had 
a negative effect on coping ability (89%) and on emotions in relation to feeling 
frustrated about problems with footwear (63%). Key footwear difficulties included; 
79% reported being limited in the number of shoes they could wear, 76% reported 
having difficulty finding footwear appropriate for a special occasion, and 71% found 
it hard to find footwear that did not hurt their feet (Table 8.9). These key footwear 
difficulties were reported by those with dermatology and musculoskeletal 
involvement. Footwear difficulties were female predominant, with a proportionally 
higher strength of agreement for all statements about footwear problems, limitations 
and impact. Despite high proportions of people with PsA indicating limitations in 
footwear choice, the impact from footwear difficulties on daily activities (41%) and 
work life (24%) was less frequently reported. Although the 6-month study period 
traversed 3 weather seasons; winter (July and August), spring (September to 
November) and summer (December), 60% of participants reported that they were 
restricted to the same type of footwear all year round. 
 
Important footwear features most frequently reported by people with Achilles 
enthesitis were light-weight (n=59, 28%), a soft heel counter (n=54, 26%) and heel 
height (n=47, 23%), whereas the most frequently reported by people with plantar 
fasciitis was arch support (n=163, 51%). Dorsal toe pain (80%) and toe deformities 
including bunions (74%) were key features for the majority of participants, with 
subsequent impact on footwear choice distinctly related to the importance of a 
cushioning sole (65%) and adequate toe-box fit (52%). Thongs and supportive sandals 
were more frequently worn by people with bunions, toe deformities and dry cracked 
heels. Most frequently worn footwear by people with skin and nail psoriasis affecting 
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the feet were; lace-up sneakers (42%) and being barefoot or with socks or slippers 
(34%). In addition, slip-on sneakers were frequently worn by people with skin 
psoriasis (n=43, 27%) and supportive style sandals by people with toenail psoriasis 
(n=76, 24%).  
 
8.6 Self-management  
In total, 309 people with PsA felt that they were not coping well (moderately to 
severely) with their foot problems (57%) (Table 8.10). Relevant domains of impact for 
those not coping with PsA-related foot involvement included severity of global pain 
(75%) and foot pain (82%), interference with daily life (92%) and emotional well-
being (61%), and difficulties with footwear (89%). Although social support was 
considered important to coping well with PsA-related foot involvement (32%), half of 
all respondents felt there was a lack of support for people with PsA from friends, 
family and health professionals. 
 
A significant relationship was identified between the severity of foot and ankle pain 
over the past month and ability to cope with foot problems, including 0 to 3 coped very 
well (n=235), 4 to 6 moderate (n=220) and 7 to 10 coped very poorly (n=89) over the 
past month, when compared using the Kruskal-Wallis test. Distributions of the foot 
and ankle pain severity scores were not equal for each of the groups as assessed by 
visual inspection of the box plots, meaning that it was only possible to determine 
whether the scores for each of the groups were significantly higher or lower than each 
other. The mean rank scores for foot and ankle pain severity were significantly 
different from each other in relation to the coping groups, χ2(2)=114.355, p=<0.0001. 
Post hoc pairwise comparison identified that foot and ankle pain severity scores were 
significantly higher for 7 to 10 severe when compared with 0 to 3 mild (p=<0.0001), 
4 to 6 moderate when compared with 0 to 3 mild (p=<0.0001) and 7 to 10 severe when 
compared with 4 to 6 moderate (p=<0.0001). A significant relationship was also 
identified between the ability of respondents to cope with foot problems over the past 
month in relation to whether they identified that there was a lack of support for people 
with the disease from friends, family and/or health professionals (n=270) compared 
with those who did not (n=279). A Mann-Whitney U rank test was conducted to 
compare the scores relating to the ability to cope with foot problems between both 
202 
 
groups. The median score for coping with foot problems for respondents who indicated 
a perceived lack of support for people with the disease (5) was significantly higher 
(less able to cope) than those who did not (4), z=3.517, p=0.0004.  
 
A variety of coping strategies were used by participants to cope with their foot 
problems, with the most common being to ‘get on with it, despite the problem’ (74%) 
and to ‘accept limitations’ (68%) and the least common at 3% reporting that coping 
mechanisms were not utilised (Table 8.10). The Chi-square test of independence was 
conducted to examine whether there was any relationship between the frequency of 
different coping strategies used in relation to PsA disease duration, including less than 
2 years, 2 to 4 years, and 5 years or more. All expected cell frequencies were greater 
than 5. A statistically significant relationship was identified between disease duration 
and the coping strategies; to ‘pace and plan’ (χ2(2)=6.134, p=0.047) and ‘try to keep 
in control of the problem’ (χ2(2)=17.956, p=<0.0001). A pairwise post hoc z-test 
analysis in relation to ‘try to keep in control of the problem’ revealed that this coping 
strategy was used to a significantly higher degree by participants of 5 years or more 
disease duration (52.5%), when compared with 2 to 4 years (39.8%) and less than 2 



















Table 8.10. Coping and support with foot problems in participants with psoriatic 
arthritis. 




Coping with foot problems, NRS (0-10) 4 (2) 544 62 
Coping with foot problems, NRS (0-10)  544 62 
     0 to 3, Coped very well  235 (43%)   
     4 to 6 220 (40%)   
     7 to 10, Coped very poorly  89 (17%)   
Typical ways in which you cope with your foot 
problems, n (%) 
 550 52 
     Get on with it, despite the problem  408 (74%)   
     Accept limitations 378 (68%)   
     Try to keep in control of the problem 242 (44%)   
     Pace and plan 241 (44%)   
     Get support from family, friends and/or health  
     professionals  
176 (32%)   
     Hide the problem from others 131 (24%)   
     Do not think about the problem  106 (19%)   
     None, I do not use coping strategies 18 (3%)   
Lack of understanding about the disease, n (%) 432 (79%) 549 53 
Lack of support for people with the disease, n (%) 270 (49%) 549 53 
Neither of these, n (%) 92 (17%) 549 53 
Need assistance to help take care of feet, n (%) 228 (42%) 545 61 
Self-manage foot problems, n (%)  488 (90%) 545 61 
Belong to a patient support group, n (%)  225 (41%) 549 57 
NRS Numerical Rating Scale 
 
A total of 228 respondents (42%) indicated that they required assistance with 
undertaking basic foot care, and a similar proportion of participants reported 
membership to a patient support group for their PsA (n=225, 41%). Self-care in respect 
of foot problems was undertaken by the majority of participants (90%), and the mean 
(SD) out-of-pocket expenditure on foot care over the past 12 months was estimated to 
be $600 (669) with a range of $0 to $8000. Perceived effectiveness of self-care 
activities for foot problems was most frequently reported to be mild or moderate 
(n=328, 74%). Of the 64 respondents who reported having had foot and ankle surgery 
(12%), the mean (SD) cost of their foot care over the past 12 months was $680 (639) 




8.7 Healthcare service access and support 
The majority of respondents received current rheumatology services for their PsA 
(84%) and nearly two thirds (62%) reported having received podiatric care (Table 
8.11). Of the 518 respondents who had sought foot healthcare, 81% had accessed 
rheumatology services, 73% the GP and 53% podiatry, with 87% having accessed two 
or more health services (median 4.5, range 0 to 8 health services accessed). The 
majority of respondents (78%) reported having had a foot examination by their 
rheumatologist.  
 
Table 8.11. Access to healthcare by participants with psoriatic arthritis-related foot 
problems. 




Currently see a rheumatologist for PsA, n (%) 495 (84%) 589 17 
Currently see a podiatrist for your feet, n (%) 130 (24%) 541 65 
Ever seen a podiatrist for your feet, n (%) 337 (62%) 540 66 
Had any foot or ankle surgery, n (%) 64 (12%) 541 65 
     Foot problem improved with surgery, n (%)  38 (59%) 64 65 
Rheumatologist asks about feet, n (%) 438 (82%) 538 68 
Rheumatologist examines feet, n (%) 420 (78%) 538 68 
Who have you seen about your foot problems?, 
n (%) 
 537 71 
     Rheumatologist 434 (81%)   
     GP/Doctor 394 (73%)   
     Podiatrist 284 (53%)   
     Physiotherapist 176 (33%)   
     Foot massage or reflexologist 106 (20%)   
     Dermatologist 88 (16%)   
     Pedicurist 77 (14%)   
     Surgeon 37 (7%)   
     Traditional Chinese medicine 31 (6%)   
     Nurse 15 (3%)   
     Occupational therapist 14 (3%)   
     No one 19 (3%)   
     Other (immunologist, exercise physiologist, 
neurologist, osteopath, chiropractor, pain 
management specialist, radiologist, sports 
medicine specialist, myotherapist, orthotist, 
aromatherapist, retail footwear shop) 
33 (6%)   





Variations in current access to rheumatology services for the management of PsA were 
observed across the Australian states and territories (Figure 8.8), with the highest level 
of access being in the Australian Capital Territory (n=26, 93%) and the lowest being 
in the state of Victoria (n=95, 74%). A Chi-square test of independence was conducted 
between participants having seen and not seen a rheumatologist about their PsA 
relative to the states and territories of Australia (n=598). All expected cell frequencies 
were greater than 5. There was a statistically significant association between seeing/not 
seeing a rheumatologist across Australian states and territories, χ2(6)=17.095, 
p=0.008. A pairwise z-test post hoc analysis with Bonferroni correction revealed that 
the proportion of respondents who had not seen a rheumatologist about their PsA was 
significantly higher in Western Australia (93%) than in all of the other Australian 
states and territories at p=0.05. Furthermore, the proportion of respondents who 
reported that they had seen a rheumatologist was significantly higher in Victoria (26%) 
compared with the other Australian states and territories at p≤0.05. The Northern 
Territory was excluded from the analysis due to no responses. 
 
Figure 8.8. Mosaic plot to show the variation in current access to rheumatology 
services for management of PsA across the different Australian states and territories, 
with the vertical axis indicating the proportion of those who currently see or do not see 
a rheumatologist for their PsA and the width of the horizontal axis bars indicating the 
relative number of respondents from the Australian states and territories. 
ACT Australian Capital Territory, NSW New South Wales, QLD Queensland, SA South 
Australia, TAS Tasmania, VIC Victoria, WA Western Australia. 
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In total, 32% of participants reported that the professional foot care they had received 
was ineffective (n=167) and 32% were not confident that the health professionals had 
a good understanding of how PsA affected their feet (n=162). The relationship between 
the respondents’ perceptions of the effectiveness of foot healthcare they had received 
and their confidence in the health professionals’ understanding of how PsA affects the 
feet in relation to each type of health professional seen was examined using the Chi-
square test of independence. All expected cell frequencies were greater than 5 with 
regards to the rheumatologist, GP, physiotherapist and podiatrist, which were the most 
frequently seen health professionals for foot problems in PsA. A significant 
relationship was identified between the respondents’ perception of effectiveness of 
foot healthcare and having received rheumatology (χ2(4)=9.629, p=0.0472), GP 
(χ2(4)=19.022, p=0.0008), physiotherapy (χ2(4)=14.479, p=0.0059) and podiatry 
services (χ2(4)=20.308, p=0.0004). In relation to rheumatologists, pairwise testing 
revealed that there was a significant difference between the respondents who rated the 
effectiveness of the foot healthcare they had received as ‘moderately effective’ and 
‘very effective’ at p<0.05. In relation to having seen the GP for foot problems, foot 
healthcare rated ‘not at all effective’ (89%) and ‘mildly effective’ (83%) were 
significantly higher in proportion to all the other ratings of effectiveness at p≤0.05. In 
relation to those who saw a physiotherapist, foot healthcare rated as ‘moderately 
effective’ was significantly higher in proportion to all the other ratings of effectiveness 
at p≤0.05. With respect to podiatry, there was a significant difference between the 
respondents who rated the effectiveness of their foot healthcare as ‘mildly effective’ 
compared with all the other ratings of effectiveness at p≤0.05.  
 
Significant relationships were identified in the respondents’ confidence that their PsA-
related foot problems had been understood by the GP (χ2(4)=20.549, p=0.0004) and 
the rheumatologist (χ2(4)=29.429, p=<0.0001). However, no significant associations 
were found in the respondents’ confidence in the podiatrists’ understanding of foot 
problems in PsA (χ2(4)=3.688, p=0.449). Significantly greater proportions of 
respondents who indicated that they saw a GP for their foot problems rated their 
confidence in the health professionals understanding of PsA-related foot problems as 
‘mildly confident’ (89%), followed by ‘not confident at all’ (85%) and then all the 
other ratings of confidence jointly (p≤0.05). Respondents who saw a rheumatologist 
rated their confidence in the health professionals understanding of PsA-related foot 
207 
 
problems as ‘very confident’ to a significantly greater degree (92%), followed by both 
‘extremely confident’ (90%) and ‘moderately confident’ (84%) and then the remaining 































9 Discussion and Conclusion 
This chapter discusses the findings of the survey in the context of the available 
literature. Key results are presented with emphasis on clinical implications for the 
management of the foot and ankle in people with PsA. Limitations of the survey and 
future research directions are outlined and discussed. 
 
The results of each of the three interlinked phases of research presented in this thesis 
were discussed at the end of each relevant chapter. The findings from each research 
phase contributed to the next, which culminated in the cross-sectional survey among 
people with PsA-related foot involvement. Major components of work were; 1) the 
generation of the conceptual framework to inform survey content and 2) the robust 
processes of survey pre-testing and dissemination, which provided a best practice 
template for other researchers. A strategic and holistic approach was taken to the task 
of survey development, establishing the sampling frame, the survey dissemination plan 
and programme of activities for survey promotion including the study website, 
Facebook page, video and animation. Therefore, the discussion will focus on the 
survey results with emphasis on the conceptual and methodological rigor of the 
preceding survey design and conduct.  
 
9.1 Context  
Two principal themes were identified in the literature that describe foot involvement 
in PsA: 1) an established higher involvement of the hallmark features of disease (such 
as peripheral arthritis, enthesitis and dactylitis) in the lower limbs compared with the 
upper limbs, and 2) the persistence of localised disease activity in the foot independent 
of global disease. As disease persistence in PsA has been shown to severely impact on 
functional outcomes and quality of life (Husted, et al., 2001; Husted, et al., 2007; 
Cresswell, et al., 2011), it is important to better understand foot involvement and its 
impact in order to inform future targeted disease-specific assessments and 
interventions. Limitations in previous research on foot involvement in PsA include; 
few PsA-specific cohorts, use of small sample sizes, findings from predominantly 
European countries with no local data for Australia where health service provision and 
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footwear habits are different, discrete site-specific focus on anatomical structures with 
no comprehensive and integrated description of foot involvement, and no exploration 
of the full impact of localised disease in the foot from the patient perspective. To 
improve understanding of foot involvement in PsA, the main objective of this thesis 
was to provide a comprehensive description of the nature, extent and location of foot 
problems and the impact they have on daily life from the perspective of people with 
PsA. To achieve this, a national survey to obtain large-scale data on foot involvement 
in people with PsA living in Australia was conducted. To the best of the authors 
knowledge, this is the largest survey of people with PsA-related foot problems and the 
first to examine the impact of foot involvement in PsA from the patient perspective. 
Key findings will be discussed in this chapter in two main stages; 1) the 
representativeness of the sample and success outcomes of the survey and 2) foot 
involvement and its impact on people with PsA. 
 
9.2 Sample representativeness and distribution 
In total, there were 606 survey completions (10% response rate) in the current study. 
Sample size requirements of this study were difficult to estimate in the absence of 
national patient databases and with unknown PsA prevalence in Australia or New 
Zealand. The total target population was estimated from the major sites for 
dissemination to be 6000 people with PsA in Australia, which, in light of these 
contextual challenges, was considered the best approach in order to gain an 
appreciation of the potential survey reach and response relative to reach. Similar New 
Zealand-based foot surveys received 197 web-survey completions from people with 
inflammatory arthritis (49% response rate, n=400 target sample) (Brenton-Rule, et al., 
2014) and 131 postal survey completions (32% response rate, n=400 target sample) 
were received from people with systemic lupus erythematous (SLE) (Otter, et al., 
2016). Although New Zealand has a smaller general population than Australia, 
approximately 295,000 New Zealanders are living with at least one type of 
inflammatory arthritis (Arthritis New Zealand, 2018) and indicates that previous 
approaches may not have identified the full target population to estimate response 
rates. However, based on these existing published sample sizes (Brenton-Rule, et al., 
2014; Otter, et al., 2016), the current study survey response of PsA-specific 
participants was a very good response rate. The full survey completion rate from 
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participants that attempted the survey was 91.95% overall due to partial completion, 
which is evidence of a successfully developed survey. 
 
It is difficult to measure the success of the survey response due to the lack of 
comparable surveys. In the UK, sample sizes in previous foot-specific surveys of 
people with RA range from 413 to 883 (Firth, et al., 2008; Otter, et al., 2010; Graham, 
et al., 2017; Wilson, et al., 2017a), with the time frame for data collection poorly 
reported across studies. Higher response rates would be expected from previous UK-
based studies given that the majority had recruited from established NHS (National 
Health Service) hospital patient databases and/or major NHS teaching hospitals with 
rheumatology outpatient departments that have embedded specialist podiatry services. 
Furthermore, comparison with RA populations may not be appropriate given the 
higher prevalence of RA when compared with other discrete sub-groups of rheumatic 
conditions such as PsA. Therefore, the high survey completion numbers in the current 
study were encouraging.  
 
High completion rates suggest that the survey had sufficient reach to the target 
population and that the target sample was willing and able to complete the survey. 
Therefore, successful survey response in the current study may be attributed to the 
rigorous process of survey development and dissemination using best practice methods 
in survey research. The survey had a strong conceptual framework generated by the 
in-depth exploration of the patient experience that was linked to the ICF, which 
achieved good conceptual coverage of items important and relevant to both patients 
and health professionals. Extensive rounds of survey pre-testing among the target 
population, health professionals and experts further optimised potential response rates 
by improving the overall quality, functioning and representativeness of the survey 
instrument. A targeted dissemination strategy increased survey reach by utilising 
mixed modes of administration (paper and online), a range of promotional materials 
(posters, flyers, emails with reminders, study website, study Facebook page, study 
video and animation), and a range of dissemination sites (clinic-based services, online 
support organisations and social media groups), followed by snowballing and 
crowdsourcing sampling techniques. Robust strategies for survey development, 
sampling and genuine community engagement made a powerful contribution to 
response rates and the scale of information collected. Despite the substantial length of 
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the survey, there were high survey completion rates and low rates of missing data (95% 
of respondents with less than 5% missing data).  
 
High levels of data completeness suggest that people with PsA had a strong desire to 
share their experience of foot problems, and that the incorporation of insightful and 
meaningful concepts, generated by those with the disease, resonated with survey 
respondents and had a positive effect on fuller survey completion. Therefore, high 
response rates with minimal missing data demonstrates the value of embedding the 
patient perspective in research activity and in the development of measures in PsA, 
which aligns with the GRAPPA-OMERACT recommendations (Tillett, et al., 2015a; 
Orbai, et al., 2017a). Significant time and resource investment into robust survey 
development and dissemination strategies was considered worthwhile and there is 
limited reporting on this aspect of survey design in other foot-specific research, 
making it difficult to determine if this occurred.  
 
The risk of bias associated with observational study designs such as cross-sectional 
surveys is relatively high (Galea and Tracy, 2007). Survey research provided the 
opportunity to sample a wide geographical area not restricted to a particular region, 
health service or clinic-based sample. A strength of the current study was the 
population-based sample of people with PsA-related foot problems living in Australia, 
the sample size was large and similarities were noted in sample characteristics between 
the current study and previous clinic-based samples of adults with PsA described in 
the literature including: age, disease duration, patient global assessment and global 
pain (Gladman, et al., 1987; Kane, et al., 2003b; Gelfand, et al., 2005; Gladman, et al., 
2005; Husted, et al., 2007; Lindqvist, et al., 2008; Gladman and Chandran, 2011; 
Rahman, et al., 2017). The representative nature of the sample could not be ensured 
due, in part, to the sampling strategy used, which is accounted for in chapter 9 section 
9.8 limitations pages 244-246. Characteristics of the current survey sample were 
interpreted favourably in the context of these previous PsA-specific studies, with the 
age-groups of the survey participants reflecting that of the target population and with 
proportional responses across ethnicities and geographical regions in Australia. 
 
Non-response in survey research is an important concern as it can lead to bias if 
respondents and non-respondents differ systematically, which can adversely affect the 
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results of the study and limit generalisability of findings (Groves, et al., 1992; Barriball 
and While, 1999). Recruitment of respondents was based on self-selection, which 
means that it is completely left to individuals to select themselves for the survey 
(Bethlehem, 2010). Whilst it is acknowledged in the literature that survey samples will 
never be exactly equal to the population characteristics they intend to estimate 
(Greenacre, 2016), strategies to reduce non-response bias were incorporated into the 
research processes of the current study with careful planning and management of 
sample selection, recruitment and data collection. Additional analyses are ongoing to 
determine the extent of bias with respect to key demographic and clinical 
characteristics in order to quantify the impact of non-response on study results and 
increase insight into these data. Deficiencies in the study sample will be accounted for 
in the interpretation and generalisability of results and will inform the direction of 
future work. Sample representation will be discussed in respect of 1) online survey 
response, 2) gender, 3) Australian states and territories, 4) ethnic groups, 5) health 
socioeconomics and 6) comorbidities. 
 
9.2.1 Online response  
Online survey response accounted for 93% of all responses in the current study. Mixed 
modes of administration were used in order to increase potential response rates and 
reduce selection bias. Although paper surveys were distribution to targeted 
rheumatology services in every state and territory across Australia (n=650) and were 
sent to potential participants on request (n=6), the online survey was substantially more 
successful. These findings are in concordance with previous studies that have shown 
respondents with PsA prefer web-based surveys over paper versions and find them 
easier to complete (Chandran, et al., 2007; MacKenzie, et al., 2011; Magrey, et al., 
2019). PsA typically affects the age-group that has one of the highest proportions of 
internet users and who access the internet every day in Australia (Australian Bureau 
of Statistics, 2016e). In 2016, 80% of all households had internet access Australia-
wide and mobile devices were used by 91% of connected households, with access and 
use reported to be steadily increasing (Australian Bureau of Statistics, 2016e). 
Therefore, it was not unexpected that most survey responses were received online. 
Nonetheless, access is not universal and participation in online surveys can be 
influenced by gender and social deprivation (Fricker and Schonlau, 2002). Indeed, the 
majority of participants in the current study were women (89%), in full time 
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employment (30%), with higher education levels (75%) and from higher 
socioeconomic areas (43%), which is consistent with the demographic characteristics 
reported to influence response rates to online health surveys (Fricker and Schonlau, 
2002; Turrell, et al., 2003; Bethlehem, 2010). In addition, those who completed the 
paper survey were slightly older, more were retired and had a lower level of education 
compared with the online sample, which is consistent with previous studies on postal 
survey respondents (Siemiatycki and Campbell, 1984; Macera, et al., 1990; Etter and 
Perneger, 1997).  
 
Data collection relied in principle on the online arm of the study, which could be 
criticised for bias towards those who use technology and engage well with online 
resources. In contrast to the UK where leading centres have large early arthritis 
registers that could be targeted for recruitment, this does not exist in Australia and the 
current method of sampling was the only way to capture this type of data.  
 
9.2.2 Gender  
PsA has no gender preference with an incidence ratio close to 1:1 (Gladman, 1998) 
and there have been no reported gender-related differences in disease expression of 
peripheral features (Gladman, et al., 1992; Gladman, et al., 1993). Therefore, near 
equal survey completions between males and females would be expected, but low male 
response rates (n=68, 11%) were found in the current study. Previous foot-specific 
studies have identified gender-related differences in foot healthcare-seeking 
behaviour, which include the under-reporting of foot problems in men (Munro and 
Steele, 1998; Hjelm, et al., 2002; Graham, et al., 2017), and that fewer men access care 
in relation to their foot health (Wilson, et al., 2017a). Although foot problems have 
been described as more prevalent in women in the general population (Dunn, et al., 
2004; Thomas, et al., 2011), prevalence differences could, in part, be explained by 
higher levels of reporting in women than men. Indeed, health survey research indicates 
that women show a greater propensity for responding than men (Etter and Perneger, 
1997; Fricker and Schonlau, 2002) and previous PsA-specific research further supports 
lower engagement with health information in men (Drăgoi, et al., 2013; Kavanaugh, 
et al., 2016). Therefore, low male responses rates were most likely due to lower 
motivation for health engagement compared with women. Whilst this was not an 
unexpected result in the current study, caution should be taken with the interpretation 
214 
 
and generalisability of the gender influenced concepts such as with reported 
frequencies of comorbidities known to be more common in women and with footwear 
components where gender-specific differences have been identified. Future work 
should include finding mechanisms to specifically target males in order to determine 
PsA-specific foot health concerns, priorities and impacts in men living in Australia. 
 
9.2.3 Australian states and territories  
Poor sample representation from the Northern Territory was identified during the 
survey dissemination phase and targeted survey promotion did not increase local 
response rates (including 3 online local health networks and 2 rheumatology services 
at regional localities). The Northern Territory has a distinct demography in comparison 
with other Australian states and territories. The Northern Territory population 
represents 1% of the total population of Australia and with a median age of residents 
of 32 years it has the youngest population in Australia, six years younger than the 
national median age (Australian Bureau of Statistics, 2016d). In addition, the Northern 
Territory has the largest group of overseas-born residents (31%) with a high proportion 
(53%) from non-English speaking countries (Philippines and India), and it has a large 
indigenous community comprising nearly a third (30%) of the Northern Territory 
population (Australian Bureau of Statistics, 2016a). Therefore, having fewer people, a 
higher proportion of young people (outside the peak age of PsA onset (Duarte, et al., 
2012)), and a higher proportion of groups affected by health inequalities in the 
Northern Territory (McConville, et al., 2013), correlated with the lower survey 
response received. 
 
Despite online survey administration that can be accessed remotely, slower internet 
speeds and less reliable connectivity may have contributed to the limited reach of the 
survey to rural and remote regions such as in the Northern Territory. An alternative 
approach could have been to identify the sampling frame through GP practices and 
hospital units across Australia. However, lower rates of utilisation and access to 
primary health services have been shown to relate to rurality and indigenous status 
(Schofield, et al., 2008; Butler, et al., 2010). Therefore, this previous evidence suggests 
that stronger resource investment to access the target population through clinical 
services may not have made much difference to the survey sample representation, with 
a high chance that those target groups would still not respond. Furthermore, there is 
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very limited evidence showing what percentage of indigenous Australians have PsA 
and what details do exist suggest it to have low prevalence (Minaur, et al., 2004). 
Although gaps in the survey sample provide initial insight into factors that may 
influence foot health in PsA, in recognition that survey findings may not be 
generalisable to the whole of Australia further work into mechanisms that target 
specific groups is required in order to capture important perspectives from difficult-
to-reach people. 
 
9.2.4 Ethnic groups  
The different ethnic groups represented in the survey sample were relatively 
proportional to those reported in the Australian population (Australian Bureau of 
Statistics, 2016b). The majority of survey respondents were Australian European and 
British (91%). Whilst it was an English language survey that required a certain level 
of English and health literacy, extensive survey pre-testing confirmed that the survey 
was understandable and easy to fill-out by people with no school certificate and by 
people from different ethnic backgrounds. Previous studies on non-response in health 
surveys have indicated that foreigners participate less than nationals (Bergstrand, et 
al., 1983). However, other studies have found that racial and ethnic minorities are as 
willing as other groups to participate in health research (Wendler, et al., 2005). 
Therefore, poorer sample representation from different ethnic groups in the current 
study could, in part, be due to healthcare barriers related to cultural and language 
differences. Hence, efforts to increase minority participation in health research should 
focus on culturally sensitive practices and data collection methods to specifically target 
and engage those from different ethnic backgrounds (Sullivan, et al., 1995; Butler, et 
al., 2013; Brady, et al., 2018). Whilst non-respondents can be defined from the survey 
sample, further work to determine the foot health needs of non-respondents is required. 
 
9.2.5 Health socioeconomics  
Under a quarter of the survey respondents were living in a relatively deprived 
socioeconomic area (23%), as determined by the Index of Relative Socio-economic 
Advantage and Disadvantage (IRSAD) scores obtained from postcodes. Non-
respondents to health survey research are more likely to be from socially deprived 
areas (Urwin, et al., 1998). Therefore, health surveys tend to underestimate the effects 
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of low socioeconomic status on health status due to selection bias, with lower 
participation from the lower educated, not working individuals with a poor health 
status (Lorant, et al., 2007). Although the majority of strategies to improve survey 
participation were adopted from the literature on survey research where possible 
(Edwards, et al., 2009), the use of monetary incentives or lotteries suggested to elicit 
higher response from economically disadvantaged groups were not employed due to 
lack of funding (Etter and Perneger, 1997; Lorant, et al., 2007; Edwards, 2010). The 
influence of social deprivation (referring to low income, inadequate housing, 
unemployment, ill health), on foot involvement and access to foot healthcare in PsA 
populations has not been established. Information about social determinants of health 
could be used to inform future decisions on healthcare resource allocation and service 
provision in order to reduce health inequalities (Marmot, 2006; Butler, et al., 2010; 
Butler, et al., 2013). The survey was constructed to capture postcodes, the IP addresses 
of online respondents and healthcare access information in order to identify the 
regional location of specialist services and allow state-specific differences to be 
explored in future analysis. PsA population access to foot care may be variable and 
potentially influenced by different patterns of foot care service provision, how these 
data reflect the situation in different geographical areas will be the focus of further 
investigation. 
 
9.2.6 Comorbidities  
Comorbidities are common and represent an important contextual factor in PsA 
(Leung and Thumboo, 2016). Similar to previous research, nearly half (43%) of people 
with PsA in the current study had more than one comorbidity (Husted, et al., 2013; 
Sanchez‐Carazo, et al., 2014). Comorbidities in PsA often contribute additional 
disease burden with worse patient-reported disease activity scores, disability, pain and 
worse quality of life than in people with PsA alone (Kotsis, et al., 2012; Husted, et al., 
2013; Magrey, et al., 2013; Husni, 2015; McGonagle, et al., 2015; McHugh, 2015; 
Brikman, et al., 2016). Therefore, comorbidity in PsA may have contributed to higher 
foot pain scores, greater activity limitation and reduced ability to cope with foot 
problems in the current study sample. In addition, foot problems from comorbidities 
such as diabetes, obesity, osteoarthritis and fibromyalgia remains a factor in 
determining their relative contribution to symptoms and functioning, which may have 
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led to under or over-reporting of PsA symptoms. Therefore, findings from this study 
may be subject to bias as confounding variables were not adjusted for. However, 
eliminating the impact of comorbidities comes at the expense of external validity and 
loss of generalisability in a real-world context. Recognition of the common 
comorbidities in PsA that have a direct or indirect effect on foot involvement may have 
important clinical implications for the potential increase in perception and reporting of 
foot pain, and influence on patient-reported outcome measures.  
 
Consistent with the current study findings, previous studies have shown that the 
majority of people with PsA were overweight or obese (Soltani-Arabshahi, et al., 2010; 
Bhole, et al., 2012; Jamnitski, et al., 2013; Bostoen, et al., 2014; Haroon, et al., 2014; 
Labitigan, et al., 2014; Eder, et al., 2015; Puig, et al., 2015). Obesity in PsA and its 
potential impact on foot pain, physical activity and exercise participation are addressed 
in section 9.4.2.  Diabetes was reported in 10% of the survey sample, which is similar 
to the 12%-19% prevalence observed among people with PsA in a previous 
population-based cross-sectional study (Dreiher, et al., 2013). Depression, anxiety and 
fibromyalgia had higher self-reported frequencies in the current study (41%, 39% and 
20% respectively) compared with previous prevalence estimates based on clinical 
indices and patient-reported outcome scores (22%, 36% and 18% respectively) 
(McDonough, et al., 2014; Brikman, et al., 2016). Female gender has been associated 
with a higher prevalence of depression, anxiety (Freire, et al., 2011; Bandinelli, et al., 
2013b; McDonough, et al., 2014) and fibromyalgia in PsA (Salaffi, et al., 2014; 
Brikman, et al., 2016), which may explain higher self-reported frequencies of these 
comorbidities in the current study with a higher proportion of female survey 
respondents (89%). Future analysis using multivariate analysis techniques is planned 
in order to better understand the associations and relative contribution of impact from 
foot problems.  
 
Comorbidities in PsA are known to influence treatment adherence, health behaviours 
and perceived health status (Carroll, et al., 2004; Betteridge, et al., 2016; Brikman, et 
al., 2016), and their influence should be taken into consideration by health 
professionals in the assessment and treatment of PsA at a global and local level. With 
increasing recognition that communication among health professionals is critical when 
comorbidities in PsA are present (Ogdie, et al., 2015), perhaps the role of the podiatrist 
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should include appropriate discussions with patients regarding depression, anxiety 
and/or obesity with emphasis on early recognition and referral, which supports a 
multidisciplinary approach for both the psychological and physical consequences of 
psoriatic disease.  
9.3 Foot involvement and its impact on people with PsA 
To the best of the authors knowledge, the current survey was the largest national 
survey of foot problems among people with PsA and one of the first studies to 
comprehensively describe PsA-related foot involvement in a large population-based 
sample. Findings of the present study indicate that foot involvement and foot-related 
functional impairment and disability are common among people with PsA and that the 
severity appears to be largely independent of disease duration. Furthermore, survey 
results demonstrated heterogeneity of disease features present in the foot and ankle 
that varied substantially between individuals. Novel findings in this study are the 
trends between site-specific foot involvement and their impact on the lives of people 
with PsA, their experiences with footwear and their foot care needs, which have not 
been previously captured in clinical or image-based studies. 
 
PsA is associated with a high disease burden that reduces functional capacity and 
quality of life compared with healthy controls and those with psoriasis alone (Husted, 
et al., 1997; Zachariae, et al., 2002). Whilst global disease severity and impact have 
been demonstrated, this study contributes new knowledge by identifying the body 
region-specific impact of localised disease in the foot in a large PsA sample. A diverse 
range of foot problems were reported, the majority of respondents had several foot 
pathologies with pain affecting multiple regions of the foot. Extensive foot 
involvement suggests that a high level of active foot disease and/or structural changes 
may have been missed or undertreated with clinical relevance for foot-related 
functional impairment and disability. Whilst foot pain and deformities may occur 
irrespective of inflammatory processes among older adults in the general population 
(Roddy, et al., 2007; Thomas, et al., 2011), the site-specific involvement of disease-
related factors such as enthesitis, dactylitis, skin and nail psoriasis, as recognised in 
the current study, provides important information about impact on foot-related 
disability in PsA. The broad distribution and heterogeneity of foot problems found in 
the current study supports the need for early and comprehensive foot assessments and 
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foot care that is coordinated and tailored (specialist and targeted) to individual needs 
in order to improve outcomes for people with PsA. 
 
The proportion of self-reported foot pain and local disease manifestations in the current 
study were considerably higher than an earlier clinic-based study using a smaller 
sample size from a single centre (Hyslop, et al., 2010a) (Table provided in Appendix 
11). Variations between the study findings are likely to be explained by the differences 
in sampling. The previous study used a convenience sample recruited from a single 
hospital site with embedded podiatry services compared with the current self-report 
survey that was conducted without the bias of a specific clinic or geographical region. 
By obtaining data from a larger sample size the current study attempted to reduce 
potential errors inherent in smaller samples. Future comparative study using a similar 
survey approach to sampling a large PsA population across the UK and other countries 
is warranted. 
 
9.3.1 Enthesitis  
Enthesitis was defined as self-reported problems with the ‘plantar fascia (under the 
heel or arch)’ and ‘Achilles tendon (back of the heel)’. Enthesitis was the most 
common disease feature at the plantar fascia (57%) followed by the Achilles tendon 
(38%) reported by the current survey sample. These findings were broadly consistent 
with previous PsA-specific ultrasound-based studies that reported prevalence rates of 
10%-57% and 32%-76% respectively (D'Agostino, et al., 2003; Falsetti, et al., 2003; 
Delle Sedie, et al., 2011; Woodburn, et al., 2013; Harman and Tekeoğlu, 2017). Foot 
symptoms in PsA can be due to inflammatory or biomechanical processes or both. The 
current survey captures the presence of symptoms resembling disease features at the 
location of these structures, which provides a clinically relevant description of site-
specific foot involvement in PsA. The novel finding of this study is that there was a 
trend towards greater levels of foot-related disability reported by people with 
symptoms of enthesitis at the rearfoot than with other foot pathologies (as indicated by 
difficulties with standing, walking and climbing stairs and by walking slower than 
others).  
 
High impact associated with rearfoot involvement related to reduced mobility and 
interference with daily routine, social activities, exercise and sleep, which were all 
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reported in higher frequencies by those with Achilles tendon problems compared with 
plantar fasciitis. Decreased biomechanical loading of the Achilles tendon with slower 
walking velocity has been demonstrated when the entheses and adjacent structures are 
inflamed (Woodburn, et al., 2013). Therefore, study findings could suggest that whilst 
avoidance of load transfer to parts of the forefoot may be possible, off-loading the 
rearfoot during gait is likely to be more difficult with severe functional consequences. 
This may also explain persistence of rearfoot involvement since load bearing is carried 
through inflamed and/or deformed musculoskeletal structures. These inferences are 
largely hypothesised and merit further investigation using combined inflammatory and 
biomechanical analysis of PsA sub-groups with a site-specific focus, which may also 
direct management strategies that attempt to off-load high stress areas with the aim of 
reducing foot pain in people with PsA. 
 
Plantar fasciitis was significantly more common in women than men in the current 
study. This is similar to findings reported in non-inflammatory arthritis groups  (Urse, 
2012; Moustafa, et al., 2015; Reb, et al., 2015) and was associated with risk factors 
related to mechanical overloading (obesity, prolonged standing), which suggests the 
important role of mechanics in the aetiology of plantar fasciitis in PsA. Conversely, 
the trend between increased global disease activity and self-reported plantar fasciitis 
would suggest an inflammatory role with plantar fasciitis being a localised 
manifestation of global disease. However, the majority of the survey sample were 
under the care of rheumatology and taking DMARDs, which would normally indicate 
tight control of active inflammation. Whilst plantar fasciitis is one of the classic 
hallmark features of PsA (D'Agostino and Olivieri, 2006), it can be of mechanical 
origin unrelated to systemic disease (Furey, 1975; Wearing, et al., 2006) and a 
common clinical challenge in PsA can be determining the relative contribution of 
inflammatory and/or pathomechanical features. With no gender-related differences in 
PsA-specific disease features reported in the literature, this study result indicates that 
plantar fasciitis may be associated with mechanical features than a result of 
inflammatory disease, which progresses current understanding of disease 
manifestations in PsA having not been previously reported. In addition, it may be 
important to consider the influence of comorbidities such as diabetes and fibromyalgia 
in this context, which are associated with an increased enthesitis prevalence 
(Fernandez-Suerio, 2012) and increased plantar fascial thickness (Giacomozzi, et al., 
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2005). Therefore, the importance of mechanical or inflammatory mechanisms driving 
plantar fasciitis is not clear and suggests that this is multifaceted, complex and warrants 
further investigation. 
 
Emotional impact of region-specific foot involvement on people with PsA was 
revealed in the survey, with a trend towards impaired physical function from rearfoot 
enthesitis being associated with greater levels of frustration compared with other foot 
pathologies. In addition, there was a trend towards sleep disturbance being associated 
with rearfoot enthesitis compared with other foot pathologies. This is consistent with 
a previous study that found enthesitis was associated with poor sleep quality in PsA 
by using the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), which 
tests 13 entheses sites with local pressure and includes the insertion of the Achilles 
tendons (Gezer, et al., 2014). Whilst it is known that people with PsA commonly suffer 
from sleep disorders and that they have a considerable impact on emotional health and 
quality of life (Duffin, et al., 2009; Gezer, et al., 2014; Gossec, et al., 2014), the current 
study reveals the foot-specific impact. Lack of sleep has been attributed to worse pain 
ratings (Finan, et al., 2013), withdrawal from favoured activities and fatigue that may 
lead to reduced physical fitness (Betteridge, et al., 2016). There was a trend between 
Achilles enthesitis and plantar fasciitis in the current study both being associated with 
greater foot pain severity and poorer coping. High foot disease burden in those with 
rearfoot enthesitis suggests that treatments in early disease should be directed towards 
prevention of rearfoot involvement. Survey respondents with rearfoot enthesitis 
preferred lace-up sneakers or being barefoot or in socks/slippers, and important 
footwear features were cushioning, light-weight, soft heel counter and arch support, 
which identifies aspects of care to focus on for podiatrists in clinical practice. 
Prospective studies are needed in order to fully explore the relationship between 
rearfoot enthesitis, foot pain, footwear and quality of life. 
 
It should be acknowledged that involvement of the functional entheses such as the 
peroneal and tibialis posterior tendons around the ankle will be interpreted in future 
analysis of the foot pain diagrams. However, currently it is not possible to determine 
the precision of the anatomical localisation of site-specific pathology mapped to the 
foot pain diagrams, and it may require future validation with combined clinical and 
image-based assessment.  
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9.3.2 Dactylitis and forefoot involvement  
Dactylitis was reported by 40% of the survey sample, which is consistent with previous 
clinical PsA cohort studies (Brockbank, et al., 2005; Gladman and Chandran, 2011; 
Kavanaugh and Mease, 2012; Gladman, et al., 2013). Although dactylitis is regarded 
as a marker of disease severity associated with clinical joint damage and impaired 
function (Brockbank, et al., 2005; Geijer, et al., 2015), limited research to date has 
defined the specific impact of toe dactylitis in a PsA population beyond associated 
mechanical factors (Wilkins, et al., 2016). Key domains of impact for respondents with 
dactylitis and lesser toe deformities were associated with footwear and body image. A 
greater proportion of people with toe involvement reported feeling embarrassed or 
self-conscious about their toes (67%) and footwear choice (38%) compared with other 
foot pathologies. Despite the load bearing function of the toes having some impact on 
physical function (walking barefoot, climbing stairs and driving), footwear discomfort 
and restrictions had greater impact by diminishing the ability to cope with foot 
problems. Although embarrassed by the appearance of their toes, open-type footwear 
was worn by most people with toe involvement with consequent important footwear 
features including a wider fit, having plenty of toe room, cushioning and support. 
Whilst it can be considered that footwear is a key modifiable contextual factor for 
those with toe involvement in PsA, the emotional burden related to self-management 
should not be neglected during clinical consultation. With current joint damage 
predictive of future damage (Gladman and Farewell, 1999), these study findings may 
support vulnerability for further progression of toe deformity. It remains unclear if a 
window of opportunity to actively treat those people with toe involvement has been 
missed, and possibly even missed at the point of diagnosis given the considerable 
diagnostic delay. Biomechanical factors, localised anatomy and increased functional 
demands require further investigation.  
 
In contrast to previous studies (Ghanem, et al., 2007; Hyslop, et al., 2010a; Delle 
Sedie, et al., 2011; Turner, et al., 2014), low levels of MTPJ deformity were reported 
in the current study. It is highly likely that this difference can be explained by foot 
deformity being clinician assigned rather than self-reported, with previous studies 
having used image-based measures of metatarsal head prominence. It is unlikely that 
the current study cohort was free from metatarsal head deformity, but self-perceived 
deformity was low. This is consistent with previous podiatry survey research where a 
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clinician may record the presence of mild deformity previously unrecognised by the 
respondent (Garrow, et al., 2004).  Lack of deformity perceived by people with PsA 
could have important clinical implications for foot health education and management 
initiatives. An alternative approach in future survey research would be to consider 
using diagrams of foot pathologies such as the hallux valgus diagrams used in previous 
research (Roddy, et al., 2007). However, most participants during survey pre-testing 
felt confident with self-reporting foot problems finding additional diagrams 
unnecessary. Another way to compare the reliability of clinician-diagnosed foot 
deformity with self-report would be to allow respondents to upload foot photographs 
to the survey with instructions on the particular foot views required, which could form 
part of future research among those respondents who indicated an interest to participate 
in further study. Lesser toe deformities, one of the most common foot problems (45%) 
reported in the current study, have been associated with MTPJ subluxation and altered 
mechanical loading patterns in previous foot-specific research in PsA (Turner, et al., 
2014). However, previous research found no relationship between MTPJ pain and 
functional changes in PsA (Turner, et al., 2014), which may be due to the impact of 
possible inflammatory features at the rearfoot not having been taken into account. 
Given the high frequency of rearfoot involvement reported in the current study, future 
research using metrics of global foot function such as velocity of centre of pressure 
may have value in elucidating relationships between foot-related pain, function and 
disability. Another explanation may be that early functional adaptation to local disease 
activity at the MTPJs may have occurred, which accounts for lower levels of foot-
related functional impairments compared with other region-specific pathologies in the 
midfoot and/or rearfoot. Further biomechanical research is warranted to understand 
the mechanisms for pain and localised disease activity.  
 
9.3.3 Dermatological manifestations  
Toenail psoriasis (57%) was the most commonly reported dermatological feature 
(above dry cracked heels, hard skin and corns) and skin psoriasis affecting the feet and 
ankles was the least common (29%). Occurrence rates of clinical features of psoriasis 
(skin and nail) vary considerably in the literature and are often not foot-specific. 
Although dermatological symptoms (soreness, tenderness and pain) were reported as 
mild or not present, the emotional burden and impact on footwear choice was high. 
This suggests that whilst key clinical indicators of pain and impaired function may not 
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be reported, health professionals should have a line of direct questioning to determine 
the extent of impact and clinical importance attributed to skin and toenail features as 
disease burden may be high. Emotional well-being, that can have a direct or indirect 
effect on PsA-related foot involvement and self-management, has been consistently 
rated as a key impact domain by people with PsA and represents an important 
contextual factor in the assessment of localised PsA disease activity in the foot.  
 
Identification of toenail psoriasis as an important contributor to the impact of disease 
in a large PsA data set represents a measure of survey success. This finding links back 
to the earlier qualitative insights relating to concerns raised by patients about toenail 
involvement that were poorly recognised by health professionals. The importance and 
relevance of nail disease to people with PsA followed through to the survey design, 
capturing the impact of dermatological features affecting the feet and confirming it on 
a larger scale. This further demonstrates the value of the rigorous approach to survey 
design, which has also informed the interpretation of the data by having in-depth 
understanding of the connections between impact domains. The major intent of this 
research was to move beyond a simple description of disease features and to 
comprehensively define the localised impact and disease burden, which may inform 
future clinical management. Findings should highlight to health professionals to look 
beyond pain and function, and to perhaps find out how patients feel about the impact 
of localised disease. Small-scale qualitative cohort findings have been supported in the 
large-scale survey, but had a more basic approach been taken to producing a survey 
this important information on psychological aspects (emotions, coping, understanding) 
would have been missed.  
 
Current study results confirm the profound burden of concurrent psoriasis in PsA that 
has been previously reported in global disease (Boehncke and Menter, 2013), and 
highlights the body-region specific impact of dermatological manifestations affecting 
the feet. In previous studies that have used the Leeds Foot Impact Scale in Rheumatoid 
Arthritis (LFIS-RA) to determine the impact of localised disease in PsA (Hyslop, et 
al., 2010a; Woodburn, et al., 2013; Turner, et al., 2014; Wilkins, et al., 2016), the 
authors acknowledged that the tool would not adequately capture dermatological 
involvement. This study confirms those concerns with high disease burden specifically 
attributed to dermatological involvement and highlights the need for disease-specific 
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measures. Rheumatology and podiatry health professionals may under-appreciate the 
major psychosocial impact from dermatological involvement of the feet in PsA and 
that the impact may be similar for both men and women. This study identifies the 
urgent need to raise awareness of the specific ways in which the dermatological 
manifestations can impact people with PsA in order to improve understanding and 
support for those suffering with these features and their families.  
 
Skin psoriasis affecting the feet and ankles was significantly associated with psoriatic 
toenail involvement. Whilst this association has been previously suggested (Langley, 
et al., 2005), foot-specific information is limited. This association has important 
clinical relevance when traumatic nail conditions and fungal nail infections complicate 
the clinical picture. Clinical uncertainty in differentiating psoriatic nail disease from 
other nail conditions is common (Patience, et al., 2018). Although future clinical 
verification of these findings are required, this association provides clinically useful 
information that suggests nail involvement is more likely to be psoriatic when skin 
psoriasis is present in the feet. Whilst there is wide recognition in the PsA literature 
that plantar psoriasis negatively effects quality of life measures (Farley, et al., 2009; 
Chung, et al., 2014; Engin, et al., 2017), the impact from toenail psoriasis on daily life 
and ability to cope with PsA-related foot involvement may be poorly recognised with 
limited research to determine its specific impact. Health professionals should seek to 
identify the concomitance of skin and toenail psoriasis and awareness of this possible 
association may also help with potential PsA diagnosis.  
 
9.4 Activity and participation impact 
9.4.1 Exercise participation  
Physical exercise was limited by foot problems in the majority of participants (83%), 
with few achieving the recommended amounts of moderate and vigorous intensity of 
exercise each week outlined in Australian Government public health guidelines for 
adults (Australian Government Department of Health, 2020). Insufficient physical 
exercise is one of the leading risk factors for cardiovascular disease and is strongly 
associated with poor general health status (WHO, 2018). Cardiovascular disease is 
more prevalent among people with PsA (such as myocardial infarction and stroke) than 
the general population (Horreau, et al., 2013; Jamnitski, et al., 2013) and those with 
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psoriasis alone (Eder, et al., 2013). The increased risk has been attributed to a higher 
prevalence of traditional risk factors (hypertension, obesity, diabetes mellitus), as a 
result of chronic systemic inflammation and decreased physical activity due to reduced 
functional capacity (Husted, et al., 2011; Dreiher, et al., 2013; Husted, et al., 2013; 
Beinsberger, et al., 2014; Khraishi, et al., 2014; Radner, et al., 2016). With foot pain, 
foot-related functional impairments and proximal involvement identified as major 
barriers to exercise participation, these findings highlight the significant impact of foot 
involvement on PsA-specific global health and functioning and identifies the need for 
effective evidence-based interventions for reducing foot pain and improving function 
among this patient group.  
 
Localised disease impact on the ability to exercise and maintain fitness as well as the 
unwanted consequence of weight gain were key concerns raised in the earlier 
qualitative work, which are supported by the survey results. Despite limited evidence 
showing the benefits of regular exercise in PsA, it is recommended to improve 
functional capacity and quality of life (Lubrano, et al., 2009; Roger-Silva, et al., 2018; 
Thomsen, et al., 2018). Health professionals have an important role in encouraging 
regular and adequate levels of health-enhancing physical activity among people with 
PsA. However, the high impact of the disease on body image and the perceived lack 
of social support by people with PsA identified in the present study may contribute to 
an increased susceptibility to adopt negative health behaviours. Integral to engaging in 
exercise is the confidence and trust that people with PsA have in health professionals 
in terms of exercise knowledge and understanding the disease (Chimenti, et al., 2014). 
This suggests that disease-specific understanding may improve compliance and uptake 
of physical activity in PsA. This would need to be shown in further research, but 
highlights the importance of social support and the lack of understanding about the 
disease among health professionals perceived by patients that was identified as a 
concern in the qualitative work. Shown in this large PsA cohort are the themes revealed 
in the qualitative interviews, which allows a more sophisticated appreciation of the 
richness of the data set and shows the strength of this research. Survey data was 
collected on physical exercise in order to undertake future work to determine the foot-
specific contribution to reduction in physical activity as well as the integration of 
information related to global disease, comorbidities and coping. Addressing concerns 
about exercise, approached in a way that instils confidence and that demonstrates 
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understanding of the individual patient journey, may have important implications in 
clinical management with a focus on building positive relationships, providing 
emotional support and increasing motivation.  
 
9.4.2 Obesity  
In recognition that over half the study sample were obese (56%) and had foot pain 
(92%), it is important to understand the mechanisms that may contribute to the 
association of symptoms and impact. It is well established that foot pain is commonly 
associated with obesity among adults in the general population (both men and women) 
(Butterworth, et al., 2013; Butterworth, et al., 2015a; Mickle and Steele, 2015; Dufour, 
et al., 2017). Whilst obesity in PsA has been associated with decreased levels of 
patient-reported physical health (Husted, et al., 2013), there are limited data on the 
added burden of comorbidity on foot health outcomes in PsA and impact from the 
patient perspective is lacking. Mechanisms that may contribute to the impact include 
the link between obesity, high plantar pressures and increased mechanical load on 
musculoskeletal structures (Butterworth, et al., 2015b; Dufour, et al., 2017); and the 
increased inflammatory burden related to the metabolic activity of adipose tissue 
(Russolillo, et al., 2013; Di Minno, et al., 2014). However, specific to PsA is the link 
between micro-damage triggered by high mechanical stress at key anatomical sites in 
the lower limbs and disease pathogenesis (Benjamin and McGonagle, 2001; 
McGonagle, et al., 2001).  
 
Several studies have suggested that obesity may be a risk factor for the development 
of PsA (Soltani-Arabshahi, et al., 2010; Love, et al., 2012), may impact on disease 
activity and reduce the likelihood of achieving minimal disease activity during 
treatment with traditional or biologic DMARDs (Russolillo, et al., 2013; Versini, et 
al., 2014; Lupoli, et al., 2016). Therefore, those with obesity in the current survey 
sample may have had a reduced response to therapy with increased disease severity at 
a global and foot level. Whilst it is not known if foot pain predisposed the obesity or 
visa-versa in the current study, foot pain and/or problems reportedly reduced physical 
activity and were a potential deterrent to participation in exercise. People with PsA 
who are overweight or obese are often encouraged to lose weight, not only for potential 
increased benefit from therapy but also for decreased risk of other comorbidities 
associated with obesity such as diabetes and cardiovascular disease (Husni, 2015). 
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Therefore, foot problems may be contributing to a major health issue for people with 
PsA, regarding the increased cardiovascular risk and inability to exercise for its 
protective effect. Planned future regression analysis to identify the important 
contributing factors to reduced physical activity and exercise participation will permit 
more detailed exploration of these concepts.  
 
Current evidence in the general population suggests that reducing body mass can lead 
to a reduction in foot pain in overweight and obese adults (McGoey, et al., 1990; 
Hooper, et al., 2007). However, the influence of weight loss on foot involvement in a 
PsA population is not known, and key challenges highlighted in the survey data relate 
to the vicious cycle of foot pain and related-disability, physical exercise and body 
weight. Alternative strategies suggested when foot pain is inhibiting ambulation 
include recommending non-weight bearing exercise to aid with weight loss (Mickle 
and Steele, 2015). Given that mechanical stress is one of the triggers of local 
inflammation in PsA (Tönük, et al., 2016), further investigation into such strategies in 
order to determine the role of physical activity and biomechanical factors that might 
influence PsA-related foot involvement will be important. The degree to which obesity 
and biomechanical–related factors are modifiable, if at all, may also have important 
clinical implications for the management of PsA-foot involvement, which require 
further study. These findings suggest that future PsA foot-specific clinical trials for 
developing interventions should consider data stratification by body weight, and 
should focus on the importance of exercise ability and weight reduction as 
interventional strategies alongside local mechanical based approaches for the 
prevention and early treatment of obesity.  
 
9.4.3 Participation in activities of daily living  
Impact from foot involvement was considerable on ability to undertake physical 
activity with most participants reporting that foot problems had interfered with 
activities of daily living. Whilst musculoskeletal and dermatological manifestations in 
the feet had limited daily routine and social/leisure activities, impact from foot 
problems on work or family life were less frequently reported. Although 45% of the 
survey reported that their work status had changed due to PsA, the majority (70%) 
were in remunerative employment or engaged in work-related activity. These results 
suggest that foot problems and footwear difficulties have a minimal impact on work-
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related disability in PsA. An explanation could be that participation is a balancing 
process where people with PsA, who are typically at working age, may prioritise work 
productivity and make adjustments elsewhere in order to fulfil normal life roles. 
Balancing and redefining normal life has been previously identified as critical to the 
process of coping with rheumatic disease (Grønning, et al., 2011). This explanation 
would need further research and may also be related to the high use of biologics 
reported in the survey sample, which has been shown to improve work productivity 
and reduce absenteeism (Tillett, et al., 2017b). This current study provides new 
insights into the specific and substantial impact of foot problems on foot-related 
functional impairments and disability in PsA. Key domains of impact identified in this 
study were mobility, social/leisure activities, exercise, emotional well-being, coping 
and footwear.  
 
9.4.4 Falls 
Adults with PsA-related foot problems have an increased number of reported falls. 
Limited research evidence exists to suggest that falls are common in PsA. With falls 
not previously reported in the PsA literature or by health professionals and expert 
groups, this unique study finding was captured in the survey directly as a result of the 
robust design process. Falls were identified by people with PsA-related foot 
involvement in the qualitative interviews (n=5, 24% with a mean (SD) age of 63 (8) 
years) and that resulted in its inclusion as a survey item, it was then retained by patients 
during survey pre-testing and by majority expert consensus as a relevant concept, 
which has subsequently demonstrated falls on a large-scale in this patient group. This 
highlights the importance of gaining an in-depth understanding about relevant 
concepts from people with the disease as part of a rigorous survey development 
process. However, in the context of how the data was collected (retrospective recall 
and cross-sectional design) and with the associated limitations of this approach being 
acknowledged, this result should be interpreted with caution. Falls recall can lead to 
under-reporting of falls incidence due to forgetting a fall and particularly those without 
injury (Cummings, et al., 1988; Hale, et al., 1993; Peel, 2000). However, previous 
studies on falls recall have focused predominantly on the elderly aged 70 years and 
over (Ganz, et al., 2005), which may not reflect the accuracy of recall in young and 
middle-aged groups more typical in PsA. Given that comorbid conditions and 
psychotropic medication use is a significant risk factor for falls (Lamb, et al., 2005; 
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Stanmore, et al., 2013), it is noted that 41% and 39% of the survey sample reported 
having depression and anxiety respectively, which could be a contributory factor to 
increasing falls risk. Comorbidities in PsA are common and eliminating the impact of 
comorbidity may reduce external validity and generalisability. Whilst it is recognised 
that there may be some controversy related to the potential for error in determining 
falls through retrospective recall and in determining the relative contribution of 
comorbidities to problems in function, the data shows a significant relationship 
between those with foot problems and those who reported a fall. Despite these 
limitations, the current study findings suggest that future prospective studies are 
warranted in order to provide definitive conclusions regarding causes of falls in people 
with PsA.  
 
Falls in PsA identified by the current study represents new knowledge contribution in 
this field of research that has not been previously reported in the large longitudinal and 
prospective PsA data sets. This unique finding in a PsA-specific population is 
consistent with previous research in RA that found self-reported foot-related 
functional impairments were associated with a greater risk of falls (Brenton-Rule, et 
al., 2016). However, a major difference is the younger age of those reporting falls with 
the majority aged between 40 and 59 years compared with those typically aged over 
60 years in RA populations (Armstrong, et al., 2005; Hayashibara, et al., 2010; 
Stanmore, et al., 2013) and older adults aged over 65 years in the community 
(Deandrea, et al., 2010). Whilst several previous studies have investigated the 
contribution of foot and lower limb characteristics to falls risk in RA populations 
(Jamison, et al., 2003; Armstrong, et al., 2005; Smulders, et al., 2009; Hayashibara, et 
al., 2010; Levinger, et al., 2012; Stanmore, et al., 2013; Brenton-Rule, et al., 2016) and 
healthy older adults (Menz and Lord, 2001; Menz, et al., 2005; Menz, et al., 2006; 
Chaiwanichsiri, et al., 2009; Mickle, et al., 2009; Mickle, et al., 2010), there is limited 
falls research in PsA. With falls generally associated with elderly adults (Deandrea, et 
al., 2010), it is possible that health professionals may not identify the potential falls 
risk in younger people with PsA at working age, who consequently do not receive 
tailored appropriate treatment that addresses potential falls risk. Falls are associated 
with a significant burden of morbidity and mortality such as serious injuries, hospital 
admission or admission to care homes, fear of falling, decreased independence and 
reduced quality of life (Lamb, et al., 2005; Stanmore, et al., 2013). Therefore, falls in 
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PsA can have potentially devastating consequences and an awareness of the risk 
factors associated with falls in PsA may help health professionals to identify and better 
manage younger people with increased falls risk. Falls in PsA warrants future 
prospective investigation and highlights the potential role of podiatric interventions in 
foot-specific falls prevention strategies. 
 
9.5 Contextual factors 
9.5.1 Footwear impact  
Footwear has been perceived as an external expression of disease by people with RA, 
which negatively impacts on self-identify, self-esteem and lifestyle (Williams, et al., 
2007a). Whilst several qualitative studies have explored perceptions of footwear in RA 
(Williams and Nester, 2006; Williams, et al., 2007b; Williams, et al., 2010; Williams 
and Graham, 2012), limited research exists on footwear experiences in PsA (Carter, et 
al., 2019a). Significant patient involvement and the qualitative approach taken in the 
current study revealed a richness of data relating to important footwear issues and 
related disease impact in PsA, which guided parts of the survey development and 
design. Although climate and weather is known to drive footwear choice (Brenton-
Rule, et al., 2014), there is a paucity of research on footwear worn in Australia. One 
previous Australian-based study found footwear difficulties in RA that related to 
comfort, aesthetics and seasonal variation (Hendry, et al., 2013b). However, PsA is a 
distinct disease entity with specific disease features such as Achilles enthesitis and 
dactylitis and hence footwear preferences and problems cannot be extrapolated from 
other groups, highlighting the necessity for the current survey research.  
 
The most commonly worn footwear type was walking shoes (lace-up and slip-on 
sneakers) followed by sports shoes and supportive sandals in a large representative 
sample of people with PsA. Previous studies have also found these footwear types to 
be popular amongst those with inflammatory arthritis (Silvester, et al., 2010; Brenton-
Rule, et al., 2014; Carter, et al., 2016; Stewart, et al., 2018; Brenton-Rule, et al., 2019). 
Although comparisons with previous studies are difficult due to methodological 
variations, there appears to be consistency in the preferred footwear categories of 
diverse arthritic-populations (Barwick, et al., 2018). Footwear types worn the most 
were those with desirable features that have been associated with improved foot health 
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outcomes among people with RA (Hennessy, et al., 2007) and gout (Rome, et al., 
2013). For example, sports shoes commonly have both cushioning and supportive 
properties. However, footwear construction and condition can vary significantly 
(Dufour, et al., 2009) and self-reported footwear choice may not represent actual 
footwear habits. Given the reported popularity of wearing walking shoes, sports shoes 
and supportive sandals, further research to evaluate the evidence for the clinical 
effectiveness of commercially available footwear interventions for foot pain and foot-
related functional impairment and disability in people with PsA may be warranted. 
 
No shoes (barefoot) or wearing socks/slippers was reportedly common during a typical 
week (36%). Nearly a quarter (27%) of the study sample reported wearing poor 
footwear (fashion sandals, moccasins and thongs/flip‐flops), which implies a shoe 
design that lacks support and shock absorption. These findings are similar to previous 
studies reporting footwear with poor structural characteristics in people with different 
types of inflammatory arthritis (Silvester, et al., 2010; Brenton-Rule, et al., 2014; 
Brenton-Rule, et al., 2019). It has been previously suggested that wearing poor 
footwear may be due to financial restrictions or a lack of awareness of the importance 
of good quality footwear in reducing foot pain and foot-related disability (Rome, et 
al., 2011; Brenton-Rule, et al., 2019). In addition, whilst wearing open-type, minimal 
footwear may reflect difficulties in finding footwear that fits and does not hurt, it may 
also be related to sociocultural and climate factors in Australia. Previous studies 
conducted in the UK (Naidoo, et al., 2011), Australia (Hendry, et al., 2013b), New 
Zealand (Silvester, et al., 2010; Brenton-Rule, et al., 2014) and Singapore (Carter, et 
al., 2016) acknowledge that temperature, humidity and rainfall can play a key role in 
influencing footwear habits. Future planned analysis beyond the scope of this thesis 
will be to examine possible associations between sociodemographic factors, 
geographical locations in Australia (including tropical and temperate climates as well 
as remote, regional and urban areas) and different types of footwear worn, footwear 
preferences and difficulties with footwear. Footwear differences identified across 
Australia will be clinically useful for management decisions and will inform the 
direction of future intervention studies. Future research will also include comparisons 
with large population-based PsA-specific samples in other countries in order to explore 




Despite thongs/flip-flops being a popular choice of footwear among the general 
population in Australia and with the study period conducted over both spring and 
summer months, lower than anticipated frequencies of those wearing thongs/flip-flops 
were reported in the current study (17%). These study findings were consistent with 
similar New Zealand-based studies that reported thongs/flip-flops were worn by 10% 
to 16% of people with inflammatory arthritis (Brenton-Rule, et al., 2014), RA 
(Silvester, et al., 2010), SLE (Stewart, et al., 2018) and gout (Rome, et al., 2011; 
Brenton-Rule, et al., 2019). However, in recognition that the Australian continent has 
several different climate zones compared with New Zealand, thongs/flip-flops are 
commonly worn throughout the year in the warmer climates in Australia (Finnis and 
Walton, 2008). Current study findings suggest that people with PsA presenting with 
different inflammatory features may have different footwear needs. Greater intrinsic 
foot muscle strength and peak ankle joint dorsiflexion moments are required during 
gait in thongs/flip-flops compared with barefoot or in other footwear types (Zhang, et 
al., 2013; Price, et al., 2014). Additional biomechanical demands observed when 
wearing thongs/flip-flops may make them a less popular footwear choice among 
people with PsA with predominant rearfoot involvement of the entheses around the 
ankle reported in the survey sample. Limited gait research on foot function in PsA has 
identified the impact on footwear restrictions from higher LFIS-RA sub-scale scores 
(Hyslop, et al., 2010b; Woodburn, et al., 2013; Turner, et al., 2014; Wilkins, et al., 
2016), but these findings did not inform on optimal footwear characteristics. 
Therefore, gaining an appreciation of what people with PsA have self-selected and 
consider important in regards to footwear may provide early insights. Given the 
heterogeneity of presentation in PsA, further analysis to understand how disease 
manifestations in the feet affects footwear choice may help to determine the role of 
footwear interventions in the management of this patient group. Study findings have 
direct relevance for the management of foot involvement in PsA given the effects of 
footwear properties on gait parameters and plantar pressures known to influence foot 
pain and foot-related functional impairment and disability. Further research is needed 
to investigate potential changes to gait parameters associated with footwear and 
associated improvements to patient-reported outcomes in a PsA population. 
 
Cushioning, support and fit were the most important features when choosing footwear 
in the current study, which is consistent with previous studies in people with RA 
234 
 
(Williams and Nester, 2006; Silvester, et al., 2010), gout (Rome, et al., 2011) and 
inflammatory arthritis (Brenton-Rule, et al., 2014). These findings may suggest that 
people with inflammatory arthritis prioritise these features due to disease-related foot 
problems. The convenience of taking shoes on/off easily was also important and may 
reflect difficulties related to hand and/or spine involvement typical in PsA, with most 
respondents (74%) having reported reduced mobility due to other parts of their body. 
 
Whilst there was no difference in the most commonly worn footwear types between 
men and women in the current study, a higher proportion of women agreed with all 
statements relating to difficulties experienced with footwear (discomfort, limitations, 
impact). Although these results should be interpreted with caution as the survey sample 
was under-representative of male respondents, current findings were consistent with 
the literature on footwear differences between sexes. Previous research on footwear in 
older people has reported marked gender differences relating to footwear choice, fit 
and comfort (Menz and Morris, 2005; Dufour, et al., 2009). Women compared with 
men are more likely to; suffer foot pain (Munro and Steele, 1998; Menz and Lord, 
2001), report footwear difficulties (Sullivan, et al., 2015), suffer more foot pain when 
wearing footwear (de Castro, et al., 2010), and to choose footwear with characteristics 
not recommended to promote mobility and foot health (Hockey, et al., 2013). With 
sociocultural factors more likely to influence female footwear choice than factors 
relating to medical or foot conditions (Hockey, et al., 2013), gender associations with 
footwear among people with PsA living in Australia requires further study using a 
balanced sample.   
 
This is the first study to report the PsA-specific impact of footwear on daily life. 
Difficulties with footwear due to both musculoskeletal and dermatological disease 
features of PsA in the feet were a major contributing factor to negative emotional well-
being and self-perceived inability to cope with foot problems. Survey results suggest 
that the inability to find comfortable footwear and restrictions in the number and type 
of footwear worn had a substantial impact on emotional health and quality of life in 
PsA. Difficulties with footwear had greater impact on special occasions than on daily 
routine and work activities for both men and women. Current study findings provide 
initial insight into understanding the role of footwear in both limiting and facilitating 
activity and self-management. The qualitative methods used in this study that enabled 
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researchers to gain a true understanding of patient experiences and linking to the ICF 
has influenced the way in which data may be interpreted. Footwear, healthcare systems 
and psychological status (emotions, coping) were important contextual factors linked 
to the ICF, which have been shown to influence foot-related functional impairments 
and disability in PsA. Contextual factors (environmental and personal) have been 
consistently rated as important by people with PsA. Footwear represents a key domain 
of impact and an important contextual factor in the assessment of PsA-related foot 
involvement. Survey results further improve understanding of the critical role 
contextual factors play as barriers or facilitators in self-management of foot 
involvement in PsA. Further directed work on footwear is required to determine the 
effect of contextual factors in outcome measurement, as well as longitudinal 
prospective studies and randomised controlled trials (RCTs) that may help to 
determine the clinical effectiveness of footwear among people with PsA.  
 
9.5.2 Self-management and coping strategies   
The impact triad of rheumatic diseases previously proposed that the personal impact 
of rheumatic conditions may be influenced by the patient’s ability to cope with 
symptoms, the perceived severity and personal importance (Sanderson, et al., 2011). 
Consistent with the proposed theory of the impact triad, the majority of participants 
reported moderate to severe global and local pain, moderate to severe difficulty coping 
with localised disease, and moderate to extreme perceived importance of foot problems 
(as determined by the extent to which respondents rated their foot problems as 
troublesome). Survey data supports the impact triad in people with PsA-related foot 
involvement and emphasises the importance of incorporating the patient perspective 
into the assessment of disease and personal impact. Coping was mostly influenced by 
foot pain severity, experiences with footwear and the availability of social support 
from friends, family and/or health professionals. Coping represents an important 
component of impact that was revealed by people with PsA in the qualitative 
interviews, but was poorly recognised by health professionals. Linking to the ICF 
highlighted key differences between aspects of coping as an activity and cognitive 
function that were integrated into the survey design (for example, the coping strategies 
included in the survey mapped to a range of ‘b’, ‘d’ and ‘pf’ ICF categories; handling 
stress and other psychological demands, temperament and personality functions, 
experience of self and time functions, thought functions, adapting to changes in daily 
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routine, looking after one’s health, managing one’s own activity level and personal 
factors). It was the strength of the survey development methods that ensured insights 
into the psychological burden (embarrassment, frustration and ability to cope) from 
patient interviews were captured on a larger scale by the survey. Interpretation of 
survey findings and connections in the data have been informed by these valuable 
insights into the patient experience and from having had the opportunity to gain an in-
depth understanding of key concepts (for example, the influence of social support on 
coping ability and the emotional burden relating to feelings of embarrassment and/or 
frustration). Knowledge of the patient perception of coping may be important for 
health professionals in order to better interpret the extent of impact from foot 
involvement in PsA, but future analysis of these issues is required to inform targeted 
self-management interventions. Both disease duration and activity were relevant to 
coping with foot problems, with global pain severity reducing coping ability and with 
the coping strategy to ‘try to keep in control of the problem’ being most commonly 
used by those with an established PsA disease duration (5years or more). Consistent 
with previous research (Grønning, et al., 2011), it might be expected that people with 
longer disease duration are more familiar with the coping process than those newly 
diagnosed and thus make better adjustments and accept changes more easily during 
the disease course. Further data analysis is required to determine the complex barriers 
and facilitators to coping with foot problems in order to identify those that are most 
important, effective and/or potentially modifiable.  
 
9.6 Healthcare access and support 
9.6.1 Healthcare access  
Access to podiatry services was higher in the survey sample (current access at 24%, 
past access at 62%) compared with access previously reported in a UK-based clinical 
study (21%) (Hyslop, et al., 2010a). One explanation may be that respondents to health 
surveys have been shown to demonstrate greater interest in managing their disease, 
higher healthcare utilisation, better health status and more positive health-related 
behaviours than non-respondents (Macera, et al., 1990; Paganini-Hill, et al., 1993; 
Grotzinger, et al., 1994; Lamers, 1997; Reijneveld and Stronks, 1999). However, 
despite higher access rates to podiatry services, the majority of participants reported 
having severe foot pain and a diverse range of disease-related foot problems. These 
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findings may suggest that PsA-related foot health needs have not been fully met by 
podiatry and/or rheumatology health professionals and raises questions regarding the 
effectiveness and/or continuity of foot care received. Inadequate standards of 
rheumatic foot care provision have been previously reported in Australia, with a lack 
of foot care specialists in the rheumatology field and dedicated services (Hendry, et 
al., 2013a). There have been no PsA-specific podiatry intervention studies to date and 
the different disease manifestations between RA and PsA suggest that it should not be 
assumed that interventions will translate across disease spectrums. This study has 
shown that despite high uptake of podiatry services, foot care seems to have been 
ineffective and with a lack of any evidence base for practice this result is probably not 
unexpected. Integration of podiatry within expert-led rheumatology teams may lead to 
improvements in foot health outcomes for people with PsA. Whilst provision of 
effective, timely and targeted care is recommended for the appropriate management of 
rheumatic foot disease, PsA-specific research into beneficial strategies that address the 
localised inflammatory and/or biomechanical features that may be responsible for the 
persistence of foot involvement is warranted.  
 
Different levels of access to rheumatology services for management of PsA were 
observed across Australian states and territories, which may indicate potential national 
variations in healthcare access linked to unmet need in PsA. However, data from this 
study does not necessarily represent actual access to healthcare and effectiveness, but 
rather perceptions of foot care that may be subject to response and recall bias. Planned 
future investigation of study data in relation to rural and urban areas in Australia will 
help to identify socioeconomic and geographical factors linked to unmet need in PsA.   
 
A wide range and high number of professional and non-professional health services 
were accessed by participants with associated out-of-pocket expenditure on foot 
healthcare, indicating a significant treatment and financial impact. Survey results 
suggest an under-treatment of PsA-related foot involvement that may be associated 
with financial burden related to seeking appropriate care, which is similar to previous 
survey findings related to global disease burden in PsA (Kavanaugh, et al., 2016).  In 
the PsA core domain set, treatment burden is in the outer circle on the PsA research 
agenda, which comprises financial hardship and time commitment related to the 
impact of treatment (Orbai, et al., 2017a; Orbai, et al., 2017b). Although the survey 
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data may be subject to response and recall bias, the results suggest that there is unmet 
need for effective treatment of foot pain and/or problems, with 96% (n=518) of 
participants having accessed healthcare for their feet and nearly a third reporting that 
the care was ineffective (32%). Whilst it is recognised that the survey made no attempt 
to undertake any formal health service access evaluation, these early insights suggest 
that future studies should investigate issues related to access, provision, cost and 
utilisation of foot care services in order to inform the organisation and delivery of 
healthcare to people with PsA. 
 
9.6.2 Diagnostic delay  
Diagnostic delay from symptom onset to diagnosis was a mean (SD) 5.5 (2) years 
reported in the current study, which supports concerns in recent articles on the 
considerable diagnostic delay that remains in PsA (Coates and Helliwell, 2017; 
Holland, et al., 2017; Van den Bosch and Coates, 2018). Diagnostic delay was a key 
concern and source of frustration for participants in the qualitative investigation of the 
current study, which contributed to reduced confidence in health professionals and the 
perceived lack of understanding about the disease by patients (Carter, et al., 2019a). 
Results from the current survey confirm that challenges related to the screening and 
diagnosis of PsA are a wider problem across different regions and health services in 
Australia. Delays in diagnosis of more than 6 months to 2 years have been associated 
with an increased prevalence of clinical joint damage, poorer function and quality of 
life in cross-sectional studies (Gladman, et al., 2011; Haroon, et al., 2015) as well as 
in longitudinal cohort studies (Tillett, et al., 2013). With the majority (n=440, 76%) of 
survey respondents reporting that symptoms were present for 5 years or more prior to 
diagnosis, this could explain the high proportion of peripheral joint deformity in the 
toes and consequent impact on functioning reported in the current study (45%). 
Despite wide recognition of the importance of early diagnosis to prevent long-term 
structural damage, disability and the associated socioeconomic consequences, PsA still 
represents a considerable diagnostic and therapeutic challenge for health professionals 
(Van den Bosch and Coates, 2018).  
 
PsA-related foot problems can often be poorly recognised by patients and 
misdiagnosed by health professionals (Carter, et al., 2019b). Hallmark features of PsA 
such as Achilles enthesitis and plantar fasciitis are common in community-dwelling 
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adults (Menz, et al., 2010) and psoriatic nail disease can often be mistaken for fungal 
nail infections (Patience, et al., 2018). In addition, there is limited emphasis on 
rheumatology in undergraduate podiatry curriculums in Australia, which may explain 
poor recognition of PsA carried through into clinical practice (based on an informal 
review of university podiatry unit outlines that indicated a percentage coverage of 
rheumatology between 3% and 12% of the entire programme). Foot examinations are 
also often omitted from standard clinical indices for the assessment of disease activity 
in PsA and insufficient musculoskeletal expertise among GPs, rheumatologists and 
dermatologists has been suggested as a reason for the poor identification of PsA (Van 
den Bosch and Coates, 2018; Carter, et al., 2019b). This concept emerged in the 
qualitative study with rheumatologists reporting their reluctance to identify foot 
problems with few options for onward referral due to the lack of provision and access 
to specialised podiatry services in both public hospitals and private clinics. With foot 
involvement predominant and persistent in PsA, further work to increase awareness 
and understanding about the disease among patients and health professionals is 
required in order to reduce delays in initial presentation to health services, time to 
referral to rheumatology clinics and time to diagnosis. Current study findings will be 
used in future work to highlight important manifestations of the disease in the feet and 
ankles in order to prompt health professionals to use the full clinical picture of an 
individual patient to make effective management decisions.   
 
9.6.3 Global disease management in the context of local disease  
Biologic agents were taken by a relatively high proportion of the survey cohort (43%) 
in comparison with 12% use reported by Hyslop, et al., (2010) in a previous foot-
specific study in PsA, which was conducted in a leading UK-based specialist 
rheumatology service. Currently, there are no differences between Australian and UK 
pharmacological prescribing guidelines for PsA, but there may have been limited 
access to biologics with sparse evidence of their efficacy and safety 10 years ago when 
the Hyslop, et al., (2010) study was undertaken. Based on PsA pharmacological 
treatment algorithms (Gottlieb, et al., 2008; Ritchlin, et al., 2009; Gossec, et al., 2016), 
it could be inferred that 55% (n=319) of the current survey cohort have experienced 
failure of conventional DMARDs with subsequent targeted escalation to combined 
therapy (12%) or biologic treatment (43%). Despite tight control of systemic disease 
with aggressive pharmacological treatment approaches indicated by biologic 
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intervention, a high level of disease features in the feet were reported among survey 
respondents. Definitive strategies to attain suppression of localised inflammation in 
the foot and maintain optimal function are limited with no validated foot-specific 
outcome measures to define ‘tight control’ of local disease. Current study findings 
provide initial insight into pharmacological treatment regimes in PsA that may not be 
efficacious in lowering active disease levels in the foot, with local anatomical and 
biomechanical factors potentially responsible for disease persistence. These findings 
suggest that frequent foot screening and comprehensive foot assessments for people 
with PsA may be warranted. However, with no clinical or image-based assessments in 
the current study, no conclusions regarding disease suppression can be drawn. Given 
that nearly half of the participants were on biologic therapy, this provides the 
opportunity to explore in future research any correlation between global disease 
activity in those on biologic therapy, foot pain severity and patterns of hallmark disease 
features in the foot such as dactylitis, enthesitis and toe deformity. 
 
9.6.4 Healthcare understanding and effectiveness 
In the current study 68% of people with PsA reported that their health professional had 
a good understanding of how PsA affected their feet. However, in the Survey of Health 
Care conducted by the Australian Bureau of Statistics in 2016 on experiences with 
health professionals (GPs, specialist doctors, health professionals) of those aged 45 
years and over in the general population, the majority (91%) of people reported that 
their health professional had a good understanding of their health, healthcare needs 
and preferences (n=35495, 29% response rate). GP and rheumatologist knowledge and 
understanding of foot examination and PsA presentation in the foot is critical for 
timely and targeted treatment of localised disease, with survey results indicating that 
the majority of participants had accessed GP and rheumatology services for their foot 
problems (73% and 81% respectively). Despite the majority of respondents having 
recalled undergoing a foot examination by their rheumatologist, foot health outcomes 
seem to be poor given the high impact of localised disease reported in the survey. The 
accuracy of recall can be questioned, but nonetheless it suggests that people with PsA 
perceived that foot examinations were undertaken. A wider focus on disease features 
affecting the feet is required in order to incorporate a comprehensive foot examination 
as standard, instead of the current limited focus on peripheral joint counts by 
241 
 
rheumatologists. Health professionals require sufficient training to provide optimal 
foot healthcare and outcomes for people with PsA, in the absence of national PsA-
specific foot health guidelines.  
 
The qualitative interviews identified that experiences with healthcare seemed to 
mediate the severity of localised disease impact for people with PsA, and that 
engagement with foot healthcare was influenced by their perception of confidence in 
the health professional and their understanding about the disease. This major theme 
was also recognised by the health professionals who reported service deficiencies 
leading to suboptimal foot disease management. These key insights relating to lack of 
confidence and understanding were carried through into the survey development 
process and have been shown to be important for people with PsA on a large-scale by 
the survey data, which demonstrates the merit of the meticulous survey design process. 
Survey results suggest that compared with the rheumatologist and physiotherapist, 
podiatry treatment was reported to be less effective. In total 53% of participants had 
seen a podiatrist about their foot problems compared with 81% who had seen the 
rheumatologist and 33% the physiotherapist. Higher frequency of interactions with 
rheumatologists may be a factor in developing a rapport and supportive relationship, 
as well as the typical regular reviews or intensive treatment periods for patients 
receiving physiotherapy. Whereas in podiatry, whilst dermatological manifestations 
may require regular routine treatment, musculoskeletal manifestations are likely to 
represent much shorter episodes of care, which may have resulted in the patient 
perception of poor personal interaction and service dissatisfaction. Alternatively this 
finding may, in part, be explained by the distinct lack of specialist podiatry 
rheumatology services in the public health system in Australia (Hendry, et al., 2013b; 
Hendry, et al., 2013a). Using professional registration as a metric for clinical interest, 
there are only 57 allied health professional members of the Australian Rheumatology 
Association (Australian Rheumatology Association, 2020), which is considerably 
lower in comparison with equivalent European associations with more than 800 allied 
health members (such as the European League Against Rheumatism - EULAR). 
Previous qualitative research in RA concluded that timely and individualised 
management of foot health by empathic and knowledgeable practitioners was pivotal 
to ensuring that the known benefits of foot-specific interventions were realised 
(Williams and Graham, 2012). Despite the fact that evidence for the efficacy of 
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podiatry interventions in the management of people with PsA is required (Patience, et 
al., 2018), this study finding identifies the need for specialist training of podiatrists, 
which could help to drive specialist service provision in Australia. Further work to 
explore the podiatry undergraduate curriculum rheumatology content, postgraduate 
training provision and career opportunities for podiatrists in the rheumatology field in 
Australia will help to inform future educational initiatives.   
 
The lack of specialist podiatry services within the public health setting in Australia 
presents an opportunity to define service structure and provision. Current survey 
findings provide valuable insight into the impact of PsA-related foot involvement, but 
prior to seeking to influence connected care provision it may be important to consider 
the evidence base for various aspects of care. Survey findings could inform future RCT 
development that may be used for podiatry service recommendations. Therefore, the 
absence of established services represents a distinct advantage for Australia as a 
possible site for future RCT research as there would be no obstruction to the 
withdrawal of services, since they do not exist. This is in contrast to the UK, for 
example, where there are established models of care for rheumatic foot disease that 
would require research studies to withhold existing services and treatment, which are 
currently provided regardless of the lack of an evidence base in PsA. This suggests 
when developing future studies for interventions that Australia would be considered a 
prime site for research in this area.  
 
9.7 Contribution of Knowledge  
This programme of research addresses the knowledge gap by providing new insights 
into the patient perspective on the impact of foot involvement in PsA:   
 
Qualitative investigation into the patient experience of foot involvement in PsA 
revealed new information on the impact of localised disease in the foot, which was 
profound and widespread across all aspects of life. Discordance between the views of 
people with PsA and health professionals was revealed, which indicated that health 
professionals may underappreciate the psychological burden associated with foot 
involvement. This qualitative study also provided new PsA-specific knowledge related 
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to health service deficiencies in foot disease management in Australia and New 
Zealand.  
 
Linking to the ICF is a relatively new approach to defining disease impact in the 
rheumatology field and this study was innovative in using this framework to define 
region-specific impact on functioning. The list of ICF categories generated in this 
study represents concepts translated into a universal language that comprehensively 
describes the functioning of people with PsA-related foot involvement, provides the 
starting point for future foot-specific outcome development, and an opportunity to 
compare foot-related functioning across other rheumatic diseases. Inclusion of an 
occupational therapy perspective in the interpretation of impact highlighted the 
importance of a multidisciplinary team approach to PsA for future studies.    
 
The survey development protocol provides a significant methods contribution to 
standard survey research protocols and can be used as a template by other healthcare 
researchers for broader application. Survey development was heavily compliant with 
best practices and guidelines for survey conduct and reporting. Merit of the 
methodological approach and the value of embedding the patient perspective in 
research activity were supported by subsequent successful survey outcomes, which 
yielded a high survey response and completion rates despite the survey length. With 
poor adherence to quality criteria in previous health survey research widely 
acknowledged, this survey protocol presents a novel high-quality worked example of 
survey design and conduct in podiatry-led research. 
 
The survey findings strengthen and build on existing literature that indicates foot 
problems are common in PsA and new knowledge is added on the impact of disease 
features affecting the feet in PsA from a large and relatively representative population-
based sample. This study provides the broadest description of foot involvement and 
foot-related functional impairments and disability reported in people with PsA to date. 
With previous data on PsA-specific foot involvement predominantly generated from 
European studies, this national survey conducted in Australia provides locally 
representative data and a unique account of foot problems and their impact on daily 
life, footwear choice and foot care needs. The survey results provide a rich data set 




Appropriate management of foot involvement in PsA is poorly understood and 
indications for referral to rheumatology and/or for specialist podiatry services are not 
clearly defined, which is compounded by diagnostic challenges related to disease 
heterogeneity. The assessment of the foot health needs of this patient group is the first 
step in planning and providing appropriate services, which should be based on an 
understanding of foot involvement within the community and an appreciation of the 
most important areas of impact on daily life. This programme of research provides a 
better understanding of patient perspectives on the impact of foot involvement on daily 
life, which should be used to assist in decisions regarding the clinical management of 
foot problems in PsA. Research findings from this PhD provide a strong conceptual 
foundation for further study that should aim to improve the patient experience and 
generate effective assessment and treatment strategies for improving foot health 
outcomes.  
 
9.8 Limitations  
Limitations to the other programs of work have been covered in the relevant chapters. 
The survey findings should be interpreted in the context of limitations inherent in 
health surveys including selection bias, accuracy of self-report and sample 
representation. First, it is possible that people with foot problems were more likely to 
respond to the survey, which potentially introduces selection bias. Although the 
sample was not restricted to those with foot problems, previous studies on survey non-
response found that respondents were more likely to have experienced the topic of 
interest (Sica, 2006). Therefore, survey results may overestimate the severity and 
extent of PsA-related foot involvement. Whilst 92% of the sample had experienced 
foot pain over the past month, over half of the sample (55%) did not consider their foot 
pain to be the most painful part of their body and approximately half the sample 
reported mild to moderate levels foot pain (n=273, 53%), which could indicate a 
relatively balanced sample. Although sources of response bias were reduced by not 
limiting recruitment to specific clinics or geographical regions and by using mixed 
modes of survey administration (paper and online), it is possible that participants who 
volunteered to take part in survey research may not be representative of the general 




Second, this study relied on information collected by self-report relating to the 
diagnosis of PsA and foot pathologies. Survey results depend on accurate recognition 
and appropriate reporting by respondents and self-report may have under or 
overestimated the PsA-related foot involvement. Previous studies have indicated that 
patients’ self-report of chronic medical conditions is reasonably accurate (Martin, et 
al., 2000) and self-report of common foot problems has been shown to be reliable in 
RA (Wilson, et al., 2015). Whilst reliability of reporting was not formally tested in the 
current study, rigorous survey pre-testing demonstrated high levels of accuracy in the 
interpretation of survey items including identification of foot conditions. Therefore, 
survey pre-testing provided a high degree of confidence for accurate and appropriate 
self-reporting and for the acceptability of one-month recall periods among people with 
PsA. Nonetheless survey research can be subject to self-report errors and recall bias, 
which may have influenced the results and should be accounted for in the interpretation 
of study findings. 
 
Finally, survey data was specific to the Australian context, which may not be 
representative of PsA populations in different countries. A major objective of the 
survey was to obtain locally representative data due to limited research on relevant 
sociocultural, climate and healthcare system factors that may influence foot 
involvement in Australia. Survey results should be interpreted relative to the context 
of Australia and inherent aspects including climate, footwear and health service 
provision, which may not be generalisable to other groups with different contextual 
factors. Cross-cultural adaptation of the current survey in different countries to analyse 
between-country differences has been planned (Europe and Singapore), which will 
increase insight into these data. Despite extensive mechanisms to obtain a broad 
representative sample, there remained a small number of discrepancies within the 
sample (gender, regional, ethnicity, online response, item non-response) that hampered 
interpretation of results and generalisability of findings. In addition, the 10% survey 
response rate may have created item non-response bias leading to potential sources 
of error in reporting of the survey findings (Groves, 2006; Davern, 2013; Lewis, et al., 
2013). Although gaps in the survey sample provide initial insight into factors that may 
influence foot health in PsA, further work into mechanisms that target specific groups 
is required in order to capture important perspectives from difficult-to-reach people. 
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Cross-sectional surveys are vulnerable to influence from the high variability in PsA 
disease course as the survey data represents a snapshot in time. Although the 
heterogeneity of disease features among the survey sample reflects the varied nature 
of PsA, future longitudinal studies are required to determine change over time and 
causal relationships. This study provides the most comprehensive description of 
nature, extent and impact of foot problems reported in people with PsA to date, which 
demonstrates the importance of performing population-based studies that are broadly 
representative of people with PsA.  
 
9.9 Future Work 
The programme of work for this PhD was intended to provide a large comprehensive 
data set in order to permit detailed analyses to be undertaken at a post-doctoral level.  
Areas for future work and more in-depth exploration of the data have been 
purposefully integrated throughout the chapters. Survey results will be used to inform 
a programme of future research with the aim of developing targeted disease-specific 
assessments and management strategies in order to improve foot health outcomes in 
people with PsA. Key areas of planned future work are described as follows:  
9.9.1 Advanced statistical modelling of survey data  
The comprehensive and potentially related data included in the survey will require 
advanced statistical modelling in order to fully appreciate the level of impact and 
complex relationships between factors that were alluded to by people with PsA in the 
earlier qualitative work. The linking exercise to the ICF will permit a greater 
understanding of where data sits within the understanding of disease impact and will 
provide the basis for preliminary work towards the development of a PsA foot-specific 
outcome tool. Furthermore, gaps in the survey sample will be addressed in this future 
work in order to gain better representation from specific non-respondents such as men, 
those from the Northern Territory, rural and remote regions, different ethnic groups 
and socioeconomic backgrounds.  
9.9.2 Dissemination of survey findings to people with PsA  
One of the most important next steps will be to close-the-loop by informing the target 
population of the survey findings, which adheres to good practices for reporting survey 
data in health research and aligns with important concepts from the current study about 
increasing support and understanding. In addition, survey findings will be published 
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on the study website and Facebook page. Dissemination of study findings serves an 
important role in bridging the gap between health professionals, researchers and 
consumers of health information, and contributes to research impact in the PsA 
community beyond the academic setting. 
9.9.3 Multi-national adaptation and implementation of the survey  
Cross-cultural adaptation of the current survey will be undertaken in order to examine 
the prevalence, nature and impact of PsA in the foot for implementation in different 
countries. The research team have undertaken preliminary work to identify potential 
participating sites through clinical networks in other countries, which include New 
Zealand, Singapore, Spain and the UK. Survey data collection in a number of different 
countries worldwide will identify important differences in climate, culture and 
healthcare delivery that may alter the patient experience of foot problems in PsA. 
Cross-cultural research involving survey data collection requires specific 
methodological practices to ensure that the instrument maintains the meaning and 
intent of the original items, while also being culturally relevant and comprehensible to 
participants in the target country population. Successful data collection in other 
countries will provide a comparable data set to determine key factors influencing foot 
health and daily functioning, and will build a bank of international survey data on the 
foot in PsA. 
9.9.4 Development of a PsA foot-specific patient-reported outcome measure  
Development and validation of a PsA-specific patient-reported outcome measure to 
assess foot involvement will allow the clinical measurement of site-specific disease 
impact and evaluation of the efficacy of foot care interventions in PsA. A core-set of 
foot-specific domains will be established from the current conceptual framework and 
survey data to inform instrument development. Future work may be to develop an 
online application software programme (App) for the patient-reported foot-specific 
outcome measure in PsA where certain responses would trigger recommendations for 
a consult and assessment with a rheumatologist and/or podiatrist.  
9.9.5 Integrated assessment of PsA-related foot involvement with combined 
clinical examination, ultrasound imaging of local inflammatory features and 
biomechanical analysis of foot function  
Clinical validation of proposed statistical models using objective measures will be 
warranted. To better understand the underlying inflammatory and biomechanical 
mechanisms that influence disease persistence in the foot in PsA, an integrated 
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approach to assessment is required. Future studies will combine the assessment of 
clinical and gait metrics with ultrasound imaging to detect local inflammatory disease 
in the foot. A core-set of reliable foot-specific measures will need to be established in 
order to inform the standardised assessment of the foot in PsA. The relative 
contribution of site-specific involvement will be determined by categorising people 
with PsA according to clinical disease sub-groups, with focus on functional entheses 
as prime targets for localised disease in the foot. Whilst such investigations have led 
to paradigmatic changes to therapeutic approaches to foot disease management in RA, 
these future studies represent unique strategies applied in PsA. Findings will help to 
inform future prospective studies and targeted PsA-specific intervention research for 
foot involvement. 
 
9.10 Conclusion  
The qualitative research provided in-depth insight into foot involvement in PsA from 
the patient perspective and revealed its profound and far-reaching impact on daily life, 
which was translated into the universal language of the ICF. Combined with health 
professional and expert opinion this formed the basis to robustly develop a national 
survey, the implementation of which provided a detailed description of PsA in the foot 
and a rich data set to support ongoing research at a post-doctoral level. The survey 
protocol presents a robust template that could be used in other diseases or anatomical 
region-specific studies. Survey findings will form the basis for future intervention-
based studies and outcome measure development in order to improve the patient 
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Health District (SSA/18/HAWKE/78, access request RESP/19/066); Western Sydney 
University Human Research Ethics Committee (H12973, H10299); Auckland 
University of Technology Ethics Committee (AUTEC 17/320); and Waitemata 
District Health Board of Auckland, New Zealand (RM/3907). Written informed 














































































































































































































Appendix 2: Participant consent forms, information sheets 
and data collection forms 
Site names were added as per site specific agreement to each of the following forms: 
 
 
[Insert Site Name] 
CONSENT FORM 
Interviews of people with psoriatic arthritis 





agree to participate in the study described in the participant information statement attached to 
this form.  
 
2. I acknowledge that I have read the participant information statement, which explains why I 
have been selected, the aims of the study and the nature and the possible risks of the 
investigation, and the statement has been explained to me to my satisfaction.  
 
3. Before signing this consent form, I have been given the opportunity of asking any questions 
relating to any possible physical and mental harm I might suffer as a result of my participation 
and I have received satisfactory answers.  
 
4. I understand that I can withdraw from the study at any time without prejudice to my relationship 
with the [insert site] 
  
5. I acknowledge that the information obtained in this study will be used as part of the 
development of the self-administered patient survey. I agree that research data gathered from 
the results of the study may be published, provided that I cannot be identified.  
 
6. I understand that if I have any questions relating to my participation in this research, I may 
contact Kate Carter on telephone +61 0410 855 915, who will be happy to answer them.  
 
7. I acknowledge receipt of a copy of this Consent Form and the Participant Information 
Statement.  
 
8. I consent to the collecting of information from my medical records. 
 
9. I agree to the interview being audio recorded. I understand that all personal information will be 
kept strictly confidential and safeguarded in a password-protected file. I understand that the 
data will be analysed at Western Sydney University. 
 
10. I wish to receive a copy of the findings from this study (please tick one): 
Yes □ No □ (If yes, please state your email or postal address below) 
 
_________________________ _______________________ _______________  
Signature of participant Please PRINT name Date  
 
_________________________ _______________________ _______________  
Signature of witness Please PRINT name Date  
 
_________________________ _______________________ _______________  










[Insert Site Name] 
CONSENT FORM 
Focus groups with health professionals 





agree to participate in the study described in the participant information statement attached to 
this form.  
 
2. I acknowledge that I have read the participant information statement, which explains why I 
have been selected, the aims of the study and the nature and the possible risks of the 
investigation, and the statement has been explained to me to my satisfaction.  
 
3. Before signing this consent form, I have been given the opportunity of asking any questions 
relating to any possible physical and mental harm I might suffer as a result of my participation 
and I have received satisfactory answers.  
 
4. I understand that I can withdraw from the study at any time without prejudice to my relationship 
with the [insert site] 
  
5. I acknowledge that the information obtained in this study will be used as part of the 
development of the self-administered patient survey. I agree that research data gathered from 
the results of the study may be published, provided that I cannot be identified.  
 
6. I understand that if I have any questions relating to my participation in this research, I may 
contact Kate Carter on telephone +61 0410 855 915, who will be happy to answer them.  
 
7. I acknowledge receipt of a copy of this Consent Form and the Participant Information 
Statement.  
 
8. I agree to the focus group being audio recorded. I understand that all personal information will 
be kept strictly confidential and safeguarded in a password-protected file. I understand that the 
data will be analysed at Western Sydney University.  
 
9. I wish to receive a copy of the findings from this study (please tick one): 
Yes □ No □ (If yes, please state your email or postal address below) 
 
_________________________ _______________________ _______________  
Signature of participant Please PRINT name Date  
 
 
_________________________ _______________________ _______________  
Signature of witness Please PRINT name Date  
 
 
_________________________ _______________________ _______________  








Participant Information Sheet 
Interviews of people with psoriatic arthritis 
Health/Social Science Research  
[Insert Site Name] 
 
Title  The nature, extent and localisation of foot problems in people 
with psoriatic arthritis. 
Protocol Number  Protocol Version 1.0 
Co-Investigators [Insert Investigators] 
Principal Investigator [Insert Investigators] 




You are invited to take part in this research project, which is called the nature extent and 
localisation of foot problems in people with psoriatic arthritis. You are invited to participate in 
this study because you have psoriatic arthritis and foot problems and are attending the 
Rheumatology Clinic at [Insert Site Name]. We wish to know more about your experiences of 
foot problems and how they impact on your life.  
 
This Participant Information Sheet and the Consent Form tells you about the research project. 
It explains the processes involved with taking part. Knowing what is involved will help you 
decide if you want to take part in the research. 
 
Please read this information carefully. Ask questions about anything that you don’t understand 
or want to know more about. Before deciding whether or not to take part, you might want to 
talk about it with a relative, friend or local health worker. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. If 
you decide you want to take part in the research project, you will be asked to sign the consent 
section. By signing it you are telling us that you: 
• Understand what you have read 
• Consent to take part in the research project 
• Consent to be involved in the research described 
• Consent to the use of your personal and health information as described. 
 
You will be given a copy of this Participant Information Sheet to keep. 
 
2. What is the purpose of this research? 
 
The objective of this study is to interview people with psoriatic arthritis to gain insight and 
understanding into their experience of foot problems and the impact of these problems on life 
and daily activities. 
 
The purpose of this study is to find out about the foot problems experienced by people with 
psoriatic arthritis. The information from the interview will be used to inform the development of 
a survey to find out about the foot problems experienced by a much larger group of people 
with psoriatic arthritis in Australia, New Zealand and Singapore. The results of this research 
will be used by the researcher Miss Kate Carter to obtain a Doctor of Philosophy [PhD] degree. 
 
Little is known about the prevalence of foot problems in this patient group and most of our 
knowledge comes from studies done in Europe. We wish to better understand foot problems 
in this patient group by developing a survey that will be completed by a large group of people 









work will lead to more effective assessment and treatment of psoriatic arthritis-related foot 
problems in the future. 
 
The study has been initiated and will be conducted by the researcher, Miss Kate Carter, from 
the School of Health and Science at Western Sydney University, together with the Division of 
Rheumatology at [Insert Site Name]. 
 
3. What does participation in this research involve? 
 
To take part in this study you should be over 20 years old, have psoriatic arthritis and have 
experience of past or present foot problems. If you decide to take part in the study, the 
researcher will confirm your eligibility to take part in the study using the screening information 
provided. If the screening form shows that you meet the requirements and you agree to 
participate, then you will be enrolled in the study. If you do not meet the criteria on the 
screening form, we will regretfully be unable to include you in this study. 
 
Your participation in the study will involve taking part in an interview to talk about your 
experiences of foot problems related to your psoriatic arthritis and how it impacts on your life. 
Before you begin the interview you will be asked to complete a questionnaire about your foot 
health. Additional information will be collected by looking through your medical records, this 
will include age, gender, ethnicity, body mass index, occupation, duration of psoriatic arthritis, 
disease activity measures and current medications. In the interview you will be asked 
questions about your foot health, footwear, how foot problems may affect your daily activities 
and about previous treatments you may have received for your feet. 
 
The interview will be audio recorded to help with data analysis. The audio recording will be 
transcribed and during this process participants will be de-identified ensuring anonymity during 
data analysis. The data will be used to develop a survey to evaluate foot problems and their 
associated impact in a large group of people with psoriatic arthritis. This research project has 
been designed to make sure the researchers interpret the results in a fair and appropriate way. 
 
Approximately 18 patients will be taking part in this study. This research project will take place 
between November 2017 and February 2018. Your participation in the study will take 
approximately 60 minutes of your time on one occasion. The study will be conducted at [Insert 
Site Name]. There are no costs associated with participating in this research project, nor will 
you be paid. 
 
4. Other relevant information about this research project 
 
We will be conducting interviews at [Insert Site Name] and at [Insert Site Name]. This will allow 
us to collect local data that will be used to inform the content of the survey that will be 
completed by a large group of people with psoriatic arthritis in Australia, New Zealand and 
Singapore. 
 
5. Do I have to take part in this research project? 
 
Taking part in this study is voluntary. If you do not wish to take part, you do not have to. If you 
decide to take part and later change your mind, you are free to withdraw from the project at 
any stage. Your decision on whether to participate or not will not affect your treatment or 
medical care at [Insert Site Name]. If you decide to take part, you will be given this Participation 







6. What are the possible benefits of taking part? 
 
There will be no clear benefit to you from your participation in this research. However, by 
improving our understanding foot involvement in people with psoriatic arthritis, future patients 
may be able to receive better assessments and treatments. In addition, by finding out about 
the epidemiology of foot complaints and the impact they have on patient’s lives, 
rheumatologists and podiatrists will have a better awareness of how people with the disease 
are affected. 
 
7. What are the possible risks and disadvantages of taking part? 
 
There will be no risks or side effects from the interview carried out in this study. If you 
experience any distress during the interview, please inform the researcher and the interview 
will be discontinued.  
 
8. What if I withdraw from this research project? 
 
If you decide to leave the research project, the researchers will not collect additional personal 
information from you, although personal information already collected will be retained to 
ensure that the results of the research project can be measured properly and to comply with 
law. You should be aware that data collected up to the time you withdraw will form part of the 
research project results.  If you do not want your data to be included, you must tell the 
researchers when you withdraw from the research project. 
 
9. What happens when the research project ends? 
 
If you decide to participate, you will be told of any important information that is learnt from the 
study, which might affect your assessment and management of this patient group. If you wish 
to receive feedback on the result of this research please indicate yes on the applicable section 
in the consent form, and then the results will be sent out to you in the form of a written 
summary. Any published work will be accessible upon request. 
 
10. What will happen to information about me? 
 
By signing the Consent Form, you consent to the research team collecting and using personal 
information about you for the research project. Any information obtained in connection with 
this research project that can identify you will remain confidential.  
 
Your information will only be used for the purpose of this research project and it will only be 
disclosed with your permission, except as required by law. The personal information that the 
research team collect and use will be your personal information and information from the 
interview. 
 
It is anticipated that the results of this research project will be published and/or presented in a 
variety of forums. In any publication and/or presentation, information will be provided in such 
a way that you cannot be identified, except with your express permission.   
 
Each participant will be allocated an identifying code under which all data will be recorded. 
This will ensure that anonymity is achieved during data analysis and any future publications. 
The data from the study will be stored electronically on a secure server, which can only be 
accessed by the study investigators. 
 
In accordance with relevant Australian, New Zealand and/or [Insert State/Territory of Site] 
privacy and other relevant laws, you have the right to request access to the information 
















any information with which you disagree be corrected. Please inform the research team 
member named at the end of this document if you would like to access your information. 
 
11. Who is organizing and funding the research? 
 
The research is being conducted by Miss Kate Carter, a PhD student at Western Sydney 
University. This study has no sponsor and no source of funding. You will not be paid to 
participate in this research study.  
 
12. Who has reviewed the research project? 
 
All research in Australia involving humans is reviewed by an independent group of people 
called a Human Research Ethics Committee (HREC). The ethical aspects of this research 
project have been approved by the HREC of [Insert Site Name]. This project will be carried 
out according to the National Statement on Ethical Conduct in Human Research (2007). This 
statement has been developed to protect the interests of people who agree to participate in 
human research studies. 
 
13. Further Information and who to contact 
The person you may need to contact will depend on the nature of your query. For further 
information about this study you may contact the primary researcher Kate Carter. 
 
Research contact person 
 
14. Complaints contact person 
The conduct of this study at [Insert Hospital Name] has been authorised by the South Western 
Sydney Local Health District, any person with concerns or complaints about the conduct of 
this study may also contact the Research Governance Officer on (02) 8738 8304, email: 
research.support@sswahs.nsw.gov.au and quote project number [xx/xxx] 
 
 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 
This information sheet is for you to keep. 
Name Kate Carter 
Position PhD student at Western Sydney University  










Participant Information Sheet 
Focus groups with health professionals 
Health/Social Science Research  
[Insert Site Name] 
 
Title  The nature, extent and localisation of foot problems in people 
with psoriatic arthritis. 
Protocol Number  Protocol Version 1.0 
Co-Investigators [Insert Investigators] 
Principal Investigator [Insert Investigators] 




You are invited to take part in this research project, which is called the nature extent and 
localisation of foot problems in people with psoriatic arthritis. Thank you for responding to our 
email. You have been invited because we are looking for health professionals with past or 
current experience of managing people with psoriatic arthritis and foot problems. Your contact 
details were obtained from the consultant rheumatologist [insert name, at insert site name] 
and co-investigator [insert name, at insert site name].   
 
This Participant Information Sheet and the Consent Form tells you about the research project. 
It explains the processes involved with taking part. Knowing what is involved will help you 
decide if you want to take part in the research. 
 
Please read this information carefully. Ask questions about anything that you don’t understand 
or want to know more about. Before deciding whether or not to take part, you might want to 
talk about it with a relative, friend or local health worker. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. If 
you decide you want to take part in the research project, you will be asked to sign the consent 
section. By signing it you are telling us that you: 
• Understand what you have read 
• Consent to take part in the research project 
• Consent to be involved in the research described 
• Consent to the use of your personal and health information as described. 
 
You will be given a copy of this Participant Information Sheet to keep. 
 
2. What is the purpose of this research? 
 
The objective of this preliminary study is to undertake a focus group with health professionals 
involved in the management of patients with psoriatic arthritis. Health professionals including 
rheumatology nurses, podiatrists and consultant rheumatologists will be asked to share their 
knowledge and understanding of foot problems and the associated impacts experienced by 
this patient group. The information from the focus group will be used to inform the development 
of the patient survey to find out about the foot problems experienced by people with psoriatic 
arthritis in Australia, New Zealand and Singapore. The results of this research will be used by 
the researcher Kate Carter to obtain a Doctor of Philosophy [PhD] degree. 
 
Little is known about the prevalence of foot problems in this patient group and most of our 
knowledge comes from studies done in Europe.  We wish to better understand foot problems 







with psoriatic arthritis in Australia, New Zealand and Singapore. We hope that this body of 
work will lead to more effective assessment and treatment of psoriatic arthritis-related foot 
problems in the future. 
 
The study has been initiated and will be conducted by the researcher, Miss Kate Carter, from 
the School of Health and Science at Western Sydney University, together with the Division of 
Rheumatology at [Insert Site Name].  
 
3. What does participation in this research involve? 
 
To take part in this study you must be over 20 years old and have experience of or are currently 
managing patients with psoriatic arthritis. If you decide to take part in the study, the researcher 
will confirm your eligibility to take part in the study using the screening information provided 
on your invitation email. If you meet those requirements and you agree to participate, then you 
will be enrolled in the study. If you do not meet the criteria on the screening form, we will 
regretfully be unable to include you in this study. 
 
Your participation in the study will involve taking part in a focus group to talk about your 
knowledge and experience of managing patients with psoriatic arthritis-related foot problems. 
Before you begin the focus group you will be asked for some personal information including 
your age, gender, ethnicity, occupation, qualifications and the number of years of experience 
you have managing people with psoriatic arthritis. In the focus group you will be asked 
questions about your experience and perspectives on the following items relating to patients 
with psoriatic arthritis: foot health, footwear, impact of foot problems on daily activities and 
emotional health, foot assessments and foot care.  
 
The focus group discussion will be audio recorded to facilitate data analysis. The audio 
recording will be transcribed and during this process participants will be de-identified ensuring 
anonymity during data analysis. The data will be used to develop a survey to evaluate foot 
problems and their associated impact in a large group of people with psoriatic arthritis. This 
research project has been designed to make sure the researchers interpret the results in a fair 
and appropriate way. 
 
Approximately 6 to 8 health professionals will be taking part in this focus group. You will have 
until the end of October to decide whether or not you would like to participate in this study. 
This research project will take place between November 2017 and February 2018. You will be 
contacted during this period to arrange a suitable date and time for the focus group, which will 
take approximately 60 minutes of your time on one occasion. The study will be conducted at 
[Insert Site Name]. There are no costs associated with participating in this research project, 
nor will you be paid. 
 
4. Other relevant information about this research project 
 
We will be conducting two focus groups, one at [Insert Site Name] and one at [Insert Site 
Name]. This will allow us to collect local data that will be used to inform the content of the 
survey that will be completed by a large group of people with psoriatic arthritis in Australia, 
New Zealand and Singapore. 
 
5. Do I have to take part in this research project? 
 
Taking part in this study is voluntary. If you do not wish to take part, you do not have to. If you 
decide to take part and later change your mind, you are free to withdraw from the project at 
any stage. Your decision on whether to participate or not will not affect your employment or 
relationship with your manager. If you decide to take part, you will be given this Participation 







6. What are the possible benefits of taking part? 
 
There will be no clear benefit to you from your participation in this research. However, by 
improving our understanding foot involvement in people with psoriatic arthritis, future patients 
may be able to receive better assessments and treatments. In addition, by finding out about 
the epidemiology of foot complaints and the impact they have on patient’s lives, 
rheumatologists and podiatrists will have a better awareness of how people with the disease 
are affected. 
 
7. What are the possible risks and disadvantages of taking part? 
 
There will be no risks or side effects anticipated from the focus group carried out in this study. 
Whilst all care will be taken to maintain privacy and confidentiality, you may experience 
embarrassment if one of the group members were to repeat things said in a confidential group 
meeting. If you experience any distress during the focus group, please inform the study 
investigator and the discussion will be discontinued.  
 
8. What if I withdraw from this research project? 
 
If you decide to leave the research project, the researchers will not collect additional personal 
information from you, although personal information already collected will be retained to 
ensure that the results of the research project can be measured properly and to comply with 
law. You should be aware that data collected up to the time you withdraw will form part of the 
research project results.  If you do not want your data to be included, you must tell the 
researchers when you withdraw from the research project. 
 
9. What happens when the research project ends? 
 
If you decide to participate, you will be told of any important information that is learnt from the 
study, which might affect your assessment and management of this patient group. If you wish 
to receive feedback on the result of this research please indicate yes on the applicable section 
in the consent form, and then the results will be sent out to you in the form of a written 
summary. Any published work will be accessible upon request. 
 
10. What will happen to information about me? 
 
By signing the Consent Form, you consent to the research team collecting and using personal 
information about you for the research project. Any information obtained in connection with 
this research project that can identify you will remain confidential.  
 
Your information will only be used for the purpose of this research project and it will only be 
disclosed with your permission, except as required by law. The personal information that the 
research team collect and use will be your demographic personal information and information 
from the focus group interview. 
 
It is anticipated that the results of this research project will be published and/or presented in a 
variety of forums. In any publication and/or presentation, information will be provided in such 
a way that you cannot be identified, except with your express permission.   
 
Each participant will be allocated an identifying code under which all data will be recorded. 
This will ensure that anonymity is achieved during data analysis and any future publications. 
The data from the study will be stored electronically on a secure server, which can only be 

















In accordance with relevant Australian, New Zealand and/or [Insert State/Territory of Site] 
privacy and other relevant laws, you have the right to request access to the information about 
you that is collected and stored by the research team. You also have the right to request that 
any information with which you disagree be corrected. Please inform the research team 
member named at the end of this document if you would like to access your information. 
 
11. Who is organizing and funding the research? 
 
The research is being conducted by Miss Kate Carter, a PhD student at Western Sydney 
University. This study has no sponsor and no source of funding. You will not be paid to 
participate in this research study.  
 
12. Who has reviewed the research project? 
 
All research in Australia involving humans is reviewed by an independent group of people 
called a Human Research Ethics Committee (HREC). The ethical aspects of this research 
project have been approved by the HREC of [Insert Site Name]. This project will be carried 
out according to the National Statement on Ethical Conduct in Human Research (2007). This 
statement has been developed to protect the interests of people who agree to participate in 
human research studies. 
 
13. Further Information and who to contact 
The person you may need to contact will depend on the nature of your query. For further 
information about this study you may contact the primary researcher Kate Carter. 
 
Research contact person 
 
14. Complaints contact person 
The conduct of this study at [Insert Hospital Name] has been authorised by the South Western 
Sydney Local Health District, any person with concerns or complaints about the conduct of 
this study may also contact the Research Governance Officer on (02) 8738 8304, email: 
research.support@sswahs.nsw.gov.au and quote project number [xx/xxx] 
 
 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 
This information sheet is for you to keep. 
Name Kate Carter 
Position PhD student at Western Sydney University  




































































Hospital Anxiety and Depression Scale (HADS) 
 
Instructions: Emotions can affect how we experience pain. Read each item and circle the 
reply that comes closest to how you have been feeling in the past week. Don’t take too long 
over your replies: your immediate reaction is best.  
 
I feel tense or ‘wound up’:  A   I feel as if I am slowed down:  D  
Most of the time  3   Nearly all of the time  3  
A lot of the time  2   Very often  2  
Time to time, occasionally  1   Sometimes  1  
Not at all  0   Not at all  0  
     
I still enjoy the things I used to enjoy:  D   I get a sort of frightened feeling like 
‘butterflies in the stomach’:  
A  
Definitely as much  0    Not at all  0  
Not quite so much  1    Occasionally  1  
Only a little  2    Quite often  2  
Not at all  3    Very often  3  
     
I get a sort of frightened feeling like 
something awful is about to happen:  
A   I have lost interest in my 
appearance:  
D  
Very definitely and quite badly  3   Definitely  3  
Yes, but not too badly  2   I don’t take as much care as I should  2  
A little, but it doesn’t worry me  1   I may not take quite as much care  1  
Not at all  0   I take just as much care as ever  0  
     
I can laugh and see the funny side of 
things:  
D   I feel restless as if I have to be on 
the move:  
A  
As much as I always could  0    Very much indeed  3  
Not quite so much now  1    Quite a lot  2  
Definitely not so much now  2    Not very much  1  
Not at all  3    Not at all  0  
     
Worrying thoughts go through my 
mind:  
A   I look forward with enjoyment to 
things:  
D  
A great deal of the time  3   A much as I ever did  0  
A lot of the time  2   Rather less than I used to  1  
From time to time but not too often  1   Definitely less than I used to  3  
Only occasionally  0   Hardly at all  2  
     
I feel cheerful:  D   I get sudden feelings of panic:  A  
Not at all  3    Very often indeed  3  
Not often  2    Quite often  2  
Sometimes  1    Not very often  1  
Most of the time  0    Not at all  0  
     
I can sit at ease and feel relaxed:  A   I can enjoy a good book or radio or 
TV programme:  
D  
Definitely  0   Often  0  
Usually  1   Sometimes  1  
Not often  2   Not often  2  














































Example of cognitive interview script  
 
 The purpose of this interview is to find out how easy it is for you to complete the 
survey and how relevant the questions are to you. 
 You will be asked to read and answer the survey questions one by one and then 
answer questions about what you think of the survey instructions and questions. 
 The information you provide in the interview will be used to correct any errors in 
order to ensure that the survey is clear to understand, straightforward to 
complete and that it asks questions about what is important and relevant to you. 
 There are no right and wrong answers to the question and please do not worry 
about criticising the survey as it will only improve it. 
 
Survey Introduction  
 
Do you think the introductory statement is easy or hard to follow [Comprehension]? 
 
Do you have any particular comments or suggestions about the introduction 
[General probe]? Introduction 
 
Section 1 About who you see 
 
Can you tell me, in your own words, what the instructions are asking you to do 
[Interpretation]? Q1 and 2 
 
Do you have any particular comments or suggestions about this part of the survey 
[General probe]? Section1 About who you see 
 
Section 2 About you 
 
Do you find it easy or hard to answer the general questions about you in this section 
[Comprehension]? Do you think anything is missing? Q3 to 8 
 
Do you think that the answers you can choose from allow you to answer the 
questions in the way that you want [Response]?  Do you think anything is missing? 
Q 9, 10, 11 and 12. 
 
Do you find this question easy or hard to answer [General probe]? Q13 
What do the words ‘anxiety’ and ‘depression’ mean to you [Interpretation]? Q14 
 
How does answering this question make you feel? For example, happy or sad 
[Specific probe]? Q14 
 
Can you tell me, in your own words, what the instructions are asking you to do 
[Interpretation]? Q15 
 
How confident are you that you can remember how many times you fell over the 
past 12 months?  On a scale of one (not at all confident) to seven (extremely 
confident) [Judgement]?  Q15 
 
Do you have any particular comments or suggestions about this part of the survey 





Section 3 About your psoriatic arthritis 
 
Is it easy or hard for you to remember when your symptoms first started [Recall]? 
Q16 
 
Is it easy or hard for you to remember when you received a diagnosis of your 
condition [Recall]? Q17 
 
Do you think that the response options allow you to answer the questions in the way 
that you want [Response]? Would you prefer to put a date instead? Q16 and 17 
 
Do you think the order of these two questions should be reversed? Q16 and 17 
 
How confident are you that you can remember your medications? On a scale of one 
(not at all confident) to seven (extremely confident) [Recall, confidence] Q18 
 
Do you feel confident answering this question? [Confidence]? Q19 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]?  Q19 
 
Can you tell me, in your own words, what the instructions are asking you to do 
[Interpretation]? Q20 
 
Do you think the instructions are easy or hard to follow [Comprehension]? Q20 
 
How confident are you that you could record the correct location of your body pain 
on the diagram? [Confidence] Q20 
 
How else would you like to record your body pain [Specific probe]? Can you think 
of a better way? [Specific probe]? Q20 
 
What does the term ‘all the ways that your PSORIASIS and ARTHRITIS affects 
you’, ‘all the ways that your PSORIASIS affects you’ and ‘all the ways that your 
ARTHRITIS affects you’ mean to you? [Interpretation, comprehension] Q21  
 
How confident are you that you can remember how much pain you have had over 
the past week? On a scale of one (not at all confident) to seven (extremely 
confident) [Recall, confidence] Q21 
 
Is this question relevant to you [General probe]? Q22 
 
Do you think you can remember how long the stiffness in your joints last for in the 
morning over the past week [Recall]? Q22 
 
Is it easy or hard to follow the skip instruction [Comprehension]? Q22 
 
Do you have any particular comments or suggestions about this part of the survey 







Section 4 About your feet 
How confident are you that you can remember if you have ever had pain in your feet 
and ankles which lasted for one day or longer [Recall]? Q23 
 
Do you feel that the timescale of this question is appropriate [Specific probe]? Q23 
 
Is it easy or hard to follow the skip instruction [Comprehension]? Q23 
 
Do you think you can remember if you have had pain over the past month your feet 
and ankles which lasted for one day or longer [Recall]? Q24 
 
Do you feel that the timescale for asking about your foot pain is appropriate 
[Specific probe]? Q24 
 
How confident are you that you are able to mark accurately where you have or had 
experienced pain on the diagram?  On a scale of one (not at all confident) to seven 
(extremely confident) [Judgement]? Q24 
 
Can you show me by pointing to your feet where you have previously experienced 
pain [Comprehension, judgement]? Q24 [interviewer records on data sheet] 
 
How else would you like to record your foot pain [Specific probe]? Can you think of 
a better way? [Specific probe]? Q24  
 
Is it easy or hard for you to remember the severity of pain you have experienced 
over the past month [Recall]? Q24 (VAS) 
 
Can you repeat this question in your own words [Paraphrase]? Q25 and 26 
 
Do you think the instructions are easy or hard to follow [Comprehension]? Q27 
 
Do you think you can remember how the symptoms in your feet and ankles change 
during a typical day [Recall]? Q27 
 
What do the words ‘my feet are better if I keep my joints moving’ mean to you 
[Interpretation]? Q27 
 
What do the words ‘randomly change’ mean to you [Interpretation]? Q27 
 
Do you think that the answers you can choose from allow you to answer the 
questions in the way that you want [Response]?  Q27 
 
Do you think that any of the questions are repetitious? Please indicate the questions 
you think are and why [Repetition]. Q27  
 
How comprehensive do you think this section is with asking about pain in the feet 
and ankles? On a scale of one (not at all comprehensive) to seven (extremely 
comprehensive) [Judgement]? Section4 About your feet 
 
Do you have any particular comments or suggestions about this part of the survey 






Section 5 About other foot and ankle symptoms 
Do you think the instructions are easy or hard to follow [Comprehension]? Q28 
 
How confident are you that you remember the different types of symptoms you 
experience in your feet and ankles [Recall]? Q28 
 
What do the words ‘numbness, tingling or altered sensation’ mean to you 
[Interpretation]? 
 
Can you repeat this question in your own words [Paraphrase]? Q29 
 
Do you find it easy or hard to decide to what extent the symptoms in your feet and 
ankle have been troublesome [Judgement]? Q29 
 
Do you think that the question 28 and 29 are repetitious? Please suggest any 
changes [Repetition]. Q28 and 29 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Would you prefer to provide more 
details? Q30 
 
What do the words ‘deformity’, ‘crooked’, ‘bunions’ and ‘sausage toe’ mean to you 
[Interpretation]? Q30 
 
Can you show me ‘the front of your foot (excluding toes)’ by pointing to it 
[Comprehension, judgement]? Q30 [interviewer records response on data sheet] 
 
How important do you think this section about other symptoms in the feet and ankles 
is to people with psoriatic arthritis? On a scale of one (not at all important) to seven 
(extremely important) [Judgement]? Section5 About other foot and ankle symptoms 
 
Do you have any particular comments or suggestions about this part of the survey 
[General probe]? Section5 About other symptoms 
 
Section 6  About your lower legs and feet skin psoriasis  
Do you think the instructions are easy or hard to follow [Comprehension]? Q31 
 
Can you show me ‘your lower legs’ by pointing to it [Comprehension, judgement]? 
Q31 [interviewer records response on data sheet] 
 
Do you think the instructions are easy or hard to follow [Comprehension]? Q32 
 
What do the words ‘skin psoriasis’ mean to you [Interpretation]? Q31 and Q32 
 
Is it easy or hard to follow the skip instructions [Comprehension]? Q32 
 
How confident are you that you can remember if you have had skin psoriasis 
affecting your feet and ankles over the past month [Recall, confidence]? Q32 
 
Do you feel that the timescale of this question is appropriate [Specific probe]? Q32 
 
How confident are you that you are able to mark accurately where you have or had 
experienced skin psoriasis on the diagram?  On a scale of one (not at all confident) 




How else would you like to record the location of your skin psoriasis on your feet 
[Specific probe]? Can you think of a better way? [Specific probe]? Q32 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Would you prefer to provide more 
details? Q32 
 
What do the words ‘thick hard skin (callus)’ and ‘splitting’ mean to you? 
[Interpretation, comprehension] 
 
Can you tell me, in your own words, what the instructions are asking you to do 
[Interpretation]? Q32 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Q32 
 
How important do you think this section about skin psoriasis affecting the feet is to 
people with psoriatic arthritis? On a scale of one (not at all important) to seven 
(extremely important) [Judgement]? Section6 About your skin psoriasis 
 
Do you have any particular comments or suggestions about this part of the survey 
[General probe]? Section6 About your skin psoriasis 
 
Section 7 About your toenails 
 
Do you think the instructions are easy or hard to follow [Comprehension]? Q33 
 
What do the words ‘toenail psoriasis’ mean to you [Interpretation]? Q33 
 
Is it easy or hard to follow the skip instructions [Comprehension]? Q33 
 
What does the term ‘toenail psoriasis affecting your life’ mean to you 
[Interpretation, comprehension]? Q33 
 
Do you feel that the timescale of this question is appropriate [Specific probe]? Q33 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Would you prefer to provide more 
details? Q33 
 
How do words like ‘embarrassed’ and ‘self-conscious’ make you feel? [Specific 
probe] Q33 
 
How will you can remember how many toenails have been affected over the past 
month [Recall]? Q33 
 
Can you tell me, in your own words, what the instructions are asking you to do 
[Interpretation]? Q33 
 
What do the words ‘pitting’, ‘ridges’, in-grown’ and ‘thick skin under the nail’ mean to 
you? [Interpretation, comprehension] Q33 
 
Do you think that the answers you can choose from allow you to answer the 




How important do you think this section about toenail psoriasis is to people with 
psoriatic arthritis? On a scale of one (not at all important) to seven (extremely 
important) [Judgement]? Section7 About your toenail psoriasis 
 
Do you have any particular comments or suggestions about this part of the survey 
[General probe]? Section7 About your toenail psoriasis 
 
Section 8 About your experiences with footwear 
 
Can you tell me, in your own words, what the instructions are asking you to do 
[Interpretation]? Q34 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Q34 
 
Is this question relevant to you [General probe]? Q34 
 
Can you tell me, in your own words, what the instructions are asking you to do 
[Interpretation]? Q35 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Q35 
 
Is this question relevant to you [General probe]? Q35 
 
Can you tell me, in your own words, what the instructions are asking you to do 
[Interpretation]? Q36 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Q36 
 
Do you think any of the items in questions 34, 35 and 36 are repetitious? Please 
suggest any changes [Repetition]. Q34, 35 and 36 
 
Can you repeat this question in your own words [Paraphrase]? Q37 
 
Do you think that any of the questions are repetitious? Please indicate the questions 
you think are and why [Repetition]. Q37 
 
What do the words ‘prescription extra-deep/wide footwear’ and ‘self-bought extra 
deep/wide footwear’ mean to you [Interpretation]? Would pictures be helpful?  Q37 
 
Can you repeat this question in your own words [Paraphrase]? Q38 
 
Do you think that the answers you can choose from allow you to answer the question 
in the way that you want [Response]? Q38 
 
Can you repeat this question in your own words [Paraphrase]? Q39 
 
How confident are you that you know that cold weather is a reason for making your 
foot symptoms better or worse [Judgement, Confidence]? Q39 
 




How confident are you that you know that hot weather is a reason for making your 
foot symptoms better or worse [Judgement, confidence]? Q40 
 
How important do you think this section about footwear is to people with psoriatic 
arthritis? On a scale of one (not at all important) to seven (extremely important) 
[Judgement]? Section8 About your experiences with footwear 
 
Do you have any particular comments or suggestions about this part of the survey 
[General probe]? Section8 About your experiences with footwear 
 
Section 9 About your feet and your daily life 
 
Can you tell me, in your own words, what the instructions are asking you to do 
[Interpretation]? Q41 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Q41 
 
Can you repeat this question in your own words [Paraphrase]? Q42 
 
Do you think the instructions are easy or hard to follow [Comprehension]? Q42 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Q42 
 
Is it easy or hard to follow the skip instruction [Comprehension]? Q42 
 
Do you think the instructions are easy or hard to follow [Comprehension]? Q43 
 
Do you think you can remember how many times you did these activities in the past 
week [Recall]? Q43 
 
Do you think the instructions are easy or hard to follow [Comprehension]? Q44 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Q44 
 
How confident are you that you can remember to what extent your feet have 
interfered with your daily activities [Judgement]? Q45 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Q45 
 
What do the words ‘embarrassment’ and ‘self-conscious’ mean to you 
[Interpretation]? Q46 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Would you prefer to provide more 
details? Q46 
 
How does answering this question make you feel? For example, happy or sad 
[Specific probe]? Q46 
 
What do the words ‘size of my foot’, ‘deformity at my ankle and heel’ and ‘swelling’ 
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mean to you [Interpretation]? Q46 
 
Can you repeat this question in your own words [Paraphrase]? Q47 
 
How confident are you that you can remember how well you have coped with your 
foot problems over the past month [Recall, confidence]? Q47 
 
How important do you think this section about how your feet affect daily activities is 
to people with psoriatic arthritis? On a scale of one (not at all important) to seven 
(extremely important) [Judgement]? Section9 About your daily activities 
 
Do you have any particular comments or suggestions about this part of the survey 
[General probe]? Section9 About your daily activities 
 
Section 10 About your foot problems and who you see 
 
Can you repeat this question in your own words [Paraphrase]?  Q48 
 
How confident are you that you can remember how much of a problem your feet 
have been over the past month [Recall, confidence]? Q48 
 
Can you repeat this question in your own words [Paraphrase]? Q49 
 
Do you think that the answers you can choose from allow you to answer the 
question in the way that you want [Response]? Q49 
 
What does the word ‘dermatologist’ and ‘pedicure’ mean to you [Interpretation]? 
Q49 
 
Can you repeat this question in your own words [Paraphrase]? Q49 
 
How confident are you that you can decide how effective the help you received has 
been [Judgement]? Q49 
 
Is it easy or hard to follow the skip instruction [Comprehension]? Q49 
 
Can you repeat this question in your own words [Paraphrase]? Q50 
 
Do you find it easy or hard to decide how effective your management of your own 
foot problems has been [Judgement]? Q50 
 
Is it easy or hard to follow the skip instruction [Comprehension]? Q50 
 
Can you repeat this question in your own words [Paraphrase]? Q51 
 
Do you feel that the timescale of this question is appropriate [Specific probe]? Q51 
 
What does the word ‘rheumatologist’ mean to you [Interpretation]? Q52 
 
Do you find this question easy or hard to answer [General probe]? Q52 to Q57 
 
How important do you think this section about who you see and how you manage 
your foot problems is to people with psoriatic arthritis? On a scale of one (not at all 
important) to seven (extremely important) [Judgement]? Section10 About your foot 




Do you have any particular comments or suggestions about this part of the survey 
[General probe]? Section10 About who you see 
 
 
End of Survey  
Would you provide your contact details in order to be invited to participate in future 
studies related to this research? 
 
Would you like the option to go back and edit or review your responses? 
 
Do you think the option to complete a separate questionnaire is burdensome? 
 
 
Overall, do you have any particular comments or suggestions about the survey 
[General probe]? 
 
Do you feel, on the face of it, that the draft survey appears to measure the problems 
you have with your feet and the impact it has on your life [Face validity]? 
 
Do you feel that the draft survey consists of a broad range of items that are all relevant, 
in their coverage, to the problems you have with your feet and the impact it has on 






















Example of focus group survey pre-testing script 
 
The purpose of this focus group will be to identify and correct as many issues and 
potential sources of error as possible with the draft survey, based on your own 
knowledge and insight.  Please read through the draft survey. Below is a list of 
questions that ask you to appraise the draft survey based on your own knowledge of 
patients with feet affected by psoriatic arthritis. The questions ask you to consider the 
acceptability of the survey in different ways; quality of the questions, anticipated 
respondent burden and clarity of instructions from the patients’ perspective. We will 
discuss as a group the problems identified and your recommendations for addressing 
the problems in each section of the draft survey.  
 
General questions to consider:  
 
1) Do you think that the wording and terminology of the items are clear?  
2) Do you feel that the response options of the items are acceptable? 
3) Can you think of any problems or issues that you might encounter as a 
patient? 
4) Do you think that the instructions are clear and that it is simple to navigate? 
5) Do you think that any of the items are repetitious? Please indicate which 
items and why. 
6) Do you think that the respondents will have the motivation, knowledge and 
ability to answer the questions?     
7) Do you feel that the items that make up the survey are meaningful to 
patients?  
8) Do you think there is sufficient coverage of items in each section?  
 
Web-based survey questions: 
 
1) Are you able to use the navigation features easily? 
2) Do you have difficulty clicking the correct radio buttons when filling out the 
grids? 
3) Is it easy or hard to scroll to see the questions? 
4) What issues do you encounter on your electronic device?  
5) Do the interactive pain diagrams perform in the way that you would like? 




Overall, do you feel, on the face of it, that the survey appears to measure the 
nature, extent, localisation and impact of psoriatic arthritis-related foot 
involvement on patients’ daily lives?   
 
Content Validity 
Overall, do you feel that the survey consists of a broad range of items that are 
all relevant, in their coverage, to the nature, extent, localisation and impact of 











Google Forms  
Google Form1: Link and examples 
https://docs.google.com/forms/d/1s0v1yndndVbIz886J7uUpskMTUjdkKtneM5nY4IcFbU/vi
ewform?edit_requested=true 
   





























Participant Information Sheet 
 
 
Project Title: The nature, extent and localization of foot problems in people with psoriatic 
arthritis. 
 
Project Summary:  
You are invited to participate in a research study being conducted by podiatry PhD student 
Kate Carter under the supervision of Professor Deborah Turner, from the School of Health and 
Science at Western Sydney University, Australia, and of Professor Keith Rome, from the 
Faculty of Health and Environmental Science at Auckland University of Technology, New 
Zealand. 
 
Foot problems are common in people with inflammatory arthritis. However, little is known about 
the nature and extent of foot problems related to psoriatic arthritis. Most of our knowledge 
comes from a few studies conducted in European countries. We wish to better understand the 
foot problems and the impact they have on daily life, footwear choice and the foot care needs 
of people with psoriatic arthritis. Findings from this study will help us understand the level of 
foot involvement in this disease and will direct future work on how to better assess and treat 
the problems. The study aim is to find out about the foot problems experienced by people with 
psoriatic arthritis in Australia and New Zealand. 
 
How is the study being paid for?  
The research is part of a PhD being undertaken at Western Sydney University. This study has 
no sponsor and no source of funding. You will not be paid to participate in this research study.  
 
What will I be asked to do? 
You will be asked to complete an online or paper-based survey. The survey will ask for some 
personal information about you such as your age, gender and ethnicity and questions related 
to your psoriatic arthritis and any foot problems you may have.  
 
To take part in this study you should be aged 18 or over, have psoriatic arthritis and live in 
Australia or New Zealand. If you agree to participate in this study, you will not need to sign a 
Participant Consent Form. Consent will be implied by returning or completing the survey. 
 
How much of my time will I need to give? 
The survey should take no more than 20 minutes to complete. 
 
What benefits will I, and/or the broader community, receive for participating? 
There will be no clear benefit to you from your participation in this research. However, by 
finding out what is important to people with psoriatic arthritis related foot problems and the 
impact they have on daily life, health professionals will have a better understanding of how 
people with the disease are affected and better assessments and treatments can be 
developed in future studies.  
 
Will the study involve any risk or discomfort for me? If so, what will be done to rectify 
it? 
There are no risks anticipated with the completion of the survey. However, if you do not want 
to answer a question, then you will have the option to proceed to the next question. If you wish 
to stop completing the survey, then you have the option to discontinue at any time.  
 
How do you intend to publish or disseminate the results? 
It is anticipated that the results of this research project will be published and/or presented in a 
variety of forums including student theses, peer-reviewed journals and conference 
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presentations. In any publication and/or presentation, information will be provided in such a 
way that the participant cannot be identified. 
 
Will the data and information that I have provided be disposed of? 
Please be assured that only the researchers will have access to the raw data you provide. 
However, your data may be used in other related projects for an extended period of time. The 
related projects include all those about foot problems affecting people with inflammatory 
arthritis and these projects may be ongoing over the next 5 years. 
 
The survey responses are anonymous and all data from the survey will be stored electronically 
on a secure server, which can only be accessed by the study investigators. If you wish to 
participate in future related studies you will have the option to provide your contact details, this 
information will be securely stored electronically but separately from the main survey data. 
Each participant will be allocated a unique identifying number under which all data will be 
recorded ensuring anonymity will be achieved during data analysis and any future publishing 
of results. 
 
Can I withdraw from the study? 
Participation is entirely voluntary and you are not obliged to be involved. If you do participate 
you can withdraw at any time by discontinuing your completion of the survey. If you do 
participate you will be unable to withdraw the information you have submitted. This is because 
the survey responses are anonymous, not including identifiable information, and therefore the 
research team will be unable to identify what responses were specifically given by you in order 
to remove them. Whatever your decision related to completion of the survey, it will not affect 
your medical treatment or your relationship with the medical staff or the organisation.  
 
Can I tell other people about the study?  
Yes, you can tell other people about the study by providing them with the researcher’s contact 
details below.  They can contact the researcher Kate Carter to discuss their participation in 
the research project and obtain the web-link for the survey or a paper-based information sheet 
and survey (with stamped addressed envelope). 
 
What if I require further information? 
Please contact Kate Carter should you wish to discuss the research further before deciding 
whether or not to participate. 
 
 
What if I have a complaint? 
If you have any complaints or reservations about the ethical conduct of this research, you may 
contact the Ethics Committee through Research Engagement, Development and Innovation 
(REDI) on Tel +61 2 4736 0229 or email humanethics@westernsydney.edu.au. 
 
Any issues you raise will be treated in confidence and investigated fully, and you will be 
informed of the outcome. The information sheet is for you to keep.This study has been 
approved by the Western Sydney University Human Research Ethics Committee. The 





Appendix 3: Supplementary data for qualitative study  
Supplementary Data Tables. Perspectives of patients and health professionals on the experience of living with psoriatic arthritis-related foot 
problems: A qualitative investigation 
 
Theme 1 – Foot and ankle structural and functional manifestations of psoriatic arthritis. Exemplars from the transcripts were identified to support 
each of the themes 
Foot and ankle 
manifestations 
Descriptions and exemplars 
Foot pain  
Quality of pain 
Severity of pain  
 
Walking with pain 
 
Unpredictable and 




localising foot pain 
 
Objectification of foot 
pain  
Foot pain descriptors included ‘sore’, ‘throbbing’, ‘sharp’, ‘burning’ and ‘aching’.  
Foot pain severity ranged from mild to ‘unbearable’ pain. Severe foot pain was described as ‘excruciating’, 
‘phenomenal’, ‘through the roof’, ‘intense’, ‘killing me’, ‘a world of pain’, ‘makes you want to cry’, ‘massive’, 
‘crawling on the floor with pain’, ‘extreme’, ‘the worst pain I have ever had’, ‘ridiculous’, ‘hurts like hell’ and 
‘absolute agony’. Sites of involvement were at the forefoot, midfoot and rearfoot. 
Foot pain was likened to walking on ‘stones’, ‘pebbles’, ‘lumps’ ‘hot rocks’, ‘the bone’ and ‘it feels like every bone 
is crushed’. 
“they are totally random” (S16), “there’s no rhyme nor reason” (S13 and S16), “it’s just such an unpredictable 
illness” (S06), “it never actually goes away, it’s always there” (S21), “it’s there all the time” (S17), “it’s underlying” 
(S02), “It’s been constant” (S10) 
Difficulty with describing and localising foot pain appeared to be related to 1) participants being unable to 
distinguish between symptoms related to the joints or the skin, 2) the fluctuating nature of symptoms or 3) the lack 
of attention given to long-standing manifestations by patients; “I can’t pin-point identify where the pain is coming 
from but the pain is there” (S10), “The joints ache but it’s hard to tell when you’ve got the um skin condition as 
well.” (S14), “It’s hard to say because it varies” (S02), “it’s just a part of me because I’ve had it for so long” (S14) 
Some participants described their pain as an entity with a separate existence or identity. The objectification of pain 
appeared to be a coping strategy by gaining control and creating a distinction between their body and the disease; 
“it’s like this thing that just doesn’t shut itself off” (S02), “I live in my body but this is something that shouldn’t be 
there…I do feel like I’m disconnected from it” (S11) 
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Sensations relating to 
temperature  
Most participants reported swelling in the feet and ankles; “My ankles both of them were double to what they were, 
really ridiculous.” (S03). Swelling was worst in hot weather; “In summer I find like my foot is quite swollen, I think 
that is because of the heat.” (S09) 
Stiffness was worst in the morning, after rest or in cold weather; “The stiffness is there” (S21), “I have to get up and 
move around because of the stiffness” (S04), “kind of stiff in the mornings” (S12) 
Some participants reported a loss of sensation in their feet. Although there were different distributions of numbness, 
it was mainly reported to affect the toes; “I do get numbness in my feet…mainly my toes um tingling and numbness.” 
(S14)  
Some participants reported sensations of cramp in the feet or lower legs at night, at rest and when walking; 
‘cramping” (S02), “goes into a bit of spasm” (S20), “I get a bit of cramp in my toes” (S19) 
“By a few hours you’re really sort of starting to feel the fatigue in your feet and the pain is coming back” (S02), “My 
feet get tired very quickly” (S21) 
“I know cold definitely affects me now” (S16), “I can wake up with it ice cold” (S21), “my feet are quite cold, they 






Midfoot deformity  
 
Toe deformities included claw, hammer, bunion, subluxation, splayed toes, joint thickening and acro-osteolysis. 
Descriptors of toe deformity included ‘angular’, ‘crooked’, ‘curled over’, ‘buckled up’, ‘notches’, ‘the bone is really 
thick’ ‘disfiguring’, ‘disjointed’, ‘scrunched up’, ‘shrunk’, ‘twisted’, ‘seized up’, ‘can’t grip with my toes’, 
‘movement has decreased’ and ‘can’t bend that joint’. Toe deformity was a commonly reported manifestation, the 
consequences of which were loss of movement and grip, and difficulty with walking and footwear.  
Deformity at the ankle and midfoot was reported by 4 participants and related to tarso-metatarsal bony remodelling 
to the dorsal midfoot, acquired flat foot deformity, subluxation of the navicular and ankle joint arthritis with 
malalignment. Descriptors of ankle and midfoot deformity included ‘rolling over’, ‘prolapsed’, ‘curving in’, ‘that bit 
there sticking out’ and ‘they’re deformed’. 
Skin and toenail 
changes 
Skin psoriasis  
 
Corns and calluses 
 
The main features of skin psoriasis on the feet included ‘soreness’, ‘itching’, ‘splitting’, ‘bleeding’, ‘dry’, ‘cracked’, 
‘deep cuts’, ‘redness’ and ‘scaly skin’. The pain related to plantar skin psoriasis was described as like ‘walking on 
broken glass’ or ‘needles’. “I can’t walk. It really stops me from functioning…at times I’ve been crawling on the 
ground to get from A to B until I went to the hospital” (S14), “The only thing that does stop me is breaks in the 




Venous skin changes 





Foot surgery  
Callus and corns were described mainly at the plantar metatarsophalangeal joints and dorsal aspects of the toes and 
were associated with a lack of fatty-padding, pressure from footwear and alterations to their walking pattern; ‘thick 
skin’, ‘painful corn’. 
Venous skin changes such as telangiectasia, haemosiderosis, varicose eczema, varicose veins and venous ulcers were 
reported to affect the lower legs, ankles and dorsum of the feet; “that’s the staining from the varicose veins” (S21) 
A few participants had experienced ulcerations and infections in their feet including cellulitis; “I have had an 
infection and um it took ages to clear up. I think it was that one [left 2nd proximal interphalangeal joint dorsal aspect] 
...Shoes rub on the joint, it does blister and can get infected” (S19) 
Toenail psoriasis descriptors included ‘thick’, ‘hard’, ‘split’, ‘break off easily’, ‘lifts up’, ‘wave shaped’, ‘painful’, 
‘psoriasis under the nail’, ‘thin’, ‘discoloured’ and ‘pitting’. When compared with fingernail psoriasis, equal 
proportions of participants felt that their fingernails (n=5) or toenails (n=5) were worse affected by psoriasis.    
Foot surgery had been performed in 3 participants including an ankle triple arthrodesis with surgical revisions, and 
tendon repairs of a tibialis posterior tendon tear and an Achilles tendon rupture. 
 
Theme 2 – The impact of foot problems on the lives of people with psoriatic arthritis. Exemplars from the transcripts were identified to support 
each of the themes 
Impact areas  Descriptions and exemplars 
Body image 
 
Skin and toenail 
change  
Foot shape change  






Male and female participants commonly felt their feet were ‘not normal’, ‘revolting’, ‘horrible’, ‘ugly’, ‘awful’ and 
‘hideous’.  
The manifestations of psoriatic arthritis including skin and toenail psoriasis, swelling and deformity were disliked by 
participants due to being visibly different to others; “I hate the way they look” (S11), “tree stumps for legs” (S02), 
“everybody’s eyes goes there.” (S01), “they look like little claws to me.” (S11), “they’ve actually got fatter or wider” 
(S03), “aesthetically it’s like always trying to cover what that front of the foot looks like” (S05) 
“I feel a bit embarrassed to walk alongside with my family members because I mean, I used to be limping.” (S10); “I’ll 
be limping around right and people will be asking me ‘what’s wrong with your feet?’…It doesn’t feel good” (S07) 
“you can’t really dress to look good” (S06), “I can’t wear open shoes” (S18), “I think that’s probably more acute for 
woman” (F05 –rheumatologist) “wearing trousers…so I cover up the legs” (S19) 
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Strategies to hide 
the appearance of 
foot problems 
Increased body weight attributed to foot pain that affected their ability to walk was associated with negative comments 
about body image; “Now look at me - big fat heap” (S04), “because of this (plantar skin psoriasis) and the arthritis you 
put a lot of weight on… Like with my ankle now I can’t exercise” (S14), “the vicious cycle” (F06 - rheumatologist) 
“I don't do much for the simple fact I get embarrassed” (S14), “I’m always wearing a closed-in shoe” (S18), “I don’t 
want to draw attention to the feet” (S19). Participants worried about people’s perceptions that they might have an 
underlying medical conditions; “I don’t want to be noticeable with these things” (S20), “they don’t want to look 














Instability and falls 
Participants described experiencing foot pain and stiffness in the mornings or after periods of inactivity such as sitting; 
“when I get out of bed um it’s extremely painful” (S17), “you’ll get up out of a chair and you’ll walk and you get this 
excruciating pain” (S16) 
Standing for longer than 5 to 20 minutes for some participants aggravated their foot symptoms. All participants who 
reported difficulty standing had rearfoot problems such as ankle arthritis, ankle tendinopathy, plantar fasciitis or plantar 
skin psoriasis. Participants reported standing and waiting for the pain to ease before initiating gait, weight bearing 
carefully to start, feet not working properly and taking a while to get going. Other participants reported that foot pain 
intensified with sitting and after periods of activity; “if I sit down that’s when my feet start to hurt” (S11). Participants 
reported shifting weight from one foot to the other and having to either keep moving or sit down. “if I stand I sort of lift 
my foot up” (S09) 
“Well when its bad you just can’t walk” (S03), “The most troublesome thing at the moment is just not being able to 
walk at a normal speed” (S12), “the longer I walk the more pain I get” (S04), “I am quite conscious that I can’t help but 
limp” (S20), “you can’t walk, you can’t run, you can’t do anything you want to do” (S21) 
Participants felt they had to take one step at a time, they had to pace themselves and be careful due to pain and 
unsteadiness. “I avoided climbing up and down stairs” (S10), “just hold onto the rails and walk slower” (S14) 
Foot pain affected foot stability for some participants who felt ‘unsteady (S09, S17)’ or ‘unstable (S16)’ on their feet or 
that they had a loss of ‘balance (S03, S19, S21)’ in their feet. Plantar skin psoriasis, numbness, a sudden flare of foot 
psoriatic arthritis and loss of foot strength were also attributed to sensations of foot instability. One participant used a 
walking stick because of foot problems (S17), but 2 participants refused to use a walking aid not wanting to look older 




















The majority of participants expressed how functional limitations meant that they could not do what they wanted to do 
in daily life and how it was ‘debilitating (S17)’, ‘interferes with life (S20)’, ‘makes life difficult (S16)’ and ‘life is 
ruined (S01)’. “I have to change my life around…I can’t do a quarter of the stuff I used to do” (S04)  
Driving was reported to be difficult because of foot pain for some participants, but for others the main problem was the 
worsening of foot pain and stiffness after driving due to prolonged sitting; “while driving is fine, it’s just after getting 
out of the car” (S07) 
Sleep functions were affected by foot pain for a few participants relating to sleep interruptions and difficulty falling 
asleep on some or most nights. For some, the bed sheets caused foot pain by putting pressure on painful toes or catching 
on split toenails, and for others foot soreness, throbbing, cramp, plantar skin psoriasis caused sleep loss. Participants 
described positioning feet carefully in bed or taking pain medication to facilitate sleep. Feelings of stress and irritability 
were a result of sleep loss; “I’ve learnt how to sleep without too much discomfort. But as I said the feet cannot even 
touch each other because it hurts” (S13), “I don’t sleep properly and that puts stress on me” (S08) 
Difficulty with self-care was related to thick psoriatic toenails being difficult to cut and toe deformities that require the 
ability to reach further; “I can’t cut my toenails…they’re quite thick now and because the toes are turned over” (S06), 
“I can’t actually look under the sole of my foot, because I can’t get the angle so you really don’t know what’s going on 
under there” (S19) 
“it makes me feel that I’m useless” (S10), “that can be embarrassing if you’re shopping…all of sudden you look down 
and there’s blood and you think no!” (S03), “Um like I feel older than I am…Like it makes me sad because I can’t do 
things but I just put up with it...I just have to deal with it.” (S09). For some, there was a strong sense of ‘losing control’ 
and “a snow-balling kind of effect” (S02) 
Social participation 
restrictions 







“my social life was ruined” (S10). Many participants felt unable to engage in social activities that required weight 
bearing and non-weight bearing for any length of time. For example, participants were unable to walk barefoot on the 
beach due to foot pain or the surgical boot, they were concerned about walking much slower than other people, taking 
too long to climb or descend stairs, being unable to dance at a wedding and with having difficulty sitting for too long in 
the car or at the cinema; “Oh very painful yep. And I can’t really go out with friends much. I really just stay at home 
yeah” (S07) 
Leisure activities were important in the context of social participation and restrictions included walking for pleasure, 
hiking, fishing and dance classes. Loss of sports activities included the gym, Pilates, swimming, aqua-aerobics, golf, 

















Fear of foot injury 
always I used to be (at the) gym, I used to play soccer, a lot of things like, I always used to be fit and active… But now 
everything is stopping me. Yeah I feel lazy.” (S01) 
“other people just don't realise they go ‘Oh yeah get over it’ you know, they don't understand how it does affect your 
life with getting up, walking, just simple things.” (S14)  
The social stigma of having skin and toenail psoriasis, toe deformity, walking differently and footwear restrictions were 
mentioned as reasons for limiting social participation. “I don’t like to go out because I hate wearing, I can’t wear some 
sort of shoes. And so I don’t really want to go out.... It’s like affected a little bit of my life but like I just have to try and 
just move on you know.” (S09) 
Weddings were frequently cited by participants and health professionals as a source of significant distress due to 
footwear restrictions as well as the expectation of dancing and prolonged standing; “if I go to a wedding...I can’t wear 
thong…I just go there and sit down there, I don’t do much. Don’t do dancing” (S01), “it’s just a nightmare for them” 
(F04 – rheumatologist)  
 “if I was in pain I would still force myself to participate” (S02) 
Exercise was considered a valued activity by some participants for the benefits of improved health and psychological 
well-being; “I want to walk because I want to stay active and fit you know. I don’t want to be you know housebound.” 
(S06). The harbouring of shame and judgement was expressed through their reluctance to attend social occasions. 
Fear of foot injury caused by themselves, others or environmental factors; “I’ve constantly got a fear of somebody um 
stepping on my feet.” (S05), “I’m absolutely petrified. It drives me nuts.” (S13). All participants who had a fear of foot 
injury described extreme levels of pain in relation to any type of physical trauma sustained to the foot; ‘unbelievably 
painful’ (S11), ‘really painful’ (S20). Injuries to the feet and hands playing sports in younger life were also described by 
some participants as a perceived cause of disease onset in later life; “I put that down to sporting injuries the same as my 
hands” (S13) 
Family life 






Walking disability interfered with planning and going on holiday with the spouse and family members for 3 
participants; “last year we went to India you know, it was a dream trip of a lifetime trip, I could not walk... the pain was 
very bad” (S10) 
For those participants with children, the impact on their ability to be a parent was a key concern. Participants referred to 
missing out on time with their children, having difficulties playing with and looking after the children and being unable 



















out on stuff for them.” (S11).  The selfless nature of being a parent served as a coping strategy for a few women, who 
focused their attention on their children and away from their foot pain and disease. 
Fear for the future was also associated with being worried about their children inheriting the disease, which was 
described by participants and by the health professionals; “it will limit my mobility, that’s more of a concern than the 
pain really. Or it’s more kind of …upsetting or frightening I guess (S12 – having newborn baby)   
The proactive choice not to engage in an intimate relationship and not to have children (to spare them the possibility of 
inheriting the disease) was reported by one female participant (S05).  
Participants avoided talking about their foot pain and condition because of a perceived lack of understanding about the 
disease by close family members; “you get sick and tired of justifying why you’re not getting better” (S16) 
Having family members with IA conditions served as a point of comparison in terms of symptom severity and disease 
course, which appeared to have a positive influence on coping skills such as stoic attributes, acceptance and motivation; 
“my son has got skin psoriasis, he was covered in it and his nails are in a worse state than mine.” (S19), “my whole 
family like my mum, my dad, my brothers and sisters, I am the youngest in the family and they are all nice and healthy, 
and I am the only one that got sick, and they’re all worried why this thing happened.” (S01) 
Family support included assistance with self-care (toenail and skin care, foot massage, taking shoes/socks on and off), 
allowing the participant time to rest, doing the shopping, and providing financial security. Talking with their spouse and 
close family members about their psoriatic arthritis-related foot problems and gaining their understanding was 
important for some participants; “thankfully my wife and my son they’re quite understanding. They understood the 
problem and they helped me a lot.” (S10)    
Emotions relating to family activities restrictions included sadness, helplessness, worry, frustration, depression and low 
self-worth; “sometimes I feel bad for everything, like I’m a disappointment to my wife.” (S01), “It’s sad…I was very 
much depressed” (S10) 
Some participants described trying to hide their foot pain and emotions from family members to prevent overburdening 
them; “But I like to hide my pain. I do not like to show my pain to others. I take my pain myself… I do not like to 
disturb my wife.” (S01) 
Participants reported how family gatherings and going out with their spouse to a restaurant or social event had 
interfered with existing coping strategies such as pacing and planning and pain avoidance behaviour; “it’s ridiculous 































Thirteen of the twenty-one participants had either retired or ceased working due to PsA. The impact of foot problems on 
the ability to work were in relation to the nature of the occupation such as having to sit, stand, walk and use stairs or 
ladders; “I quit my job...because it’s mostly you have to stand…get on the ladder…physically get down on the 
floor…It’s very physical.” (S07 – with Achilles tendinopathy and plantar fasciitis). Some of the health professionals 
reported that their patients who were manual labourers, drove for a living or worked in the retail industry were affected 
the most by foot problems at work; “I was working in a factory…the whole day standing. So that's how it got worse you 
know.” (S01)  
 “I have to go between sitting and standing…it impacts the way I facilitate.” (S05), “if you’re sitting at the desk your 
whole body starts ceasing up…the feet also play up the same as the rest of the body” (S16), “mainly sitting at a desk um 
there really hasn't been any work impacts” (S12), “it’s racing between the different locations” (S05) 
Whilst it was considered that some employers were willing to make workplace adaptations to enable individuals at 
work, most felt that employers were unsympathetic and lacked understanding about their disease, and thus failed to 
make work-related changes; “There’s just no recognition, understanding or acceptance at all of doing even minor 
things to modify their workplace environment to keep them at work.” (F04 – rheumatologist) 
The consequence of that being that 6 participants had to leave the workplace entirely or try to find a less physically 
demanding job with skills that may not be transferable. Modifications requested but denied included regular breaks, 
more time in the office and a chair for sitting.  
Of the participants who were unemployed, they talked about a perceived lack of understanding by disability 
employment services and difficulty finding suitable employment; “they are pushing me hard to like go and find a job. I 
like to work. I love to work…they see me like this they think I am healthy, but the pain is there” (S01) 
Being unable to wear job-related footwear was also cited as a cause of potential job loss by one of the rheumatologists 
working in a public hospital in a lower socioeconomic area of Sydney Australia; “I know one patient…he was going to 
lose his job if he couldn’t wear the steel capped boots.” (F05 - rheumatologist)  
For female participants, they experienced difficulty with or finding suitable footwear for work pertaining to comfort, fit 
and support; “I really have to watch what shoes I wear” (S09) 
Female participants were also generally dissatisfied with footwear provision services due to limited choice of styles for 
work; “they’re not great looking shoes…how many you know suit pants am I going to be able to wear that to work 





Men and women who need to present a business-like, professional or a fashionable look were mentioned by health 
professionals as having difficulties with work footwear aesthetics; “supportive footwear may not have the appearance 
that that individual wants for certain things like their work role” (F02 – rheumatologist) 
One participants expressed relief in finding a comfortable shoe provided by an orthopaedic service in Auckland New 
Zealand, which enabled her to continue working in her retail job; “…getting shoes that are comfortable…that made a 
huge difference because I was in a job that was standing all day…” (S19 – therapeutic shoe) 
Feelings of stress, helplessness, low self-worth and frustration were also alluded to; “I don’t know what to do” (S01). 
Fear of discrimination and fear of future inability to work were identified. Stress related to inconvenient medical 
appointments during working hours, taking sick leave, loss of independence and financial insecurity were reported. 
Coping with work involved strategies such as pushing yourself, pacing and planning and desire to maintain 
independence; “I don’t try to let it, like I still have to go to work and still have to do what I have to do. I just try and do 
less of it. Like I try and rest in between… but some days I can’t keep pushing myself to go and do it. So yeah that’s a 
bit hard but I manage” (S09) 
For 2 participants the non-disclosure of their disease and foot functional limitations to work colleagues and managers 
was of personal importance; “you try to keep everything a secret especially people that you worked with. Because you 
know you don’t want to be discriminated against” (S05), “I don’t tell anyone at work like it’s really sort of 
gossipy…and I just don’t want to be a part of that” (S11) 
 
Theme 3 – Mediating factors that influenced the severity of impact from foot problems on the lives of people with psoriatic arthritis. Exemplars 
from the transcripts were identified to support each of the themes 
Mediating 
factors 








Younger age groups were identified as experiencing a greater severity of impact from foot involvement on altered body 
image and limitations to daily activities, social and work life. Pre-existing lifestyle changes related to increasing age was 
considered to reduce disease impact; “Some of the hardest ones I’ve had to treat are the younger ones.” (F16 –
rheumatologist) 
Females experienced a greater severity of impact from foot problems on their body image and ability to find suitable 
footwear for work and social occasions compared with men; “for women it’s important” (F09 – rheumatologist), 










Polynesian ethnicities such as Mauri and Pacific Islander people were reported by the health professionals in Auckland 
New Zealand as tending to have more comorbidities and being more likely to have poor medication compliance and 
disease activity control. This appeared to reflect the nature of marginalised populations, vulnerable groups and cultural 
traits; “the comorbidities particularly diabetes with the Polynesians is quite big” (F12 – rheumatologist) 
Bigger sized feet in this ethnic group was also reported to cause a greater impact on footwear restrictions; “Steel capped 
boots for particularly Pacific Islanders that have big feet to start with…it is very difficult” (F12 – rheumatologist) 
Having a lower socioeconomic status was associated with delayed access to health care, more comorbidities and fewer 
resources (for example health insurance, income and available monies), which resulted in a greater difficulty with foot 
disease management and a greater severity of impact from foot involvement in psoriatic arthritis; “When I think about the 
ones that I’ve struggled with…I think they’re probably lower socioeconomic on average” (F16 –rheumatologist). 
Diagnostic delay of foot problems was reported by a rheumatologist working in both the public and private sector in 
Sydney Australia to be a consequence of lower socioeconomic status. 
Disease 
characteristics 









Disease characteristics such as late diagnosis, longer disease duration, an unpredictable disease course and additional 
morbidity were reported by health professionals to lead to a greater severity of impact on foot problems related to psoriatic 
arthritis. An earlier diagnosis was described by health professionals as resulting in positive disease outcomes; “I think 
earlier in the disease it’s a little bit clearer the inflammatory aspects” (F06 – rheumatologist), “in general we’re all better 
at treating and managing these problems if you get the patient early enough hopefully” (F14- rheumatologist) 
People with psoriatic arthritis receiving an earlier diagnosis were more likely to be those attending a private rheumatology 
practice, to have a higher socioeconomic status and acute inflammatory foot involvement. Whilst having a longer disease 
duration was related to more complex and established foot disease, it was also associated with positive coping strategies 
reported by participants and health professionals such as a greater degree of acceptance and adaptation; “I’m at the point 
now where I wouldn’t mind. In the past I wouldn’t have done it [wear open-shoes with toenail psoriasis].” (S02)  
Health professionals reported that disease course variability was a distinct feature of psoriatic arthritis and made it a 
difficult disease to manage; “…Whereas if you had rheumatoid arthritis with the equivalent problem you either would be 
able to play soccer or you wouldn’t be able to play soccer and you would adjust to it.” (F13 – rheumatologist) 
Having to contend with the volatility and constancy of foot symptoms as part of an unpredictable disease course was 
reported by participants to have a detrimental effect on their ability to cope and on their emotional well-being; “they come 
and go, that is the annoying part of the whole thing. If it was constant all the time I think it would be more easy to get your 
















disease and foot 
problems by 
patients 
“And I think too I’ve learnt ways around using the hands um whereas the foot I haven’t yet and I’m not sure what to do 
because you need your feet to get around” (S20), “the Achilles tendons they’re tender nearly all the time…that worries the 
hell out of me” (S13), “It is very important…when the pain is there I am just locked…I can’t drive, can’t walk, that's the 
worst thing.” (S01), “Everything else I can deal with. But it’s the psoriasis, so the psoriasis can be quite debilitating. So I 
can, if I had to trade one off for the other I’d take the sore feet and let go of the psoriasis” (S05), “it’s not something that 
you look at every day in the sense of – you know I’ve got my hands right … they’re in my face basically, I see them all the 
time, but my feet are in my shoes and you know they’re sort of down there and you know – you don’t really look at them 
so you kind of forget about them” (S02)  
Some participants revealed a lack of knowledge about their foot problems associated with psoriatic arthritis; “but that 
[metatarsalgia] of course has got nothing to do with the psoriatic arthritis or I don’t know if it does or not. I don’t know” 
(S03), "I didn't realise that this [skin psoriasis] could affect that [Achilles tendon] you know” (S13), “No I mean I’d never 
heard of psoriatic arthritis…I had no idea that could be where I was going with psoriasis” (S11) 
A lack of understanding and awareness about the disease led to diagnostic delays for some participants; “I didn’t even 
know I had arthritis in my feet…when I first started having foot problems, which was in my early 20’s, it didn’t even dawn 
on me that I should go and see a doctor…the pain was just so ridiculous…I don’t even know why I didn’t pursue it” (S02) 
Non-disclosure of foot problems by patients to the rheumatologists due to a lack of understanding about foot involvement 
led to symptoms being tolerated until they become a lot worse; “it started happening about half way through last year. 
Yeah. Well I didn't know, I just thought ‘Oh it’s the arthritis’ and it kept getting worse so I told [my rheumatologist] 
towards the end of last year and she sent me for a scan” (S014 – torn peroneal tendon) 
A few participants felt that education about their foot condition and how to maintain foot health was very important and 
one participant suggested that too much information could be detrimental; “I think education is huge, huge really is” 
(S21), “I try to do as much research as I can and look after myself as much as I can so” (S05), “I don’t know whether it’s 
better to read information or better to live in the dark sometimes” (S11), “They feel happier to understand what the 
problem is a bit better…I think that’s very powerful, um just the education about it [foot involvement]” (F14 – 
rheumatologist) 
Experiences 
with health care 
services 
 
Positive experiences with health care services, providers and interventions; “You know it’s like I’ve had the best care, the 
best doctors, the best nurses looking after me” (S05), “on the Remicade I started to notice a lessening in the pain in the 
feet, hands, everywhere…the psoriasis basically fell off me within the first 6 weeks it was gone or not gone like…so yes I 
































mean I just can’t stop talking about it” (S10), “it’s been wonderful…I wasn’t going to the rheumatologist until…one of the 
[podiatrists] suggested that I go” (S03) 
Negative experiences with health care services and suboptimal foot disease management.  
Over one third of participants (n=8) reported a delay to receiving a diagnosis of PsA, of which over half (n=5) presented at 
onset with foot problems including plantar skin psoriasis (S14), metatarsophalangeal joint synovitis (S19), ankle joint 
synovitis (S02), tibialis posterior tendinopathy (S12), plantar fasciitis (S07) and Achilles enthesitis (S07, S19). Diagnostic 
delays in those presenting at onset with foot problems were reportedly due to either 1) participants ignoring foot symptoms 
due to a lack of awareness about the disease and the connection between skin psoriasis and musculoskeletal symptoms 
(S02, S14, S19), or 2) health professionals treating it as a non-inflammatory musculoskeletal condition (S07, S12). Overall 
there was a strong sense of resentment regarding diagnostic delay, with one participant recognising the detrimental 
consequences to the severity and extent of his joint-related disability (S13).  
Diagnostic delay; “It’s harder to diagnose psoriatic arthritis… GPs don’t think about it…I think the bottleneck is the 
referring point” (F17 – rheumatologist), “I was treating it as a normal Achilles tendinitis and plantar fasciitis” (S07), “I 
think one of the difficulties that I’ve had is just finding specialists who um have seen my particular um problems or 
something like them.” (S12), “people who have psoriasis, nail disease, scalp disease, are not warned that they should be 
looking out for [psoriatic arthritis] …but the vast majority of people have never been told that.” (F14 - rheumatologist)  
Non-disclosure of foot problems to rheumatologists by patients; “The other thing about the foot pain is that people often, I 
think, don’t complain of it because we don’t specifically ask about it.” (F04 – rheumatologist), “not being able to walk on 
your feet was part of the auto-immune…I thought it was normal” (S18), “it’s just something that I tolerate and I just put up 
with it…like how much help can I truly get? ...can anything be done?” (S02), “it [the foot problem] doesn't seem to be as 
debilitating as the you know, the pain in the shoulder” (S16)  
Lack of foot examination during rheumatology consultations; “I look at what people complain about. If they don’t 
complain about their feet, I don’t look at them” (F13 – rheumatologist), “you’ve got 200 things to cover in the visit” (F04 – 
rheumatologist). 
Nearly all the rheumatologist agreed that they would not routinely ask about or assess the feet unless the patient reported 
having foot and ankle symptoms. This combined with the non-disclosure of foot problems by patients to the 

























Challenges related to foot examination; “…they can be really hard to examine” (F04 - rheumatologist). Challenges related 
to foot management; “their biologic agent has actually helped all the rest of them, but it’s done nothing much for their feet” 
(F04 – rheumatologist), “My hardest people with foot problems is usually psoriatic not rheumatoid” (F16 – 
rheumatologist), “what is the standard of care we should provide for people with inflammatory arthritis…what does the 
literature say?” (F05 – rheumatologist), “I also acknowledge that it’s just a um you know it’s a difficult condition to treat 
and assess so um yeah I understand there’s just not that many resources available” (S12) 
Multiple comments from the health professionals suggested that active foot disease persisted in many cases despite 
achieving tight control of the disease with pharmacological treatment. Minimal improvements from pharmacological 
management triggered feelings of uncertainty and frustration. 
Lack of access to podiatry services; “We don’t have a podiatry service” (F13 – rheumatologist –New Zealand), “there is a 
huge need in the public system…you need this interdisciplinary approach” (F08 – podiatrist). 
The unknown cause of foot pain and lack of access to podiatry services reinforced the reluctance to examine the feet to the 
extent where a position of non-progression was reached between the rheumatologist and patient due to the persistence of 
foot symptoms; “you don’t examine them because you and the patient kind of become co-dependent about how bad their 
feet are! And you don’t do anything about it.” (F04 - rheumatologist)  
Barriers preventing uptake of podiatry services by people with PsA were 1) lack of podiatry service provision in the public 
health system, 2) lack of referral by their GP or rheumatologist, 3) lack of understanding of the role of podiatry with the 
perception that no further care options were available, 4) low priority given to foot problems, 5) low expectations of non-
pharmacological therapy effectiveness, 6) dissatisfaction with previous podiatry care received and 7) financial constraints; 
“my thoughts of podiatry was more um you know err just clipping nails…not thinking about insoles or correcting the 
posture or anything like that (S02), “I would have thought I’d get more benefit out of having another immunosuppressant” 
(S02) 
A lack of podiatrists with specialist interest, training and knowledge in inflammatory was identified; “I may as well have 
gone and paid 20 bucks to get my toes painted” (S11)  
The high cost of podiatry care also contributed to unfulfilled expectations from expensive but ineffective treatments; 
“Private podiatrists can be very expensive, $600 not uncommon (F17 – rheumatologist) …and they’re still not better” (F16 
- rheumatologist)  
Lack of understanding about the disease; “when it first started the pain was in the pads of my feet and up the back of my 
heels...it was quite a severe pain and of course my doctor really didn’t seem to know anything much about it” (S19), 
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“Unless you see a proper skin doctor, doctors do not understand” (S14), “I’ve asked other podiatrists what that could be 
and they haven’t been able to give me an answer on it either” (S03), “I think most don’t actually bring up those fears in 
their routine consultation” (F14 – rheumatologist), “I think as clinicians we just concentrate on trying to get the disease in 
remission but we sort of don’t realise how much that has an impact on their quality of life” (F09 – rheumatologist) 
This was reinforced by receiving conflicting information from health professionals about their condition, which led to 
confusion and a loss of confidence in the quality of their health care; “Very conflicting! ...What one person says another 




Whilst lack of social support increased physical and emotional burden, supportive relationships with family, friends, 
employers and health professionals had a positive impact on functioning, participation, self-care strategies, personal 
finances and emotional well-being; “Yeah like I have heaps of support.” (S09) 
A few participants found it easier to confide in people with psoriatic arthritis; “it’s just hard to talk to anyone about it, like 









Coping strategies included stoicism, adaptation, gaining control, endurance, hope, learning, pacing and planning, adjusting 
expectations, comparison, setting goals, self-tolerance, attuning to the body, acceptance and detachment. 
Feelings relating to the impact of foot involvement included bad temper, fear, depression, embarrassment, envy, 
frustration, helplessness, stress, uncertainty and low self-worth. 
Self-care included massage, pedicure, gel insoles, use of a pumice stone and hot or cold foot baths, with a trial and error 
approach. Those with plantar skin psoriasis were amongst the most experimental, having reportedly tried a wide range of 
moisturising ointments, washes, creams and lotions. The most commonly reported self-care activities for foot pain was to 
take pain medication, to rest or to keep moving. Self-care strategies; “I’ve got them shoes for wearing around at day time – 
they are the best thing that happened to me [sketcher slip-on shoes]. They’re great.” (S04), “I lost about 12 kilos and the 
relief in my feet was great.” (S11). Although there was some knowledge about the increased risk of infection related to 
their medication, a small number of participants undertook self-care that could be considered inappropriate; “I’ve got an 
oversized pair of wire cutters believe it or not” (S13), “you name it I’ve tried it…I’ve you know, I’ve tried weeing on it 
because someone said that helps with the urea, that didn’t help that only stung like anything” (S03), “I tried them massage 
thongs and that but they’re too bad, you know the ones with the long spikes on them, but they go right through me bones 
and everything” (S08)  
Experiences 
with footwear 
Important footwear features that provided comfort and accommodation for foot and ankle manifestations of psoriatic 
































upper, ‘light weight’, easy to get on/off, ‘soft’ and ‘stretchable’ materials, ‘supportive’, ‘thick cushioning sole’ and with 
arch support or room for an insole; “the fact that you can adjust the width to suit.” (S19) 
Commonly worn footwear by the participants included Sketchers (slip-on and lace-up), slippers (indoors), thongs, Ugg 
boots, walking shoes (sneakers and sports shoes), therapeutic sandals, a surgical boot, sandals, contoured thongs and 
contoured sandals; “if I go out anywhere, I pretty well wear sketchers” (S15), “I wear sketchers and those sandals…but 
that’s all I can wear.” (S17)  
Whilst all 3 participants in Auckland New Zealand made reference to contoured sandals, one participant of 18 in Sydney 
Australia used a contoured sandal; “an orthotic type shoe” (S20), “they’re Ziera… because they do have a slight arch 
support…they’re wide and they’re comfortable and usually they’re leather and they’ve got more give (S21)” 
Enabling factors; “I am very happy with the shoes I have with the inserts (sports shoes with insole) …it’s very helpful… 
I’m quite happy the pain has sort of improved by about 75 to 80%” (S10), “I kind of get paranoid in having an open-toed 
shoe… there’s more risk of damage to your feet…so I just always go to the sneakers” (S02)  
Difficulties; “I just find it hard to wear different shoes” (S09), “I’m very limited in the type of shoes, they all have to be 
soft and it makes it difficult.” (S05), “I’ve tried a lot of shoes…they’re about the only ones I can wear” (S13 – male 
participant), “I can’t really wear any shoes that I can’t put my orthotic in and that kind of really limits you” (S06), “I can’t 
wear normal shoes.” (S21), “wherever I go its just sneakers… you’d like to be able to um have something that’s a bit 
different.” (S02) 
Sensations of pressure and tightness exacerbated foot symptoms; “tight shoe – no good” (S04), “they [toes] are twisted 
upward now, the impact that that has rubbing in my shoes makes it very very hard to find shoes” (S05). Difficulties also 
included not being able to reach to tie laces or to take shoes on and off; “I need help getting them on at the back” (S04) 
Participants reported needing to wear a shoe one size bigger than their actual foot size to improve comfort; “my foot’s got 
bigger…it’s really hard to get a shoe on my foot that’s the main, it’s not the length it’s the width” (S14) 
One participant reported that wearing a thong one size too big caused her to fall outside twice; “taking the next size gave 
more toe room…it was the shoes both times that caused the fall” (S21) 
Some participants reported having multiple pairs of the same shoe or prolonged use of a comfortable shoe. A few female 
participants reported having multiple pairs of shoes at home in their cupboards that remain unworn due to foot pain and 
altered foot shape; “I have a whole cupboard full of designer shoes that I can’t touch” (S21), “I have a massive shoe 









Female participants reported being unable to wear nice looking shoes, high-heeled shoes or shoes appropriate for the 
occasion, which also limited clothes choice; “Women are very vocal about not being about to wear high heeled shoes.” 
(F06 – rheumatologist), “They still want to conform to those social norms.” (F02 - rheumatologist), “shoes are the biggest 
problem for me” (S11) 
Female participants expressed dissatisfaction with footwear provision services, the high cost of footwear and the design of 
supportive footwear ranges; “People don't design shoes properly” (S21), “apart from being expensive to buy footwear…I 
bought some…can’t fit my foot in it” (S02), “Even some of the sports shops fit you with shoes and you go home and they 
hurt you even more than ever.” (S21) 
“By the end of the night I’m limping around like an old man of a hundred” (S04), “if I have to wear different footwear like 
then I go ‘oh nah’ I can’t go there coz I haven’t got those shoes” (S09), “you can’t go in sandals in an evening dress…so I 
just don't go.” (S21) 
“Like if I go to a wedding, funeral, club or anything I dread it! I’ve got to put socks and shoes on.” (S04), “the sizing is 
really frustrating” (S02), “not being able to wear my shoes and that sort of stuff really annoys me.”  (S11), “it’s 










More participants reported difficulties with footwear and foot symptoms worsening in warm/summer weather (n=7) due to 
hot feet, sweating and swelling; fewer reported worsening in cold/winter weather (n=5) due to cold feet, joint pain and 
enclosed shoes; “I think sometimes the weather has something to do with it. I wonder sometimes those really humid days” 
(S17), “in summer I find like my foot is quite swollen, I think that is because of the heat. Um winter is fine” (S09), “it’s 
worse in summer” (S11), “the arthritis is more active in your feet because of the winter because of the cold” (S14) 
Climate was reported by two thirds of participants (n=14) to have a minimal influence on footwear choice with the same 
style of shoe being worn all year round regardless of the season. Thongs, walking shoes (including sneakers and sports 
shoes) and sandals (including a therapeutic sandal) were worn in both summer and winter seasons by most participants; 
“Jangles all year round!” (F12 – rheumatologist in New Zealand).  
Some participants expressed a general preference to wear socks, slippers and closed-in shoes (including Ugg boots) in the 
winter and to be barefoot or in open shoes (thongs and sandals) during the summer. A few participants experienced 
difficulty wearing closed-in shoes in the summer from swelling and feet becoming too hot and conversely open shoes in 
summer hindered the ability to hide visible foot problems; “I struggle to get my shoes on in summer” (S11 - Australia) 
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Appendix 4: Conference abstracts 
 
 
EULAR 2019 Abstract 1 
Category: (b) Health Professional in Rheumatology/Practice and Research.  
Sub-category: Clinical topics by disease (21) Psoriatic arthritis. 
 
PATIENT AND CLINICIAN PERSPECTIVES USED FOR SURVEY DEVELOPMENT TO 
INVESTIGATE THE NATURE, EXTENT AND IMPACT OF FOOT PROBLEMS IN PEOPLE 
WITH PSORIATIC ARTHRITIS 
 
K. Carter1, S. Walmsley1, K. Rome2, D.E. Turner1 
1Podiatry, School of Science and Health, Western Sydney University, Sydney, Australia.  
2Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, 
New Zealand.  
 
Background: Despite recognition that hallmark features of psoriatic arthritis (PsA), such as 
enthesitis, are predominant and persistent in the foot and ankle [1], limited research has 
focused on the foot. Few published studies have used RA-specific outcome measures unlikely 
to capture the dermatological impact in PsA and there has been little incorporation of the 
patient perspective [1]. The importance of patient and clinician involvement as a central 
component of research design has been identified in PsA [2, 3], and provides a basis for 
defining what should be measured to represent comprehensively the experience of people 
with PsA-related foot problems and important domains of impact. 
 
Objectives: To develop a survey based on the views of people with PsA and clinicians on 
foot problems, their impact and the foot care needs.  
 
Methods: Interviews of people with PsA-related foot problems and focus groups with clinicians 
on their understanding of the patient experience were undertaken in Sydney, Australia and 
Auckland, New Zealand. A representative sample from public and private sector, from lower 
and higher socioeconomic geographical areas, as well as clinicians with different professional 
backgrounds was sought. Based on the themes from the qualitative interviews, previous 
research [1, 3] and clinical experience, survey items were generated by the research team 
using a consensus based approach. The survey was pre-tested using a 4-stage method that 
comprised; cognitive de-briefing of people with PsA, expert review panels of subject and 
survey design experts, cultural sensitivity assessment and pilot testing. All focus groups and 
interviews were audio-record, transcribed verbatim and survey items were revised based on 
comments made.  
 
Results: The final 60-item self-administered survey was developed based on feedback from 
each of the 4-stages, which related to wording, comprehension, timescales, content, 
repetition, number of survey items and overall survey design. Key survey domains included 
demographic (10%) and socioeconomic data (10%), global disease information (18%), foot 
and ankle characteristics (18%), and the impact of foot problems on daily life including daily 
routine, footwear choice, family life, work and accessing health care (44%). Percentage 
coverage of items directly reflects the dominant concerns of people with PsA-related foot 
problems and clinicians. Whilst priorities for clinicians included the diverse expression of 
disease and determining the nature of foot symptoms as mechanical or inflammatory, a key 
theme from patients was the psychological impact of foot involvement on daily life coupled 
with self-management strategies (coping skills, self-care activities and availability of social 
support), which was poorly recognised by clinicians. Consequently, nearly a quarter of survey 
content was dedicated to these areas of impact highlight by patients (23%). Engaging patients 
and clinicians in the survey development methods ensured that face and content validity were 
confirmed and cognitive and usability standards were achieved. 
 
Conclusions: By incorporating the views of those with the disease and of clinicians into the 

















and clinicians was achieved whilst minimising responder burden. This is the first study to 
develop a survey on foot involvement in PsA based on best practice methods in qualitative 
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EULAR 2019 Abstract 2 
Category: (b) Health Professional in Rheumatology/Practice and Research.  
Sub-category: Clinical topics by disease (21) Psoriatic arthritis. 
 
LINKING THE PATIENT EXPERIENCE OF FOOT INVOLVEMENT RELATED TO 
PSORIATIC ARTHRITIS TO THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING, 
DISABILITY AND HEALTH 
K. Carter1, C. Tannous2, S. Walmsley1, K. Rome3, D.E. Turner1 
1Podiatry, School of Science and Health, Western Sydney University, Sydney, Australia.  
2Occupational Therapy, School of Science and Health, Western Sydney University, Sydney, 
Australia. 
3Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, 
New Zealand.  
 
Background: Previous research has shown merit in linking domains of impact in psoriatic 
arthritis (PsA) to the International Classification of Functioning, Disability and Health (ICF) to 
categorise the effect of global disease [1, 2]. Localised disease predominance and persistence 
in the foot in PsA is well recognised [3], but limited foot-specific research exists and there are 
no outcome measures to comprehensively assess foot involvement and its impact in PsA. To 
date little is known about the patient experience of foot involvement and how this may link to 
the ICF to capture disease impact.  
 
Objectives: To categorise the patient experience of PsA-related foot problems by linking it 
to the ICF. 
 
Methods: Participants were recruited from rheumatology outpatient clinics in Sydney, 
Australia and Auckland, New Zealand. People with PsA were interviewed about their foot 
problems and the impact they have on daily living until qualitative data saturation. Three multi-
disciplinary focus groups were undertaken with clinicians to explore their understanding of the 
patient experience. All interviews were audio-recorded and transcribed. Codes, representing 
concepts obtained from the interviews, were linked to the most appropriate ICF category 
according to established linking rules [4]. All codes were independently linked to the ICF by 2 
investigators and a third investigator for adjudication. Investigator professional backgrounds 
included occupational therapy and podiatry.  
 
Results: Twenty-one people with PsA-related foot problems and 17 experienced clinicians 
participated. Over 100 distinct ICF categories were linked to the interview and focus group 
codes. The most represented ICF category was environmental factors (33%) followed by body 
functions (26%), activities and participation (25%) and body structure (16%). Environmental 
factors relevant to patients were shoes and assistive devices, healthcare access and climate. 
Clinicians identified a greater proportion of body functions and fewer activity and participation 
categories compared with patients, indicating a possible mismatch of key concerns. Concepts 
that could not be precisely linked to the ICF were related to coping, aspects of time and 
knowledge, consistent with previous work. Difficulties in linking highly specific information to 
categories such as sensations of pain, sensations of skin and emotional functions revealed a 
limitation in the ICFs ability to discriminate between various effects of the disease, a shortfall 
previously noted. Toenail changes were frequently cited by patients and linked to domains of 
body image and social relationships. Interdisciplinary group analysis demonstrated merit as 
differences between the predominantly medical approach by podiatry and psychosocial 
approach by occupational therapist in clinical practice led to additional ICF categories being 
identified between clinicians, which mostly related to cognitive functions.  
 
Conclusions: Despite the localised anatomical focus of this study, the effect of foot 
problems in PsA was linked to all components of the ICF, confirming the profound impact on 

















is a major limitation in defining foot disease burden. These findings offer new knowledge using 
patient and clinician perspectives that could inform the development of an instrument to 
measure the impact of foot involvement in PsA. 
 
References:  
1. Gudu T, et al. J Rheumatol. 2017;44(2):193-200. 
2. Taylor WJ, et al. J Rheumatol. 2010;37(9):1885-91. 
3. Hyslop E, et al. Ann Rheum Dis. 2010;69:928.  

























2019 Patient Experience Symposium Abstract 1 
Oral Presentation 
 
The abstract aligns with the following key words:  
 Customer empowerment: The patient voice 
 Improving our workforce: Staff and provider engagement 
 Customer empowerment: Integrated care 
Abstract 1: 
Psoriatic arthritis (PsA) can lead to marked functional impairments with involvement in the 
lower limbs including joints and tendons. Research from the UK shows that foot-related 
impairment and disability persists in a high proportion of people with PsA despite targeted 
pharmacological management.  The basis for this is poorly understood in the UK, where 
podiatry services are integrated within multidisciplinary rheumatology teams, and there is a 
lack of locally representative information on PsA-related foot involvement. The study objective 
was to explore the nature, burden and management of foot problems in people with PsA by 
interviewing patients and health professionals in Australia and New Zealand. Findings 
revealed that foot problems caused functional disability and altered body-image, which 
impacted on work, social and family life and had psychological consequences. Positive self-
management strategies and experiences with health-care was found to help reduce the 
severity of impact from foot problems. Whilst health professionals recognised the functional 
and visual impact that foot problems have on daily life, the emotional burden may be under-
appreciated. Both patients and health professionals perceived deficiencies in the diagnosis, 
assessment and treatment of foot problems. This was the first study to explore foot 
involvement from the perspective of people with PsA and health professionals in Australia and 
New Zealand. This research approach provided an in-depth insight into the experiences of 
people with PsA who live with foot problems. Future work involves generating large-scale local 
data on foot involvement in PsA needed to develop targeted disease-specific interventions. 
 
Summary of abstract 1: 
This study explored the nature, burden and management of foot problems in psoriatic arthritis 
(PsA) from the perspective of patients and health professionals in Australia and New Zealand. 
Concepts relevant and important to people with PsA-related foot problems were identified and 
the health professionals understanding of the patient experience was revealed. The impact of 
foot involvement in PsA is wide-reaching and spread across all aspects of life. Both patients 
and health professionals perceived suboptimal foot disease management from symptom 













2019 Patient Experience Symposium Abstract 2 
Oral Presentation 
 
The abstract aligns with the following key words:  
 Change for the better: Creative solutions in healthcare 
 Change for the better: Education 
 Improving our workforce: Clinical excellence 
 Customer empowerment: Integrated care 
 
Abstract 2:  
As many features of inflammatory arthritis (IA) manifest early in the feet, podiatrists have a 
prominent role in the screening, diagnosis and management of IA-related foot disease. 
International recommendations advocate integration of podiatry within rheumatology 
multidisciplinary teams (MDT) to optimise patient outcomes.  Despite widespread recognition 
of the importance of foot care, podiatry services for people with IA in Australia are not well 
embedded within the public health system. Currently, two key challenges exist 1) unmet 
demand for IA-related foot care due to inadequate provision of podiatry services within 
rheumatology MDTs and 2) lack of specialist training and knowledge across medical and allied 
health professions for the management of foot problems in IA. To ameliorate these issues, a 
monthly specialist foot clinic, delivered by a university academic centre within a private 
rheumatology MDT clinic, was piloted for 2-years. Aims were to provide expert-led podiatry 
consultations for people with IA, develop rheumatology-podiatry partnerships, rapid referral 
pathways and undergraduate podiatry training in complex foot care. Main findings were that a 
relatively high proportion of patients had previously accessed individual foot care services. 
Consequently, patient’s recognised the benefits to a comprehensive, one-stop, coordinated 
package of care. Patient’s reported having better understanding of their foot problems with 
two key objective measures providing visual representation of inflammatory (ultrasound 
imaging) and mechanical (plantar pressure) features. Disease activity detected in the foot 
informed change to pharmacological intervention or targeting of residual inflammation with 
local intra-articular injection therapy. Personalised non-pharmacological interventions for 
mechanical impairments delivered a combined therapeutic approach.  
 
Summary of abstract 2: 
To better meet the needs of people with inflammatory arthritis (IA)-related foot problems in 
Australia a specialist foot clinic was established through an academic clinical partnership and 
was piloted for 2-years. Key priorities were to provide expert-led high quality foot care, to 
facilitate knowledge transfer between professions, and to build future capacity within the 
podiatry work force with embedded university undergraduate training. Fully integrated 
rheumatology-podiatry consultations ensure compliance with international quality standards. 
Caseload data will be presented and the key take-home findings from provision of targeted 




























Appendix 5: Linking to the International Classification of 
Functioning, Disability and Health  
 
Supplementary Table 1. Examples of linking qualitative concepts to ICF categories. 
Examples of linking concepts to ICF categories: 
“Toe deformity” – s75021: Ankle joint and joints foot and toes. 
 
“Tendon problems - Achilles tendon” - s7502: Structure of ankle and foot. 
 
“Walking change – Slower” – b770: Gait pattern functions. 
 
“Daily life impact - Difficulty standing” - d4154: Maintaining a standing position. 
 
“Footwear choice – Difficulty finding shoes” – e1150: General products and 
technology for personal use in daily living. 
Examples of more than one concept being linked to an ICF category: 
Body function ICF category b28015: Pain in lower limb was linked to concepts such 
as “aching”, “burning”, “deep pain”, “dull”, “generalised pain”, “heavy pain”, 
“niggling pain”, “nagging pain”, “sharp”, “stabbing”, “stinging”, “sore”, “tender”, 
“severe”, “shooting” and “throbbing”. 
 
Body function ICF category b152: Emotional functions was linked to concepts such 
as “fear”, “embarrassment”, “envy”, “frustration”, “upset”, “distressed”, “worried”, 
“bad tempered”, “dread” and “depressed”. 
 
Environmental factor ICF category e1150: General products and technology for 
personal use in daily living was linked to concepts relating to difficulties with 
footwear characteristics such as “fit”, “heel-height”, “width”, “closed-in”, “open-
toed”, “heel counter” and “fastening”.  
Examples of more than one ICF category being linked to a concept that contains 
sub-concepts: 
“Family support with toenail cutting” - e310: Immediate family, and d5204: Caring 
for toenails. 
 
“Foot pain trigger – Walking” - b28015: Pain in lower limb, and d450: Walking. 
 
“High cost of footwear” – e1150: General products and technology for personal use 
in daily living, and e1650: Financial assets. 
 




“Work impact - Difficulty sitting for long periods” - d4153: Maintaining a sitting 
position, and d850: Remunerative employment. 
 
“Climate/Summer - Difficult wearing closed-in shoes to hide toenails” - s8301: 
Toenails, b1801: Body image, e225: Climate, and e1150: General products and 
technology for personal use in daily living.  
ICF International Classification of Functioning, Disability and Health. 
 
Accuracy of Analysis  
In total, 66 additional ICF categories were identified by the 2nd rater during the 
independent linking process. Nearly half of the additional ICF categories identified 
were from the component Body Functions (n=31, 47%), with chapter b1: mental 
function being the most represented including higher-level cognitive functions, 
temperament and personality, experience of self and time, energy and drive, and 
orientation functions. Disagreements between the raters occurred most frequently with 
the 3rd level ICF categories.  
 
The percentage total agreement (PTA) for health professional concepts and the ICF 
components ranged from a minimum of 63.8% for Activities and Participation to a 
maximum of 85.5% for Body Functions.  Similarly, with the patient concepts the PTA 
was lowest for Activities and Participation (74.9%), but highest for Body Structures 
(87.5%). Overall, for patient and health professional concepts combined, the PTA 
ranged from a maximum of 86.3% for Body Functions to a minimum of 72% for 
Activities and Participation (Supplementary Table 2). 
 
Good levels of interrater agreement were identified for the majority of ICF categories 
in relation to the linking of patient and health professional concepts, ranging from 0.62 
(95% confidence interval (CI) 0.55, 0.69) for patient concepts and the Activities and 
Participation Component to 0.79 (CI 0.72, 0.86) for patient concepts and the Body 
Structures component.  However, very good interrater reliability was identified for 
Body Functions and the patient concepts at 0.81 (CI 0.78, 0.86), while moderate 
interrater reliability was established for health professional concepts and Activities and 
Participation at 0.48 (CI 0.38, 0.58).  When patient and health professional concepts 
were combined, interrater reliability ranged from moderate to very good levels across 
the ICF components, ranging from moderate interrater reliability for Activities and 
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Participation at 0.59 (CI 0.53, 0.64) to very good for Body Functions at 0.81 (CI 0.78, 
0.85) (Supplementary Table 3).  
 
Supplementary Table 2. Percentage total agreement between two raters for concepts 
linked from health professionals, patients and overall for each of the ICF components. 












Body Structures 80.8 87.4 85.6 
Body Functions 85.5 86.5 86.3 
Activities and 
Participation 
63.8 74.9 72.0 
Environmental Factors 82.4 85.0 84.1 
ICF International Classification of Functioning, Disability and Health. 
 
Supplementary Table 3. Kappa values and 95% confidence intervals for interrater 
agreement between two raters for concepts linked from health professionals, patients 
and overall for each of the ICF components. 












Body Structures 0.71 (0.61, 0.81) 0.79 (0.72, 0.86) 0.76 (0.71, 0.82) 
Body Functions 0.70 (0.63, 0.79) 0.81 (0.78, 0.86) 0.81 (0.78, 0.85) 
Activities and 
Participation 
0.48 (0.38, 0.58) 0.62 (0.55, 0.69) 0.59 (0.53, 0.64) 
Environmental Factors 0.70 (0.60, 0.80) 0.72 (0.65, 0.79) 0.71 (0.65, 0.77) 






Appendix 6: Target sample calculation 
The estimated worldwide prevalence of PsA is 0.16% to 0.35% in the general 
population. In a total Australian population of 24.77 million, 0.16% and 0.35% of the 
general Australian population is approximately 40,000 to 80,000 people. In a total New 
Zealand population of 4.78 million, approximately 7600 and 16,700 people in the 


















































Item total = 9
Item total = 4
Item total = 12
Item total = 3
Item total = 28
Item total = 4
Item total = 5
Item total = 10
Item total = 6
Item total = 13
Item total = 11
Item total = 14
Item total = 6
Item total = 4
Item total = 6
Item total = 1
Item total = 15
Survey Draft 2
Items deleted = 4 Items added = 16
Items not revised = 4Items revised = 34
 
Figure 1 of 7. Process and outcome of the revision and refinement of the paper-based survey draft 1 based on the multidisciplinary rheumatology 





















Item total = 26
Item total = 20
Item total = 24
Item total = 5
Item total = 5
Item total = 9
Item total = 4
Item total = 14
Item total = 2
Items revised = 38 
Items added = 3
Survey Draft 3
Items deleted = 0
Items not revised = 9 
 
 
Figure 2 of 7. Process and outcome of the revision and refinement of the paper-based survey draft 2 based on cognitive interviews of people with 























Item total = 3
Item total = 7
Item total = 6
Item total = 15
Item total = 12
Item total = 4
Item total = 5
Item total = 7
Item total = 4
Items revised = 13
Survey Draft 4
Items deleted = 0 Items added = 4
Items not revised = 49
 
 

































Item total = 31
Item total = 14
Item total = 22
Item total = 12
Item total = 9
Item total = 2
Item total = 4
Item total = 5
Item total = 10
Item total = 8
Item total = 11









Item total = 16
Item total = 9
Cultural sensitivity Item total = 5
Survey re-drafting 
process
Items not revised = 22Items revised = 35
Items added = 0Items deleted = 2
Items deleted = 5 
Items revised = 28 Items not revised = 31 
Items added = 0
 
Figure 4 of 7. Process and outcome of the revision and refinement of the paper-based survey draft 4 based on cognitive interviews of people with 




by people with 
PsA of the web-
based survey 
(n=6)






Item total = 1
Item total = 9
Item total = 1
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Item total = 3
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Items revised = 7 Items not revised = 52 
Items deleted = 0 Items added = 0
 
 
Figure 5 of 7. Process and outcome of the revision and refinement of the web-based survey draft 4 based on the cognitive interviews of people 




















Item total = 5
Item total = 17
Item total = 15
Item total = 2
Item total = 10
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Item total = 1
Item total = 1
Items revised = 21 Items not revised = 38
Items deleted = 0Items added = 0
 
 






















Item total = 4
Item total = 5
Item total = 9
Item total = 10
Item total = 3
Item total = 4
Item total = 2
Survey Final Draft
Items revised = 4 Items not revised = 52
Items deleted = 3 Items added = 0
 
 
Figure 7 of 7. Process and outcome of the revision and refinement of survey draft 6 based on the subject expert review resulting in the final survey 
instrument (draft 7). Pilot testing of the paper-based survey (n=3) and the web-based survey (n=3) among people with psoriatic arthritis followed 








Question  Response Codes 
1 Where do you live? Australia = 1 
New Zealand = 2 
2 What is your post code? Post code 
3 How old are you? Years 
4 Are you male or female? 0 = male, 1 = female, 2 = 
Prefer not to state  
5 Approximately how tall are you? Feet and Inches OR cm 
6 Approximately how much do you 
weight 
Stone/lbs OR kg 
7 What is your ethnic group 1 = Australian European 
2 = English 
3 = Irish 
4 = Scottish 
5 = Italian 
6 = Lebanese 
7 = Greek 
8 = New Zealand European 
9 = German 
10 = Dutch 
11 = African 
12 = Middle Eastern 
13 = Southeast Asian 
14 = Chinese 
15 = Indian 
16 = Aboriginal 
17 = Torres Strait Islander 
18 = Maori 
19 = Pacific Islander 
20 = Other 
8 What is your current work status?  
Please tick all that apply? 
1 = In full time paid work 
2 = In part time paid work 
3 = In casual or contracted 
paid work 
4 = Completely 
retired/pensioner 
5 = Partially retired 
6 = Disabled or too sick to 
work 
7 = Self-employed 
8 = Doing unpaid work 
9 = Studying 
10 = Looking after 
home/family 
11 = Unemployed 
12 = Other (please specify 







Question  Response Codes 
9  Has your work status changed due to 
your psoriatic arthritis? 
Yes = 1 
No = 0 
Not originally coded 
10 What is your highest qualification?  
Please tick the appropriate box. 
1 = No school certificate or 
other qualifications 
2 = School or intermediate 
certificate (or equivalent) 
3 = Higher school or leaving 
certificate (or equivalent) 
4 = Trade/apprenticeship 
5 = Certificate/diploma 
6 = University degree or 
higher 
11 Do you currently see a rheumatology 
for your psoriatic arthritis? 
Yes = 1 
No = 0 
12 Approximately how long ago did your 
symptoms of PsA start? 
Years and months 
13 Approximately how long ago where you 
diagnosed with psoriatic arthritis? 
Years and months 
14 Please tick any medications that you 
are currently taking for your psoriatic 
arthritis or psoriasis 
1 = Methotrexate 
2 = Arava (Leflunomide) 
3 = Salazopyrin 
(Sulphasalazine) 
4 = Plaquenil 
(Hydroxychloroquine) 
5 = Enbrel (Etanercept) 
6 = Otezla (Apremilast) 
7 = Orencia (Abatacept) 
8 = Cyclosporin 
9 = Anti-inflammatories 
(Nurofen, Voltaren, Mobic, 
Celebrex) 
10 = Humira (Adalimumab) 
11 = Cosentyx 
(Secukinumab) 
12 = Stelara (Ustekinumab) 
13 = Remicade (Infliximab) 
14 = Simponi (Golimumab) 
15 = Cimzia (Certolizumab) 
16 = Xeljanz (Tofacitinib) 
17 = Prednisolone 
(Steroids) 
18 = Not currently taking 
any medication for my 
psoriatic arthritis or skin 
19 = Other medications for 
psoriatic arthritis or 
psoriasis not on the list 
20 = Alternative or 
complementary medicines 
15 Please mark on the diagrams below 
ALL the parts of your body where you 






Question  Response Codes 
have had any ache or pain that you 
believe is due to your psoriatic arthritis, 
which has lasted for one day or longer 




1 = pain 
2 = no pain  
16 Which part of your body has been the 
MOST painful or sore over the past 
month? Please tick ONE box only. 
1 = Head and neck 
2 = Shoulders 
3 = Elbows 
4 = Wrists 
5 = Hands and Fingers 
6 = Back 
7= Hips 
8 = Knees 
9 = Ankles 
10 = Feet and toes 
11 = Or Not sure 
12 = Unable to select only 
one 
0 = No pain  
17  In all the ways that your ARTHRITIS 
affects you, how would you rate the 
way you have felt over the past week? 
  
Please pick one number to rate the way 
you have felt. 
0 = Excellent to 10 = Poor 
11 point NRS 
18  In all the ways that 
your PSORIASIS affects you, how 
would you rate the way you have felt 
over the past week? 
0 = Excellent to 10 = Poor 
11 point NRS 
19 In all the ways that your ARTHRITIS 
and PSORIASIS, as a whole, affects 
you, how would you rate the way you 
felt over the past week? 
  
Please pick one number to rate the way 
you have felt. 
 
0 = Excellent to 10 = Poor 
11 point NRS 
20 How much PAIN have you had 
because of your psoriatic arthritis over 
the past week? 
  
Please pick one number to indicate 
how severe your pain has been. 
 
0 = Excellent to 10 = Poor 
11 point NRS 
21 Have you been diagnosed with any of 
these conditions? Please tick ALL that 
apply. 
1 = Diabetes 
2 = OA 
3 = Fibromyalgia 
4 = Anxiety 
5 = Depression 
 
 





Question  Response Codes 
in your feet and ankles that 
has lasted for one day or longer? 
0 = No 
23 IF YES, please pick one number 
to indicate how severe your foot and 
ankle pain has been over the past 
month. 
0 = No Pain to 10 = worst 
pain ever 
11 point NRS 
 
IF NO, skip to question 26.  
-998 = Skipped question 
24  Please mark on the diagrams 
below ALL the places on your feet and 
ankles where you have had any ache 
or pain that has lasted for one day or 
longer over the past month. 
Hot Spot 
Maximum 10 clicks per 
diagram 
Left and right foot - top and 
bottom 
Left and right foot – medial 
and lateral views 
Left and right foot – 
posterior view 
 
1 = pain 
2 = no pain 
-998 = Skipped question 
25 How do the symptoms (such as pain, 
ache, discomfort) in your feet and 
ankles change during a typical day? 
To what extent you agree with the 
following statements? 
 
The symptoms in my feet are worse in 
the morning 
 
The symptoms in my feet are worse at 
the end of the day 
 
The symptoms in my feet are worse 
after rest or inactivity 
 
The symptoms in my feet are better 
with activity such as walking 
 
The symptoms in my feet are there all 
day 
 
The symptoms in my feet can seem to 
randomly change from day to day 
1 = Strongly Agree 
2 = Agree 
3 = Neither agree or 
disagree 
4 = Disagree 
5 = Strongly disagree 
-998 = Skipped question 
26 Apart from pain, how often do you have 
any of the other following symptoms in 
your feet and ankles? 
Swelling 
Stiffness 
Cramp at the back of the leg or foot 
Numbness, burning or tingling 
Hot feet 
Cold feet 
4 = All the time 
3 = Very often 
2 = Often 
1 = Not very often 





Question  Response Codes 
Tired feet – aching feeling 
27 Overall, to what extent do you find the 
symptoms listed above in your feet and 
ankles troublesome (cause trouble, 
annoyance or difficulty)? 
Please pick one number to indicate 
how troublesome your symptoms have 
been. 
0 = Not troublesome at all 
to 10 = Extremely 
troublesome 
11 point NRS 
28 What problems have you had or 
currently have with your feet? Please 
tick ALL that apply. 
1 = Crooked or bent toes 
2 = Bony bump at the side 
of the big toe (Bunions) 
3 = Swelling of the entire 
toe (Sausage toe) 
4 = Hard skin or corn 
5 = Deformity at the front of 
the foot (excluding toes) 
6 = Open wound / sore that 
has taken over a week to 
heal 
7 = Achilles tendon (back 
of the heel) 
8 = Plantar fascia (under 
the heel or arch) 
9 = Flat feet 
10 = Dry cracked heels 
11 = Deformity at the ankle 
and heel 
12 = Size of my feet 
(changes in length and 
width) 
29 Have you ever 
felt embarrassed or self-
conscious about any of the foot 
problems listed above? 
Yes = 1 
No = 0 
30 Do you have psoriasis on the skin of 
your feet? 
Yes = 1 
No = 0 
31 Do you have psoriasis on the skin of 
your lower legs (knee to ankle)? 
Yes = 1 
No = 0 
 
IF NO, skip to question 35. 
-998 = Skipped question 
32 Do you currently see 
a dermatologist for your psoriasis? 
Yes = 1 
No = 0 
-998 = Skipped question 
33 Please indicate how psoriasis has 
affected the skin on your feet and 
ankles over the past month. Please 
tick ALL that apply. 
1 = Splitting of the skin 
2 = Itching of the skin 
3 = Bleeding of the skin 
4 = Redness of the skin 
5 = Pain and discomfort of 
the skin 
6 = Thick hard skin (callus) 





Question  Response Codes 
skin 
-998 = Skipped question 
34 Please indicate how much the skin 
problems (including psoriasis, hard 
skin, skin infection) on your feet 
and lower legs have affected your life 
over the past month. 
 
How sore, tender or painful has the 
skin on your feet and lower legs been? 
 
How embarrassed or self-
conscious have you felt because of 
the skin on your feet and lower legs? 
 How much has the skin on your feet 
and lower legs interfered with your daily 
activities or social and leisure 
activities? 
 
How much has the skin on your feet 
and lower legs influenced 
the footwear you wear? 
0 = Not at all 
1 = Mildly 
2 = Moderately 
3 = Extremely 
-998 = Skipped question 
35 Do you think that you currently have 
toenail psoriasis? 
1 = Yes 
0 = No 
36 Please indicate any problems you have 
had with your toenail psoriasis over 
the past month. Please tick ALL that 
apply. 
1 = Thickened nail 
2 = Splits in the nail 
3 = Nail lifts up (nail 
separates from the skin 
underneath) 
4 = Pitting in the nail (small 
pits in the nail)  
5 = Nail peels or breaks off 
6 = Ridges in the nail (lines 
across the nail) 
7 = Discoloured nail (white, 
yellow, brown) 
8 = Build up under the nail 
9 = Wave shaped nail 
10 = In-grown toenail 
 
IF NO, skip to question 38. 
-998 = Skipped question 
37 Please indicate how much your toenail 
psoriasis has affected your life over 
the past month. 
 
How tender or painful have your 
toenails been? 
 
How embarrassed or self-
conscious have you felt because of 
your toenails? 
 
0 = Not at all 
1 = Mildly 
2 = Moderately 
3 = Extremely 





Question  Response Codes 
How much have your toenails 
interfered with your daily 
activities or social and leisure 
activities? 
 
How much have your toenails 
influenced the footwear you wear? 
38 To what extent have you had difficulties 
in undertaking the following activities 
because of your feet?    
 
Standing for 5 minutes 
 
Walking for 5 minutes 
 
Walking barefoot 
Going up and downstairs 
5 = Unable to do 
4 = Very difficult 
3 = Moderately difficult 
2 = Slightly difficult 
1 = Not difficult 
39 Have you had difficulties with any of the 
activities listed above because of 
problems in other parts of your 
body?  
Yes = 1 
No = 0 
40 How many times did you do each of 
these activities in the past week? 
 
Walking continuously for at least 10 
minutes (for recreation or exercise or to 
get to or from places) 
 
Moderate physical activity (like gentle 
swimming, social tennis, gardening or 
work around the house) 
 
Vigorous physical activity (that made 
you breathe harder or puff and pant, 
like jogging, cycling, aerobics, 
competitive tennis, but not household 
chores or gardening) 
 
1 = Every day of the week 
2 = 4 – 6 times in a week 
3 = 2 – 3 times in a week 
4 = Once a week or less 
5 = Never 
41 Have your feet interfered with your 
daily activities over the past month? 
 
Going to the shops 
Looking after your home 
Leisure or social activities 
Being a parent or carer 






5 = Yes, interfered a lot 
4 = Yes, interfered a little 
3 = No, not at all interfered 
0 = Not relevant 
42 To what extent do you agree with the 
following statements? 
 
1 = Strongly agree 
2 = Agree 





Question  Response Codes 
I walk slower than others 
I limp or shuffle or feel unstable when 
I walk 
I feel embarrassed or self-
conscious about the way that I walk 
I feel frustrated by the problems with 
my feet 
I stay indoors most of the 
day because of my foot problems 
 
disagree 
4 = Disagree 
5 = Strongly disagree 
43 How many times have you fallen to the 
floor or ground over the past 12 
months? 
 0 = 0 falls 
1 = 1 fall 
2 = 2 falls 
3 = 3 falls 
4 = 4 or more falls 
44 What type of footwear do you wear 
the MOST during a typical week? 
Please tick ALL that apply. 
1 = Fashion sandals, 
thongs or jandals 
2 = Supportive style 
sandals 
3 = Ballet flats or 
moccasins 
4 = slip on sneakers 
5 – lace-up sneakers 
6 = sports shoes 
7 = Business or court shoe 
8 = High heels 
9 = Work boot such as steel 
toe-capped 
10 = Supportive walking 
boot 
11 = General boot (heeled 
or flat) 
12 = Prescribed or 
customised shoes (extra 
deep/wide footwear) 
13 = Barefoot only, socks or 
slippers  
45 What are the top 5 most important 
factors to you when choosing 
footwear? Please tick FIVE boxes only. 
1 = Plenty of room around 
my toes 
2 = Style 
3 = Wider fit 
4 = Support 
5 = Closed-in 
6 = Arch support or fits 
insole 
 7 = Cushioning shoe 
8 = Adjustable straps 
9 = Light weight 
10 = Cost 
11 = Soft around the back 
of my heel 
12 = Breathability 
13 = Easy to get on/off 





Question  Response Codes 
in box below) 
15 = Heel height 
16 = Open-toed 
46 To what extent do you agree with the 
following statements 
about difficulties you may have with 
your footwear? 
 
It is hard to find footwear that do not 
hurt my feet 
I have difficulty in finding footwear 
that fits my feet 
I am limited in the number of shoes I 
can wear 
I have difficulty with daily 
activities due to discomfort from my 
footwear 
I am limited in the kind of work I can 
do due to difficulties with my 
footwear 
I have difficulty in finding footwear 
appropriate for a special occasion 
I feel frustrated about the problems I 
have with footwear 
I feel embarrassed about the 
footwear I wear 
I find that I am restricted to the same 
type of footwear all year around 
 
1 = Strongly agree 
2 = Agree 
3 = Neither agree or 
disagree 
4 = Disagree 
5 = Strongly disagree 
47  Considering your foot problems overall, 
how well did you cope (manage, deal, 
make do) with your foot problems over 
the past month? 
  
Please pick one number to indicate 
how well you have coped. 
0 = Coped very well to 10 
coped very poorly 
11 point NRS 
48 Please indicate the typical ways in 
which you cope with your foot 
problems. Please tick ALL that apply. 
1 = Accept limitations 
2 = Pace and plan 
3 = Get on with it, despite 
the problem 
4 = Hide the problem from 
others  
5 = Do not think about the 
problem 
6 = Try to keep in control of 
the problem 
7 = Get support from family, 
friends and/or health 
professionals 
8 = None, I do not use 
coping strategies 
49 Considering all the people around you 
(family, partner, friends and others), do 
you believe that there is a:     
1 = Lack of understanding 
about the disease 





Question  Response Codes 
Please tick ALL that apply. 
 
people with the disease 
3 = Neither of these 
50 Do you belong to a patient support 
group (such as Arthritis Australia or 
Arthritis New Zealand) for your psoriatic 
arthritis or psoriasis? 
Yes = 1  
No = 0 
51 Do you need assistance to help take 
care of your feet properly? 
Yes = 1  
No = 0 
52 Have you tried to manage your own 
foot problems (such as applying 
products, using devices or purchasing 
particular footwear)? 
Yes = 1 
No = 0 
52 IF YES, how effective do you feel you 
have been at managing your foot 
problems? 
4 = Extremely effective 
3 = Very effective 
2 = Moderately effective 
1 = Mildly effective 
0 = Not at all effective 
 
IF NO, skip to question 54. 
-998 = Skipped question 
53 Considering all the ways you may have 
tried to care for your feet (for 
example, paying for nail care, footwear, 
padding, creams, insoles, massage 
etc.) in the past 12 
months, approximately how much 
have you spent of your own money? 
$ Value 
-998 = Skipped question 
54 Who have you seen about your foot 
problems? Please tick ALL that apply. 
0 = Occupational therapist 
1 = GP/Doctor 
2 = Other (please specify in 
the box below) 
3 = Rheumatologist 
4 = Dermatologist 
5 = Podiatrist 
6 = Foot 
massage/reflexologist 
7 = Physiotherapist 
8 = Surgeon 
9 = TCM 
10 = Nurse 
11 = Pedicure 
12 = I have not seen 
anyone 
54 IF YES, how effective was the help you 
received overall? 
4 = Extremely effective 
3 = very effective 
2 = moderately effective 
1 = Mildly effective 
0 = Not effective at all 
 
IF NO, skip to question 55. 
-998 = Skipped question 





Question  Response Codes 
that the health professionals you have 
seen had a good understanding of how 
psoriatic arthritis affects your feet? 
2 = Very confident 
3 = Moderately confident 
4 = Mildly confident 
5 = Not at all confident 
-998 = Skipped question 
55 Has your rheumatologist ever asked 
about your feet? 
1 = Yes 
0 = No 
56 Has your rheumatologist ever 
examined your feet? 
1 = Yes 
0 = No 
57 Have you ever seen a podiatrist about 
your feet? 
1 = Yes 
0 = No 
58 Do you receive regular podiatry 
treatment for your feet? 
1 = Yes 
0 = No 
59 Have you ever had any ankle or foot 
surgery? 
1 = Yes 
0 = No 
59 IF YES, did your ankle or foot problems 
improve after the surgery? 
1 = Yes 
0 = No 
IF NO, skip to end.  
-998 = Skipped question 

































































































































































































Appendix 11: Discussion comparison table  
 
Table to compare the results of the previous clinic-based foot-specific study in 
psoriatic arthritis with the current survey results.  
  
 Current study  Hyslop, et al., (2010a) 
Number of people with PsA 606 104 
Male/Female 68/532 44/60 
Age, years 51 (12) 51 (12) 
Body mass index, kgm2 31 (7) NR 
Disease duration, years 8.5 (10) 10 (9) 
Foot pain, n (%) 519 (92%) 64 (62%) 
Foot pain (NRS 0-10, VAS 0-
100mm) 
6 (2) NR 
Global pain (NRS 0-10, VAS 0-
100mm) 
6 (2) 36 (29) 
Plantar fasciitis, n (%) 321 (57%) 27 (26%) 
Achilles enthesitis, n (%) 213 (38%) 19 (18%) 
Joint deformity, n (%) 530 (94%) 8 (4) 
Dactylitis, n (%)  223 (40%) 25 (24%) 
Skin psoriasis, n (%) 161 (29%) 8 (8%) 
Toenail psoriasis, n (%) 321 (57%) 13 (13%) 
DMARD therapy, n (%) 340 (59%) 73 (70%) 
Biologic therapy, n (%)  249 (43%) 12 (12%) 
Data presented as mean (SD) unless specified. DMARD Disease modifying anti-
rheumatic drug, NR Not reported, NRS Numerical rating scale, PsA Psoriatic arthritis, 
VAS Visual analogue scale. 
